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Stroke is a medical condition characterized by rapid loss of brain function which 
may lead to death. It is the 4
th
 killer worldwide with a case occurring every 4 
seconds and a death every 4 minutes. The American Health Association reported 
that the total medical expenditure for stroke management was about USD60 billion 
annually. With recombinant plasminogen activator being the only approved 
thrombolytic agent, long term disability arising from stroke has become a global 
economic burden. In addition, unavailability of blood-based biomarkers, like 
Troponin I and T which are used for acute myocardial infarction, makes accurate 
diagnosis for stroke patients a challenge. Therefore, there is a need to look for 
novel early biomarkers and therapeutic agents for stroke. As such, microRNAs 
were considered as potential candidates which could be explored for these 
purposes. microRNAs are small non-coding RNA molecules that are capable of 
either activating or silencing the expression of many functional genes. This study 
aims to identify microRNA-based biomarkers for stroke as well as to investigate 
their therapeutic potential. 
 
In this study, the use of microRNAs in understanding the pathophysiology of 
stroke in experimental middle cerebral artery occlusion animal models was 
investigated. Several crucial microRNAs were identified and they showed 
correlation in expression between those found in circulating blood and ischemic 
brain. Of the 114 microRNAs that were detected in the brain, 27 of them were 
found in the blood.  Among these miR-292-5p, -290, -494, -214, 140* and -320 
were found to be highly upregulated.  
iv 
 
Temporal changes in microRNA expression were examined across different 
reperfusion time points (0 to 48hr) to study their changes during the progression of 
stroke. miR-140, -143,-145, -193, -204*, -208, -210, -224, -290, -328 and -425 
exhibited a biphasic-expression pattern with the progression of infarct volume. 
Among them, miR-210 and -145 have been reported as good biomarkers of stroke 
by others recently. Implications of microRNAs on stroke were explored in greater 
depth with particular interest on identifying potential therapeutic agents. Using 
bioinformatics databases, predicted target genes regulated by the dysregulated 
microRNAs were revealed. A good correlation between microRNAs and target 
genes expression was seen. miR-124a and miR-320a were predicted to target 
aquaporin 4 a crucial molecule associated with stroke induced cerebral edema.  
 
Dysregulation in microRNAs affects the expression of respective genes and a 
series of pathways which eventually leads to the blood brain barrier breakdown. 
This is a crucial event which takes place downstream of ischemic stroke. 
Upregulation in the expression of matrix metallopeptidase 9 (Mmp9) was reported 
to be associated with blood brain barrier breakdown. In addition to Mmp9, Mmp2, 
Mmp3, Timp1, Timp 2 and Timp 3 (regulators of Mmp9) are important key 
players in disturbing the integrity of the blood brain barrier. Bioinformatics 
prediction showed that several microRNAs could target Mmp9 and its regulators. 
One microRNA (miR-320a) was found to target all 6 genes. Changes in the 
expression of miR-320a corresponded with infarct volumes across different time 
points. miR-320a showed the highest expression when the infarct volume peaked at 
24hr and decreased in expression when infarct volume reduced at 48hr reperfusion. 
v 
 
This observation implied that reduction in the expression of miR-320a could be 
beneficial for stroke.  
 
Treatment with anti miR-320a reduced the infarct volume, blood brain barrier 
permeability, tissue swelling as well as brain edema. In addition, combination 
therapy with 10mg/kg body weight of recombinant plasminogen activator and 
0.5nmol LNA anti miR-320a was found to bring about a beneficial outcome in the 
treatment of cerebral ischemia. Particularly it could widen the therapeutic window 
of recombinant plasminogen activator up to 8hr. This is almost double the 
recommended therapeutic window for recombinant plasminogen activator therapy.  
Furthermore it could minimize the risk of hemorrhagic transformation as well as 
mortality rate.  
 
Overall, this study resulted in the identification of several microRNAs which could 
serve as potential biomarkers in stroke. miR-320a was shown as a potential 
therapeutic target as well as a useful agent for combination therapy with 
recombinant plasminogen activator. Thus bringing about beneficial outcomes in 
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1.1 Stroke  
Stroke is a major cerebrovascular disease which accounts for a significant 
proportion of death and disability every year. According to the World Health 
Organization, 15 million of the world‟s population suffer from stroke each year 
and, of these, one-third does not seem to survive and another one-third remain 
permanently disabled, while the remainder show favourable recovery and lead a 
satisfactory lifestyle. Costs of palliative care for stroke patient have also become a 
huge economic burden on the world‟s health system. The American Heart 
Association (AHA) reported that the total medical expenses for the management of 
cardiovascular (CVD) and stroke patients (both direct and indirect cost) was 
$297.7 billion for the year, 2008 [1].  
 
According to the Ministry of Health (MOH) of Singapore, cerebrovascular disease 
(including stroke), has remained as the fourth principal cause of death from 2008 to 
2009 as illustrated in Table 1.1 below. Cerebrovascular diseases accounted for 
8.4% of the total deaths in 2010 and were 8
th
 in the list of causes for hospitalization 
in 2009. Although more than 80% of stroke patients survive, many of them have to 
suffer with permanent disability which reduces the quality of their lives. With the 
rapidly aging population in Singapore, it is estimated that there will be an 
exponential increase in the burden caused by stroke on both the economy and 






Category Rank for 
stroke 
No. of victims 
(Total victims) 
Source 
Principal cause of death in Singapore 







Last updated 30 Jan 2012) 
Top 10 Conditions of Hospitalisation 








sation.html (Last updated on 
30 Dec 2011) 
Leading causes of death in USA in 
2007 
3 135,952 [2] 
Top 10 causes of disability in USA in 
2005. 
10 1100000 [3] 
 
Table 1.1: Statistics on deaths, hospitalisations and disabilities due to stroke in 
Singapore and USA. 
 
 
1.1.1 Classification of stroke 
Stroke is defined as rapidly developing group of medical symptoms of focal or 
global cerebral dysfunction, lasting more than 24hr or leading to death [4].  Stroke 
can be classified into two main types: ischemic stroke and haemorrhagic stroke 
(Figure 1.1). Cerebral ischemia (ischemic stroke) accounts for ~80% of stroke 
cases in Caucasian population and makes up for two-third of stroke cases in the 
Asian countries. The remaining 15% of stroke cases are largely caused by 
intracerebral hemorrhage (hemorrhagic stroke) and the other 5% are due to 







Figure 1.1: Classification of stroke [8] 
 
 
1.1.2 Ischemic stroke and subtypes 
Ischemic stroke is the most common form of stroke which occurs as a result of 
obstruction within an artery, or a vein in the brain. Common clinical symptoms are 
focal neurological deficits, loss of consciousness and headaches. There are many 
causes of ischemic strokes. Almost 50% of ischemic stroke cases (The Internet 
Stroke Center, http://www.strokecenter.org/patients/ais.htm) are due to the 
formation of blood clot within the brain (thrombosis). Accumulation of fat deposits 
in the innermost intimal layer of the blood vessel, a process known as 
atherosclerosis, can promote the development of blood clots (thrombosis). This 


































cause turbulence in blood flow.  Consequently, the plaque can dislodge (embolus) 
and block the blood flow of a smaller vessel [9]. Furthermore, atrial fibrillation 
(irregular heartbeat) can cause dislodgment of clots that are formed in the heart. 
These clots travel through the bloodstream and may be deposited in the brain 
vessel causing a blockage. There are quite a number of risk factors associated with 
ischemic stroke such as family history, coronary artery disease, hyperlipidemia, 
hypertension, blood clotting disorders, diabetes, smoking, alcoholism and ageing. 
 
Clinically, cerebral ischemia could be categorized into 4 subtypes according to 
TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification: large-artery 
atherosclerosis, cardioembolic, small artery occlusion (lacunar) and undetermined 
etiology based on presentations from patients‟ conditions [10, 11]. Ischemia can be 
further classified as either global or focal stroke depending on the extent of 
destruction. Cerebral ischemia takes places in different regions of the brain, 
depending on the site of obstruction. The most commonly affected region is 
usually the cortex. Generally, focal ischemia is more common than global ischemia. 
Strokes can also be classified based on their duration of incidence as either 
permanent or transient. The extent of injury following the onset of stroke where the 
ischemic lesion is made up of the core and the penumbra region is commonly 
evaluated using the infarct volume [12]. Within minutes of ischemia, necrosis 
occurs in the core region whereas the surrounding penumbral cells are exposed to 
lesser extent of injury and show moderate level of energy and ion pump failure [13, 
14]. Penumbral cells are potentially targeted for therapeutic intervention as these 
cells could be rescued after occlusion.  
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1.1.3   Hemorrhagic stroke 
Hemorrhagic stroke takes place when destabilized blood vessel(s) rupture and 
bleed into the surrounding brain region [15]. Hemorrhagic stroke can be due to 
aneurysms (ballooning of a weakened region of a blood vessel) or arteriovenous 
malformations (clusters of abnormally formed blood vessels). Accumulation of 
blood compresses the surrounding brain tissue. There are two forms of 
hemorrhagic strokes: intracerebral hemorrhage (ICH) and subarachnoid 
hemorrhage (SAH). Even though both ICH and SAH result from unexpected 
breakdown of vessel(s), the site of hemorrhage differs between the two. In SAH, 
the location of the rupture leads to blood release into the space surrounding the 
brain rather than inside the brain as in the case of ICH.  
 
The prevalence of ICH is double that of SAH [16]. ICH has a 35 to 52% of 30 days 
mortality rate and accounts for 50% of stroke-induced death within the first 2 years 
[17]. ICH could be classified according to its occurrence including vascular 
malformation, hypertension-related, bleeding diathesis, cerebral amyloid 
angiopathy and other. [6]. These unfavourable conditions can lead to the loss of 
vascular integrity and result in hemorrhage. Similarly, cerebral ischemia patients 
with ICH exhibit clinical symptoms, such as headaches and loss of consciousness 
[15]. The biochemical effects of ICH includes apoptosis, necrosis, inflammation 
and development of edema [18]. Upon ICH, blood pooling into the brain tissue 
causes haematoma which then grows into a mass. Subsequently, the intracranial 
pressure increases and causes damage to the brain [15, 19]. Perihematomal region 
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(zone around the haematoma) develops inflammation, edema, apoptosis and 





Figure 1.2: Sequence of events occurring during intracerebral hemorrhage. 





1.2 Cellular changes upon stroke 
The brain is made up of two types of cells consisting of neural cells (neurons) and 
glia cells. Glia provides neurons with nourishment, protection, and structural 
support.  There are a few different types of glia in the brain including astrocytes, 
miroglia and oligodendrocytes. Astrocytes are involved in transporting nutrients to 
neurons, providing structural support and in digesting parts of dead neurons as well 
as regulating the blood brain barrier[22]. Microglia (special immune cells 
exclusively found in the brain) could digest damaged neurons and pathogens. 
While oligodendroglia cells provide insulation (myelin) to neurons to speed up the 
electrical signals (action potential) which travel along the axon.  
 
Upon ischemia/reperfusion, energy failure and excitotoxicity results in the 
spontaneous cell death of neuronal and non-neuronal cells of the core region, and 
later glial and inflammatory molecules in the surrounding penumbra region could 
also contribute to further cell death and functional loss following the initial episode 
of ischemic event. A series of biochemical events taking place in the ischemic 
cascade will eventually lead to the death of both neurons and astrocytes. Many 
studies have focused on neuronal cells mainly because neurons are highly 
vulnerable to brain insult and do not have the ability to replicate. However, there is 
increasing interest in investigating glial cells in as astrocytes which may play a 
crucial role upon and after the onset of ischemia. Therefore, dysfunction of one cell 




In general, astrocytes are more resistant to ischemia and stress than neurons mainly 
because of their high internal energy and antioxidant reserves. However, ischemia 
still disrupts many of the important neuronal supportive roles of astrocytes in the 
brain. Disruption in the function of astrocytes could contribute to potassium 
imbalances, stroke-induced edema, blood-brain barrier breakdown, metabolic 
disturbances and reduction in the anti-oxidant protection effect. Damage to 
oligodendrocytes also results in functional deficits due to demyelination. Microglia 
is the resident immune cells of the CNS and is believed to contribute to cell death 
by releasing cytotoxic factors [24, 25]. They also release chemoattractants which 
could help in recruiting neutrophils and macrophages and lead to further damage of 
the brain cells. Activated endothelial cells (triggered by signals derived from the 
ischemic parenchyma), is thought to contribute to the recruitment of leukocytes, 
which then further aid microglia in the production of phagocytic, chemotactic and 
antigen-presenting roles aimed at debris removal and remodelling of the damaged 
region. Cytokines and chemokines are the key components to these cellular 
interactions that have traditionally been attributed to cell death.  
 
 
1.3 Pathophysiology of cerebral ischemia  
Understanding the biochemical changes in the pathophysiology of stroke is 
essential for the development of new drugs. Upon brain insult, decline in cerebral 
blood flow (CBF) causes neurophysiological disruptions which trigger the 
ischemic cascade (Figure 1.3).  
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A brain area with low perfusion in which neuronal cells have lost their membrane 
potential terminally („core‟) is surrounded by a region in which intermediate 
perfusion prevails („penumbra‟) and cells depolarize intermittently („peri-infarct 
depolarization‟) (Figure 1.4). The most hypoperfused area of the brain is the core 
region, where the CBF drops to less than 7ml/100g/min resulting in spontaneous 
and irreversible injury [26]. Surrounding the core area, is the penumbral or peri-
infarct region which is made up of brain cells that are exposed to moderate 
ischemia but are still under the threat of developing permanent injury. This area 
exhibits a CBF of 7 to 20ml/100g/min [27]. The electrically non-functional tissues 
in the penumbra are still metabolically active and constitute the best targets for 
modern intervention therapies. The outer layer of brain cells with minimal 
hypoperfusion is not commonly at risk and is categorized as the “oligaemia”. This 














Figure 1.3:  Critical events in ischemic cascade and potential target sites for 
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Figure 1.4: An image of the ischemic core and penumbra, showing different 
biochemical processes that take place in them [29]. 
 
 
The pathophysiological effects triggered upon by stroke can be categorized into the 
following biochemical events: 
 
1.3.1 Energy failure and depolarization 
As a unique organ without any extensive stores of energy, the brain solely depends 
on the continuous supply of oxygen and glucose for its proper functioning. In 
cerebral ischemia, the decrease of cerebral blood flow causes depletion of oxygen 
and glucose leading to neuronal degeneration which could be classified as acute 
and delayed. Within minutes of occlusion, hypoxic conditions result in the areas of 
occlusion and thus leads to reduced ATP production due to the failure of oxidative 














 antiport to permit Ca
2+
 influx. Excessive amount of 
extracellular K
+
 also leads to membrane depolarization. Depolarized membrane 
activates voltage dependent calcium channels (VDCC) to release glutamate into the 




 imbalance causes an inflow of excess 
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water into the cells resulting in osmotic swelling and bursting of ischemic cells. 
Subsequently, more glutamate gets released into the extracellular environment. 
 
1.3.2 Excitotoxicity 
Following energy failure, the presynaptic membrane (axon terminal of neuron) 
depolarizes and releases the glutamate into the synapse and causes the extracellular 
levels of glutamate to rise [29, 30].  Astrocytes play an important role in the 
reuptake of glutamate from the extracellular space. This function is accomplished 
via the involvement of plasma membrane Na
+
-dependent amino acid transporters 




 down their respective concentration 
gradients to drive glutamate into the cell [36]. The majority of glutamate 
transporters found in astrocytes are associated with synapses [37, 38]. The two 
transporters, predominantly expressed by astrocytes are namely L-glutamate/L-
aspartate transporter (GLAST-1) and the glial L-glutamate transporter (GLT-1), 
also known as excitatory amino acid transporters (EAAT1 and EAAT2, 
respectively)[39]. During stroke, disruption in the ionic gradient (e.g. increased 
extracellular K+ levels) of the surroundings cause the reversal of the glutamate 
uptake and to release more glutamate [31]. Reverse transport not only increases the 
extracellular glutamate (increased exitotoxicity), but also leads to cell death in 
astrocytes due to the depletion of cytoplasmic glutathione resulting from the loss of 
glutamate inside the cell [40].  
 
Excessive amount of glutamate binds and stimulates a range of receptors which are 
present both in CNS glial cells as well as neurons. In normal conditions, NMDA 
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(N-methyl-D-aspartic acid) and AMPA (a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) also known as ionotropic glutamate receptors (iGluRs) as 
well as mGluR (7-transmemb-rane domain G-protein–coupled metabotropic 
receptor) are involved in maintaining the homeostasis of Ca
2+
 between the extra- 
and intracellular environment. Upon ischemia, glutamate insult from dying cells 
initiate the opening of AMPA/kainate receptors and may trigger an action potential 
in the postsynaptic neuron and lead to the inflow of Ca
2+
 [35]. NMDA receptors 
have an internal binding site for Mg
2+
 ions, creating a voltage-dependent block 
which is removed by outward flow of positive current [41]. Further depolarization 
opens NMDA receptors which also encourages more inflow of Ca
2+
.  Glutamate 
binds to the extracellular region of an mGluR and causes the G proteins bound to 
the intracellular region to be phosphorylated, leading to the changes of multiple 
biochemical pathways and ion channels in the cell [42]. Ionotropic receptors offer 
the tendency to be faster in relaying information, while metabotropic ones are 
related with a more prolonged stimulus. This eventually causes the influx of Ca
2+
 
and excitotoxicity in brain cells [32-34]. In addition, an increase in intracellular 
Ca
2+
 concentration is sufficient and necessary to cause glutamate release from 
astrocytes via Ca
2+
-dependent exocytosis [43] which could modulate the activity in 
nearby neurons.  
 
1.3.3 Free radicals and mitochondrial dysfunction 
Overload of intracellular Ca
2+
, which acts as a second messenger triggers a cascade 
of events including activation of Ca
2+
-dependent enzymes, such as protein kinase C, 
phospholipase A2 (PLA2), nitric oxide synthase (NOS), calpain and 
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cyclooxygenase as well as mitochondrial dysfunction [44, 45] which eventually 
leads to cell death. Apart from activating proteases and endonucleases, Ca
2+
 
activates mechanisms which form highly reactive free radical species. For instance, 
proteolysis by calpains and activated PLA2 produces reactive oxygen species 
(ROS) and arachidonic acid [46].  
 
Nitric oxide (NO) is generated when neuronal NO synthase (NOS) acts on arginine. 
NO then reacts with a superoxide anion to produce peroxynitrite which contributes 
to the formation of free radicals. There are 3 isoforms of NOS, including eNOS 
which is found in endothelial cells, iNOS (inducible isoform of NOS) expressed 
mainly in macrophages and nNOS in neurons [47]. Both iNOS and nNOS are 
critical elements in neurodegeneration, whereas eNOS maintains the cerebral blood 
flow and protects neurons against any insults [47]. These ROS oxidize numerous 
macromolecules, disrupt the brain cells and cause secondary cell death via the 
release of arachidonic acid, initiate mitochondrial disturbances, induce stress on 
endoplasmic reticulum and cause DNA fragmentation [48, 49]. Polyunsaturated 
fatty acids are predominantly vulnerable to peroxidation. The peroxy and hydroxyl 
radicals that were formed propagate lipid peroxidation in a positive feedback 
manner, generating irreversible changes in physical and chemical properties of cell 
membranes. 
 
Mitochondrial dysfunction can cause neuronal damage and death as a result of the 
breakdown of its energy-production machinery. The malfunction of mitochondria 
is known to be mediated by spiked levels of cytosolic calcium. These lead to the 
15 
 
induction of lytic and free radical species-producing enzymes, and stimulation of 
the mitochondrial permeability transition (MPT), which permits the formation of 
MPT pores [45]. The pores are about 2 to 3nm wide and only allow molecules 
which are lesser than 1.5kDa to travel through the mitochondrial membrane [50].  
 
During ischemia, excessive Ca
2+
 and oxidative stress trigger the opening of MPT 
and leading to two key pathophysiological consequences [50, 51]. Under normal 
conditions, the pores are shut, Ca
2+
 activated lytic enzymes and release of 
destructive radical species can disrupt mitochondrial lipids, proteins and nucleic 
acids. Protons (H
+
) can pass through the inner mitochondria without restrictions, 
interrupting the electrochemical gradient, blocking mitochondrial respiration and 
causing the abrogation of oxidative phosphorylation of adenine nucleotides. Also, 
the flow of water and solutes into the matrix results in the swelling of mitochondria, 
eventually leading to the leakage of the outer mitochondrial membrane and 
initiating apoptosis [50]. Pro-apoptotic stimuli can also increase the permeability of 
mitochondrial membrane, leading to the release of cytochrome c and caspase 9 into 
the cytoplasm and activation of caspase 3 that are involved in the apoptotic 
pathway [26, 52].  
 
1.3.4 Apoptosis  
Upon the onset of ischemic stroke, hypoxia and deficiency of nutrients cause 
necrotic cell death in the core infarct region as a direct consequence of the blocked 
artery [53]. Necrotic cells swell and ultimately burst, leaking cellular contents into 
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the surroundings and leading to inflammation [54]. Until today, the detailed 
mechanisms underlying necrosis are unclear. 
 
In contrast to the core, apoptotic or programmed cell death is more predominant 
[53] in the penumbral cells that surround the infarct region. Apoptosis [54] can be 
initiated by lack of neurotropic factors, mitochondrial dysfunction [55], oxidative 
damage, DNA damage,  death receptors [56, 57] or apoptosis-inducing factor (AIF) 
[58, 59]. Apoptosis can be triggered via  two pathways: intrinsic and extrinsic [60]. 
Mitochondrial impairment during ischemia stimulates intrinsic pathway. Pro-
apoptotic proteins including cytochrome c, caspases, endonuclease G, AIF and 
second mitochondria-derived activator of caspases/direct inhibitor of apoptosis 
protein (IAP)-binding proteins with low pI (SMAC/DIABLO) are stored in 
mitochondria. [61]. Once the mitochondria malfunction, these proteins leak into 
the cytosol and induce apoptosis. Also, activated Ca
2+
-dependent calpains can 
cleave BID, produce tBID that promote more pro-apoptotic proteins to be released 
from mitochondria [60].  
 
External stimuli can also trigger apoptosis (extrinsic pathway) via the death 
receptors. For instance TNFα and FAS ligand (FASL) bind to FAS receptor 
(FASR) and promote formation of death inducing signalling complex (DISC) [62]. 
Subsequently, DISC stimulates caspase 8 triggering the apoptotic cascade and 





1.3.5 Inflammation, blood brain barrier (BBB) disruption and edema 
Inflammation is another key process for secondary neuronal death during ischemia 
[63, 64] and it normally happens a few hours after the onset of stroke. Both 
occlusion and reperfusion can trigger various immune responses which eventually 
resulting in activation and infiltration of inflammatory cells (Figure 1.5). In 
response to ischemia/reperfusion, activated astrocytes, microglia, and endothelial 
cells start producing cytokines and chemokines, which are potent mediators of the 
inflammatory response [26]. Interleukin1ß (IL1ß) and tumor necrosis factor α 
(TNFα) are cytokines that initiate inflammatory response and normally induce 
macrophage activation, B cell and T cell maturation. IL1ß and TNFα activation 
takes place at very early stages of ischemic stroke and lasts for only a short period. 
However they induce a secondary and more lasting inflammatory response, 
mediated by activated IL6 and IL8. Chemokines assist in the localization of 
inflammatory cells to the site of injury [65]. Microglial cells and astrocytes secrete 
chemokines, which create a chemical gradient and attracts monocytes to the 
damaged site. Induction of reactive oxygen species (ROS) stimulates ischemic 







Figure 1.5: Inflammatory cascade upon cerebral ischemia [66]. 
 
 
The release of activated cell adhesion molecules results in leukocyte recruitment, 
aggregation and adhesion to vascular walls. There are 3 major groups of cell 
adhesion molecules: selectins, immunoglobulin superfamily cell adhesion 
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molecules (IG-CAMs) and integrins. Selectins are involved in the interaction 
between leukocytes and endothelial cells in the periphery of the infarct. Both 
intercellular adhesion molecule type 1 (ICAM1) and vascular cell adhesion 
molecule type 1 (VCAM1) are the important immunoglobulin superfamily 
molecules that function during the acute phase of brain ischemia. Integrins play a 
part in clot generation and stabilization, leukocyte cell adhesion, bind collagen, 
laminin and fibronectin as well as form part of the structure of extracellular matrix. 
[66].  
 
The existence of these activated inflammatory cells causes the release of various 
agents including cytokines, matrix metalloproteinases (especially MMP9), nitric 
oxide (NO) and more ROS. They cause advanced cellular injuries. Once 
leukocytes adhere to the vascular walls, they migrate via the endothelium with the 
support of MMPs and cause the breakdown of the blood brain barrier (BBB), 
leading to vascular edema and eventually hemorrhagic transformation [67, 68].  
 
BBB separates circulating blood from brain extracellular fluid in the CNS. It serves 
as the brain's protective shield by regulating soluble factors and cellular exchanges 
from blood to brain. The BBB is a specialized system of brain microvascular 
endothelial cells (BMVEC) [69]. The close interaction between endothelial cell 
and other components include extensive tight junctions (TJs) [70], pericytes, 
astrocytes, neurons, the extracellular matrix and its basement membrane [71] 
ensure proper functioning of the CNS.  In normal conditions, the BBB is intact. 
The endothelial cell tight junctions restrict the paracellular flux of hydrophilic 
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substances that can go through the BBB. However, small lipophilic molecules, for 
instance O2 and CO2 are allowed to diffuse freely across plasma membranes [72]. 
 
Breakdown of the BBB and the access of plasma contents allow more diffusion of 
water and salts into cells and aggravate brain edema [73]. During ischemia and 
reperfusion, the components of BBB such as tight junction (TJs) and basement 
membrane are disrupted following various pathophysiological events which results 
in an increase in the permeability and subsequently breakdown of the BBB [74, 
75]. 
 
There are 2 main phases of brain edema, an early intracellular (cytotoxic) edema, 
followed by a later stage of extracellular (vasogenic) edema [76, 77]. Under 
ischemic conditions, depletion of ATP, anoxic membrane depolarization and 
increased intracellular uptake of Na
+
 cause an inflow of water and eventually 
leading to cell swelling and progression of cytotoxic edema in the core region. The 
development of neuronal necrosis lasting for more than 4 to 6hr after the ischemic 
cascade results in BBB breakdown, increased permeability and movement of 
intravascular proteins and fluids. This disruption initiates vasogenic edema leading 
to further accumulation of water into the neurons. It has been demonstrated that 
inflammatory genes (especially MMP9), free radicals, nitric oxide synthase, 
vascular endothelial growth factor and aquaporins (AQPs) play respective roles in 




Quite a number of studies have reported inflammatory markers which are 
beneficial or detrimental during stroke, while others show controversial findings 
(Table 1.2). Several studies have reported the application of biomarkers in the 
diagnosis of ischemic stroke. MMP9 is one of the biomarkers which highly 
correlate with ischemic stroke. In one of the ischemic stroke patients‟ study, 
expression of MMP9 mRNA was found as a predictor of poor outcome and 
mortality. MMP9 concentration was found to be nearly 3 fold higher in non-
survival patients in comparison to others and 1.9 times higher in patients with post-
stroke modified Rankin score (mRS)>2 than patients with mRS</=2 [80]. MMP9 
was determined within the first 9hr from stroke onset [81]. In a later report, MMP9  




Denes et al. [84] proposed that the inhibition of IL1 using  IL1 receptor could be 
therapeutically beneficial in several diseases which are risk factors for stroke, and 
have potential in the management of acute stroke. In addition, the intracerebral 
injection of recombinant IL1 significantly aggravated the condition of ischemic 
stroke and excitotoxicity damage in vivo models of stroke [88-91]. In another 
study, the expression of IL1β mRNA was induced by MCAo within 15min and 
necrotic injury was observed after 1 to 2 day(s) [93].  
 
Bogoslovsky et al. [94] demonstrated that high levels of ICAM1 is correlated with 
































































Description of effects References 
1. MMP9 MMP9 mRNA was a predictor of poor outcome 
and mortality in stroke. 
[80] 
As biomarker for diagnosis of ischemic stroke. [81, 82] 
Mice deficient in MMP9 had smaller infarcts 




Pre-clinical and clinical evidence that inhibition 
of IL1 by IL1 receptor antagonist may be 
valuable in the management of acute stroke. 
[84] 
IL1 showed the presence of END (early 
neurological deterioration) and infarct volume. 
[85] 
Mice deficient in IL1 had smaller infarcts 
compared to wild type. 
[86] 
Increased IL1β protein a few hours later after 
ischemia. 
[87] 
Recombinant IL1 exacerbates ischaemic and 
excitotoxic injury in vivo. 
[88-91] 
Overexpression or treatment with IL1Rα 
reduced infarct size. 
[92] 
IL1β mRNA elevations within 15 to 30min 
after ischemia. 
[93] 












Potential biomarkers may predict tissue injury 
and stroke severity in early ischemia. 
[94] 
Inhibiting ICAM1 mRNA with antisense 





Blocking ICAM1 with antibodies improves 
outcome from experimental stroke. 
[96-98] 
Mice deficient in ICAM1 had smaller infarcts 
compared to wild-type mice. 
[99, 100] 
Increased expression of ICAM1 in ischemic 
brain within hours after stroke onset, peaking at 





 4.     Selectins 
   (P-/E-) 
Expression of P-selectin plays a role in 
triggering BBB dysfunction at 24hr after 
transient focal cerebral ischemia. 
[104] 
Treated with antibodies /inhibitors against 
selectin was associated with improved 
neurological outcome.  
[105-107] 
Induced in the animal models of focal cerebral 
ischemia. 
[108] 

























Description of effects References 
4.  Selectins 
(P-/E-) 
Upregulation promotes ischemic inflammatory 
responses and increases injury due to ischemic 
stroke. 
[105, 106] 
5. MCP1 MCP1-deficiency lessens the inflammatory 
response following experimental MCAo 
(impairment in the induction of IL6, 1β and 
granulocyte-colony stimulating factor 
expression) and MCP1-deficient mice 
developed smaller infarcts 36hr after MCAo. 
[110] 
Inhibition or deficiency is associated with 
reduced injury. 
[109] 


























6. IL10 IL10 offers neuroprotective effect by acting via 
IL10 receptor and PI3K/AKT and STAT3 
signal transduction pathways. 
[111] 
Gene transfer of IL10 has been found to be 
beneficial in cerebral ischemic models. 
[112] 
Subjects (5 years old inhabitants of Leiden, 
Netherlands) with low IL10 levels have an 
increased risk of stroke.  
[113] 
Overexpression of TGFβ1 using an adenoviral 
vector protected mouse brains from ischemic 
stroke and reduced the accompanying 
inflammatory response. 
[114] 
Exogenous administration beneficial for 
cerebral ischemia models.  
[115] 
 7. IL4 IL4 knockout mice show increased infarct 
volume. 
[116] 
 8. TGFβ Intranasal TGFβ1 may have therapeutic 
potential for MCAo mice. 
[117] 
Cultured neurons may be protected from 
ischemia-like insults by microglia-secreted 
TGFβ1. 
[118] 
Neuroprotective effect. [119] 
Intranasal TGFβ1 may have therapeutic 
potential for MCAo mice. 
[117] 
 
Overexpression of TGFβ1 protected mouse 
brains from ischemic stroke. 
[114] 
 
Cultured neurons may be protected from 






























Description of effects References 
 8. TGFβ Cultured neurons may be protected from 
ischemia-like insults by microglia-secreted 
TGFβ1. 
[118] 
Overexpression of TGFβ1 protected mouse 
brains from ischemic stroke.  
[114] 
May contribute to the recovery of ischemic 
stroke. 
[120] 
TGFβ protects hippocampal neurons against 
degeneration caused by transient global ischemia. 
[121] 
TGFβ protects mouse neocortex from ischemic 
injury in vivo and prevents glutamate 





































Description of effects Contradicting 
evidences 
References 
9. TNFα Presence of END (early 
neurological 
deterioration) and infarct 
volume. 
 [85] 
Biphasic pattern of 
expression with a second 
peak at 24 to 36hr. 
 [123, 124] 
Administration of 
recombinant TNFα 
protein worsens ischemic 
brain. 









Inhibition of TNFα 
reduces ischemic brain 
injury. 
Mice deficient in 
TNFα receptors have 
larger infarcts. 
[126, 127] 
Initial increases 1 to 3hr 
after ischemia onset.  
 [128] 
 
10. VCAM1 Increased VCAM1 in the 
plasma and CSF with 
recent cerebral ischemic 
patients, and correlated 
to stroke severity.  
Treatment with anti-
VCAM1 antibodies 
did not have any 
effect on stroke 
outcome. 
[129-132] 
Biomarker for diagnosis 
of ischemic stroke. 
 [82] 
Increases in VCAM1 






Table 1.2: “Unfavourable”, “beneficial” and controversial findings in 
inflammatory markers. 
 
potentially be used to predict the extent of tissue injury and stroke severity during 
early stage of ischemic stroke. In an antisense oligonucleotide study, knockdown 
of ICAM1 protein was found to lessen the brain injury due to ischemic stroke [95] 
and blocking of ICAM1 with antibodies offers beneficial outcome on experimental 
stroke model [96-98]. 
 
Despite these unfavorable inflammatory proteins, there are “beneficial” proteins 
which could potentially offer better outcome from neuronal injury due to ischemic 
stroke [121, 122]. A recent study on primary cortical neurons in culture treated 
with IL10 improved the survival of cells after exposure to glutamate or OGD and 
suggested that IL10 is potentially neuroprotective by acting though IL10 receptor 
and PI3K/AKT and STAT3 signal transduction pathways [111]. Increasing the 






































IL6   Pro-inflammatory.  [53] 
Presence of END (early 
neurological 




value for in-hospital 
mortality. 
 [134] 
mRNA and bioactivity 







Elevated IL6 in CSF of 
acute stroke patients 
correlate with reduced 
infarct volume. 






administration of IL10 reduced the ischemic injury [115], whereas, subjects (5 
years old inhabitants of Leiden, Netherlands) with low IL10 levels were reported to 
have higher risk for stroke [113]. 
 
Another interesting molecule, IL4 was reported to offer neuroprotective effect in 
stroke models. Loss of function of IL4 in IL4 knockout mice was found to worsen 
the outcome and this condition was reversed by giving exogenous IL4. These 
findings demonstrated IL4 signalling lessens inflammation in the core and 
highlighted its potential favourable role for activated astrocytes in the penumbra 
region [116]. 
 
Intranasal administration of TGFβ1 in mice post MCAo, could decrease the infarct 
volume, promote better functional recovery and improve neurogenesis [117]. 
Overexpression of TGFβ1 via an adenoviral vector protected mice from ischemic 
stroke and potentially decreased the accompanying inflammatory response [114]. 
In vitro cultured neurons were also found to be protected from ischemia-like insults 










1.4 Diagnosis of stroke, limitations and problems 
Accurate diagnosis of stroke is critical in managing patients. Ischemic stroke is 
diagnosed primarily by imaging methods and several evaluation tests [138]. 
Computed tomography (CT) and magnetic resonance imaging (MRI) are common 
tools for the diagnosis of ischemic stroke [138]. CT methods commonly used are 
CT angiography (CTA) and perfusion CT (PCT). These CT techniques are not 
always available upon admission to hospital, but they may provide evidence of the 
site of occlusion and the length of vessel occluded, although estimates of perfusion 
deficits may not be accurate. CT offers difficulties in diagnosing patients with mild 
ischemia. MRI may be a better technique for early diagnosis but is more costly and 
less widely available. Its limitation is also the long scanning time required and that 
may delay treatment. MRI may also be not feasible in acutely ill patients as they 
are often restless. Hence, identification of a sensitive and specific biomarker 
similar to troponin I/T in myocardial infarction may be useful in aiding the 
diagnosis of acute cerebral ischemia. 
 
 
1.5 Biomarkers and neuroprotectants in stroke 
Biomarkers are substances of biological origin which are found in an abnormal 
amount in body fluids, or tissues and may suggest the presence or extent of a 
disease such as stroke. The term biomarker (biological marker) was first introduced 
as a Medical Subject Heading (MeSH) term in 1989. Biomarkers are defined as the 
measurable and quantifiable biological parameters such as biological substances, 
specific hormone and enzyme concentration, and specific gene phenotype 
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distribution in a population. Biomarkers could be used as the indices for health- 
and physiology-associated assessments, for instance risk factors for diseases, 
metabolic processes, psychiatric disorders, environmental exposure and its effects, 
diagnosis and prognosis for diseases, pregnancy, cell line development and 
epidemiologic studies. Twelve years later, the definition of a biomarker was 
standardized as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” [139]. 
 
Blood biomarkers are gaining popularity in the diagnosis of cerebrovascular 
disease. It can be a rapid blood test to confirm a clinical and imaging diagnosis of 
ischemic stroke and based on a simple and low-cost technology.  Currently, there is 
no known sensitive and brain specific biomarker for rapid diagnosis of stroke. 
Table 1.3 lists a few of those proteins that have been studied as potential 
biomarkers in the diagnosis of ischemic stroke. Eight of the seventeen protein 
markers including TNFα, MMP2, MMP9, VEGF, MCP1, VCAM, ICAM1 and IL6 
shown in the Table 1.3 consist of inflammatory markers. These markers have been 
found to be increased in body fluids from the onset of stroke. Unfortunately, most 
of them do not appear to be specific for brain injury as they may also arise in 
response to trauma, injuries or inflammation in other tissues. Nevertheless, visinin-
like 1 protein forms the only marker reported at the genetic level. Hence, there is 
also a need for more biomarkers at the genetic level to be discovered as they could 




An ideal biomarker for cerebral ischemia would, besides having the characteristics 
of building up in concentration in blood/serum, should diffuse rapidly from the 
ischemic tissue into the bloodstream, have a half-life of at least a few hours and 
should be brain specific [140].  
 
 
Type Biomarkers References 
Protein NSE Neuronspecific enolase [140, 141] 
S100β Cytosolic calcium binding protein [142-144] 
D-dimer Fibrin degradation product [145] 
vWF von Willebrand factor [146] 
BNGF B type neurotrophic growth factor [81] 
MBP Myelin basic protein [147, 148] 
GFAP Glial fibillary acidic protein [144, 149] 
TNFα Tumor necrosis factor alpha [150] 
MMP9 Matrix metalloproteinase 9 [146, 151] 
MMP2 Matrix metalloproteinase 2 [150] 
VEGF Vascular endothelial growth factor [146] 
BDNF Brain derived neurotrophic factor [81] 
MCP1 Monocyte chemotactic protein 1 [81] 
VCAM Vascular cell adhesion molecule [82] 
ICAM1 Intercellular adhesion molecule 1 [150] 
UCHL1 Ubiquitin C-terminal hydrolase L1 [144] 
IL6 Interleukin 6 [152] 
Gene expression VSNL1 Visinin-like 1  [153] 
  
    Table 1.3: List of some biomarkers reported from different studies. 
 
 
Despite the importance in discovering specific and sensitive biomarkers for stroke, 
there have been many attempts to find a potential neuroprotectant. Over the past 
decade, clinical trials aimed at finding suitable neuroprotectant(s) against stroke 
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have met with no success. Most of the potential agents that are found to be 
promising in the laboratory, eventually failed to meet the requirements prescribed 
in clinical settings. Some clinical trials on stroke are shown in Table 1.4. The 
clinical trials not only demonstrate the lack of a proper therapy for stroke but also 
emphasize the need to find more therapeutic agents or targets. For example, free 
radical scavenger, NXY-059 has been shown to be neuroprotective in experimental 
animals. Unfortunately, this encouraging finding was not reproducible in SAINT-II 
(US) trial which was conducted to verify results in SAINT-I that was promising. It 
was concluded that though NXY-059 was safe to use, it was ineffective as a 




Clinical trial Status References 
Albumin Therapy for Neuroprotection in 
Acute Ischemic Stroke (ALIAS) 
Ongoing 
(Estimated completion: 1 Jun 2015) 
[154] 
Field Administration of Stroke Therapy 
Magnesium, (FAST-MAG, Phase III 
Study Start Date: January 2005  
Estimated Study Completion Date: June 
2013. 
 
Rapid Response of an Astrocyte Modulator 
in Acute Cortical Stroke (RREACT) 
Ongoing  
Treatment of Subarachnoid Hemorrhage 
with Human Albumin (ALIASAH) 
Ongoing  
Intravascular Cooling in the Treatment of 
Stroke-Caffeinol (ICTuS-C) 
Ongoing  
Intravenous Magnesium Sulfate in 
Aneurysmal Subarachnoid Hemorrhage, 
IMASH-III 
Completed and published (2010)  
The results failed to support a clinical 
benefit of intravenous magnesium sulfate 
infusion over placebo infusion in patients 







Intravascular Cooling in the Treatment of 
Stroke-Longer rt-PA window  (ICTuS-L) 
Completed and published (2010) 
This study established the feasibility and 
preliminary safety of combining 
endovascular hypothermia post stroke with 
intravenous thrombolysis. A definitive 
efficacy trial was suggested to determine 














Clinical trial Status References 
Desmoteplase In Acute Ischemic Stroke 
(DIAS-2) 
Completed & published (2009) 
The findings unable to demonstrate that 
desmoteplase given 3 to 9hr after the onset 




Stroke Prevention by Aggressive 
Reduction of Cholesterol Levels 
(SPARCL) 
Completed & published. 
This study could not find any difference in 
the effect of statin treatment in reducing 
these events in subjects with or without 






Magnesium in Aneurysmal Subarachnoid 
Hemorrhage (MASH II, Phase III) 
Completed and published (2008)                                    
Primary outcome was found to be poor 
clinical outcome as measured by the 




Stroke-Acute Ischemic NXY -059 
Treatment (SAINT-I/II) 
Completed & published (2008)                                 
NXY-059 was reported ineffective for 
treatment of acute ischemic stroke within 





Edaravone and Argatroban Stroke Therapy 
(EAST), Phase IV 




Intravenous Magnesium Efficacy in Stroke 
(IMAGES) 
 
Completed & published  
The positive results in LACS failed to be 
attributed to general issues of severity, time 
of treatment, blood pressure, or other 
baseline factors. A large trial of Magnesium 
treatment in LACS suggested to be carried 








Dose Escalation Study of Desmoteplase in 
Acute Ischemic Stroke (DEDAS) 
Completed & published (2006) 
Treatment with IV desmoteplase 3 to 9hr 
post ischemic stroke onset was safe. 
Improved clinical outcome, especially in 
patients fulfilling all MRI criteria when 
give at a dose of 125µg/kg desmoteplase 
appeared to improve The results of DEDAS 
positively support the findings from its 
predecessor study,  Desmoteplase in Acute 
Ischemic Stroke (DIAS). 
[173] 
Early GABAergic Activation Study In 
Stroke (EGASIS) 
Completed & published (2006) 
The data could not confirm the primary 
hypothesis of the study. Diazepam 
treatment likely to be beneficial in 
cardioembolic infarct patients, safe for 
acute ischemic stroke, however may not be 








Very Early Nimodipine Use in Stroke 
(VENUS) 
Completed & published (2001) 
The findings from this study failed to 
support the hypothesis  
[177] 
Clomethiazole Acute Stroke Study 
(CLASS) 
Completed & published (1999) 
This drug was safe to be given to 








Clinical trial Status References 
Flunarizine in Stroke Treatment (FIST) Completed & published (1996) 
Flunarizine was not able to improve 
neurologic and functional outcome in acute 









Randomized Trial of Tirilazad Mesylate in 
Acute Stroke (RANTTAS) 
completed & published 
Subacute CT infarct volume associated 
modestly with 3month clinical outcome as 
evaluated by widely used neurological and 
functional assessment scales. The modesty of 
this linkage constrains the application of 
infarct volume as a surrogate end point in 
ischemic stroke clinical trials. 
[182-184] 
 
Table 1.4: Some of the clinical trials in stroke therapy. Adapted from [185]. 
 
 
1.6 Recombinant tissue plasminogen activator (rt-PA) 
rt-PA is the only FDA approved treatment for acute ischemic stroke [186]. 
Previously, the therapeutic window was limited to 3hr. In the ECASS III trials, it 
was demonstrated that the therapeutic window can be extended to 4.5hr [187]. rt-
PA (fibrinolytic serine protease) initiates the process of clot degradation by 
cleaving plasminogen into the activated enzyme plasmin, promoting the 
degradation of fibrin-based clots that block the blood vessels [188, 189]. Figure 1.6 
illustrates the function of rt-PA in the vascular compartment. The half-life of rt-
PA's proteolytic activity in the blood is 3 to 7min [190].  
 
Experimental animal stroke models showed that rt-PA reduced infarct volume and 
improved the functional outcome [192, 193]. In 1995, the National Institute of 
Neurological Disorders and Stroke (NINDS) established that acute administration 




Figure 1.6: Roles played by tPA in the vascular compartment. In plasma, tissue-
type plasminogen activator (tPA, mainly released by endothelial cells) cleaves the 
zymogen plasminogen (PLG) into active plasmin (PLN). Plasmin facilitates the 
degradation of fibrin (key component of blood) and promotes the blood reperfusion. 
This fibrinolytic process of tPA and plasmin could be inhibited by Type-1 







 for intervention therapy 
against stroke. FDPs are fibrin degraded peptides. Adapted from [191]. 
 
 
window. Also, this study showed that rt-PA significantly reduced incidence of 
long-term disabilities despite a slight increase in the risk of intracerebral 
hemorrhage. rt-PA was also the only approved drug by the Food and Drug 
Administration for the treatment of acute ischemic stroke. Studies have also 
reported non fibrinolytic properties of rt-PA, including the effect of rt-PA. It was 
found to bring about neuronal injury, hemorrhagic transformation (HT) and BBB 
disruption [194-197]. Figure 1.7 show the functional role played by rt-PA in the 






Figure 1.7: Roles played by tPA in brain parenchyma. tPA has effect on the 
neuronal functioning. Three major phases of action of tPA in brain homeostasis are 
(A) Upon any injury/trauma, tPA is discharged from the presynaptic terminal (from 
activated microglia or others vascular compartment), tPA is also known to control 
the activation of microglia (indicated by +). (B, i) In the extracellular area, tPA 
aggravates the degradation of extracellular matrix (ECM) by triggering the 
cleavage of plasminogen (PLG) into activated plasmin (PLN). (B, ii) Serpins (e.g. 
type-1 plasminogen activator inhibitor, PAI-1) and neuroserpin (NSP) could arrest 
the action of tPA, tPA or clearance by astrocytes also. (C) tPA can act with low-
density-lipoprotein receptor-related protein (LRP) or NMDA receptors resulting 
with an in the activation of protein kinase A (PKA) or enhancing the release of 
Ca
2+
. Thus tPA could bring about excitotoxicity and late phase long term 
potentiation (L-LTP). Adapted from [191].  
 
 
It has been demonstrated that rt-PA binds to low-density lipoprotein receptor-
related protein (LRP) and induces the release of matrix metalloproteinase that 
subsequently results in the breakdown of blood brain barrier [198, 199]. rt-PA also 
mediates excitotoxicity by activating NMDA receptor which potentiates calcium 
influx into neurons leading to excitotoxicity [200-202]. It is also known that rt-PA 
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in the CNS is facilitated by both plasminogen-independent and -dependent 




Figure 1.8: Domains of rt-PA and the respective functional process of each 
domain. Adapted from [194] 
 
 
Plasminogen-independent association between rt-PA and LRP1 in neurons 
potentially trigger a γ-secretase-regulated transmembranous proteolysis of LRP1 
by nuclear translocation of the cytoplasmic domain of LRP1 and cell death [203]. 
In addition, the end product of plasmin causes damaging outcome such as initiation 
of the chemokine macrophage chemoattractant protein (MCP1) [204], the 
activation of microglial cells by its interaction with annexin II [205] and 




Although thrombolytic treatment (rt-PA) given within 3hr after the onset of 
symptoms has shown beneficial effects for acute clinical ischemic stroke (The 
NINDS rt-PA Stroke Study Group, 1995), most of the acute stroke patients are 
admitted to hospital and diagnosed later than 3hr from the onset of stroke. A 
delayed treatment with rt-PA has resulted with an increased risk of hemorrhagic 
transformation and an exacerbated brain injury (The NINDS rt-PA Stroke Study 
Group, 1995, 1997) [207-209].   
 
Administration of rt-PA between 3 to 6hr of stroke onset in rat models of embolic 
stroke caused a substantial increase in the prevalence and volume of intracerebral 
hemorrhage [83, 210, 211] and later rt-PA administration noticeably worsened 
neurologic status of the brain [83]. On the other hand, some experimental stroke 
studies reported a reduced mean infarct volume [210, 212] and a trend in 
neurological improvement upon delayed rt-PA treatment [212].  
 
Recently, the European Cooperative Acute Stroke Study (ECASS)-3, reported that 
rt-PA (Alteplase
®
) treatment administered between 3 to 4.5hr after the onset of 
symptoms significantly improved clinical outcomes in acute ischemic stroke 
patients when compared with placebo [213, 214]. It is very crucial to extend the 
therapeutic window of rt-PA treatment for beneficial clinical outcome and 
minimize the adverse effects following the delayed treatment. As mentioned by 
Fisher et al. [215], the new direction for stroke therapy relies on increasing the 




1.7 MicroRNA (miRNA) 
For decades, RNAs have been thought to play only a supplementary role as 
mediators in the transmission of genetic material from genes to proteins. Recent 
discovery of a species of short non-coding RNAs, named as miRNAs, has 
revolutionized this perspective. miRNAs are a class of small, non-coding RNAs. 
They are 18 to 22 nucleotides in length [216, 217]. Ever since the discovery of the 
first miRNA [216, 218], more of them are being continuously identified in the 
genome of majority eukaryotic organisms.  
 
To date (August 2012), 21264 miRNA entries symbolizing hairpin precursor 
miRNAs, expressing 25141 mature miRNAs across 193 species have been 
reported. These small RNAs function as novel endogenous modulators of gene 
expression both at the transcriptional and translational level. miRNAs could 
modulate the expression of about 60% of the protein-coding genes by targeting 
specific messenger RNAs (mRNAs), by either inhibiting or activating them [219]. 
This phenomenon is known as RNA interference (RNAi) [220].  It is also known 
that some miRNAs could interact with the promoter of the genes and bring about 
transcriptional control on gene expression [221].  
 
1.7.1 Biogenesis 
miRNAs are found within both intragenic and intergenic sites in the genome [222, 
223] as well as in introns or exons of protein-coding regions. They can be present 
either individually or in clusters [217, 224]. Figure 1.9 illustrates the biogenesis of 
miRNAs. They are transcribed by RNA polymerase II (RNA Pol II) to generate 
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single-stranded primary miRNA transcripts (pri-miRNA) in the nucleus [225]. 
Even though RNA polymerase II and RNA polymerase III (RNA Pol II and III) are 
both present in any given cell, it is thought that the majority of mammalian 
miRNAs are transcribed by RNA Pol II. Pri-miRNA transcripts can be more than 
1kb long and often contain stretches of uridine residues. Longer transcripts are 




         Figure 1.9: Biogenesis of miRNAs. Adapted from [226]. 
 
 
Upon transcription of pri-miRNA, the transcripts are processed by a RNase III 
ribonuclease called Drosha that complexes with a RNA-binding protein, 
DGCR8/Pasha, into ~60 to 70 nucleotides long stem-loop structures known as the 
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precursor miRNAs (pre-miRNAs) [227-229]. The pre-miRNAs are exported out of 
the nucleus by the Ran-GTP (RAs-related nuclear protein) dependent Exportin-5 
into the cytoplasm [230, 231].  
 
Within the cytoplasm, further processing of the pre-miRNAs by RNAse III enzyme 
known as Dicer takes place resulting in the formation of 18 to 22 nucleotides long 
mature miRNA duplexes [232, 233], which are then incorporated into a 
ribonucleoprotein complexes, referred to as RNA induced silencing complexes 
(RISC) [234]. During RISC assembly only one strand of the miRNA, the guide, is 
incorporated [235, 236]. The RISC complex identifies its targets for translational 
modulation via complementary base pairing, and the target mRNAs will be either 
degraded or repressed, resulting in the termination of the translation process.  
 
1.7.2 RNA inhibition  
Endogenous miRNAs function primarily via translational inhibition of gene 
expression [216, 237]. The gene inhibition by miRNA was first discovered in C. 
elegans where there was a detectable difference between mRNA concentration and 
protein synthesis [218]. Generally, these small RNAs target and bind to 
complementary sites within the 3′ untranslated regions (3‟UTRs) of the mRNA. In 
order for cleavage or degradation of the target mRNAs to occur, miRNAs have to 
bind to the mRNA in a complementary fashion.  
 
miRNAs with partial complementarity to target mRNAs, result in messenger 
repression where the target mRNAs are stored in P-bodies for degradation or future 
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use [218, 238, 239]. Due to imperfect complementarity, a single miRNA can 
possibly recognize and target more than 100 mRNAs [240]. Translational 
suppression destabilizes mRNA via deadenylation and subsequent decapping [241-
244]. Thus, it is also possible for several miRNAs to act on the different regions 
within a 3‟ UTR or a single miRNA can bind to multiple regions within a target 
gene and cause maximal inhibitory effect on gene expression. 
 
1.7.3 RNA activation  
Although miRNAs are generally known to modulate translational inhibition, recent 
evidence [221, 245, 246] suggest that miRNAs can switch from translational 
repression to activation, depending on the physiological conditions. Translational 
activation also needs complementary base pairing between miRNAs and target 
mRNAs. For instance, miR-373 has been demonstrated to bind to complementary 
promoter sequences to regulate gene expression [247]. Li et al. [248] demonstrated 
small RNA induced gene activation using synthetic dsRNAs that could bind to 
promoter sites and eventually stimulate gene expression. The same phenomenon 
has also been reported by Janowski et al. [249]. 
 
1.7.4  miRNA databases 
Currently about 60% of all cellular mRNAs have been predicted to be targeted by 
miRNAs [250, 251]. Interaction between mRNA-miRNA is dependent on the seed 
region, first 2 to 8 nucleotides on the 5‟ end of the miRNA, the nucleotides 
surrounding the seed region, and the complementarity of the 3‟ end of the miRNA 
to its targets [252]. Although various softwares at sites such as MicroCosm 
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(www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/), mirGen (www.diana. 
pcbi.upenn.edu/miRGen.html), TargetScan (www.targetscan.org), PicTar (pictar. 
mdc-berlin.de/), MAMI (mami.med.harvard.edu/) and MiRanda (www.microRNA 
.org), RegRNA.org (http://regrna.mbc.nctu.edu.tw/html/prediction.html), miRDB 
(http://mirdb.org/miRDB/) are available to predict miRNA targets, the limitation is 
the ability of the miRNAs with less than perfect complementarity to actually 
modulate their mRNA targets, especially in mammalian systems. The validity of 
these predictions therefore needs to be confirmed experimentally. Numerous 
experimental studies have been carried out to validate the bioinformatics 
predictions using techniques such as luciferase reporter. 
 
  
1.8 Stroke and miRNAs 
miRNAs have enormous potential as ideal biomarkers of stroke. A recent study on 
miRNA expression profiling in stroke patients provided evidence for miRNAs as 
potential biomarkers in diagnosis and prognosis of ischemic stroke [253]. Laterza 
et al. [254] demonstrated that there are detectable changes in miRNA expression in 
plasma in response to brain damage. miR-124 is a brain specific miRNA that has 
been detected in plasma after MCAo. miR-218 has been found to be brain specific 
[255, 256], whereas miR-342 and let-7e have been reported to be expressed in 
primary cortical neurons [256]. There is also evidence that miRNA expression 
changes during stroke progression [257, 258]. Numerous miRNAs have been 
reported to be involved in the pathophysiological effects triggered upon stroke 
including enhanced glutamate induced neurotransmission, calcium toxicity, 
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formation of free radicals and nitric oxide, mitochondrial dysfunction, 
inflammation, edema, apoptosis and other forms of cell death. 
 
Upon onset of cerebral ischemia, extracellular levels of glutamate increase 
dramatically [259]. NMDA receptor and post synaptic density 95 (PSD95) 
mediated synaptic signalling was reported to be involved [260]. miR-125, -135, -
320, and -327, have been demonstrated to target PSD95 [255, 261, 262] and 
postulated to play a role in NMDA receptor signalling [263]. In another study, 
miR-181b was reported to suppress a subunit of ionotropic AMPA glutamate 
receptor (GRIA2), which is involved in rapid fast excitatory neurotransmission 
[264]. GRIA2 is an essential component in synaptic plasticity development and the 
formation of dendritic spines [265]. miR-9, a brain-specific miRNA, seems to 
regulate the extracellular glutamate concentration which may modulate the degree 
of excitotoxicity in neuronal cells during stroke [261, 266]. miR-125b was 




-dependent pathological events are critical targets in the treatment of stroke. 
Six miRNAs (miR-25, -92, -124a, -290, -374 and -494) have been found to target 
genes encoding visinin-like 1 protein (VSNL1) [97], a neuronal calcium sensor 
protein which is found in the cerebellum. The VSNL1 protein is a novel and 
known biomarker for stroke. It has been found in the cerebrospinal fluid of rats 




iNOS and nNOS play critical roles in neurodegeneration, whereas eNOS regulates 
the cerebral blood flow and protects neurons against any insult [267]. NO reacts 
with a superoxide anion to form peroxynitrate which contributes to oxidative 
damage following glutamate excitotoxicity events. Enhancing the activities of 
miR-221 and -222 indirectly suppressed the protein expression of eNOS [268] in 
Dicer siRNA-transfected cells [269]. miR-221/222 targeting eNOS may be a 
possible mechanism involved in the ischemic cascade. A further study has reported 
that the overexpression of miR-146a could suppress the expression of 
lipopolysaccharide (LPS)-induced NO and iNOS [270]. 
 
Cyclooxygenase 2 (COX2) is a validated target of miR-101 [271]. COX2 is 
involved in the generation free radical species in the arachidonic acid pathway. 
Studies have shown that COX2 is readily induced in neuronal cells during cerebral 
ischemia. 
 
Mitochondrial dysfunction can cause cell injury and cell death due to energy 
failure. miR-1 targets insulin-like growth factor (IGF) which is a functional 
inhibitor of apoptosis due to mitochondrial dysfunction and cytochrome-c release 
[272, 273]. Also, miR-1 has been shown to be up-regulated in cardiomyocytes in 
response to oxidative stress or during hyperglycemia [274, 275]. miR-21 that is 
known to play an anti-apoptotic role in U87 glioma cells [276] has also been 
shown to attenuate apoptosis by targeting FAS-ligand [277]. Furthermore, recent 
evidence indicated that miR-21 can protect neurons from apoptosis during cerebral 
ischemia, by targeting FAS-ligand [278]. Other miRNAs such as miR-29b, -15a 
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and -16 have also been demonstrated to enhance apoptosis by suppressing the anti-
apoptotic BCL2 [279, 280]. let-7a has been reported to target caspase-3 [280]. Pro-
apoptotic protein BIM has been shown to be targeted by the miR-17-92 cluster, 
miR-181a and miR-25 [281-283]. miR-497 has been reported to be involved in 
apoptosis following OGD [284]. It targets anti-apoptotic protein, BCL2 and 
BCL2L2/BCLW (BCL-2-like protein 2). miR-200c has also been shown to induce 
FAS-mediated apoptosis by targeting FAS-associated protein-tyrosine phosphatase 
1 (FAP1) [285].  
 
Autophagic cell death is also frequently associated with ischemia [286] and there 
are known markers for autophagic death, such as Beclin-1 and microtubule-
associated protein1 light chain 3 (LC3). They have been found to interact with pro-
apoptotic proteins, such as BCL2 and BCLXL (B-cell lymphoma-extra-large). 
Hence, miRNAs targeting these proteins might be of interest in cerebral ischemia 
[54]. 
 
Inflammation is one of the main pathways for secondary neuronal death in cerebral 
ischemia [63, 64]. Tili et al. [287] reported that overexpression of B cells in the 
transgenic miR-155 mouse model (Eμ-miR-155) increased the level of serum 
TNFα, suggesting a possible function for miR-155 in modulating inflammatory 
markers like TNFα. miR-146a plays a critical role in a feedback mechanism upon 
extensive inflammation following induction by IL1ß. Here, an increased level of 
miRNA-146a was found to inhibit the release of IL8 and RANTES (Chemokine 
(C-C motif ligand 5) [288]. In addition to these, miR-106a that targets 
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interleukin10 (IL10), an anti-inflammatory cytokine [289], miR-21 that targets 
MMP inhibitors, such as reversion-inducing-cysteine-rich protein with kazal motifs 
(RECK), tissue inhibitor of metalloproteinase 3 (TIMP3) [290] and miR-181b that 
targets TIMP3 [291] have been found to be useful in the study of cerebral 
ischemia.  
 
Harris et al. [292] have shown that miR-126 expressed in endothelial cells targets 
VCAM1 expression, and a loss-of-function of miR-126 enhances TNFα-stimulated 
VCAM1 expression and leukocyte adherence to endothelial cells. Also, an 
important inflammatory marker, IL6 was reported as an enhancer of let-7a 
expression which in turn promotes cell survival by increasing the phosphorylation 
of signal transducers and activators of transcription-3 (STAT3) [293].  
 
Furthermore, cerebral edema, a consequence of stroke, is considered to be 
mediated via water channels known as Aquaporins (AQP). Recently, Sepramaniam 
et al. [294] reported that miR-320a brings about down-regulation of AQP 1 and 4 
which are highly expressed in ischemic brain. 
 
 
1.9 Target prediction for various aspects of cerebral ischemia 
With the availability of bioinformatics tools such as Microcosm, TargetScan, 
miRGen, miRNA.com and RegRNA, a correlation between miRNAs and target 
mRNAs can be predicted. A single miRNA could target several mRNAs which 
may potentially act as regulators that modulate various genes in the inflammatory 
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cascade of stroke. For instance, MMP9 that is involved in inflammatory response 
of ischemic cascade is also known to act as the indicator for the progression of 
ischemia. It has been reported to be upregulated upon acute ischemia and upon 
administration of rt-PA [295, 296]. Increased expression of MMP9 is also 
associated with the hemorrhagic transformation of ischemia [151]. Hence, 
identifying miRNAs that could regulate MMP9 levels could be useful therapy for 
stroke. Furthermore due to the complex network of interaction between miRNAs, it 
is highly likely that hundreds of miRNAs are dysregulated in ischemic stroke. 
Unfortunately, there is still a lack of extensive miRNA profiling data for cerebral 
ischemia which would serve as a platform for target identification in stroke. 
Nevertheless, a database search performed to examine at the miRNAs targeting 
inflammatory markers showed that majority of them are evolutionarily conserved 
across different species, and some even showed conservation between vertebrates 
and invertebrates [222, 223, 297, 298].  
 
 
1.10   miRNAs as biomarkers for cerebral ischemia 
The expression of miRNAs always precedes the expression of genes, synthesis of 
proteins as well as the induction of biochemical pathways involved in 
inflammation and cell death. Thus, miRNAs could appear as very early, stable, 
specific and sensitive blood borne biomarkers for stroke. Tan et al. [253] recently 
presented miRNA expression profiling in stroke patients and proposed that 
miRNAs could be useful biomarkers in the diagnosis and prognosis of ischemic 
stroke. There are also reports supporting temporal changes in the expression of 
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miRNAs during stroke progression [299] as well as specific expression patterns at 
different regions of the brain [300, 301]. 
 
Also, serum miRNAs have been shown to be useful biomarkers in diagnosis of 
pathological conditions [302-305]. Laterza et al. [254] reported that some 
measureable changes in the expression of miRNA as a response to brain damage. 
For instance, miR-124 known as a brain specific miRNA has been identified in 
plasma after ischemic stroke.  
 
The discovery and identification of specific miRNAs as important modulators in 
response to ischemia has revealed a new avenue in clinical settings whereby these 
small RNAs could be established as excellent non-invasive disease biomarkers.  
 
 
1.11    miRNAs as potential therapeutic targets for stroke 
Recently, miRNAs have been identified as potential therapeutic agents against 
diseases such as cancer [306, 307], type 2 diabetes [308, 309], and hyperlipidemia 
[310]. Thus, it is tempting to suggest that brain specific miRNAs could be 
exploited as potential therapeutic agents against stroke. 
 
Antisense oligonucleotide technology to repress and inactivate endogenous 
miRNAs, administration of exogenous siRNA, inhibitor or precursor miRNAs 
could be used to replace or increase the effect of miRNA in an in vivo system. 





oligonucleotides, has been found to be more stable and safer to use [311]. Thus it 
may be possible to use anti miRNAs or precursor miRNAs, to regulate their 
various targets and possibly bring about a beneficial outcome in stroke. 
 
Hence, innovative approaches could be further developed so that they can be 





















1.12 Objectives of study 
1. As there is still no beneficial biomarker and/or therapeutic target for stroke, it is 
important to identify new biomarkers and/or therapeutic targets of stroke from 
ischemic brain tissues and blood samples.  
2. It is essential to first understand the roles of stroke-associated genes in the 
pathogenesis of ischemic stroke in a laboratory setting and later translate the 
results into a clinical setting (bench to bedside applications).  
3. To understand the progression of ischemic stroke from the onset until the 
recovery phase, miRNA profiling in animal MCAo models at different 
reperfusion time points will be useful. Hence, it is important look at the 
changes in miRNAs expression under different reperfusion times.  
4. An NMDA agonist, MK801 which is known to bring about recovery of 
cerebral ischemia in rats will be used in the MCAo models. The corresponding 
changes in protein and miRNA expression in these models will be examined 
with the hope of identifying important molecules that are associated with stroke.   
5. Identifying differences and similarities in miRNA expression between suture 
and embolic models could provide a better understanding of the reasons for 
repeated failures in translating laboratory findings into clinical discoveries.  
6. The embolic model will be established to enable the study to be extended to 
include the implications of rt-PA therapy in miRNA expression.  
7. Identifying potential miRNAs which could be used in stroke therapeutics and 
studying the implications of modulating at least one of them in in vivo stroke 
models. The implications of the miRNA will be studied in both suture as well 












2.1.1 Animal procedure and anaesthesia 
2.1.1.1 Animal  
Male Sprague-Dawley and Wistar (~270 to 320g) rats were obtained from the 
Laboratory Animal Centre (National University of Singapore, Singapore) and 
maintained on an ad libitum intake of standard laboratory chow and drinking 
water. All animals were handled according to the guidelines given by the Council 
for International Organization of Medical Sciences on animal experimentation 
(WHO, Geneva, Switzerland) and the National University of Singapore 
(IACUC/NUS) guidelines for handling laboratory animals. Total number of animals 
used for this work was 695 of which 506 were used for middle cerebral artery occlusion. 
 
2.1.1.2      Anesthesia 
Ketamine       75mg/kg  
Xylazine       10mg/kg 
These were dissolved in sterile NaCl (0.9%) and used to anesthetize the rats. 
 
2.1.2      Buffers and solutions 
2.1.2.1      Tetrazolium-blue stock solution 
Tetrazolium-blue     0.4g    
DMSO       5ml  
Deionized water     95ml 




2.1.2.2 2,3,5-triphenyltetrazolium chloride 2% w/v (TTC)  
2, 3, 5-triphenyltetrazolium chloride (Sigma) 1g 
Dissolved in sterile NaCl (0.9%) to a final volume of 50ml. 
 
2.1.2.3 Phosphate-buffered saline (PBS; 1X) 
NaCl       8g 
KCl       0.2g 
Na2HPO4.2H2O     1.4g  
KH2PO4      0.24g  
These were dissolved in 1l of sterile, deionized water and the solution was adjusted 
to pH7.4. 
 
2.1.2.4  2-(N-Morpholino) ethanesulfonic acid (MES) stock buffer (12X) 
MES free acid monohydrate    1.2M 
MES sodium salt     0.89M   
This solution was made up to the desired volume with deionized water and 
sterilized using a 0.22 m filter. It was kept at 4  C and protected from light. This 
solution was discarded when it turned yellowish in colour. 
 
2.1.2.5 Trichloroacetic acid (60%) 
Trichloroacetic acid     60g 
Trichloroacetic acid was dissolved in sterile, deionized water and adjusted to a 




2.1.2.6 Evans blue (2% in 0.9% NaCl) 
Evans blue      2g             
Evans blue was dissolved in sterile, deionized NaCl (0.9%) to a final volume of 
100ml. 
 
2.1.3     Isolation of RNA from brain tissues 
2.1.3.1     Ethanol 
Ethanol (75  v v) was diluted in sterile, deionized water and stored at 4  C. 
 
2.1.4    Isolation of RNA from whole blood 
2.1.4.1    NaCl (5M) 
NaCl        2.922g  
NaCl dissolved in sterile, deionized NaCl (0.9%) to a final volume of 10ml. 
 
2.1.4.2 Wash 1 : Ethanol (70%) : Denaturation Solution (30%) 
EtOH (100%)       24.5ml 
Denaturation solution     10.5ml 
 
2.1.4.3 Wash 2 : Ethanol (80%) : NaCl (50mM) 
Ethanol (100%)       56ml 
NaCl (5M)         0.7ml 





2.1.5   Denaturing agarose gel electrophoresis 
2.1.5.1   MOPS running buffer (10X) 
Morpholinopropanesulfonic acid (MOPS, pH7.0)   0.4M  
Sodium acetate     0.1M   
EDTA (pH 8.0)     10mM   
 
2.1.5.2 Deionized formamide 
Formamide (500ml) was stirred with 500mg of Dowex XG8 bed resin for 1hr 
followed by filtration via Whatman No. 1 paper. Deionized formamide was stored 
at room temperature and protected from light. 
 
2.1.5.3 Formaldehyde 
Formaldehyde (37% v/v) was prepared and stored at room temperature. 
 
2.1.5.4 Ethidium bromide 
Ethidium bromide was dissolved in deionized water (10mg/ml) and stored at room 
temperature, away from light.  
 
2.1.5.5 RNA loading buffer 
Glycerol (50% v/v)     2.5mg 
Bromophenol blue (0.4% w/v)   3ml   
EDTA (pH 8.0)     1mM   




2.1.5.6 RNA sample buffer  
Deionized formamide     10µl   
Formaldehyde 37%     3.5µl   
MOPS running buffer  (10X)    2µl  
RNA loading buffer     1µl   
 
2.1.6 RNA polyacrylamide electrophoresis 
2.1.6.1 TBE running buffer (10X) 
Tris base       0.9M   
Boric acid      0.9M   
EDTA (pH 8.0)     0.02M   
Dissolved in deionized water and made up the volume to 1l.  
 
2.1.6.2 Small RNA sample buffer  
Deionized formamide     10µl   
TBE running buffer (10X)    2µl   
RNA loading buffer     3µl   









2.1.7 Agilent RNA 6000 Nano kit 
RNA Nano chip  
Agilent RNA 6000 Nano gel matrix 
Agilent RNA 6000 Nano marker  
Agilent RNA 6000 ladder 
RNA Nano dye concentrate 
Electrode cleaner 
Spin filters 
The individual components for the set up and running of the bioanalyser were 
available as the Agilent RNA 6000 Nano kit. Upon arrival of the kit, the Agilent 
RNA 6000 Ladder was heat denatured for 2min at 70  C and cooled down 
immediately on ice. It was stored as 2 l aliquots in RNase free vials at -70  C 
 
2.1.8 Oligonucleotide microarray 
2.1.8.1 Affymetrix® mRNA microarray  
2.1.8.2 RLT buffer 
RLT buffer (Qiagen)     1ml  
β-mercaptoethanol (14.3 M)    10µl   
This solution was prepared just prior to use and is stable at room temperature for 1 
month. 
 
2.1.8.2.1  Fragmentation Buffer (5X) 
KCH3COO      500mM  
Tris-acetate (pH8.1)     200mM  
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Mg(CH3COO)2     150mM  
This solution was made up to the desired volume with DEPC treated water and 
sterilized using 0.22 µm filter. It was aliquotted and kept at room temperature. 
 
2.1.8.2.2 Hybridization buffer (2X) 
MES stock buffer (12X)    0.1M   
NaCl       1M   
EDTA       0.02M   
Tween 20      0.1% v/v   
This solution was made up to the desired volume with autoclaved deionized water 
and sterilized through a 0.22 m filter. It was kept at 4  C and protected from light.  
 
2.1.8.2.3 Non-stringent wash buffer (Wash buffer A) 
NaCl       0.9M  
NaH2PO4      0.06M   
EDTA       0.006M  
Tween 20      0.01% v/v   
The solution was made up to the desired volume with deionized water and 
sterilized via a 0.22 m filter. It was kept at 4  C and protected from light.  
 
2.1.8.2.4 Stringent wash buffer (Wash buffer B) 
MES stock buffer (12X)    0.1M  
NaCl       0.1M   
Tween 20      0.01% v/v 
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This solution was made up to the desired volume with deionized water and 
sterilized via a 0.22 m filter. It was kept at 4  C and protected from light.  
 
2.1.8.2.5 MES Stain buffer (2X) 
MES stock buffer (12X)    0.1M   
NaCl       1M   
Tween 20      0.05% v/v 
This solution was made up to the desired volume with deionized water and 
sterilized via a 0.22 m filter. It was kept at 4  C and protected from light. 
 
2.1.8.2.6 Goat IGG stock 
The antibody stock (10mg ml) was resuspended in 5ml P S and kept at 4  C. 
 
2.1.8.3      Illumina® mRNA microarray  
2.1.8.3.1 Reverse transcription master mixture (for 20μl reaction) 
T7 Oligo(dT) primer     1µl   
First strand buffer (10X)    2µl    
DeoxyNTP mixture     4µl 
RNase inhibitor     1µl   







2.1.8.3.2 Second strand master mixture (for 100μl reaction) 
RNase free water     63μl  
Second strand buffer (10X)    10μl   
DeoxyNTP mixture     4μl   
DNA polymerase     2μl   
RNase H      1μl   
Prepared and kept on ice. 
 
2.1.8.3.3 In Vitro Transcription (IVT) master mixture (for 25μl reaction) 
T7 Reaction buffer (10X)    2.5μl   
T7 Enzyme mixture     2.5μl   
Biotin-NTP mixture     2.5μl   
 
2.1.8.3.4 Hybridization mixture  
Hybridization E1 buffer    187.5μl   
Formamide      112.5μl   
 
2.1.9 miRNA microarray 
2.1.9.1 μParaflo™ miRNA microarray platform 
2.1.9.1.1 6X SSPE buffer 
NaCl       0.90mol/l  
Na2HPO4      60mmol/l  
EDTA (pH 6.8)      6mmol/l   
Formamide       25% v/v  
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2.1.9.2 Real-time PCR 
2.1.9.2.1 Reverse transcription master mixture 
Reverse transcription buffer (10X)   1µl   
MgCl2 (25mM)      2.2µl   
DeoxyNTPs mixture (2.5mM)   2µl   
Random hexamers (50µM)    0.6µl   
RNase inhibitor (20U/µl)    0.2µl 
MultiScribe
TM
 reverse transcriptase (50U/µl)  0.25µl 
RNase free water     1.75µl 
The individual components were obtained from the Taqman reverse transcription 
kit (Applied Biosystem, Caelsbad, CA, USA). 
 
2.1.10 Stem-loop real-time PCR  
2.1.10.1 Reverse transcription master mixture for Taqman® miRNA assay  
Reverse transcription buffer (10X)   1.5µl   
DeoxyNTPs mixture (100mM)   0.15µl   
RNase inhibitor (20U/µl)    0.19µl 
MultiScribe
TM
 reverse transcriptase (50U/µl)  1µl 
RNase free water     4.16µl 
The individual components for the miRNA reverse transcription mixture were 
obtained from the Taqman miRNA reverse transcription kit (Applied Biosystem, 





2.1.10.2 Reverse transcription master mixture for 18S TaqMan® assays 
Reverse transcription buffer (10X)   1µl   
MgCl2 (25mM)      2.2µl   
DeoxyNTPs mixture (2.5mM)   2µl   
Random hexamers (50µM)    0.6µl   
RNase inhibitor (20U/µl)    0.2µl 
MultiScribe
TM
 reverse transcriptase (50U/µl)  0.25µl 
RNase free water     1.75µl 
 
2.1.11 Isolation of proteins 
2.1.11.1 Working colour reagent  
100 parts of colour reagent A mixed with 1 part colour reagent B (GE Healthcare). 
Each individual assay requires 1ml of working colour reagent. Working colour 
reagent can be stored at 4 to 8ºC for up to one week or as long as the optical 
absorbance (A480) of the solution remains below 0.025 at 480 nm. 
 
2.1.11.2 Lysis buffer 
Urea       7M  
Thiourea      2M    
CHAPS (USB Corporation, Cleveland, USA) 2% w/v  
IPG Buffer pH 3-10 NL    0.5% v/v   
Dithiothreitol (DTT) (Bio-Rad, USA)  65mM   
Protease inhibitor      1% v/v   
Nuclease mixture     1% v/v   
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The components of the lysis buffer were purchased from GE Healthcare, UK 
unless otherwise stated.  
 
2.1.12 Two-dimensional gel electrophoresis 
2.1.12.1 PAGE gel preparation (12.5%) 
H2O        2.75ml   
1.5M Tris-HCL pH8.8 (from 4  C)   1.63ml   
Acrylamide (40%)      2.03ml   
SDS (10% w/v)      65µl   
APS (10% w/v)      43µl   
TEMED       4µl   
 
2.1.12.2 Equilibration buffer 
Urea       6M    
Tris-HCl (pH 8.8)     75mM   
Glycerol      30% v/v   










2.2 Methods  
2.2.1 Animal models 
2.2.1.1 Surgical manipulation and neurological measurements in animal 
models 
2.2.1.1.1 Transient focal middle cerebral artery occlusion (intraluminal  
                 filaments or suture method) 
Adult Sprague-Dawley/Wistar rats were anesthetized intraperitoneally with 
200µl/100g weight of ketamine and xylazine (section 2.1.1.2). The animal was 
considered sufficiently anesthetized when there was a complete loss of pedal 
reflex. The body temperature of the animal was maintained by placing the rat on 
the Right Temp Homeothermic Warming System set at 37±0.5°C (Kent Scientific 
Corporation, Torrington, CT). The region around the neck of rat was also shaved 
and its fur was cleaned.  
 
The left Middle Cerebral Artery (MCA) was temporarily occluded using a „suture‟ 
model of focal ischemia described by Longa et al. [312] (Figure 2.1A). In brief, a 
skin incision was made from the petrous bone to the scapula and the neck muscles 
were dissected to gain access to the common carotid artery (CCA). The CCA, the 
origin of internal carotid artery (ICA), the external carotid artery (ECA), the 
occipital artery (OA), and the superior thyroid artery (STA) were then exposed 
(Figure 2.1B). OA and STA were cauterized using Aura 20 watt bipolar 
electrosurgical coagulator (Kirwan Surgical Products, Inc., Massachusetts, USA). 
The bifurcation of the ICA and the ICA was dissected carefully as close to its 
entrance to the skull as possible. The pterygopalatine artery (PPA) that is proximal 
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to the skull was ligated using 5/0 Silk Black, (B.Braun, Melsungen, Germany). The 
ECA was also ligated as proximal as possible but still proximal to its branching 
(Figure 2.1C). Microvascular clips (World Precision Instruments, Inc. Sarasota, 
FL) were applied to the proximal side of CCA and ICA.  
 
The origin of the ECA was tied loosely with 5/0 Silk Black, and an incision was 
made in the ECA (Figure 2.1D). A 4/0 silicon rubber-coated monofilament 
(Doccol Corporation, CA, USA) was carefully inserted into and through the lumen 
of ECA, the stump of ECA was tightened together with the monofilament inside 
and the clip on ICA was removed. The monofilament was further introduced 
carefully into ICA until it was wedged intracranially, which was normally about 
17mm from the bifurcation (Figures 2.1E) and the clip on CCA was released. After 
60min, a clip was applied to CCA again and the suture was gently pulled through 
the ligation (to allow reperfusion to take place) and the ligation on ECA stump 









































(B)                                                           (C) 
  
(D)                                                            (E)         
  
Figure 2.1: Diagrams of middle cerebral artery occlusion (suture method MCAo) 
procedure (A) The extracranial and intracranial vascular relations exploited in the 
„suture‟ model of transient MCAo. Vessel sizes have been enlarged for clarity and 
cervical dissection is shown on the left. Mid- middle; a- artery; Com- common; 
Ext- external and Int- internal. Adapted from [312]. (B) Dissection and exposure of 
common carotid artery (CCA), external carotid artery (ECA), the glomus 
caroticum and the vagus nerve. (C) The external carotid artery (ECA) was ligated 
as distal as possible. (D) Incision was made on the stump of the ECA. (E) The 
silicon coated suture was introduced into ICA until it was wedged intracranially, at 






2.2.1.1.2 Transient focal middle cerebral artery occlusion (embolic method) 
Wistar rat was anesthetized and prepared for surgery as described in section 2.1.1.2. 
The body temperature of the animal was maintained at 37±0.5°C on the Right 
Temp Homeothermic Warming System (Kent Scientific Corporation, Torrington, 
CT). The procedure for creating embolic stroke model was carried out as described 
by Zhang et al. [83, 314-317]. 
 
2.2.1.1.2.1 Preparation for homologous clot  
A day before the embolic MCAo procedure, a rat was anaesthetized. Femoral 
artery was isolated and cannulated and arterial blood was withdrawn into 50cm of 
PE-50 tubing (Polyethylene tubing, ID 0.58mm, OD 0.965mm, Becton Dickinson, 
Haryana, India). The clot was kept in the tube at room temperature for 2hr and then 
stored at 4  C for up to 24hr before use. 
 
2.2.1.1.2.2 Preparation of modified PE-50 catheter 
Modified PE-50 catheter was prepared for injecting the clot to MCA region. 
Firstly, PE-50 tube was cut into 40 to 50cm pieces. Both ends of the tube were held 
with forceps and the middle of the tube was heated up with a flame. The heated 
tube was pulled and tempered to make the tip of the catheter to an outer diameter 
of about 0.35 to 0.40mm. The catheter was then cut in the middle to produce two 






2.2.1.1.2.3 Preparation for injection of the clot 
The PE-50 tubing containing the clot was then cut to 4cm length and connected to 
a 3ml syringe with 23G needle and filled with saline. The clot was transferred into 
a petri dish filled with saline. Subsequently, the clot was aspirated into a 30cm PE-
10 tube connected to a 3ml syringe with 30G needle. The clot was washed by 
moving the clot back and forth (at least 5 times) in the PE-10 tube. Subsequently, 
the PE-10 tube was connected to the modified PE-50 catheter and the clot was then 
transferred into the modified PE-50 catheter. A 1ml syringe with 23G needle was 
pre-filled with saline and then connected to the modified PE-50 catheter with the 
coil-like blood clot and ready for use.  
 
2.2.1.1.2.4 Embolic model middle cerebral artery occlusion (MCAo) 
The initial procedure for the preparation of the embolic model MCAo was similar 
to the intraluminal model MCAo (section 2.2.1.1.1). The modified PE-50 catheter 
(instead of silicon rubber-coated monofilament) was inserted into ECA and the clip 
at the ICA was declamped to allow the modified PE-50 catheter to be gently 
advanced further into ICA about 15mm long from the cut end of the ECA (at this 
point, the tip of the catheter remains at 2 to 3mm from the origin of the MCA).  
The clot was injected gently with 10µl of saline and the catheter was removed from 
the ECA after 5min and the ligature at the cut end of ECA was also tightened. The 











Figure 2.2: Introduction of clot for embolic model MCAo. The catheter placed 
into the external carotid artery (ECA) and advanced into the internal carotid artery 
(ICA) of the rat, with its tip at 2mm from the origin of the middle cerebral artery 
(MCA). A pre-washed clot (black) in the modified catheter is then introduced. 







2.2.1.1.3  Laser-doppler flowmetry  
To evaluate the CBF (cerebral blood flow) reduction during MCA occlusion in 
suture method and embolic ischemia, cerebral cortical perfusion was monitored by 
laser-doppler flowmetry (OxyFlo, Oxford Optronix, UK) during pre-occlusion, 
immediately post occlusion, at the time of reperfusion and before the end point of 
the experiments. The CBF was then expressed as a percentage of the relative flow 
calculated from the pre ischemic baseline levels. On average, 70 to 80% cut off of 
CBF reduction as compared to pre-ischemic baseline levels was observed upon 
occlusion. 
 
In order to measure the CBF, the rats were prepared as described in section 
2.2.1.1.1 and 2.2.1.1.2. The area of the rat‟s head above the skull was shaved and 
its fur was cleaned. An incision was made in the midline of the scalp. The temporal 
muscle was dissected from the bone. The skull of the animal was thinned (1mm in 
diameter) at 2mm posterior and 6mm lateral to the bregma using a high speed 




 Winged Infusion Set 
(Terumo Corporation, Tokyo, Japan) was cut into 5mm in length, glued on the hole 
using Krazy Glue All Purpose (Elmer's Products, Inc, Columbus, OH, USA) and 
fixed firmly using ZAP Zip Kicker PT-29 CA Accelerator (Pacer Technology, CA, 
USA) to allow placement of a 5mm LDF probe (OxyFlo XP Probe, UK) for the 
measurement of CBF. The signals of CBF were digitized using a 4 channel 
Powerlab 4SP (ML760) and recordings were displayed with Chart 5 software 




2.2.1.1.4 Neurological measurement for animal models 
The neurological status of each rat was assessed as described by Bederson et al. 
[318]. The neurological examination was carried out for 5min. In brief, each rat 
was evaluated carefully 24hr post MCAo procedure and a grading scale (0 to 3) 
was employed to evaluate the effects of occlusion (Table 2.1). The neurological 
examination was conducted sequentially. 
 
Firstly, rats were held gently and carefully by the tail, suspended about a meter 
above the floor, and examined for any forelimb flexion. Rats that extended both 
forelimbs toward the floor with no other neurological deficit were graded 0. Rats 
that exhibited any extent of consistent forelimb flexion without any other abnormal 
behaviour were assigned grade 1.  
 
Subsequently, rats were put on to a large sheet of soft, plastic coated paper (counter 
protection paper, Kimberly Clarke). While holding the tail of rats, lateral pressure 
was applied gently at the back of the rat's shoulder until the forelimbs slid for 
several inches and the same way of examination was repeated several times at 
different directions. Rats with severe neurological dysfunction exhibited minimal 
or no resistance consistently to lateral push toward the paretic side, and were 
assigned grade 2.  
 
This group of rats was then permitted to move without any restriction and were 
examined for any circling behaviour. Grade 3 was given to rats which circled 






Normal 0 No observable deficit 
Moderate 1 Forelimb flexion 
Severe 2 Decreased resistance to lateral push 
(and forelimb flexion) without circling 
3 Same behaviour as grade 2, with 
circling 
 
Table 2.1: Neurological evaluation grading system. Adapted from [318] 
 
 
2.2.1.1.5 Histological analysis of brain infarct volume 
At the end of different reperfusion time points (0 to 48hr), the rats were sacrificed 
and their whole brains were sectioned coronally into 2mm slices using an Alto SA-
2160 brain-sectioning matrix (Roboz, Gaithersburg, MD, USA). The slices were 
incubated in 2% TTC stain (section 2.1.2.1 & 2.1.2.2) for 30min and photographed 
[319]. A white unstained area in the brain represented the infarct region. The 
surrounding (surviving) area remained in purple/red. The infarct volume was 
quantified using Image J (http://rsbweb.nih.gov/ij/)  and calculated according to an 
indirect method [320] and expressed in mm
3
, as below: 
VI = ΣA – IA x Thickness of slice / (conversion from pixel to mm2) 
where 
VI  = Infarct Volume 
CA = Contralateral Area 






2.2.1.1.6 Intraperitoneal injection of MK801  
Rats were prepared for surgery and subjected to transient MCA occlusion (suture 
method MCAo) as described in section 2.2.1.1.1. MK801 was injected 
intraperitoneally using a 29G insulin syringe (BD Biosciences, USA)  into each rat 
in the MK801 treatment group, as described by Buchan et al. [321] in three doses: 
2.5μg g body 30min prior to MCAo followed by 1.25μg g body weight at 6hr and 
14hr post occlusion. 
 
2.2.1.1.7 Intravenous administration of rt-PA 
Adult rats were prepared for surgery and subjected to transient MCA occlusion 
(embolic MCAo) as described in section 2.2.1.1.2. rt-PA (Actilyse
®
, Boehringer 
Ingelheim, Germany) infusion was given at different time points (at 3, 4, 5, 6, 8, 
10, 12 and 18hr) post occlusion of MCA. 
 
Prior to intravenous administration of rt-PA, the area on the inner surface of the 
animal‟s left hind leg was shaved and cleaned of fur. An incision was made and the 
left femoral vein was exposed by retracting the skin and muscles. The femoral vein 
was carefully isolated from the femoral artery and ligated, using 5/0 silk sutures, as 
distal as possible from its entrance to the body. A region of the vein ventral to the 
first ligature was closed with a microvascular clip and a second loose ligature was 
placed in between. A small incision was made and a PE-10 catheter (Harvard 
Apparatus Inc., USA) was inserted and held in place by tightening the second 
ligature. The other end of the catheter, which was pre-filled with 10mg/kg rt-PA, 
was connected to a 1ml syringe with 1ml of rt-PA (10mg/kg in sterile saline). The 
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rt-PA was administered with a 10% bolus and 90% continuous infusion over 30min 
as suggested by Fujiwara et al. [322] using a NE-1000 family of programmable 
syringe pumps, (Model NE-1000 Multi Phaser
TM
 (New Era Pump System Inc, 
Farmingdale, NY, USA) at different time points (3, 4, 5, 6, 8, 10 and 12hr) post 
occlusion of embolic stroke. After which, the catheter was carefully removed from 
the vein and the stump was ligated. The incision was closed using 3/0 silk sutures 
after all treatments.  
 
2.2.1.1.8 Intracerebroventricular injection (i.c.v.) of miRNAs 
For intracerebroventricular (i.c.v.) injections of miRNAs, anti-miR-320a 
(5‟UUUUCGACCCAA CUCUCCCGCU-3‟ and pre-miR-320a (5‟-GCUUCGCU 
CCCCUCCGCCUUCUCUUCCCGGUUCUUCCCGGAGUCGGA AAAGCUGG 
GUUGAGAGGGCGAAAAAGGAUGAGU-3‟) (Ambion, Inc) were prepared at 
50pmoles final concentration (leave at room temperature for 10 min) and 




 transfection agent (Ambion, Inc) (left at 
room temperature for 10 min) for 20min before administrating into eMCAo 
animals. miRCURY LNA
TM
 Power Inhibitor hsa-miR-320a (5‟ CGCCCTCTCAA 
CCCAGCTTT 3‟) (Exiqon, Denmark) was also prepared at 50pmoles final 




 transfection agent and 
scrambled miRNAs (Ambion, Inc) were considered as negative control.  
 
Intracerebroventricular injection was performed as previously described by Senn et 
al. [323]. Anaesthetised MCAo rats were placed in a stereotactic frame (David 
Kopf Instrument, Tujunga, USA). 10µl of the miRNA preparations (anti miR-320a/ 
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pre miR-320a/ LNA anti miR-320a/ scrambled miRNAs/ transfection agent) were 
injected into the left lateral ventricle at 3min intervals using a 100µl Hamilton 
micro syringe, with the coordinates of 0.8mm posterior to the bregma, 1.5mm 
lateral to the midline, and 4.5mm ventral to the outer surface of the skull under the 
guidance of a stereotaxic instrument. After the administration of above compounds, 
animals were kept for 10min before removing from the stereotactic frame. 
 
2.2.1.1.9 Concurrent intravenous administration of rt-PA and miRCURY 
 LNA™ Power Inhibitor hsa-miR-320a  
Combination therapy comprising 10mg/kg rt-PA and 0.5 or 0.75nmol of 
miRCURY LNA™ Power Inhibitor hsa-miR-320a (5‟ 
CGCCCTCTCAACCCAGCTTT 3‟) (SEQ ID NO: 1) (Exiqon, Denmark) was 
administered intravenously (concurrently) as mentioned above (section 2.2.1.1.7). 
 
2.2.1.1.10 Determination of BBB permeability 
BBB disruption was determined using Evans blue dye (EB, Sigma Aldrich, USA) 
extravasation as described by Belayev et al. [324] and Awad [325]. After removing 
the suture from animal (reperfusion takes place), 4ml/kg of EB solution (Evans 
blue 2% in saline) was infused intravenously through femoral vein for about 5min. 
After 24hr of reperfusion, the animal was sacrificed and perfused with 250ml of 
saline solution for 15min through the left ventricle to washout the remaining EB 





2.2.1.1.11 Evaluation of Evans blue content  
The brain was then sectioned into ipsilateral and contralateral hemisphere and 
weighed. Subsequently, the respective hemisphere samples were homogenized in 
the 2.5ml of phosphate-buffered saline and 2.5ml of 60% trichloroacetic acid was 
added to precipitate the protein. Samples were vortexed for 2min and centrifuged 
for 30min at 1000xg and left at room temperature for additional 30min. The 
fluorescence of supernatant was measured (excitation at 620nm and emission at 
680nm) using Varioskan Flash (Thermo Fisher Scientific, MA, USA). Calculations 
of EB content were based on external standards (100 to 500ng/ml).    
          
2.2.1.1.12 Assessment of brain tissue swelling  
The TTC-stained brain slices were used to evaluate the percentage of tissue 
swelling of ipsilateral hemisphere (MCAo hemisphere) [320, 326].  
    % tissue swelling = (IH-CH/CH) x 100 
 where   IH = Ipsilateral hemisphere 
            CH = Contralateral hemisphere 
 
2.2.1.1.13 Evaluation of brain water content and edema 
The whole brains were removed after 24hr of reperfusion and separated into the 
ipsilateral hemisphere (IH) and contralateral hemisphere (CH). After wet weight 
measurement, the samples were dried at 80°C until a constant weight was 
achieved. The percentage of brain water content (BWC) for each hemisphere was 




% of BWC = (WW-DW/WW) x 100%[327] 
 Where WW = wet weight 
                   DW = dry weight 
 
The percentage of edema formation in the ipsilateral hemisphere was evaluated 
using the following formula by Gerriets et al. [326] 
% of edema = % of BWCIH - % of BWCCH 
                                   Where IH = ipsilateral hemisphere  
                    CH = contralateral hemisphere 
 
2.2.1.1.14 Collection of brain slices and blood samples  
Whole blood samples collected from the animal via cardiac puncture upon 
euthanasia were immediately mixed with RNAlater
®
 solution (Ambion, Texas, 
USA) to prevent RNA degradation. Usually, 0.5ml of whole blood were mixed 
with 1.3ml RNAlater
®
 solution per tube and stored at -80
o
C until use. Another 
sample of whole blood was stored at 4  C overnight followed by centrifugation at 
14,500rpm for 5min to collect serum and stored at -80
o
C  until use. Ipsilateral and 






 slices) were excised from the animals 
and immediately snap-frozen in liquid nitrogen and stored at -80
o








2.2.2 Gene expression studies 
2.2.2.1 Isolation of total RNA from brain tissue 
Total RNA was isolated by a single-step method using TRIzol reagent (Invitrogen, 
Life Technologies, USA) according to manufacturers‟ instructions.  riefly, the 
samples were homogenized in 1ml of TRIzol reagent per 50 to 100mg of tissue and 
incubated at room temperature for 5min. Chloroform (0.2ml per ml of TRIzol 
reagent) was added to the homogenates and the samples were shaken vigorously 
for 15sec and incubated at room temperature for 2 to 3min. The mixture was 
centrifuged at 14,500rpm for 15min and the aqueous phase was transferred to a 
fresh tube. 3µl of RNase free DNase I was added and the samples were incubated 
in a 37
o
C water bath for 20min.  
 
Total RNA (including small RNA) was precipitated by mixing with 500µl of 
isopropanol and kept at -80
o
C overnight. On the following day, the sample was 
centrifuged at 14,500rpm for 10min and the resulting pellet was washed once with 
1ml of ice-cold 75% ethanol.  The sample was centrifuged at 14,500rpm for 5min. 
The supernatant was discarded and the pellet was dried at 37
o
C for 20min. The 
RNA was dissolved in sterilised DEPC treated water by incubating in a 60
o
C water 
bath for 10min. The concentration and integrity of RNA were determined using 
Nanodrop ND-1000 spectrophotometry (Nanodrop Tech, Rockland, Del), RNA gel 
electrophoresis and the integrity of small RNA species was verified using 





2.2.2.2 Isolation of total RNA from whole blood 
Total RNA (including small RNA) from blood was extracted using Ambion 
Ribopure blood extraction kit following manufacturer‟s protocol (Ambion, Texas, 
USA). Briefly, the sample was centrifuged at 14,500rpm for 5min. The supernatant 
was discarded and 1ml of lysis solution was added and vortexed vigorously to 
obtain a clear solution (If not, samples were separated into 2 tubes and an extra 300 
to 500µl of lysis solution were added and vortexed again).  
 
10µl acetic acid was added and the sample was incubated on ice for 5min. 400µl of 
Acid-Phenol: Chloroform was added. The mixture was vortexed for 30sec and 
centrifuged at 14,500rpm for 5min. The supernatant (~1.2ml) was transferred to 
fresh 15ml tube. 1ml of denaturation solution was added and mixed thoroughly by 
vortexing. 2.7ml of 100% ethanol was added and vortexed until the mixture 
became clear. 700µl of this solution was filtered through filter cartridge followed 
by a short spin. This step was repeated until all solution went through the filter. 
The filter cartridge was washed once with 700µl of Wash 1 (section 2.1.4.2) and 
twice with 700µl of Wash 2 (section 2.1.4.3) and centrifuged at 14,500rpm for 
5min. The filter was transferred into a new labelled collection tube. 100µl 
preheated (75 to 80
o
C) elution solution was added and sample incubated at room 
temperature for 2min and centrifuged at 14,500rpm for 1min. Another 100µl 
preheated (75 to 80
o
C) elution solution was added to the tube and sample was 





The concentration and integrity of RNA concentration were determined using 
Nanodrop ND-1000 spectrophotometry (Nanodrop Tech, Rockland, Del), RNA gel 
electrophoresis and the integrity of small RNA species was verified using 
denaturing gel (15% polyacrylamide) electrophoresis. 
 
2.2.2.3 Formaldehyde agarose gel electrophoresis of RNA 
In order to determine the integrity of the isolated total RNA, ribonucleic acids were 
separated using electrophoresis in agarose gels containing formaldehyde. 0.5g 
electrophoresis grade agarose (1% w/v) was dissolved in 43.5ml of sterile 
deionized water in microwave and cooled down to 60
o
C in a water bath. 5ml of 
10X MOPS running buffer pH 7.0, 1.5ml of 12.3M (37%) formaldehyde and 1µl of 
10mg/ml ethidium bromide (section 2.1.5.4) were added. The molten agarose was 
poured into a horizontal gel-casting tray and an appropriate „comb‟ was inserted 
immediately to create wells for sample loading inside the fume hood and the gel 
was allowed to set. After the gel had set, the comb was removed and the gel on the 
tray was placed into the electrophoresis tank containing 1X MOPS running buffer. 
RNA samples were prepared as follows, prior to loading:  
RNA (300 to 600ng)     2µl      
RNA sample buffer (section 2.1.5.6)   16.5µl    
The samples were incubated at 65
o
C water bath for 10min and loaded into wells of 
gels. The gel was run at 80V for 25min and it was destained in deionized water. 
Migration of RNA bands was documented using an Alphalmager MINI (Cell 




2.2.2.4  Polyacrylamide gel electrophoresis (PAGE) of miRNAs 
In order to determine the integrity of small RNA species, the isolated total RNA 
were separated using denaturing gel (15% polyacrylamide) electrophoresis. 2.82ml 
40% acrylamide/Bis Solution, 29:1 (Bio-Rad Laboratories, Inc, CA, USA) and 
0.75ml 10X TBE were added to 3.6g urea (Sigma Aldrich, USA) and swirled while 
incubating in a 37
o
C water bath until dissolved. 0.95ml deionised water was added 
into the solution after urea had dissolved fully. 37.5µl of ammonium persulfate 
10% w/v (International Biotechnologies, Inc, CT, USA) and 7µl TEMED (N, N, 
N‟, N‟-tetramethylethylenedi-amine) were added to the solution and the mixture 
was quickly poured into a preset gel cassette. An appropriate „comb‟ was inserted 
immediately to create the wells for sample loading. After gel was set, the comb 
was removed and the gel was fitted to a vertical electrophoresis unit which was 
filled with 1X TBE running buffer (section 2.1.6.1). The gel was pre-run for 10min 
at 100V. RNA samples were prepared as follows, prior to loading:  
RNA (300 to 600ng)     2µl     
RNA sample buffer (section 2.1.6.2)   16µl 
The samples were heated up at 95
o
C water bath for 5min and then chilled 
immediately and briefly centrifuged prior loading into wells of the gel. Gel 
electrophoresis was carried out at 100V for about 2hr. Gel was incubated in 5µl of 
EtBr (10mg/ml) in 300ml of deionised water for 15min. Migration of small RNA 






2.2.2.5       Bioanalyzer 
Agilent RNA 6000 Nano kit was used to determine RNA quality of samples used 
for mRNA and miRNA arrays.  
 
2.2.2.5.1 Preparation of gel matrix  
550μl of gel matrix (section 2.1.7) was loaded onto a spin filter and centrifuged for 
10min at 4000rpm.The filtered gel matrix was stored at 4
o
C for up to 1month as 
65µl aliquots.  
 
2.2.2.5.2 Addition of dye to gel matrix 
The RNA 6000 Nano dye was equilibrated to room temperature in the dark, for 
30min prior use. The dye concentrate was vortexed for 10sec and pulsed down. 1µl 
of the RNA 6000 Nano dye concentrate was added to a 65µl aliquot of the filtered 
gel matrix. The components were vortexed thoroughly and visually inspected to 
ensure proper mixing of the gel matric and the dye. The mixture was centrifuged 
for 10min at 14,000rpm and protected from light until use. The gel-dye mixture 
was used within a day.  
 
2.2.2.5.3 Loading of gel-dye mixture and the Nano marker onto the chip 
Prior to the loading of the gel-dye mixture, the RNA Nano chip was assemblied 
onto the chip priming station according to the manufacturer‟s instruction (Agilent, 
USA). Using a plunger-clip system, 9µl of the gel-dye mixture was loaded onto the 
first well labelled „G‟. The plunger was held down for about 30sec by a clip and 
released to observe for pressurization within the wells of the chip. Following which 
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another 9µl of the gel-dye mixture was loaded into the remaining wells labelled as 
„G‟.  The remaining 13 wells (12 samples wells and 1 RNA ladder well) were each 
filled with 5µl of Nano marker (section 2.1.7). 
 
2.2.2.5.4 Loading of RNA ladder and RNA samples onto the chip 
Once the gel-dye matrix and the Nano marker were loaded successfully, the RNA 
ladder and samples were added within the next 5min, in order to prevent 
evaporation of the pre-loaded reagent. Prior to lading, the ladder aliquots were 
thawed on ice and to minimize secondary structures, the RNA samples were heat 
denatured at 70
o
C for 2min. 1µl of the RNA ladder as well as the samples were 
loaded into the respective wells. The chip and its contents were vortexed using an 
adapted vortexer for 1min at 2400rpm. 
 
2.2.2.5.5 Running of the Agilent 2100 bioanalyzer 
The Agilent 2100 bioanalyzer was switched on for about 15min to warm up the 
system. Before the start of each run, the electrodes were cleaned with 350µl RNase 
Zap followed by 350µl RNase free water and air dried for about 10sec. The chip 
loaded with the RNA samples were inserted into the bioanalyzer and the integrity 








2.2.2.6       Oligonucleotide (DNA) microarray  
The oligonucleotide (DNA) microarray was performed using both the Affymetrix
®
 
mRNA microarray platform (Affymetrix
®
, Santa Clara, CA, USA) as described by 
Cher et al. [328] as well as the Illumina
®
 mRNA microarray.  
 
2.2.2.6.1 Affymetrix® mRNA microarray  
2.2.2.6.1.1 cDNA probe preparation 
Total RNA clean-up 
Total RNA (20 to 50µg) isolated from brain tissues was cleaned up using RNeasy 
spin columns (Qiagen, Germany) before cDNA synthesis. The final volume of total 
RNA was made up to 100µl with sterile, deionized water. RLT buffer (350ul) was 
then added into the RNA and transferred into a spin column and centrifuged for 
2min. The eluent was collected and reloaded into the spin column and then 
centrifuged for another 2min. The resultant eluent was discarded and 500µl of RPE 
buffer was added for washing the RNA. The sample was centrifuged for 2min and 
the eluent discarded.  15 to 30µl of RNase free water was added to the column until 
the β-mercaptoethanol had been removed. The sample was centrifuged for 2 to 
3min to elute the RNA. The clean RNA was quantitated spectrophotometrically at 
260nm. 
 
First strand cDNA synthesis 
In order to synthesize the first cDNA strand, the T7-(dT) primer was allowed to 




Total RNA      5µg   
T7-(dT) 24 primer (100pmol/µl)   1µl   
Total volume of 20µl was made up with RNase free water. 
The reaction was incubated at 70  C for 10min followed by pulsing down the 
samples and then kept on ice. Subsequently, the reaction mixture was added to the 
following reagents and incubation was performed at 37  C for 2min: 
First strand cDNA buffer (5X)   4µl   
DTT (100mM)     2µl 
dNTP mixture (10mM)    1µl 
The synthesis was initiated by adding in SuperScript II reverse transcriptase (1 l) 
and sample was incubated at 37  C for 1hr. The reaction was terminated on ice.  
 
Second strand cDNA synthesis 
The synthesis of the second strand cDNA was performed immediately after the 
first strand cDNA synthesis. The following reagents were added to the first strand 
cDNAs: 
5X second strand reaction buffer   30 µl   
dNTP mixture (10mM)    3µl   
E.coli DNA ligase (10U/µl)    1µl     
E.coli DNA polymerase I (10U/µl)   4µl 
E.coli RNase H (2U/µl)    1µl   
RNase free water     91µl   
The reaction mixture was incubated at 16  C (cooling water bath) for 2hr after 
mixing. After this, 2 l (10U  l) of T4 DNA polymerase was added and the 
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reaction mix was further incubated at 16  C for another 5min. The reaction was 
terminated by adding 10µl of 0.5M EDTA. 
 
Clean-up of double stranded cDNA 
There is a two-step procedure to clean up the synthesized cDNA. Firstly, phase 
lock gel (PLG; Qiagen, Germany)-phenol/chloroform extraction was performed for 
the removal of undesired proteins. Secondly, the cDNA was recovered by ethanol 
precipitation. The PLG forms an inert, sealed barrier between the aqueous and 
organic phases of phenol-chloroform extractions. The solid barrier permit more 
complete recovery of the sample (aqueous phase) and minimizes interface 
contamination of the sample. An alternative method, a standard phenol/chloroform 
extraction can be carried out instead of PLG procedure. 
 
The PLG tube was spun at 12,000xg for 20 to 30sec. Phenol: chloroform: isoamyl 
alcohol (162µl) in a 25: 24: 1 ratio saturated with 10mM Tris-HCL (pH 8.0) was 
added to the final cDNA synthesis preparation. The cDNA-phenol/chloroform 
mixture was vortexed briefly and added to the PLG tube and centrifuged at 
12,000xg for 2min. The upper aqueous phase was transferred to a fresh tube. 2.5 
volumes of absolute ethanol was added to the sample and vortexed and centrifuged 
at 12,000xg for 20min. The supernatant was then removed and the pellet was 
washed with 500µl of pre-ice-cold 80% ethanol. The supernatant was discarded 
and the pellet was washed again. The cDNA pellet was resuspended in 12µl of 




Synthesis of biotin-labelled cRNA 
This procedure is essential to produce large amounts of hybridizable biotin-labelled 
RNA targeted by in vitro transcription from bacteriophage T7 RNA polymerase 
promoter. Large quantities of single-stranded nonradioactive RNA molecules can 
be produced within a short incubation time by using T7 RNA polymerase and 
biotin-labelled nucleotides. RNA-DNA hybrids have a higher melting temperature 
than corresponding DNA-DNA hybrids, as a result, single stranded RNA targets 
give higher target avidity and greater sensitivity than DNA probes. The in vitro 
transcription reaction (BioArray, Enzo Diagnostic Inc, USA) was set up as follows: 
Template cDNA     1µg    
Reaction buffer     4µl   
Biotin labelled ribonucleotides (10X)  4µl 
DTT (10X)      4µl 
RNase inhibitor mixture (10X)   4µl   
T7 RNA polymerase (20X)    2µl    
The final volume made up to 40µl with sterile, deionized water.  
The reaction mixture was then incubated at 37  C (water bath) for 4 to 5hr, with 
mixing every 40min. The cRNA was stored at -20  C. 
 
Cleaning up and quantifying in vitro transcription (IVT) products 
The IVT clean-up reaction is important to remove unincorporated NTPs. It was 
performed as described in the section on total RNA clean up. The eluted cRNA 
was quantified using spectrophotometric analysis. As the total cellular RNA was 
the starting material, an adjusted cRNA yield was calculated to reflect carryover of 
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unlabelled total RNA. The following formula was employed to determine the 
adjusted cRNA yield.     
Adjusted cRNA yield = RNAm – (total RNAi) (y) 
       Where      RNAm = amount of cRNA measure after IVT (µg) 
               Total RNAi = starting amount of total RNA (µg) 
                                   y = fraction of cDNA reaction used in IVT 
About 0.6µg/µl of purified cRNA was needed as the minimum concentration for 
hybridization.  
 
Fragmentation of cRNA for target preparation 
The adjusted amount of cRNA was fragmented and the reaction was set up as 
follows: 
Clean cRNA      20µg  
Fragmentation buffer (5X) (section 2.1.8.2.1) 8µl    
RNase free water was added to a final volume of 40µl. 
The final concentration of RNA in the fragmentation mixture can be ranging from 
0.5 to 2 g  l. The full-length cRNA was broken down into 35 to 200bp fragments. 
The fragmentation mixture was incubated at 94  C for 35min and the reaction was 
terminated on ice. The undiluted, fragmented sample RNA was kept at -20  C. 
 
2.2.2.6.1.2 Eukaryotic target hybridization 
The hybridization cocktail for a single probe array-hybridization was prepared as 
follows: 
Fragmented cRNA     15µg   
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Control oligonucleotide B2 (3nM)   5µl   
Eukaryotic hybridization controls (20X)  15µl   
Herring sperm DNA (10mg/ml)   3µl   
Acetylated BSA (50mg/ml)    3µl   
Hybridization buffer (2X) (section 2.1.8.2.2)  150µl   
Sterile deionized water was added to make a final volume of 300µl. 
The frozen stock of 20X GeneChip
®
 Eukaryotic hybridization control cocktail 
(Affymetrix
®) which contains the genes bio , bioC, bioD and cre (codes for 
prokaryotic enzymes) was heated up at 65  C for 5min to resuspend the cRNA 
thoroughly prior aliquotting. These genes serve as hybridization controls when 
mixed with labelled eukaryotic cRNA samples. These controls are spiked into the 
samples to monitor the efficiency of target preparation, hybridization, washing and 
staining steps that have been performed.  
 
The probe array was equilibrated to room temperature immediately prior to use. 
The hybridization cocktail was heated to 99  C for 5min (heat block), whereas the 
probe array was filled with 80 or 200µl for test and whole genome chips, 
respectively. Test chips were first run to determine the quality of the prepared 
cRNA before they were hybridized on the whole genome chip using 1X 
hybridization buffer and incubating at 45  C for 10min with rotation. The 
hybridization cocktail was then transferred to a 45  C heat block and incubated 
again for 5min. Subsequently the cocktail was centrifuged at 13,000xg for 5min to 
separate the insoluble material from the hybridization mixture. The buffer solution 
was removed from the probe array cartridge and filled up with 80 or 200µl of 
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hybridization cocktail supernatant. The probe array was placed in a rotisserie box 
in a 45  C oven and rotated at 60rpm for 16hr. 
 
2.2.2.6.1.3 Washing, staining and scanning 
After 16hr, the hybridization cocktail was removed from the probe array and stored 
at -70  C. The probe array was filled up with 80 or 200 l of  uffer A (section 
2.1.8.2.3). An antibody amplification wash and stain procedure was carried out. 
Streptavidin phycoerythrin (SAPE) staining reagent was prepared and stored in the 
dark at 4  C. The stain buffer was prepared for each probe array as follows: 
MES stain buffer (2X, section 2.1.8.2.5)  600µl  
Acetylated BSA (50mg/ml)    48µl   
SAPE (1mg/ml)     12µl   
Sterile, deionized water    540µl   
 
The stain solution was mixed well and split into two aliquots of 600µl each to be 
used for the first and third staining steps respectively. An antibody mixture for the 
second phase of staining was prepared as follows: 
MES stain buffer (2X, section 2.1.8.2.5)  300µl  
Acetylated BSA (50mg/ml)    24µl   
Normal goat IGG (10mg/ml)    6µl   
Biotinylated antibody (0.5mg/ml)   3.6µl   
Sterile, deionized water    266.4µl   
The fluidics protocols, “Micro1v1” and “EukGE WS2v4” (Affymetrix® 
Microarray Suite 5.0, USA), were chosen to wash and stain the test and whole-
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genome chips, respectively, using the GeneChip
®
 Fluidics Station 400. Towards 
the end of the fluidics protocols, the probe arrays were scanned. 
 
2.2.2.6.1.4 DNA microarray data analysis 
Firstly, a grid was automatically placed over the .dat file demarcating each probe 
cell. One of the probe array library files, the /cif file, was employed by Microarray 
Suite 5.0 to determine the suitable grid size to be used. The alignment of the grid 
was confirmed by zooming on each of the four corners and on the centre of the 
image. If the grid was not aligned properly, the alignment was adjusted by placing 
the cursor on an outside edge or corner of the grid. The cursor image was changed 
to a small double-headed arrow and the grid was adjusted. The software analysed 
the hybridization intensity from the GeneChip
®
 expression probe arrays where data 
from each array were scaled to an average intensity of 800.  
 
The gene expression levels from treated and control samples were compared using 
a set of comparison metrics. Some of the metrics: Increased(I), Decreased (D) 
Marginally Increased (MI), Marginally Decreased (MD) or No change (NC). Only 
the “I” and “D” transcripts level calls were taken into consideration for further 
analysis in all microarray experiments.  
 
The presented fold change values are the mean of 3 independent microarray 
experiments. The raw data were subtracted from the data for normal brains and 




2.2.2.6.2 Illumina® mRNA microarray  
The oligonucleotide (DNA) microarray was carried out according to 
manufacturer‟s protocol (Illumina®, San Diego, CA, USA) using 400ng of total 
RNA. The raw data were subtracted from the data for normal brains and further 
filtered for signal log2 ratio (SLR>+0.5 and <−0.5) and a detection probability 
value of p<0.05. 
 
2.2.2.7.2.1 Reverse transcription to synthesize first strand cDNA 
Firstly, the volume of RNA samples (400ng) was made up to 11μl with RNase free 
water. 9μl of reverse transcription master mixture (section 2.1.8.3.1) was added to 
each RNA samples and mixed thoroughly by pipetting up and down for 2 to 3 
times. This was followed by a brief centrifugation, incubation for reverse 
transcription at 42°C for 2hr and then placing on ice to stop the reaction.   
 
2.2.2.7.2.2 Second strand cDNA synthesis 
80μl of second strand master mixture (section 2.1.8.3.2) was transferred to each 
reaction and mixed thoroughly, placed at 16°C for 2hr and then kept on ice.  
 
2.2.2.7.2.3 cDNA purification 
Prior to the cDNA purification, a minimum of 20μl of RNase free water was 
preheated to 55°C and 250μl cDNA  inding  uffer were added to each sample. 
They were mixed thoroughly by pipetting up and down for 2 to 3 times subjected 
to a spin. The mixture was pipetted immediately, passed through a cDNA filter 
cartridge and centrifuged for about 1min at 10,000xg. The flow-through was 
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discarded and the filter was washed with 500μl wash buffer and centrifuged again 
for about 1min at 10,000xg. The cDNA filter cartridge was then transferred to a 
cDNA Elution Tube and 20μl of 55°C preheated RNase free water was applied to 
the centre of the filter and left at room temperature for 2min and then centrifuged 
for 1min at 10,000xg. The purified cDNA was stored overnight at -20°C. 
 
2.2.2.7.2.4 In Vitro Transcription to synthesize cRNA 
7.5μl of IVT master mixture (section 2.1.8.3.3) was added to each cDNA sample, 
and mixed thoroughly and incubated at 37°C for 4 to 14hr. The reaction was 
stopped by adding 75μl of RNase free water to each sample to bring the final 
volume to 100μl.  
 
2.2.2.7.2.5 cRNA purification 
Prior to cRNA purification, a minimum of 200μl of RNase free water preheated to 
55°C, 350μl of cRNA  inding  uffer and 250μl of 100  ethanol were added to 
the cRNA sample and mixed by pipetting up and down 3 times. The sample was 
then passed through a cRNA filter cartridge, and was centrifuged for about 1min at 
10,000xg. The flow-through was discarded and the cRNA filter cartridge was 
replaced into a cRNA collection tube. The cRNA filter cartridge was washed with 
650μl wash buffer and cRNA was eluted with 200μl 55°C RNase free water. 
 
2.2.2.7.2.6 Assessing cRNA yield and quality (cRNA quantitation) 
The concentration and quality of cRNA solution were determined using Nanodrop 
ND-1000 spectrophotometry (Nanodrop Tech, Rockland, Del).  
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2.2.2.7.2.7 Hybridization with rat DNA chips  
Firstly, the oven (with Hyb Wheel) was preheated to 55°C. cRNA samples 
prepared (0.85µg) were made up to 11.3µl by adding RNase free water. The 
samples were left at room temperature for 10min to fully resuspend cRNA. The 
Hyb mixture 22.7µl preheated to 55°C was added to each cRNA sample. 
Hybridization and washes were performed as recommended by Illumina
®
, Inc 
(USA) for rat Bead Chips.  
 
 
2.2.2.8      Imaging and analysis 
The Beadchip was read and image was scanned using Illumina
®
 BeadArray Reader 
and data was extracted using Illumina
®
 BeadStudio Application and analysis was 




6.6.   
 
 
2.2.2.9       miRNA microarray  
The miRNA array was carried out using both the μParaflo™ miRNA microarray 
platform (version 9.1 Sanger miRNA database) according to Jeyaseelan et al. [329] 
and the LNA-based miRCURY LNA™ arrays as described in Lim et al. [330].  
 
2.2.2.9.1 μParaflo™ miRNA microarray (version 9.1 Sanger miRNA 
database) 
Total RNA (2 to 5µg) which was isolated from the brain tissues and whole blood 
samples  was size fractionated using a YM-100 Microcon filter (Millipore), and the 
94 
 
small RNAs (<300 nucleotides) isolated were 3‟-extended with a poly(A) tail with 
poly(A) polymerase. Two different oligonucleotide tags were ligated to the poly(A) 
tails of the test and control RNA samples for fluorescent dye staining. 
Hybridization was carried out overnight on a µParaflo microfluidic chip by using a 
microcirculation pump [331]. Every detection probe on the microfluidic chip 
consisted of a chemically modified nucleotide coding segment complementary to 
the target miRNA, (from miRBase 9.0; http://microrna.sanger.ac.uk/sequences/) or 
other RNA (control sequences) and a spacer segment of polyethylene, glycol to 
extend the coding segment away from the substrate.  
 
The detection probes were constructed by in situ synthesis with photogenerated 
reagent chemistry. The hybridization melting temperatures were balanced by 
chemical modifications of the detection probes. Hybridization step was performed 
using 100µl of 6X SSPE buffer (section 2.1.9.1.1) at 34°C. Tag-specific Cy3 and 
Cy5 dyes were employed for detection purpose. Hybridization images were 
collected by a laser scanner (GenePix 4000B, Molecular Devices) and a digitizer 
(Media Cybernetics). Data were analyzed by first subtracting the background and 
then by normalizing the signals with a locally weighted regression filter [332].  
 
For 2-colour experiments, the ratio of the 2 sets of detected signals (log2 
transformed, balanced) and probability values of the t test were calculated. 
Differentially detected signals were defined as those with <0.01 probability values.  
The microarray analysis comprised of several steps of sample analyses; including 
normalization, data adjustment, t test/ANOVA, and clustering. The t test was 
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performed between control and test sample groups for each set of experiments, t 
values were calculated for each miRNA, and probability values were computed 
from the theoretical t distribution. miRNAs with probability values lower than a 
critical value (typically 0.01) were chosen for cluster analysis according to a 
hierarchical method (with average linkage and euclidean distance metrics). The 
clustering plot was created using TIGR multiple experimental viewer software 
[333]. 
 
2.2.2.9.2 LNA-based miRCURY LNATM arrays 
LNA-modified oligonucleotide (Exiqon, Denmark) probes for human, mouse and 




miRNA power labelling 
All the components needed are thawed on ice. 500ng of total RNA (included 
miRNA) were used on each array which contains over 1769 capture probes that are 
complementary to human, rat, mouse and related viral sequences from miRBase 
release 11.0 (http://www.miRBase.org). Total RNAs were 3‟-end-labelled with 
Hy3 dye using miRCURY LNA
TM
 Power Labelling Kit (Exiqon). 
Firstly, the master mixture for CIP reaction (volume per reaction) was prepared as 
follows: 
Total RNA (500ng)     2µl   
Spike-in miRNA     1µl   
CIP buffer      0.5µl   
CIP enzymes      0.5µl   
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The components were mixed and pulsed down. 2µl of CIP master mixture was 
aliquoted into 0.5ml PCR tubes containing 2 l of total RNA. The tubes were 
pulsed down briefly and the mixture was incubated at 37  C for 30min and then at 
95  C for 5min on PCR cycler (GeneAmp®, PCR System 9700, Applied 
Biosystems, CA, USA). The tubes were then snapped cool on ice to stop the 
reaction. Secondly, master mixture for labelling reaction (volume per reaction) was 
prepared as follows:  
CIP reaction      4µl   
Labelling buffer     3µl   
Fluorescent label (Hy3)    1.5µl   
DMSO       2µl   
Labelling enzyme     2µl   
The components were mixed and pulsed down. 8.5µl of labelling master mix was 
added into each PCR tubes containing the 4µl CIP reaction. Following this step, all 
the samples had to be protected from light mainly due to the use of fluorophores. 
The labelling reactions were pulsed down and incubated at 16  C for 90min 
followed by 65  C for 15min on PCR cycler.   
 
Array preparation for hybridization  
Hybridization was performed on the MAUI
®
 Hybridization system according to 
manufacturer‟s protocol (Exiqon, Denmark). MAUI hybridization chamber was 
switched on and set at 56  C. The arrays were placed on the pre-heated block for 
5min. The SL mixer was aligned and adhered carefully onto the array slide in the 
jig with the tab facing away from the barcode. MAUI
®
 Gasket brayer was used to 
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press the mixer-slide with moderate pressure to ensure complete adhesion. The 
mixer-slide assembly was then removed from the jig and placed back onto the 56  C 
heated block with the mixer side up. Samples must be loaded to the mixer-slide 
assembly within 30min. 
 
Reagents preparation for hybridization 
12.5µl of RNase free water was added into each labelled reaction products to bring 
the sample volume to 25µl. 25µl of 2X Hyb buffer was added into the sample, 
vortexed to mix and followed by pulsing down. Subsequently, the samples 
(labelled sample   Hyb buffer, 50 l) were denatured at 95  C for 2min using PCR 
cycler with heated lid and then snapped cool on ice for 2 to 15min. The samples 
were spun briefly and heated to 56  C for 5min. Another 25µl of 2X Hyb buffer 
with 25µl of RNase free water was prepared and incubated at 56  C for wetting the 
tips prior to loading the samples to the mixer-slide assembly.  
 
Hybridization 
The pipette tips were pre-wetted with (Hyb + RNase free water) solution. 45µl of 
sample was aspirated (avoid bubbles formation) and loaded carefully. The pipette 
tip was removed from the vent with the plunger depressed and surface of SL-mixer 
+ array was wiped for any excess amount of samples. Adhesive port seals were 
placed directly over both the ports with forcep and pressed down simultaneously to 
seal the ports effectively. The loaded slide-mixer was then placed back onto the 
bay of MAUI mixer (pre-heated at 56  C) and loaded into the chamber slot. The bay 
was covered up with pre-wet humidity chamber and the lid was closed. The mixing 
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chamber was switched on to mode B and the slides were incubated for 16hr at 
56  C. 
 
Preparation of wash buffers  
Wash buffers (A, B and C) were prepared in autoclaved bottles using sterile 
deionized water prior washing steps after 16hr of hybridization at 56  C. 
  Wash buffer A (ml) B (ml) C (ml) 
  Salt buffer (20x) 60 20 2 
  Detergent solution (10%) 12 - - 
  Sterile deionized water 528 380 198 
  Total  600 400 200 
 
Washing and scanning 
After 16hr of hybridization, the slide-mixer assembly was removed from MAUI 
and the slides were washed gently using 400ml of pre-warmed (56  C) buffer A for 
2min. The slides were then transferred to 200ml of buffer B (B1) at room 
temperature for about 2min. Subsequently, they were washed with buffer C 
(200ml) and slides were washed by gentle plunging of the rack for 2min. Finally, 
the slides were dipped in 99% ethanol for about 1min and dried by centrifugation 
(Allegra
TM X-12R Centrifuge,  eckman Coulter, CA, USA) at 800rpm, 25  C for 
5min before proceeding with scanning at 532nm (Hy3) in an InnoScan 700, 
microarray scanner (Innopsys, Carbonne, France) and analysed on Mapix
®
 Version 





2.2.2.10     Microarray data analysis 





6.6. The median intensity (subtracted background 
intensity) for each probe was corrected and the signals with p-value <0.05 for 
Student‟s t-test and ANOVA were considered for further analysis such as 
normalization, data adjustment, t test/ ANOVA analysis and clustering. Statistical 
tests, one way ANOVA and Student‟s t-test (p<0.05), were performed between 
„control‟ and „test‟ sample groups and t values were calculated for each miRNA. p 
values were computed from the theoretical t distribution. miRNAs with p values 
≤0.05 were chosen for cluster analysis. Hierarchical clustering, K-means clustering 
and Principal Component Analysis (PCA) were performed using TIGR MeV 
software (www.tm4.org/mev/) [333]. The clustering using hierarchical method was 
carried out based on average linkage and expressed as Euclidean distance metric. 
miRNA with fold change > 1.5 was taken to be up-regulated and miRNA with fold 
change < -1.5 was taken to be down-regulated significantly. 
 
Prediction softwares used for the analysis were: DIANA MicroT 
(http://diana.cslab.ece.ntua.gr/microT/), TargetScan (http://www.targetscan.org/), 
PicTar (http://pictar.mdc-berlin.de/), Microcosm (http://www.ebi.ac.uk/enright-
srv/microcosm/cgi-bin/targets/v5/search.pl), MiRanda (http://www.microrna.org 
/microrna/home.do) and RegRNA (http://regrna.mbc.nctu.edu.tw/). 
 




6.6. The raw 
data from LNA-based miRCURY LNA
TM
 arrays were first imported into Partek as 
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GPR files. Median intensity was selected for further data processing. Heatmap and 
PCA were plotted for exploratory analysis. Further analysis was performed to get 
differentially expressed miRNAs, their mRNA targets and gene ontology.  
 
2.2.2.11 Pathway analysis 





(Ingenuity system pathway, http://www.ingenuity.com/) and Diana Lab (DNA 
Intelligent analysis, http://diana.cslab.ece.ntua.gr/pathways/) according to the 
tutorials provided by each software, respectively. 
 
2.2.2.12 Quantitative real-time PCR (qPCR) 
Changes in the expression level of a number of genes were quantitated using real- 




 green assays were used in this study. 
 
Gene-specific PCR primers and probes were designed using the PrimerExpress 2.0 
(Applied Biosystems, USA) software on mRNA sequences. The primers were 
designed to yield amplicons of approximately 100bp and were then synthesized by 
Applied Biosystems or Alpha DNA (USA). Ribosomal RNA (18S) was used as an 
internal calibrator. Reverse transcription of total RNA was first performed to 
generate cDNA strands.  
The reverse transcription reaction was set up as follows: 
Reverse transcription master mixture   8µl   
(section 2.1.9.2.1) 
Total RNA (100ng/µl)    2µl   
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For Non Template Control (NTC) reactions, 2µl of RNase free water was added 
into 8µl of reverse transcription mixture instead of DNA template. The reverse 
transcription reaction was carried out as follows: 25  C for 10min, 37  C for 60min 
and terminated by 95  C for 5min followed by 4  C until ready for PCR. TaqmanTM 





Universal Master mixture (2X) 12.5µl   
Primer-probe (20X)     1.25µl  
cDNA       5µl   
RNase free water was added to bring the final total volume to 25µl. 
 
The thermal cycling profile consisted of a denaturation step (95  C for 15sec) and 




 Green assay was carried out as follows: 
SYBR
®
 Green PCR Master mixture                          12.5µl                
Forward primer (300nM)                                           2.5µl               
Reverse primer (300nM)                                            2.5µl             
cDNA                                                                         5µl               
RNase free water was used to bring the final volume to 60µl. 
 
The real-time PCR master mixture reagents and primer-probes were obtained from 
Applied Biosystems (Carlsbad, CA, USA). Gene specific forward and reverse 
primers for SYBR green assays were purchased from 1
st
 Base (Singapore). The 
amplification was carried out at 95  C for 20sec followed by 40 cycles at 95  C for 
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3sec and 60  C for 30sec per cycle. All reactions mentioned above were performed 
in triplicate using the ABI Prism 7000 SDS (Applied Biosystems, CA, USA). 
 
2.2.2.13 Stem-loop real-time Quantitative PCR 
For miRNA detection and quantitation, reverse transcription followed by stem-loop 
real-time qPCRs were performed according to the manufacturer‟s protocols using 
miR-320a-specific primers (Applied Biosystems). All reactions were performed in 
triplicate using the Applied Biosystems 7900 sequence detection system (Applied 
Biosystems, CA, USA). Reverse transcription of total RNA was first performed to 
generate cDNA strands.  
The reaction was set up as follows: 
Reverse transcription master mixture    8µl   
(section 2.1.10.1) 
Total RNA (10ng/µl)      2µl   
 
For NTC, 2µl of RNase free water was used. The stem-loop real-time PCR (18S) 
was carried out as in section 2.2.2.11. The reaction was set up as follows: 
Taqman
TM 
Universal PCR Master mixture (2X)  12.5µl 
(No AmpErase UNGa)   
Taqman miRNA probe      1µl  
cDNA        1.33µl   
Total volume was adjusted to 25µl using RNase free water.   
The real-time PCR master mixture reagents and primer-probes were obtained from 




Reverse transcription of total RNA was carried out separately to generate cDNA 
strands from miRNAs as follows:   
Reverse transcription master mixture   7µl   
(section 2.1.10.2)  
Reverse transcription primer (5X)   3µl     
Total RNA (10ng)     5µl   
 
2µl of RNase free water was used for NTC. The reverse transcription reaction in 
this case was carried out at 16  C for 30min, 42  C for 30min and followed by 85  C 
for 5min and kept at 4  C until necessary. The resultant cDNAs were subjected to 
real-time PCR as below: 
TaqMan
®
 Universal PCR     10µl 
Master Mixture II (2X), no UNG  
TaqMan
®
 Small RNA Assay (20X)   1µl   
cDNA, product from RT reaction   1.33µl   
Total volume was adjusted to 20µl with RNase free water. 
The thermal cycling profile for Taqman assay was set at 50  C for 1sec, 95  C for 










2.2.3       Protein expression studies 
2.2.3.1       Isolation of proteins 
Total protein from the rat brain tissues was extracted by single-step method using 
TriZol reagent (Invitrogen, Life Technologies, CA, USA) according to the 
manufacturer‟s instructions.  
 
2.2.3.2 Protein quantification using method of 2-D Quant Kit (GE) 
Protein concentration was determined using the 2-D Quant Kit (GE Healthcare), 
according to the supplier‟s instructions.  
 
2.2.3.3       Two-dimensional gel electrophoresis 
Rehydration of IPG (immobilized pH gradient) 
The first dimension was run using Immobiline™ DryStrip (7cm, pH 3 to 10 NL, 
GE Healthcare, UK). Reswelling tray was levelled such that it is horizontal by 
loosening or tightening the 2 screws at the end of the tray. The strips were 
rehydrated in DeStreak rehydration solution (GE Healthcare) containing 400μg of 
rat brain sample and 0.8% v/v of IPG buffer pH 3 to 10 NL. The total volume 
(125μl per strip) of rehydration buffer was applied to the strip and left for 16 to 
18hr at room temperature for rehydration. 
 
Isoelectric focusing  
Isoelectric focusing (IEF) was performed on an IPGphor (Amersham Biosciences). 
IPGphor chamber was leveled on the benchtop using the „liquid balance‟. 108ml of 
Immobiline™ DryStrip Cover Fluid added to IPGphor and spread evenly using 
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pipettor. The IPG strips were placed with the gel side facing up, 1 strip into each 
groove of the manifold. 
 
The anode (+) end of the strip was ensured at the top of the manifold and the strips 
at the appropriate marks etched on the manifold. The gels should be straight and 
centred. The pre-cut electrode pads pre-wet with MilliQ water (approximately 
200µl of MilliQ water).  
 
The pads were blotted on filter paper and placed at the end of the strips, with the 
pads directly sitting on the gels (both ends of the strips). Two electrode assemblies 
placed on the pads on the gels side and secured by swiveling the cams into 
position, under the manifold‟s ridge. The strips were covered completed by topping 
up Immobiline™ DryStrip Cover Fluid. The safety lid was closed and Isoelectric 
focusing (IEF) was performed at 23°C according to the programme: 1hr at 200V, 
30min at 500V, 30min at 1000V, 6hr at 5000V and 5000V for 4hr. 
 
Equilibration of strips 
Each strip was then equilibrated at room temperature for 15min in 3.3ml 
Equilibration buffer (section 2.1.12.2) with DTT 1% w/v and a trace amount of 
bromophenol blue, followed by another 15min in the same solution, except that the 







To perform the second dimension, each strip was transferred on top of a 12.5% 
SDS-polyacrylamide gel (section 2.1.12.1) together with the protein molecular 
weight marker (PageRuler™ Plus Prestained Protein Ladder, Fermentas, Canada) 
and sealed with 1% agarose gel containing trace bromophenol blue. Gel 
electrophoresis was carried in Mini-Protean Tetra cell (Bio-Rad) at 60V for 10min 
and then at 100V until the blue dye front runs out (approximately 2hr in total). 
 
2.2.3.4 Colloidal Coomassie staining 
The gels were fixed in ethanol 50% v/v and phosphoric acid 3% v/v overnight. 
After washing thrice for 20min with MilliQ water, the gels were pre-incubated in 
methanol 34% v/v, phosphoric acid 3% v/v and ammonium sulphate 17% w/v for 
1hr. Coomassie blue (G-250) 0.035% w/v was then added to the solution and the 
gel was allowed to stain for 5 days with constant shaking. Then, the stained gels 
were washed with MilliQ water twice for 10min each before scanning 
(ImageScanner II, Amersham Biosciences) 
 
2.2.3.5 2-DGE analysis and MALDI-TOF-TOF 
The gels were analysed using ImageMaster 2D Platinum 5.00 version 1.1.2 
(Amersham Biosciences) for protein spot detection, quantification (based 
on %volume values), and matching. Differentially expressed protein spots from the 
ipsilateral hemisphere animal brain between sham control and MCAo gels 
(biomarkers) or between MCAo and MK801 gels (therapeutic proteins), were 
selected and excised for trypsin (Promega, Madison, MI, USA) digestion using 
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Montage Zip-plates (Millipore Singapore Pte Ltd., Singapore) according to the 
supplier‟s instructions. Subsequently, the peptide extracts were dried on speed-vac 
at room temperature after elution. 
 
The dried extract was redissolved in 1μl of matrix solution (5 mg ml α-cyano-4-
hydroxycinnamic acid (CHCA) in 0.1% TFA, 50% ACN in MilliQ water). All 
solution was pipetted out, spotted onto the MALDI target plate and air-dried. The 
peptides were analyzed by the 4800 MALDI TOF/TOF Analyzer, (Applied 
Biosystems, Framingham, MA, USA). Combined MS-MS/MS searches were 
performed with the selection of the following principles: 
a. Data Processing Software used: Data Explorer v 4.9 (Applied Biosystems) 
b. S/N Ratio in MS/MS mode for peak identification: 10 
c. Search Engine used: MASCOT v 2.1 (Matrix Science Ltd., London, UK) 
d. Mass Error: below 100ppm for MS; below 0.2 Da for MS/MS analysis. 
e. Using NCBInr Protein Database, selecting all entries, using the parent ion mass 
with an error tolerance of 100ppm and MS/MS fragment mass tolerance of 0.2Da. 
f. With carbamidomethylation of cysteine (fixed modification) and methionine 
oxidation (variable modification). 
g. Database used for searching: NCBInr (updated every two weeks). 







2.2.4 Statistical analysis 
miRNA array were compared using single factor ANOVA. All other pairwise 
comparisons were performed using unpaired Student t-test. Differences with 




2.2.5 Chemicals and reagents 
Standard analytical grade laboratory chemicals for the preparation of general 
reagents obtained from Merck, Damstadt, Germany and BDH, Poole, U.K. 
Molecular biology work was performed using molecular biology grade chemicals. 
Sources of specialty reagents used were mentioned in the text while others were 
obtained from: 
 
Alpha DNA, USA 
Random hexamers 
 
Applied Biosystems, USA 
Reagents for reverse transcription and real-time PCR 
 











Boehringer Mannheim, Germany 
Deoxyribonucleotides (dATP, dCTP, dGTP, dTTP and dUTP) 
Taq DNA polymerase 
 
Biorad, Hercules, CA, USA 









Invitrogen, Life Technologies, USA 
Reagents for oligonucleotide microarray cDNA synthesis 
 







RNase free DNase I 
 
Promega, USA 
M-MLV reverse transcriptase 
 








DMEM basal medium 
DTT 
Ethidium bromide 




MES free acid monohydrate 












































The discovery of miRNAs has been a breakthrough in genomic revolution. 
miRNAs have opened a new perspective in the overall understanding of the 
mechanisms involving modulation of gene expression, with an additional level of 
regulatory control. miRNAs play important role in the regulation of protein 
expression by binding to target messenger RNAs (mRNAs) either through partial 
or perfect complementary and target the mRNAs for translational inhibition or 
degradation respectively [217]. It is known that specific miRNAs (in mammals) 
can be identified to regulate various processes such as apoptosis, development, 
proliferation, differentiation, hematopoiesis and exocytosis [334]. These regulators 
have also been found to be differentially expressed in diseases including cancer 
[335, 336], and neuronal disorders [337].  
 
Nearly 20 to 40% of miRNAs in rat primary cortical neurons appear to be 
developmentally regulated, where the expression of miRNAs, for example miR-
128, -191, -323, -324-5p, -326, -329, and -344 have been reported to increase in 
accordance with cortical development [338]. miR-23 and -23b have been identified 
in differentiation and synapse formation [337, 339]. Participation of miRNAs in 
the initiation and progression of cancer pathogenesis has also been extensively 
investigated [340]. Recently, an expression profiling study on the serum miRNAs 
as biomarkers in the diagnosis and prognosis of pancreatic cancer has been 
reported by Liu et al. [341]. Much effort has been invested to identify useful 
biomarkers and invent new and safe therapeutics. For the past decade, miRNAs 
have been shown to be potentially useful as diagnostic and prognostic tools in 
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stroke. Though there are very limited studies available to demonstrate the 
importance of miRNAs in brain pathogenesis, the interest in understanding the 
roles of miRNA in stroke pathogenesis is observed to be steadily increasing since 
the first report by Jeyaseelan et al. [329].   
 
 
3.2 Laser-doppler flowmetry 
Laser-doppler flowmetry (LDF) is an established system used for the real-time 
measurement of microvascular erythrocyte perfusion in tissue. Also, perfusion 
could be referred to as red blood cell flux or microvascular blood flow. Rats (n=6) 
were subjected to transient MCAo for 60min and sacrificed following 24 or 48hr of 
reperfusion. The cerebral blood flow was measured using laser-doppler flowmetry 
(section 2.2.1.1.3). Left MCA occluded rats that exhibited CBF (blood perfusion 
unit) drop by 70 to 80% from the baseline (pre occlusion) using the nylon suture 
insertion method (section 2.2.1.1.1) were included in this study. Upon reperfusion, 
the CBF rebounded to about similar level as pre-occlusion (Figure 3.1). 
 
 
3.3 Neurological outcome  
During reperfusion, the animals were observed for their neurological status and 
scored according to section 2.2.1.1.4. The rats were evaluated carefully 24hr after 
surgery and scored between 0 and 3, relative to the performance of the control 











Figure 3.1: Laser-doppler flowmetry. Cerebral blood flow was measured in the 
area of the left middle cerebral artery (MCAo) at pre occlusion, upon occlusion and 




for all the tests were excluded from the MCAo group. On the other hand, reduced 
forelimb flexion was always observed in rats with decreased resistance to lateral 
push; both forelimb flexion and decreased resistance to lateral push were always 
observed in rats that displayed circling behaviour. The rats that fell under these 
categories (MCAo group) were selected and euthanized to harvest the brain and 
blood samples for further studies. 
 
 
3.4 Infarct volume 
The histological analysis of brain infarct volumes was carried out according to 
method described in 2.2.1.1.5. In brief, after 24 and 48hr of reperfusion, the rats 
were euthanized, the whole brain was harvested and sectioned into 2mm slices and 
incubated in 2,3,5-triphenyltetrazolium chloride (TTC) stain for 1hr. In the 
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unstained whereas healthy tissue was stained in purple (Figure 3.2A). The infarct 
volume was measured and presented in percentage (Figure 3.2B) of infarct volume 
based on sham-operated sample.   
 
 
3.5 miRNA expression in suture method MCAo after 24 and 48hr 
reperfusion 
Ischemic brain slices and blood samples were collected (section 2.2.1.1.14) and 
total RNA was extracted from these brain slices and the blood samples (section 
2.2.2.1 and 2.2.2.2). The concentration and integrity of RNA were determined 
using Nanodrop ND-1000 spectrophotometry (Nanodrop Tech, Rockland, Del), 
RNA gel electrophoresis (section 2.2.2.3). The integrity of small RNA species 
(miRNAs) was verified using denaturing gel (15% polyacrylamide) electrophoresis 
(section 2.2.2.4). 
 
Total RNA from these brain slices and the blood samples of respective rats were 
subjected to miRNA microarray μParaflo™ platform as described (section 
2.2.2.8.1). The analysis of miRNA array was carried out using TIGR multiple 
experimental viewer software.[333]. 114 miRNAs specific for ischemic brain 
tissue were identified. Of these, 106 and 82 transcripts were detected in the 24hr 
and 48hr reperfusion brain samples respectively. Among them 42 miRNAs were 
upregulated whereas 72 miRNAs were down regulated. Only 20 and 25 miRNAs 
















Figure 3.2: (A) Brain slices stained with TTC for sham-operated, 24 and 48hr 
reperfusion MCAo. Purplish red indicates viable cells while white indicates non-
viable cells. (B) Percentage of infarct volume for (i) sham-operated (ii) 24hr 
reperfusion MCAo (iii) 48hr reperfusion MCAo. ** denotes p<0.01 for MCAo 
with 24 and 48hr reperfusion versus sham-operated sample). Sham-operated rats 









Hierarchical clustering of the miRNAs detected in the brain showed 7 distinct 
clusters, A to G (Figure 3.3). Cluster A and D comprised of the very highly 
expressed miRNAs in both the 24 and 48hr reperfusion brain samples. The 
downregulated miRNAs were shown in clusters B and C, while miRNAs in cluster 
F was upregulated in the 24hr samples only. 
 
 
Figure 3.3: Hierarchical clustering analysis of 236 miRNAs expressed in the 
MCAo rat brain and blood. Each miRNA listed was identified in the ischemic 
ipsilateral brain slices as significantly and differentially expressed from that of 




miRNAs in Cluster E included genes that were upregulated at 48hr reperfusion 
time only. The miRNAs categorized in cluster G were found to be downregulated 
at 24hr and became upregulated after 48hr of reperfusion. A distinct expression 
was noticed for miR-138 and -145. Both miRNAs were found to be upregulated at 
both 24 and 48hr. The heatmap and Venn diagram of miRNAs identified in both 




















Figure 3.4: Heatmap for miRNAs detected in both ischemic brain and blood 






Figure 3.5: Venn diagram illustrating the overall view of miRNAs detected in the 
ischemic brain and blood samples. 
 
 
3.6 miRNAs expressed in ischemic blood samples 
Comparison of the miRNA profiling for 24 and 48hr reperfusion from ischemic 
rats showed that the miRNAs in both samples could be divided into 3 categories 
The first category consisting of miRNAs expressed at 24 and 48hr blood samples 
which potentially demonstrated the outcome of acute ischemic damage and 
recovery processes within 24 and 48hr of reperfusion respectively (Table 3.1).  
 
48hr reperfusion blood 
24hr reperfusion blood 
24hr reperfusion brain 
48hr reperfusion brain 
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miRNA 24hr MCAo blood 48hr MCAo blood 
SLR StDev SLR StDev 
rno-miR-290 3.216 0.1095 4.596 0.1789 
rno-miR-451  0.451 0.0486 1.343 0.0901 
rno-miR-195  0.430 0.0949 -2.358 0.6976 
rno-miR-494  0.225 0.1974 2.043 0.1253 
rno-miR-191  -0.236 0.0717 -0.306 0.0994 
rno-miR-320  -0.313 0.0713 0.969 0.0777 
rno-let-7d  -0.338 0.0394 -0.913 0.1097 
rno-let-7a  -0.394 0.0802 -1.377 0.1509 
rno-let-7f  -0.460 0.0771 -2.059 0.1816 
crno-let-7i  -0.554 0.1087 -2.265 0.2608 
rno-miR-185  -0.889 0.0971 -2.878 0.2611 
rno-miR-150  -0.991 0.1221 1.463 0.1470 
rno-miR-107 -1.442 0.1026 -1.573 0.1375 
rno-miR-103 -1.502 0.0983 -1.486 0.0987 
 
Table 3.1: miRNAs that were differentially expressed in the MCAo blood samples 
of rat at 24 and 48hr reperfusion time. Values expressed as signal log ratio (SLR) 
with respective standard deviation. 
 
 
There are 14 miRNAs detected at both time points and among them miR-150, -195, 
and -320 displayed an opposite trend in expression at 24 and 48hr, miR-290 was 
found to be highly expressed, whereas miR-103, -107, and -191 presented almost 
the same level of downregulation at both time points. Transcripts that were 
detected in the 24hr reperfusion blood samples only included -292-5p, -19b, miR-
106b, -16, -122a, and -23a (Table 3.2). Interestingly, an entirely new group of 
miRNAs was found in the 48hr reperfusion blood samples (Table 3.3). The 
presence of these miRNAs could be due to the progression of injury that has led to 












Table 3.2: miRNAs that were differentially expressed in the blood samples of 
MCAo rats reperfused for 24hr. Values expressed as signal log ratio (SLR) with 
respective standard deviation. 
 
 
miRNA 48hr MCAo blood only 
(not in 24hr) 
SLR StDev 
rno-miR-328 2.642 0.3747 
rno-miR-15b 2.553 0.1214 
rno-miR-214 1.925 0.2227 
rno-miR-92 1.809 0.1108 
rno-miR-140* 0.382 0.1091 
rno-miR-17 -0.480 0.0397 
rno-miR-20a -0.685 0.1122 
rno-miR-26a -0.892 0.1139 
rno-let-7c -1.050 0.1250 
rno-miR-26b -2.272 0.3508 
rno-miR-352 -2.315 0.3030 
 
Table 3.3: miRNAs that were differentially expressed in the blood samples of 
MCAo rats reperfused for 48hr. Values expressed as signal log ratio (SLR) with 







miRNA 24hr MCAo blood only 
(not in 48hr) 
SLR StDev 
rno-miR-292-5p 5.083 0.2393 
rno-miR-19b 1.553 0.3448 
rno-miR-106b 0.527 0.0760 
rno-miR-16 -0.264 0.0582 
rno-miR-122a -0.949 0.0903 
rno-miR-23a -1.351 0.1302 
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3.7 miRNAs expressed in ischemic brain tissue samples 
As for ischemic brain samples, 74 miRNAs were detected at both time points 
(Table 3.4). Thirty-two miRNAs were uniquely present in the 24hr samples (Table 
3.5) while only 8 miRNAs were detected exclusively in the 48hr samples (Table 
3.6).  
 
Ten miRNAs (miR-292-5p, -290, -327, -494, -214, -298, -140*, -223, -320, and -
330) were found to be highly upregulated upon ischemia and reperfusion for both 
24 and 48hr. miRNAs expressed in the 48hr reperfusion ischemic brain samples 
included miR-99a, -181 (a, b, and c), -195, -328, -379, and -539. There are several 
miRNAs that were expressed in the 24hr brain samples only, which are miR-16, -
17, -20a, -21, -24, -25, -30a-3p, -34a, -92, -124a, -130a, -132, -134, -151*, -210,-
215, -324-3p, -322, -329, -342, -361, -374, -382, -383, -422b, -433, -451, -497, -
505, -664, let-7d, and let-7f. The let-7 (a, b, c, and e) miRNAs have shown 
interesting expression pattern as they were first downregulated in the 24hr 
reperfusion ischemic MCAo rat brains but became upregulated during the 48hr 
reperfusion. 
 
In this study, the miRNAs that were previously reported as brain-specific and 
enriched transcripts (Table 3.7) were also discovered. In addition to them, 46 new 
transcripts were also identified (Table 3.8). Of these, miR-143 and -206 have been 
previously reported related to adiposity, muscle differentiation and skeletal muscle 
development [342-344]. miR-24 has been found to be expressed in lung and kidney 





24hr MCAo brain 48hr MCAo brain 
SLR StDev SLR StDev 
rno-miR-292-5p 11.622 1.3437 12.214 1.0259 
rno-miR-290  11.232 0.3080 13.612 0.5234 
rno-miR-327  10.405 1.1492 11.952 0.9109 
rno-miR-494  7.259 0.2080 3.103 0.2011 
rno-miR-214  6.835 0.3268 6.135 0.2014 
rno-miR-298  5.411 0.3032 5.723 0.3158 
rno-miR-140*  4.552 0.1046 3.333 0.1142 
rno-miR-223  4.307 0.5156 5.290 0.4514 
rno-miR-320  4.120 0.1667 3.513 0.0899 
rno-miR-330  3.776 0.1222 2.741 0.1396 
rno-miR-206  3.493 0.3745 3.667 0.3543 
rno-miR-129*  2.482 0.0675 2.800 0.0953 
rno-miR-191  2.312 0.0947 1.332 0.0722 
rno-miR-129  2.174 0.2681 2.202 0.1886 
rno-miR-331 1.882 0.0849 2.556 0.2200 
rno-miR-485  1.852 0.1382 1.703 0.1912 
rno-miR-99b  1.444 0.0773 1.349 0.0963 
rno-miR-185 1.199 0.0961 0.621 0.1420 
rno-miR-138  1.085 0.1137 -1.837 0.3175 
rno-miR-324-5p  0.950 0.0985 1.787 0.1816 
rno-miR-409-3p 0.868 0.1227 1.478 0.1256 
rno-miR-107 0.698 0.1094 0.603 0.0977 
rno-miR-103 0.694 0.0986 0.645 0.0795 
rno-miR-145 0.665 0.1169 3.034 0.0982 
rno-miR-100 0.371 0.0715 1.061 0.1257 
rno-miR-125b 0.275 0.0789 1.684 0.1226 
rno-miR-26a -0.269 0.1248 -0.597 0.1081 
rno-let-7a -0.327 0.1008 0.395 0.0903 
rno-miR-7c -0.346 0.1343 0.629 0.1262 
rno-miR-7b -0.432 0.1664 0.705 0.1044 
rno-miR-7e -0.446 0.1234 0.497 0.1186 
rno-miR-125a -0.508 0.1339 0.992 0.1469 
rno-miR-487b -0.515 0.0809 -1.092 0.1087 
rno-miR-143 -0.580 0.1065 -1.308 0.3050 
rno-miR-128a -0.706 0.1253 -1.344 0.1172 
rno-miR-128b -0.711 0.1453 -1.392 0.1038 
rno-miR-352 -0.723 0.1252 -1.482 0.2049 
rno-miR-150 -0.873 0.1377 0.958 0.0758 
rno-miR-222 -0.921 0.1069 -1.347 0.2088 













































Table 3.4: miRNAs that were differentially expressed in the ischemic brain 
samples of rat at 24 and 48hr from the onset of MCAo. Values expressed as signal 







24hr MCAo Brain 48hr MCAo Brain 
SLR StDev SLR StDev 
rno-miR-543 -1.041 0.1118 -1.786 0.3207 
rno-miR-23b -1.080 0.0939 -0.496 0.1127 
rno-miR-221 -1.136 0.1233 -1.276 0.1606 
rno-miR-30c -1.228 0.1308 -1.438 0.1110 
rno-miR-9 -1.329 0.1579 -2.565 0.1250 
rno-miR-7i -1.407 0.1878 -1.781 0.1774 
rno-miR-30b -1.454 0.1420 -2.204 0.0713 
rno-miR-127 -1.482 0.0724 -1.419 0.0747 
rno-miR-29a -1.523 0.1034 -1.756 0.0675 
rno-miR-126 -1.586 0.1033 -1.423 0.1095 
rno-miR-7d* -1.595 0.1973 -1.653 0.2738 
rno-miR-26b -1.708 0.2280 -2.293 0.2420 
rno-miR-301 -1.989 0.3970 -2.837 1.5140 
rno-miR-101b -2.012 0.2014 -2.272 0.7624 
rno-miR-98 -2.089 0.2306 -2.868 0.4331 
rno-miR-139 -2.252 0.1289 -5.012 0.5807 
rno-miR-27b -2.404 0.1461 -1.949 0.2369 
rno-miR-369-5p -2.450 0.4339 -4.238 1.8726 
rno-miR-335 -2.466 0.1323 -4.442 0.9563 
rno-miR-23a -2.515 0.1077 -0.886 0.0978 
rno-miR-148b -3.071 0.4463 -2.680 1.2287 
rno-miR-27a -3.158 0.2022 -2.932 0.2645 
rno-miR-218 -3.308 0.1249 -3.718 0.1803 
rno-miR-424 -3.506 0.6502 -3.474 0.7401 
rno-miR-376b -3.573 0.2936 -4.351 1.7424 
rno-miR-30e -3.816 0.5904 -4.108 0.5475 
rno-miR-101a -3.816 0.6641 -4.211 1.1805 
rno-miR-7 -3.989 0.2748 -5.211 0.7804 
rno-miR-29b -4.238 0.1624 -4.442 0.6446 
rno-miR-137 -4.351 0.2152 -5.322 0.4950 
rno-miR-29c -5.381 0.2261 -5.796 0.4965 
rno-miR-204 -5.506 0.4597 -2.204 0.2287 
rno-miR-376b* -5.644 1.8289 -2.921 1.8631 




miRNA 24hr MCAo brain only 
(not in 48hr) 
SLR StDev 
rno-miR-215 5.355 1.7094 
rno-miR-210 3.246 0.5316 
rno-miR-497 2.452 0.2702 
rno-miR-451 2.246 0.1404 
rno-miR-422b 2.136 0.1331 
rno-miR-324-3p 1.705 0.1473 
rno-miR-322 1.408 0.1540 
rno-miR-124a 1.210 0.1012 
rno-miR-134 1.148 0.1227 
rno-miR-130a 0.954 0.1129 
rno-miR-24 0.883 0.1013 
rno-miR-342 0.794 0.0937 
rno-miR-17 0.748 0.1012 
rno-miR-383 0.669 0.0932 
rno-miR-16 0.372 0.1027 
rno-miR-132 0.252 0.0437 
rno-let-7d -0.355 0.1372 
rno-let-7f -0.355 0.1297 
rno-miR-151* -0.383 0.0869 
rno-miR-361 -0.513 0.0550 
rno-miR-433 -0.591 0.0873 
rno-miR-382 -0.660 0.1111 
rno-miR-329 -0.704 0.1277 
rno-miR-20a -0.839 0.2211 
rno-miR-92 -0.932 0.1407 
rno-miR-34a -1.068 0.1480 
rno-miR-25 -1.102 0.1392 
rno-miR-21 -1.498 0.1345 
rno-miR-30a-3p -1.718 0.3007 
rno-miR-505 -1.905 0.4262 
rno-miR-664 -1.932 0.3944 
rno-miR-374 -2.690 0.4276 
 
Table 3.5: miRNAs that were differentially expressed in the ischemic brain of rat 










48hr MCAo brain only 
(not in 24hr) 
SLR StDev 
rno-miR-328 1.308 0.1543 
rno-miR-99a 1.101 0.1023 
rno-miR-181b -0.842 0.1203 
rno-miR-181a -1.211 0.1212 
rno-miR-539 -1.494 0.2099 
rno-miR-195 -1.523 0.1624 
rno-miR-181c -2.573 0.6683 
rno-miR-379 -2.699 0.4488 
 
Table 3.6: miRNAs that were differentially expressed in the ischemic brain of rat 




miRNA Tissue Specificity References 






















rno-miR-103 primary cortical neuron [338] 
rno-miR-107  
rno-miR-124a brain specific, 
ES cell-specific miRNA 
[347, 348] 
rno-miR-125a brain specific [349] 
rno-miR-125b primary cortical neuron [338] 
rno-miR-127 primary cortical neuron, 
ES cell-specific miRNA 
[338, 348] 
rno-miR-128a  brain specific [338, 349] 
 rno-miR-128b 
rno-miR-130a platelet physiology [346] 










miRNA Tissue Specificity References 
rno-miR-138  primary cortical neuron [338] 
rno-miR-139  brain specific [347] 
rno-miR-140* primary cortical neuron [338] 
rno-miR-143 heart and skeletal muscle [347] 
rno-miR-148b miRNAs from mouse primary, 
cortical neuron 
[338] 
rno-miR-150 spleen specific [350] 
rno-miR-151* primary cortical neuron [338] 
rno-miR-16  primary cortical neuron, 
ES cell-specific miRNA 
[338, 348] 
rno-miR-17  primary cortical neuron [338] 
 rno-miR-191 
rno-miR-206 heart and skeletal muscle [347] 
rno-miR-20a anti-apoptotic [351] 
rno-miR-21 primary cortical neuron, 
ES cell-specific miRNA 
[338, 348, 352] 
 
rno-miR-218 brain specific [338, 347] 
rno-miR-221 primary cortical neuron [338] 
rno-miR-24 lung and kidney, 
ES cell-specific miRNA 
[347, 348] 






rno-miR-29a primary cortical neuron, 
ES cell-specific miRNA 
[338, 348] 
rno-miR-29b ES cell-specific miRNA [348] 
rno-miR-301 primary cortical neuron, 
ES cell-specific miRNA 
[338, 348] 




rno-miR-30e ES cell-specific miRNA [348] 





























miRNA Tissue Specificity References 
rno-miR-34a ES cell-specific miRNA [348] 
rno-miR-352 primary cortical neuron [338] 
rno-miR-7 brain specific [347] 
rno-miR-9 brain specific [338, 349, 353] 
rno-miR-92 ES cell-specific miRNA [348] 
rno-miR-98 brain specific [338, 347] 
rno-miR-99a primary cortical neuron [338] 
rno-miR-99b brain & neuron specific, 
ES cell-specific miRNA 
[338, 348, 349] 
 







rno-miR-126 rno-miR-23b rno-miR-382 
rno-miR-129 rno-miR-25 rno-miR-383 
rno-miR-129* rno-miR-26a rno-miR-409-3p 
rno-miR-145 rno-miR-26b rno-miR-422b 
rno-miR-181a rno-miR-27b rno-miR-424 
rno-miR-181b rno-miR-29c rno-miR-433 
rno-miR-181c rno-miR-30a-3p rno-miR-451 
rno-miR-185 rno-miR-30a-5p rno-miR-485 
rno-miR-195 rno-miR-320 rno-miR-487b 
rno-miR-204 rno-miR-361 rno-miR-494 
rno-miR-210 rno-miR-369-5p rno-miR-497 
rno-miR-214 rno-miR-374 rno-miR-505 
rno-miR-215 rno-miR-376b rno-miR-539 
rno-miR-222 rno-miR-376b* rno-miR-543 
rno-miR-223 rno-miR-379 rno-miR-664 
rno-miR-23a   
 








3.8 miRNAs expressed in both MCAo blood and brain samples  
Among the differentially regulated miRNA transcripts, only 10 miRNAs (miR-290, 
-103, -107, -150, -185, -191, -320, -494, let-7a and let-7i were found to be 
expressed in both the ischemic blood and brain at both reperfusion times (24 and 
48hr). miR-290 was found to be highly upregulated, while let-7i was 
downregulated in 24 and 48hr reperfusion time of ischemic brain and blood 
samples. Transcripts that were common to both the ischemic brain and blood at 
24hr reperfusion are miR-16, -23a, -103, -107, -150, -185, -191, -290, -292-5p, -
320, -451, -494, and let-7 (a, d, f, and i). On the other hand, miRNAs expressed at 
48hr reperfusion in both the MCAo blood and brain were miR-26a, -26b, -103, -
107, -140*, -150, -185, -195, -191, -290, -214, -320, -328, -352, -494, and let-7 (a, 
c, and i). There are 22 miRNAs [miR-103, -107, -140*, -150, -17, -185, 191, -20a, 
-214, -26a, -26b, -290, -320, -352, -451, -494, -92, let-7 (a, c, d, f and i)] expressed 
in 24hr brain and also found in 48hr blood sample  
 
 
3.9 Gene expression studies 
An independent DNA microarray study was carried out on MCAo rat brain 
samples that were subjected to 24hr of reperfusion using Affymetrix
®
 mRNA 
microarray platform (section 2.2.2.6.1). We have chosen 659 genes (SLR ratio >1 
and <-1 and a detection probability value of <0.01) to be significant to our study 
(data were similar to those of Lu et al. [354]). Cerebral ischemia is a severe 
pathogenesis which could cause de novo expression changes of various genes (up 
or downregulation). A different expression pattern observed in ischemic and non-
130 
 
ischemic brain could help with the identification of specific genes involved in the 
pathophysiology and provide potential biomarkers or therapeutics targets in stroke. 
The high density oligonucleotide arrays could illustrate the global expression 
profile of sham-operated (control), ischemic, and MK801-treated brain samples. 
There were 412 genes found to be significantly and differentially expressed upon 
MCAo. Of these, 241 transcripts were up regulated, and 171 were downregulated, 
compared to sham-operated samples.  
 
The upregulated genes included some very important ones in ischemia cascade, 
such as Brain derived neurotrophic factor (BDNF; +SLR 2.82), Bone morphogenic 
protein receptor, type II (BMPR2; +SLR 4.92), Heme oxygenase (decycling) 1 
(HMOX1; +SLR 2.445), Potassium inwardly rectifying channel, subfamily J, 
member 16 (KCNJ16; +SLR 1.35), Microsomal glutathione S-transferase 1 
(MGST1; +2.06), MMP9 (+3.79), Protein tyrosine phosphatase 4a2 (PTP4A2; 
+SLR 1.17), Sodium channel, voltage gated, type III,α-polypeptide (SCN3A; 
+SLR 1.36), Transgelin (TAGLN; +3.14), Tropomyosin 1, (TPM1; +SLR 2.39), 
Vimentin (VIM; +SLR 2.74). The downregulation genes including Calpain 8 
(CAPN8; -SLR 2.45), Fibroblast growth factor 16 (FGF16;-SLR 1.24), Glutamic 
acid decarboxylase 1 (GAD1; -SLR 3.21), Glia maturation factor (GMFB; -SLR 
2.14), Golgi phosphoprotein 3 (GOLPH3; -SLR 1.63), Hypoxia upregulated 1 
(HYOU1; -SLR 2.58), Laminin, γ1 (LAMC1; -SLR 1.8), Mitogen-activated 
protein kinase activating death domain (MADD; -SLR 2.29), Syntaxin 1A (brain) 




In an attempt to understand the mechanism at gene level the effect of MK801 as 
neuroprotective agent in MCAo study, the expression profiles of MCAo and 
MCAo + MK801 treatment were compared. In total, there were 142 genes found to 
be differentially expressed in MCAo + MK801 treated samples compared with 
MCAo sample. Some of the genes in MK801-treated samples were upregulated or 
downregulated upon MCAo but their expression levels were found to be correlated 
with sham-operated samples. These observations support that MK801 has 
neuroprotective effects at least in animal models of stroke.  
 
 
3.10 Predicted targets genes for miRNA via miRNAs databases 
In silico analysis was performed using 5 different databases (microRNA.org, 
TargetScan3.1, miRGen, RegRNA, and Sanger). The genes (mRNAs) with the 
highest-ranking scores for each database were selected as potential targets for the 
miRNA identified in our profiling analysis. The miRNA targets that were found in 









(Detected in brain) 
Activin A receptor, type 1 precursor ACVR1 -1.98 miR-30a-5p, -30b, -30c, -
30e, -130a, -290, -382 
Adenosine A1 receptor ADORA1 -4.4 miR-150, -290, -342 
A kinase (PRKA) anchor protein 6 AKAP6 -1.19 miR-26b, -290, -543 
Aquaporin  AQP4 -1.07 miR-124a 
Activity-regulated 
cytoskeleton-associated protein 
ARC -1.12 miR-290 
 
Brain-derived neurotrophic factor BDNF 2.82 miR-134[355] 
Bone morphogenic protein receptor, type 
II (serine/threonine kinase) 










(Detected in brain) 
Calpain 8 CAPN8 -2.45 miR-7, -21, -34a, -101a, -
101b, -132, -301, -382, let-
7e 
Contactin 4 CNTN4 -1.78 miR-48b, -218, -223, -290 
CPG2 protein CPG2 -1.56 miR-290 
Double cortin and calcium /calmodulin-
dependent protein kinaselike 1 
DCAMKL1 0.575 miR-290 
24-Dehydrocholesterol 
reductase 
DHCR24 -1.06 miR-7 
Down syndrome critical region homolog 
1 (human) 
DSCR1 -0.47 miR-290 
Fibroblast growth factor 16 FGF16 -1.24 miR-9, -99a, -214, -320, -
331,-424,-494 
Fibroblast growth factor 
receptor 1 
FGFR1 -0.4 miR-214 
Glutamic acid decarboxylase 1 GAD1 -3.21 miR-23a 
Glia maturation factor, β GMFB -2.14 miR-290 
Guanine nucleotide binding protein, β1 GNB1 1.54 miR-290 
Golgi phosphoprotein 3 GOLPH3 -1.63 miR-290 
Glycerol-3-phosphate dehydrogenase 1 
(soluble) 
GPD1 -0.93 miR-214 
Heme oxygenase (decycling) 1 HMOX1 2.445 miR-494, let-7a, -let-7d 
Hypoxia upregulated 1 HYOU1 -2.58 miR-27a, -215, -292-5p 
Integrin β1 (fibronectin receptor β) ITGB1 -0.23 miR-124a[356] 
Potassium inwardly rectifying channel, 
subfamily J, member 16 
KCNJ16 1.35 miR-21, -218, -292-5p, -
342, let-7e, let-7f 
Kruppel-like factor 15   KLFL5 -1.09 miR-290 
Laminin,γ1   LAMC1 -1.8 miR-124a 
Mitogen-activated protein kinase 
activating death domain 
MADD -2.29 miR-292-5p 
Mitogen-activated protein kinase 1 MAPK1 -2.45 miR-290 
Microtubule-associated protein, RP/EB 
family, member 1 
MAPRE1 -0.97 miR-290 
Microsomal glutathione S-transferase 1 MGST1 2.06 miR-290, -292-5p 
Matrix metallopeptidase 9  MMP9 3.79 miR-125a, -125b, -127, -
132, , 298, -338,-664 
Neurogenic differentiation 1  NEUROD1 -1.03 miR-30a-5p, -30c, -124a, -
338, -383 
Nuclear receptor subfamily 4, group A, 
member 1 
NR4A1 -0.96 miR-290 




OGT -2.43 miR-290 
 
 
Prostaglandin E synthase  PTGES -1.08 miR-290 











(Detected in brain) 
Sodium channel, voltage gated, type III, 
α-lypeptide 
SCN3a 1.36 miR-214, -223, -494 
 
Septin 3  SEP3 -2.28 miR-23a, -23b, -181b, -290, 
324-5p, -328, -382, let-7d* 
Solute carrier family 17 (sodium-
dependent inorganic phosphate 
cotransporter), member 7 
SLCL7A7 -3.2 miR-7, -327 
Signal sequence receptor, γ SSR3 -2.28 miR-290 
Syntaxin 1A (brain)  STX1a -2.46 miR-24, -29a, -29b, -29c, -
298, -497 
Synaptotagmin IV  SYT4 -0.81 miR-30a-35p, 30e, -292-5p 
Transgelin TAGLN 3.14 miR-34a, -98, -139, -204, -
290, -320, -338, -382, -485, 
let-7a, let-7b, let-7e 
Tropomyosin 1, α TPM1 2.39 miR-21, -29c, -293, -338 
Vimentin  VIM 2.74 miR-92, -129, -138, -185, -
223, -320, -382, let-7a, let-
7b, let-7c, let-7d*, let-7i 
Visinin-like 1  VSNL1 -1.55 miR-25, -92, -124a, -290, 
 
Table 3.9: List of target genes that were predicted by all five databases with the 
















3.11 Real-time quantitation of gene expression 
The expression of 4 genes which may have critical roles in the ischemic cascade 
was quantified according to section 2.2.2.11. AQP 4 was downregulated at 24hr 
reperfused-ischemic brain and upregulated at 48hr reperfusion. MMP9 and 
TAGLN were upregulated at 24hr perfusion time points and found to further 
increase at later time points. VSNL1 was downregulated at both time points 
(Figure 3.6). This validated real-time PCR result was in parallel with the results 




Figure 3.6: Validation and quantification of gene expression. Real-time PCR 
quantification of target gene expression in the rat ischemic brain after 24 and 48hr 
reperfusion and comparison with DNA microarray data. Expression of 18S RNA 






3.12 Stem-loop real-time PCR for miRNAs quantification  
The expression of selected miRNAs was further validated using stem-loop real-
time PCR (section 2.2.2.12). Three miRNAs were selected for the validation for 
both ischemic brain and blood samples at 24 and 48hr reperfusion (Table 3.10). 
The validated results were correlated with the miRNA array data. 
 
 

















1.332±0.151 2.314±0.101 6.054±0.128 19.790±0.516 176.720±0.193 153.175±0.208 
48hr 
brain 
6.000±0.097 - 228.003±0.11 39.124±0.451 6.731±0.167 8.591±0.2011 
24hr 
brain 
- - 1.271±0.192 - 0.133±0.063 1.17±0.20 
48hr 
brain 
- - 14.198±0.124 - 1.414±0.017 4.12±0.125 
 
Table 3.10: Validation of the expression of miR-124a (brain enriched), -223 and -
















miRNA profiling at  




4.1 Introduction  
Identifying the onset and progression of stroke at initial phases could demonstrate 
the development of ischemic cascade which could be useful in the search for an 
effective treatment [357]. Until now, almost all stroke biomarkers are protein-
based molecules, notably visinin-like protein 1 (VSNL1), S100 calcium binding 
protein B (S100B), brain natriuretic peptide (BNP), C-reactive protein, brain 
derived neurotrophic factor (BDNF) and MMP9 [358, 359]. In the previous chapter, 
circulating miRNAs have been demonstrated to be a useful tool for the 
identification of diagnostic and prognostic markers in animal stroke model [329].  
 
By using miRNA profiles, the expression of miRNA changes at different 
reperfusion time (0, 1, 3, 6, 12, 18, 24 and 48hr) following transient middle 
cerebral artery occlusion (MCAo) in animal models have been examined and the 
results are presented in this chapter. The changes in miRNA expression were also 
correlated with changes in infarct volumes of ischemic brains. The miRNA 
expression patterns upon administration of MK801 (NMDA antagonist) was also 
examined in this study. MK801 (Dizocilpine), is a non-competitive antagonist of 
the NMDA receptor and has been used in several experimental animal models as 








4.2 Laser-doppler flowmetry  
Rats (n=6) were subjected to transient MCAo for 60min and sacrificed after 0, 1, 3, 
6, 12, 18, 24 and 48hr of reperfusion respectively. The cerebral blood flow of each 
animal was measured using laser-doppler flowmetry (section 2.2.1.1.3). Left MCA 
occluded rats that exhibited CBF drop by 70 to 0% from the baseline (pre 
occlusion) were included in this study. The results were similar to those showed in 
Chapter 3 (Figure 3.1) 
 
 
4.3 Infarct volume  
The nylon suture occluding left MCA was removed after 1hr of occlusion and the 
animals were subjected to different reperfusion times (0, 1, 3, 6, 12, 18, 24 and 
48hr). The rats were euthanized at the end of each time point and the brain slices 
were stained with TTC. Infarct volumes on the ipsilateral region were quantitated 
as described in section 2.2.1.1.5. Infarct volumes seemed to gradually increase 
from 3hr to a maximum at 24hr (100±2.34%) and then decreased at 48hr 
(84.05±1.43%) of reperfusion (Figure 4.1A & B). The infarct areas were not 
visible for 0 to 1hr samples. Since the 24hr reperfusion time point showed the 
largest infarct volume, this time point was selected to study the effect of MK801. 
The infarct volume of the MK801 treated rats showed a significant reduction by 
















(B)   
 
Figure 4.1: Histopathological analysis of brain slices coronal sections. (A) The 
photographs illustrate serial coronal section, 2mm thick, for rostral to caudal slices 
stained with TTC at different reperfusion time points (0, 1, 3, 6, 12, 18, 24 and 
48hr). Red indicates viable cells while white indicates non-viable cells. (B) Infarct 
volumes were quantitated using Image J. Results are representative of at least 3 
independent experiments and values obtained in mm
3
 are expressed as percentage 
of saline-treated control ± SEM. Sham-operated rats are the negative control.* 
denotes p < 0.05, ** denotes p < 0.01 as compared to 0hr MCAo. 



























Figure 4.2: Histopathological analysis of brain slices coronal sections. (A) The 
photographs illustrate serial coronal section, 2mm thick, for rostral to caudal slices 
stained with TTC for sham-operated, MCAo and MCAo + MK801. Purplish red 
indicates viable cells while white indicates non-viable cells. (B) Histrogram of infarct 
sizes (%) following MCAo and MCAo+MK801 treatment. Results shown are 
representative of 6 independent experiments and values are expressed in 
percentage of the saline-treated control ± SEM. Two-tailed, unpaired Students t 
test was performed, and # denotes difference between MCAo + MK801 and only 
MCAo (p<0.01). ** denotes difference compared to control at p<0.01. Data shown 
are mean ± SEM (n=6). Sham-operated rats are the negative control. MCAo rats 
are the positive control. 
    Sham-operated              MCAo            MCAo + MK801 
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4.8 Extraction of RNA and proteins from ischemic brain slices and blood 
           samples  
Total RNA (including miRNAs) was extracted from brain slices and whole blood 
as described in section 2.2.2.1 and 2.2.2.2 respectively. The integrity of the isolated 
RNA was determined on denaturing agarose gel electrophoresis (section 2.2.2.3 
and 2.2.2.4) and bioanalyzer (section 2.2.2.5; Figure 4.3). RNA samples were 
quantitated using Nanodrop ND-1000 spectrophotometry (Nanodrop Tech, 
Rockland, Del). Proteins from ischemic brain slices were extracted (section 
2.2.3.1) and quantitated (section 2.2.3.2) and stored at -80  C until use.  
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Figure 4.3: (A) RNA samples analyzed on Agilent 2100 Bioanalyzer/ RNA 6000 
Nano Kit. The RIN (RNA integrity number) was measured for all the samples. (B) 
Examples of the electropherogram of the ladder and sample wells. One marker 
peak + 6 RNA peaks on the electropherogram of the ladder well and 1 marker peak 
+ 2 ribosomal peaks on the electropherogram of the sample well were observed. (C) 
Electropherograms of ladders and some RNA samples from the ischemic brain. 
Samples with RIN value of 7 were subjected to miRNA array. (Sample 1-2: sham-
operated ipsilateral rat brain; sample 3-5: MCAo ipsilateral rat brain; samples 6-8: 
MCAo + MK801 ipsilateral rat brain) 
 
 
4.9 miRNA profiling and analysis  
miRNA profiling and analysis were performed according to section 2.2.2.8.2 and 
2.2.2.9.1. The rat miRNA array chips used represented the Sanger miRNA 
Database (version11.0). Of the 380 mature Rattus norvegicus (rno)-miRNAs, 349 
miRNAs could be identified in our profiling data of the infarct brain samples 
ladder sample 1 sample 2 
sample 3 sample 4 sample 5 
sample 6 sample 7 sample 8 
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obtained after MCAo. Of these, 331 miRNAs (Supplementary Table 1) showed 
significant (single-factor ANOVA, t test p<0.05) differential expression pattern in 
the ischemic brain. The expression of these miRNAs is illustrated as a heatmap in 
Figure 4.4. Eighteen miRNAs failed to show statistical significance (single-factor 
ANOVA test; p>0.05) difference at all-time points (0, 1, 3, 6, 12, 18, 24 and 48hr) 
include miR-101a, -122, -135a*, -139-5p, -193*, -196b, -196c, -199a-3p, -21, -26b, 
-30d, -343, -543, -598-5p, -708, -99a*, let-7 (e and f).  
 
During the early stages of reperfusion (at 1hr reperfusion time), 271 miRNAs 
(more than 80%) of miRNAs were downregulated, 35 miRNAs were upregulated, 
6 miRNAs were at baseline, and 19 miRNAs were not detected. Among these 271 
miRNAs, only 59 miRNAs remained downregulated at 24hr of reperfusion while 
212 displayed a reverse trend and became upregulated at 24hr of reperfusion. 
 
Principal component analysis (PCA) was used to further categorize the miRNAs 
and to obtain an overall picture of the miRNA expression patterns. PCA employs 
an algorithm which transforms a number of variables into a lesser number of 
unobserved variables known as principle components. The 3D plot symbolizes the 
three principal components, and the spatial arrangement of the respective samples 











Figure 4.4: Heatmap of miRNAs expressed at different reperfusion times after 
MCAo. The signal log ratio (SLR values versus sham-operated rats were used to 
construct the hierarchical clustering. Only miRNAs expressed significantly 









As illustrated in Figure 4.5A, the initial reperfusion time points (0, 1, 3 and 6hr) 
remained isolated from the later reperfusion time points (12, 18, 24 and 48hr) at the 
y-axis. An additional segregation within these two clusters can be observed when 
these profiles were examined using the z-axis (Figure 4.5B). As seen in the Figure 
4.5B, miRNA profile at 48hr reperfusion time point is separated from the 2
nd
 
cluster (12, 18 and 24hr). On the other hand, 0hr reperfusion profile remained 
isolated from all other time points and at the opposite end of the 48hr reperfusion 
profile. These observations could explain that the expression of miRNAs at initial 
reperfusion time points (1, 3 and 6hr) diverged significantly from those at later 
time points (12, 18 and 24hr). The profile of miRNAs from 48hr reperfusion 
profile being isolated and away from the other time points could be due to the 
reduction in infarct volume which may imply that recovery phase from the onset of 
stroke could have begun at 48hr reperfusion.  
 
There were a number of miRNAs that exhibited a biphasic-pattern of expression 
with the progression of infarct volume across the different reperfusion time points. 
These included miR-140, -143, -145, -193, -204*, -208, -210, -224, -290, -328, and 
-425 (Figure 4.6). These miRNAs could be potentially beneficial to trace the 
progression of ischemic cascade upon MCAo. Very interestingly, miR-223 
displayed a gradual increase in expression from 0-48hr of reperfusion time points. 
There were 19 miRNAs (miR-125b-3p, -130b, -204*, -205, -206, -210, -215, -23a*, 
-25*, -296, -299, -300-5p, -30c-1*, -345-5p, -351, -451, -483, -540 and -542-5p) 
that remained upregulated significantly at 12, 18, 24 and 48hr.  








Figure 4.5: Principal component analysis performed using TIGR Mev software. 
PCA of the ischemic rat brain samples at different reperfusion time is illustrated in 
two views. (A) The samples were well-segregated by y-axis (no. 2), two defined 
clusters (0, 1, 3 and 6hr) and (12, 18, 24 and 48hr) along y-axis (no. 2). (B) The 0 






Figure 4.6: Relative expression of selected miRNAs from the miRNA microarray 
data which demonstrated a biphasic expression during the progression of 
infarct/cell death. The values were expressed as signal log ratio (SLR). 
 
 
Notably, some miRNAs were expressed only during early reperfusion times but 
were not detected at later reperfusion time points. For instance, miR-139-3p was 
detected only at 0hr reperfusion time point, miR-199a-5p only present at 1hr 
reperfusion time point, miR-133b and 324-3p were expressed from 0 to 3hr 
reperfusion time points, miR-200c, -27a*, -296, -327, -484 and -743a were 
detected from 0 to 6hr reperfusion time points whereas rno-miR-1, -147 and -323 
were expressed from 0 to 12hr reperfusion time points. These miRNAs were absent 
at reperfusion times beyond 18hr. The presence of above miRNAs during initial 
reperfusion time points but not at later time points implies that they could serve as 




In silico analysis was carried out using 5 different databases (microRNA.org, 
TargetScan, miRGen, RegRNA and Sanger) for the prediction of miRNAs target 
genes. Putative target genes of 48 differentially expressed miRNAs in ischemic 
brain and 9 in ischemic serum samples were searched with online algorithms for 
miRNA target genes prediction filtering off those that has less than 3 hits from 
these 5 online databases. The list of miRNAs with their respective target proteins 
(prediction) for both ischemic brain and blood serum are shown in Table 4.1A and 









(MCAo +  
MK801) 
SLR 








rno-miR-128 -0.12 0.22 0.34 TF, CRP, 
GPX3 
TF, CAMK2G 
rno-miR-132 0.05 0.17 0.12 TF, CRP TF, PDIA3 
rno-miR-137 -0.34 -0.46 -0.12  NEFL 
rno-miR-138 0.48 0.25 -0.22 GPX3 PDIA3 
rno-miR-145 1.23 1.08 -0.14  DYPSL2 
rno-miR-150 -0.55 -0.06 0.50  CAMK2G 
rno-miR-153 -1.35 -1.92 -0.56  CAMK2G 
rno-miR-16 -0.05 0.07 0.12  PDIA3 
rno-miR-181a -0.31 0.17 0.48  CAMK2G, DYPSL2 
rno-miR-181b -0.07 -0.78 -0.71  CAMK2G, DYPSL2 
rno-miR-181d  -0.39 -1.28 -0.89  CAMK2G, DYPSL2 
rno-miR-185 0.51 0.64 0.13 CRP CAMK2A 
rno-miR-204 0.86 0.29 -0.57  COX5A 
rno-miR-218 0.01 -0.26 -0.27 TF TF, PPIA3 
rno-miR-223 2.26 1.68 -0.58 STMN1  
rno-miR-23a 0.21 -0.06 -0.26  NEFL 
rno-miR-24 -0.27 -0.07 0.20 GPX3 NEFL 
rno-miR-25 0.21 0.40 0.19  NEFL 
rno-miR-26a -0.02 0.21 0.23 CRP NEFL, COX5A, 
COX6A, GLUD1 
rno-miR-26b 0.09 -0.96 -1.04 CRP NEFL, COX5A, 
COX6A, GLUD1 
rno-miR-27a -0.45 -0.16 0.29  CAMK2G, CAMK2A 









(MCAo +  
MK801) 
SLR 








rno-miR-29a -0.52 -0.34 0.19  CAMK2G, DYPSL2 
rno-miR-29b -0.22 -1.00 -0.77  CAMK2G, DYPSL2, 
INEXA 
rno-miR-290 5.43 5.35 -0.08  CAMK2A 
rno-miR-30a 0.10 -0.42 -0.52  NEFL,GLUD1 
rno-miR-30b-5p 0.09 -0.23 -0.31  NEFL,GLUD1 
rno-miR-30d 0.31 0.17 -0.13  DYPSL2 
rno-miR-30c 0.19 0.08 -0.11  DYPSL2 
rno-miR-320a 0.90 1.11 0.22 ORM1 CAMK2A 
rno-miR-325-3p 0.37 0.07 -0.30 CRP, GPX3 NEFL 
rno-miR-329a -0.34 -0.17 0.17 CRP NEFL 
rno-miR-335a 0.48 -0.37 -0.85  CAMK2A, CAMK2G 
rno-miR-338a -0.59 -1.53 -0.94  CAMK2G 
rno-miR-342-3p -0.12 0.41 0.52  NEFL 
rno-miR-352 0.40 -0.42 -0.82 CRP  
rno-miR-361 0.60 0.73 0.12  NEFL 
rno-miR-376b-3p -1.03 -1.17 -0.14  NEFL 
rno-miR-379 0.24 0.22 -0.02  GLUD1 
rno-miR-383 -0.63 0.25 0.88  CAMK2G 
rno-miR-384-3p -1.14 -2.47 -1.34  CAMK2A, GLUD1 
rno-miR-433 -0.20 0.46 0.66 CRP NEFL 
rno-miR-495a -0.54 -0.36 0.18  CAMK2A, CAMK2G, 
NEFL 
rno-miR-672a 1.23 1.63 0.40  NEFL 
rno-miR-92a -0.03 0.29 0.31  NEFL 
rno-miR-92b -0.30 0.39 0.69  NEFL 














rno-miR-128 0.62 0.57 -0.04 TF, CRP, GPX3 
rno-miR-185b 0.13 -0.69 -0.82 CRP 
rno-miR-24b 0.22 -1.02 -1.24 GPX3 
rno-miR-26a 0.26 0.10 -0.16 CRP 
rno-miR-26b -0.60 0.59 1.19 CRP 
rno-miR-223b 0.77 0.50 -0.28 STMN1 
rno-miR-320b -0.33 -0.76 -0.43 ORM1 
rno-miR-352  -0.34 -0.18 0.16 CRP 
rno-miR-98b -0.86 1.09 1.95 ORM1 
 
Table 4.1: List of miRNAs and proteome. (A) miRNAs in brain. (B) miRNAs in 
blood. Proteins that were detected in brain and serum of rats subjected to MCAo 
and MCAo + MK801 treatment. Proteins identified in brain proteome were 
classified broadly according to their biological function or potential roles in 




4.10 Changes in expression of miRNAs with MK801 treatment 
Rats (n=6) were subjected to MCAo as described in section 2.2.1.1.1. MK801 
(Sigma-Aldrich Co., USA) was administered intraperitoneally at three doses: the 
first one as 2.5μg g body at 30 min prior to MCAo followed by 1.25μg g body 
weight at 6 and 14hr post occlusion according to section 2.2.1.1.6. Total RNA 
(including miRNAs) was subjected to miRNA array. A distinctive miRNAs 
expression pattern was observed between the ischemic rat brain and that treated 
with MK801 following 24hr reperfusion (Figure 4.7 and Table 4.2).  
 
From the results, a total 156 miRNAs exhibiting differential expression between 
MCAo and MCAo+MK801 treatments was identified. Among them, 44 miRNAs 
were found to be upregulated (SLR>0.4) and 47 miRNAs downregulated 
(SLR<−0.4) in MCAo + MK801 rats compared to MCA occluded rats. On the 
other hand, from the miRNAs profile of ischemic blood samples, 100 and 133 
miRNAs were found to be significantly expressed respectively (versus normal) in 
MCA occluded rats and MCAo + MK801 rats. Among these, 119 miRNAs showed 
significant differential expression in MCAo + MK801 compared to MCAo (Table 
4.3). Interestingly, 47% (MCAo) and 43% (MK801 + MCAo) of these blood 
miRNAs could be also detected in their respective ischemic brain samples. MK801 
treatment appeared to have downregulated about 48% (versus normal) and 60% 








Figure 4.7: Heatmap of the miRNAs expressed in brain samples upon MCAo and 
MCAo ± MK801 with 24hr reperfusion time. The signal log ratio (SLR) versus 
normal rats were used to construct the hierarchical clustering. Only miRNAs with 
signal intensity >300 and significant changes at p<0.05 are included. Single factor 









MCAo + MK801 
t test 
p value 
rno-let-7a   0.33 6.81E-05 
rno-let-7b 0.22 4.25E-03 0.34 1.96E-04 
rno-let-7b*     
rno-let-7c 0.17 1.87E-02 0.36 8.26E-05 
rno-let-7d 0.21 3.49E-03 0.29 4.93E-04 
rno-let-7d*  -0.96 1.11E-07   
rno-let-7e 0.37 2.15E-04   
rno-let-7f 0.25 4.78E-04 0.34 1.93e-05 
rno-miR-1 2.60 4.24E-06   
rno-miR-100 0.34 5.82E-04 0.27 4.39E-03 
rno-miR-101a -1.37 8.80E-11 -1.86 3.44E-10 
rno-miR-101b -1.31 4.52E-09 -1.22 1.73E-08 
rno-miR-106b -0.50 1.76E-07 -0.25 6.43E-05 
rno-miR-106b* -1.24 1.54E-07 -0.66 2.97E-03 
rno-miR-122   1.97 1.32E-10 
rno-miR-124     
rno-miR-125a-3p   0.42 7.06E-04 
rno-miR-125a-5p -0.67 1.93E-07 -0.22 1.14E-02 
rno-miR-125b-5p -0.56 1.25E-06   
rno-miR-126 0.15 2.35E-02 -0.25 1.54E-03 
rno-miR-126* -1.79 2.55E-05 -2.77 4.90E-07 
rno-miR-127 -0.63 2.46E-08   
rno-miR-128   0.22 3.11E-03 
rno-miR-129  1.48E-06 0.49 3.45E-06 
rno-miR-129*  2.88E-04 -0.30 4.30E-05 
rno-miR-130a   -0.30 1.21E-04 
rno-miR-132   0.17 8.45E-03 
rno-miR-133a 0.74 4.56E-06 0.63 9.65E-04 
rno-miR-133b 0.93 1.25E-06 0.86 6.37E-06 
rno-miR-134 0.14 1.61E-02 0.46 3.24E-06 
rno-miR-135a -3.09 2.55E-07 -3.46 1.84E-03 
rno-miR-135a* 0.92 1.01E-06 0.70 7.14E-05 
rno-miR-137 -0.34 4.29E-04 -0.46 1.32E-05 
rno-miR-138 0.48 3.64E-07 0.25 7.01E-04 
rno-miR-139-3p -1.31 6.79E-09 -0.72 3.68E-04 
rno-miR-139-5p -1.02 2.91E-09 -0.28 1.14E-03 
rno-miR-140* 0.20 9.92E-03 0.61 8.08E-07 
rno-miR-143 -0.14 4.18E-02   
rno-miR-145 1.23 1.21E-12 1.08 8.56E-12 
rno-miR-146a 0.22 2.95E-03 -0.37 3.60E-04 
rno-miR-146b 0.54 6.21E-06 0.41 1.66E-04 
rno-miR-148b-3p -2.87 1.04E-11 -1.84 1.87E-09 
rno-miR-150 -0.55 1.15E-05   
rno-miR-151 0.68 6.92E-08 0.43 1.06E-05 
rno-miR-151* 0.20 3.28E-03 0.24 3.57E-03 
rno-miR-152   -0.36 3.34E-03 
rno-miR-153 -1.35 3.06E-09 -1.92 1.06E-12 
rno-miR-154   0.55 4.50E-07 
rno-miR-15b 0.54 2.18E-06 0.35 8.23E-04 
rno-miR-16     
rno-miR-17 -0.55 2.68E-06 -0.54 2.69E-06 
rno-miR-181a -0.31 4.86E-04 0.17 1.55E-02 
rno-miR-181b   -0.78 1.72E-06 
rno-miR-181c -1.94 1.32E-06 -1.63 1.46E-06 
rno-miR-181d -0.39 1.61E-03 -1.28 3.85E-08 
rno-miR-182 -0.83 2.42E-03   
rno-miR-185 0.51 7.89E-08 0.64 3.14E-09 
rno-miR-186 -1.45 9.12E-10 -1.06 2.71E-06 









MCAo + MK801 
t test 
p value 
rno-miR-188 0.63 4.24E-04 1.28 4.58E-07 
rno-miR-191 -0.21 3.03E-03 0.26 5.78E-04 
rno-miR-194 -0.26 1.78E-03   
rno-miR-199a-3p 0.26 3.55E-03   
rno-miR-19b -1.02 1.59E-07 -0.76 1.95E-05 
rno-miR-203 1.18 1.06E-04   
rno-miR-204 0.86 4.38E-07 0.29 2.56E-03 
rno-miR-204* 1.74 5.34E-09 1.47 1.40E-08 
rno-miR-206 2.54 1.10E-11 1.79 3.69E-09 
rno-miR-20a -0.44 1.13E-04 -0.34 7.48E-04 
rno-miR-20b-5p -1.04 3.54E-08 -1.62 1.15E-09 
rno-miR-21 1.38 1.04E-10 0.51 1.21E-05 
rno-miR-210 0.63 6.92E-04 0.88 6.16E-05 
rno-miR-212     
rno-miR-214 2.26 1.52E-08 2.14 6.11E-09 
rno-miR-218   -0.26 1.12E-03 
rno-miR-219-2-3p     
rno-miR-219-5p 0.22 2.92E-02 -1.85 5.08E-06 
rno-miR-22* -0.71 7.96E-07 -1.11 2.03E-08 
rno-miR-221 0.22 3.35E-03   
rno-miR-222   0.38 4.76E-05 
rno-miR-223 2.26 4.27E-08 1.68 4.15E-07 
rno-miR-23a 0.21 6.84E-03   
rno-miR-23b     
rno-miR-24 -0.27 2.76E-03   
rno-miR-25 0.21 2.10E-03 0.40 9.04E-06 
rno-miR-25*     
rno-miR-26a   0.21 5.86E-03 
rno-miR-26b   -0.96 4.70E-07 
rno-miR-27a -0.45 2.41E-05 -0.16 3.77E-02 
rno-miR-27b -0.57 9.21E-07   
rno-miR-28 0.77 5.28E-07 -0.70 9.70E-06 
rno-miR-290 5.43 3.14E-12 5.35 4.37E-14 
rno-miR-292-5p 2.25 2.30E-10 2.17 1.50E-09 
rno-miR-296* -1.40 4.27E-07 -0.65 2.73E-02 
rno-miR-298   0.61 9.47E-03 
rno-miR-299     
rno-miR-29a -0.52 5.95E-08 -0.34 3.58E-06 
rno-miR-29b -0.22 2.96E-02 -1.00 6.36E-08 
rno-miR-29b-2* -0.38 6.56E-05   
rno-miR-29c -1.01 1.84E-08 -1.18 7.71E-10 
rno-miR-29c* 0.65 5.72E-07 0.79 7.21E-07 
rno-miR-300-3p 0.21 6.60E-03   
rno-miR-300-5p   -0.29 2.35E-02 
rno-miR-301a -0.83 3.56E-07 -1.34 3.76E-07 
rno-miR-30a   -0.42 8.95E-05 
rno-miR-30a*   -0.30 9.75E-03 
rno-miR-30b-5p   -0.23 2.09E-02 
rno-miR-30c 0.19 1.21E-02   
rno-miR-30c-1* 2.35 1.05E-08 1.17 3.82E-06 
rno-miR-30c-2* 0.52 4.52E-06   
rno-miR-30d 0.31 1.62E-04 0.17 1.39E-02 
rno-miR-30e -0.81 2.51E-07 -1.20 5.13E-10 
rno-miR-30e* -0.32 4.55E-03 -1.21 4.67E-09 
rno-miR-31 0.13 2.95E-02 0.18 2.39E-02 
rno-miR-320 0.90 1.02E-11 1.11 2.55E-11 
rno-miR-322 -0.54 2.10E-05 -1.70 1.11E-10 
rno-miR-322* 0.36 7.26E-05   









MCAo + MK801 
t test 
p value 
rno-miR-324-3p 0.24 2.31E-02 0.77 1.06E-06 
rno-miR-324-5p 0.29 5.17E-04 0.65 6.11E-09 
rno-miR-325-3p 0.37 3.08E-05   
rno-miR-325-5p -0.19 3.73E-03   
rno-miR-326 0.39 1.82E-02 0.43 3.38E-02 
rno-miR-327 1.48 1.11E-09 1.58 2.99E-09 
rno-miR-328   0.78 1.57E-09 
rno-miR-329 -0.34 1.49E-03   
rno-miR-330* 0.42 3.27E-06 0.64 2.48E-08 
rno-miR-331 1.14 1.40E-09 1.35 2.90E-11 
rno-miR-335 0.48 1.04E-03 -0.37 1.28E-02 
rno-miR-337 -1.14 1.53E-05 -0.94 4.14E-03 
rno-miR-338 -0.59 1.59E-05 -1.53 4.76E-09 
rno-miR-338* 0.64 8.81E-07   
rno-miR-339-3p     
rno-miR-340-3p -1.65 9.22E-08 -2.35 1.42E-02 
rno-miR-340-5p 0.22 1.92E-02 -1.83 8.34E-11 
rno-miR-341 -1.80 2.32E-07   
rno-miR-342-3p   0.41 1.21E-04 
rno-miR-342-5p 0.70 1.67E-07 0.90 1.15E-07 
rno-miR-344-3p 0.34 3.00E-05 0.31 1.86E-03 
rno-miR-345-5p 0.72 3.11E-06 1.18 7.09E-09 
rno-miR-346   0.69 2.16E-08 
rno-miR-34a 0.45 3.54E-06 0.34 4.71E-05 
rno-miR-34c 1.33 5.76E-10 0.75 2.06E-05 
rno-miR-34c* 1.28 3.64E-09 1.26 1.31E-07 
rno-miR-350 -0.39 2.05E-03 -1.27 1.05E-07 
rno-miR-352 0.40 3.43E-03 -0.42 5.61E-03 
rno-miR-361 0.60 7.92E-07 0.73 1.66E-07 
rno-miR-365 0.44 8.24E-03 -1.01 2.53E-03 
rno-miR-369-3p -2.08 4.93E-07 -4.65 1.66E-06 
rno-miR-369-5p -0.88 1.90E-07 -0.81 5.38E-06 
rno-miR-374 1.09 4.47E-06 -1.03 8.65E-05 
rno-miR-375 1.02 6.74E-08 1.10 1.05E-07 
rno-miR-376a -0.21 3.76E-02 -0.74 5.66E-04 
rno-miR-376b-3p -1.03 3.66E-09 -1.17 1.22E-09 
rno-miR-376b-5p -1.37 1.85E-09 -1.00 1.83E-07 
rno-miR-376c   -1.88 2.50E-02 
rno-miR-377 -1.32 1.48E-05   
rno-miR-378 -0.33 2.68E-04 0.22 4.97E-02 
rno-miR-379 0.24 7.81E-04 0.22 2.21E-03 
rno-miR-379* 0.58 1.78E-05 -0.36 2.25E-03 
rno-miR-380 -0.58 2.04E-05 -0.58 1.84E-03 
rno-miR-381 -0.24 9.05E-03   
rno-miR-382 0.26 9.84E-04 0.31 2.50E-04 
rno-miR-382* -0.51 6.88E-03 -1.43 2.02E-06 
rno-miR-383 -0.63 1.08E-08 0.25 2.76E-04 
rno-miR-384-3p -1.14 1.34E-08 -2.47 1.98E-11 
rno-miR-384-5p 0.79 2.53E-07   
rno-miR-409-3p -0.18 1.03E-02 0.33 2.48E-04 
rno-miR-409-5p -0.78 1.50E-05 -0.58 1.45E-02 
rno-miR-410 -1.28 7.68E-08 -0.73 2.43E-06 
rno-miR-411   -0.25 2.75E-02 
rno-miR-425 0.66 1.36E-07 0.92 1.58E-09 
rno-miR-431 -0.26 3.91E-02   
rno-miR-433 -0.20 3.32E-03 0.46 9.01E-07 
rno-miR-434 -0.28 1.16E-03 -0.33 4.93E-04 
rno-miR-448 2.35 1.58E-10 1.29 3.87E-08 












rno-miR-451 -1.20 8.85E-09 1.74 1.11E-11 
rno-miR-466b 5.58 2.98E-07 4.83 6.12E-08 
rno-miR-485 0.24 2.30E-03 0.87 1.58E-08 
rno-miR-487b -0.34 5.72E-05   
rno-miR-495 -0.54 3.70E-07 -0.36 1.40E-04 
rno-miR-497 1.49 4.31E-07 1.05 1.01E-05 
rno-miR-505 -1.13 7.65E-09 -0.37 8.34E-03 
rno-miR-532-3p -2.17 2.59E-11 -0.81 1.11E-02 
rno-miR-539 -0.45 7.78E-06 -0.44 3.49E-05 
rno-miR-541 -0.93 4.18E-09 -0.51 6.16E-06 
rno-miR-543* -0.47 5.65E-06   
rno-miR-598-3p -1.34 2.05E-10 -1.64 2.28E-09 
rno-miR-652   0.24 2.57E-02 
rno-miR-664 -0.51 2.48E-04 -0.69 2.06E-05 
rno-miR-672 1.23 6.24E-07 1.63 1.48E-07 
rno-miR-674-3p   0.56 1.06E-04 
rno-miR-674-5p 1.40 1.83E-11 1.51 1.08E-12 
rno-miR-708 -0.25 2.81E-03   
rno-miR-760-3p -0.41 4.53E-06 0.75 4.42E-09 
rno-miR-7a -0.21 1.57E-02 -0.18 4.35E-02 
rno-miR-7a* -0.53 6.66E-03 -1.57 2.03E-06 
rno-miR-7b -0.97 1.98E-04 -1.62 9.61E-07 
rno-miR-872 -0.33 7.68E-04 -0.55 2.58E-05 
rno-miR-872* 0.58 2.14E-04   
rno-miR-874 3.60 1.52E-10 3.39 4.68E-11 
rno-miR-877 0.77 8.79E-07 1.09 2.90E-08 
rno-miR-9   0.26 4.03E-04 
rno-miR-9* 0.14 2.45E-02   
rno-miR-92a   0.29 1.50E-04 
rno-miR-92b -0.30 2.06E-04 0.39 2.34E-05 
rno-miR-93 -0.13 4.47E-02   
rno-miR-98 0.94 2.01E-05 -0.46 5.49E-03 
rno-miR-99a 0.42 1.02E-05 0.66 1.12E-07 
rno-miR-99b -0.46 6.14E-06 0.54 6.76E-07 
 
Table 4.2: miRNAs which were differentially regulated in ischemic rat brain 
following MCAo and MCAo ± MK801. miRNAs in bold are detected in the 






Figure 4.8: Heatmap on the miRNAs that were expressed in both the blood and 
brain ischemic samples (MCAo ± MK801 at 24hr reperfusion). The list of 
miRNAs that are in bold letters in Tables 4.2 and 4.3 were used to construct the 
heatmap. The signal log ratio (SLR) versus normal rats was used to construct the 
hierarchical clustering. Only miRNAs with signal intensity >300 and significant 
changes at p<0.05 are included. Single factor ANOVA was performed for 








MCAo + MK801 
t test 
p value 
rno-let-7a 0.21 2.60E-03 0.31 1.42E-03 
rno-let-7b  0.31 7.63E-04 0.49 3.21E-04 
rno-let-7b*   0.72 5.97E-04 
rno-let-7c 0.35 9.28E-05 0.45 3.61E-04 
rno-let-7d  0.26 2.05E-04 0.35 8.72E-04 
rno-let-7d*    -0.27 6.71E-03 
rno-let-7e -0.32 2.69E-02 1.31 3.12E-07 
rno-miR-1 -3.09 3.61E-03 2.95 5.85E-07 
rno-miR-101a -3.07 7.13E-07 -3.66 1.22E-08 
rno-miR-101b -1.97 6.36E-07 -3.15 7.93E-12 
rno-miR-103 0.55 2.37E-08 -1.17 5.39E-13 
rno-miR-106b -0.14 2.31E-03 -2.11 0.00E+00 
rno-miR-106b* -1.19 1.23E-07 -1.03 5.36E-08 
rno-miR-107 0.57 1.71E-08 -1.12 1.62E-12 
rno-miR-122 0.67 1.09E-05 5.04 0.00E+00 
rno-miR-124 1.72 2.21E-11 1.77 1.12E-11 
rno-miR-125a-3p -0.66 3.58E-03   
rno-miR-125a-5p 0.83 8.83E-06 1.56 1.71E-09 
rno-miR-125b-5p 0.78 4.89E-08 0.59 2.66E-08 
rno-miR-126 -0.96 2.68E-07 0.19 2.92E-02 
rno-miR-127 2.11 2.42E-14 -1.06 2.87E-07 
rno-miR-128 0.62 2.01E-06 0.57 6.79E-09 
rno-miR-129   0.43 2.83E-02 
rno-miR-129* 0.72 4.60E-02   
rno-miR-130a -0.47 1.38E-02 -1.38 2.59E-08 
rno-miR-130b -0.38 3.62E-04 -1.14 6.59E-08 
rno-miR-132 2.34 3.55E-12 0.49 4.20E-03 
rno-miR-133a   1.34 6.66E-10 
rno-miR-133b -0.61 7.10E-03 1.08 1.11E-06 
rno-miR-134 0.52 1.81E-02   
rno-miR-139-5p   0.81 6.52E-03 
rno-miR-140   -0.42 3.95E-02 
rno-miR-140* 0.12 9.53E-05 -1.20 7.07E-10 
rno-miR-142-3p -2.41 2.02E-03 -5.01 4.31E-04 
rno-miR-144 -2.93 3.27E-06 -5.60 6.38E-07 
rno-miR-145   0.64 2.53E-04 
rno-miR-146a   0.59 8.71E-06 
rno-miR-146b   -0.29 3.37E-03 
rno-miR-148b-3p -1.21 1.02E-09 -1.18 1.83E-09 
rno-miR-150 0.96 1.58E-11 1.55 8.88E-15 
rno-miR-151 0.27 2.41E-03 -0.65 2.65E-08 
rno-miR-151* -0.29 1.38E-03 -0.84 8.66E-10 
rno-miR-152   0.37 2.73E-03 
rno-miR-15b  0.75 8.54E-09 1.09 6.89E-13 
rno-miR-16   -0.91 1.83E-13 
rno-miR-17 -0.40 8.98E-06 -1.51 1.20E-14 
rno-miR-17-3p -0.32 4.79E-02 -1.86 3.22E-09 
rno-miR-181a -0.27 3.07E-04 1.24 8.88E-16 
rno-miR-181b -0.88 2.68E-04 2.93 1.05E-13 
rno-miR-181c   1.02 1.31E-03 
rno-miR-181d -0.60 4.57E-03 2.02 8.78E-10 
rno-miR-182   0.86 1.66E-03 
rno-miR-183   0.65 5.18E-03 
rno-miR-185 0.13 7.01E-03 -0.69 4.75E-10 
rno-miR-186 -1.42 4.02E-08 -1.36 1.92E-09 
rno-miR-187   1.27 6.52E-06 
rno-miR-188   0.96 1.12E-04 
rno-miR-18a -0.45 4.07E-05 -2.47 7.55E-15) 









MCAo + MK801 
t test 
p value 
rno-miR-194   -0.35 1.17E-02 
rno-miR-195 -2.36 2.31E-11 -0.66 1.37E-04 
rno-miR-199a-3p 0.77 4.97E-06 0.67 1.79E-02 
rno-miR-19a -2.57 2.34E-04 -3.87 4.55E-11 
rno-miR-19b -1.50 0.00E+00 -3.30 6.39E-14 
rno-miR-200b 1.55 3.07E-09 0.86 1.55E-06 
rno-miR-200c 2.40 7.90E-14 -0.90 9.75E-07 
rno-miR-206 -0.69 4.85E-03 3.17 2.42E-13 
rno-miR-20a -0.44 6.44E-08 -1.72 2.22E-16 
rno-miR-20b-5p   -1.39 3.58E-12 
rno-miR-21 -0.24 7.14E-03 0.41 1.22E-03 
rno-miR-210 0.47 3.63E-03   
rno-miR-211   2.22 9.41E-03 
rno-miR-212   0.56 1.24E-02 
rno-miR-214   1.47 9.15E-09 
rno-miR-218*   0.87 5.75E-04 
rno-miR-22 -0.31 9.59E-04 -1.91 2.10E-09 
rno-miR-221 -0.81 1.86E-07 -1.26 1.08E-11 
rno-miR-222 0.44 2.37E-04 -0.93 5.64E-06 
rno-miR-223 0.77 4.62E-05 0.50 8.08E-04 
rno-miR-23a 0.36 7.13E-08 0.87 1.20E-08 
rno-miR-23b 0.54 1.69E-08 1.04 3.30E-09 
rno-miR-24 0.22 1.67E-03 -1.02 3.67E-12 
rno-miR-25   -0.35 1.18E-05 
rno-miR-25* 0.44 5.90E-04 -0.45 1.04E-03 
rno-miR-26a 0.26 2.02E-05   
rno-miR-26b -0.60 3.49E-05 0.59 3.90E-05 
rno-miR-27a 0.28 1.33E-02 0.46 1.76E-04 
rno-miR-27b   -0.26 1.64E-03 
rno-miR-290 -0.58 5.79E-03 2.58 9.79E-09 
rno-miR-291a-3p   1.09 7.18E-03 
rno-miR-292-5p 1.00 3.68E-06 3.84 3.11E-15 
rno-miR-296     
rno-miR-296* 0.99 4.83E-03 1.01 4.41E-02 
rno-miR-298   0.45 4.66E-02 
rno-miR-29a 0.19 2.33E-04 -0.68 3.70E-08 
rno-miR-301a -2.06 1.93E-07 -3.19 1.02E-12 
rno-miR-30a   -0.46 3.26E-06 
rno-miR-30a*   0.63 9.67E-05 
rno-miR-30b-5p   0.76 9.32E-07 
rno-miR-30c 0.28 8.44E-04   
rno-miR-30d 0.34 1.86E-04 -0.40 6.28E-05 
rno-miR-30e -1.12 2.60E-10 -1.97 8.04E-12 
rno-miR-31     
rno-miR-320 -0.33 1.37E-05 -0.76 1.19E-08 
rno-miR-324-3p 0.53 4.50E-04 0.50 1.49E-03 
rno-miR-324-5p 0.42 3.56E-04 -0.62 6.46E-05 
rno-miR-327 1.10 4.91E-05 2.78 1.74E-09 
rno-miR-328   -0.86 1.51E-07 
rno-miR-329 -0.43 6.03E-03 -1.26 6.12E-07 
rno-miR-339-3p   1.04 6.37E-04 
rno-miR-339-5p     
rno-miR-342-3p   1.65 1.75E-09 
rno-miR-346   0.82 1.14E-03 
rno-miR-34c*   2.56 3.86E-07 
rno-miR-350 -1.01 6.29E-03 -0.56 9.67E-04 
rno-miR-352 -0.34 2.25E-02   
rno-miR-361 0.67 2.67E-07 0.59 7.29E-06 









MCAo + MK801 
t test 
p value 
rno-miR-365 0.73 1.10E-02 0.89 9.74E-04 
rno-miR-374   1.51 2.93E-04 
rno-miR-375 2.66 0.00E+00 -3.97 1.63E-10 
rno-miR-377 -2.01 3.59E-11 -1.42 7.34E-09 
rno-miR-378 -0.25 2.88E-03 -0.88 3.62E-07 
rno-miR-382 1.58 5.15E-05   
rno-miR-409-3p 1.26 1.40E-03   
rno-miR-425 0.30 2.01E-05 -1.78 4.77E-13 
rno-miR-433 1.09 1.17E-04   
rno-miR-434 0.63 2.08E-02 0.49 2.21E-02 
rno-miR-451 -0.23 5.86E-05 -0.55 7.22E-08 
rno-miR-466b 0.52 1.43E-02 2.41 8.15E-09 
rno-miR-483 0.60 1.38E-02 0.67 9.91E-03 
rno-miR-484 0.28 1.32E-02 -0.67 5.82E-05 
rno-miR-494 -0.72 4.84E-03 1.08 8.38E-03 
rno-miR-500   -1.16 4.75E-06 
rno-miR-505 -0.90 1.52E-08 -1.65 2.02E-13 
rno-miR-532-3p   0.24 3.56E-02 
rno-miR-542-5p     
rno-miR-652   -0.91 9.73E-08 
rno-miR-672 -0.69 3.41E-03 3.79 8.24E-13 
rno-miR-674-5p   -0.89 7.26E-05 
rno-miR-7a   -1.39 4.65E-07 
rno-miR-872 -1.09 5.19E-06 -2.83 2.22E-16 
rno-miR-874   0.61 1.10E-02 
rno-miR-92a     
rno-miR-92b 0.14 5.03E-03   
rno-miR-93   -1.58 1.07E-13 
rno-miR-98 -0.86 1.55E-05 1.09 1.90E-06 
rno-miR-99a   -0.70 1.58E-04 
rno-miR-99b 1.45 2.55E-05 0.59 1.76E-03 
rno-miR-99b*   0.84 2.58E-03 
 
Table 4.3: miRNAs which were differentially regulated in ischemic rat blood 
following MCAo and MCAo ± MK801. miRNAs in bold were detected in the 











4.7 Correlation between mRNA and protein expression in suture method 
MCAo 
Total RNA was subjected to Oligonucleotide (DNA) microarray according to 
section 2.2.2.6.1 and total proteins were subjected to two-dimensional gel 
electrophoresis according to section 2.2.3.3. Ischemic brain and blood 
transcriptome analysis demonstrated the presence of mRNAs corresponding to the 
respective proteins which were identified by 2-D gel electrophoresis.  Of the total 
of 9,175 probes that detected from the mRNA array (detection p value<0.01) on 
the MCAo blood samples, 46.7% of genes have been found to be significantly 
upregulated (SLR>0.5) and only 0.7% mRNA were downregulated (SLR<−0.5) for 
MCA occluded rats with MK801 treatment. Almost more than half (52.6%) of the 
mRNAs identified displayed no changes in their expression pattern (SLR between 
less than 0.5 to −0.5).  
 
Transcripts that encoded the proteins identified in the proteome are listed in Table 
4.4. In the MK801-treated ischemic brain sample, 13.04% miRNA were 
upregulated, 19.6% miRNA were downregulated, whereas 67.4% of the 
significantly regulated miRNAs (92 miRNAs) showed almost baseline expression 
values (SLR<0.5 to >-0.5).  
 
The 2D polyacrylamide gel electrophoresis was carried on total proteins extracted 
from MCA occluded rat brains and blood serum at 24hr reperfusion (±MK801) are 
illustrated in Figure 4.9. As the ipsilateral hemisphere of rats had been occluded,  


























NM_024398.2 ACO2 -0.195 -0.497 -0.303 -0.034 0.490 0.524 Rattus norvegicus aconitase 2, mitochondrial (ACO2), mRNA 
NM_019383.1 ATP5H 0.014 -0.177 -0.191 -0.553 0.129 0.682 Rattus norvegicus ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
(ATP5H), mRNA 
NM_198745.1 Atp6v1e1 -0.139 -0.403 -0.058 -1.604 -1.041 0.564 Rattus norvegicus ATPase, H+ transporting, V1 subunit E isoform 1 (ATP6VIe1),mRNA 
NM_012920.1 CAMK2A -1.000 -3.882 0.941 -0.304 -0.048 0.255 Rattus norvegicus calcium/calmodulin-dependent protein kinase II alpha 
subunit(CAMK2A), mRNA 
NM_012519.1 CAMK2D 0.139 -3.773 -0.191 nd nd nd Rattus norvegicus calcium/calmodulin-dependent protein kinase II, delta 
(CAMK2D), mRNA 
NM_133605.1 CAMK2G -1.131 4.597 0.867 0.146 0.903 0.758 Rattus norvegicus calcium/calmodulin-dependent protein kinase II gamma (CAMK2G), 
mRNA 
NM_145783.1 COX5A 0.167 -0.064 -0.231 0.220 1.156 0.936 Rattus norvegicus cytochrome c oxidase, subunit Va (COX5A), mRNA 
XM_341094.2 COX6A1 0.175 0.161 -0.014 -0.808 -0.560 0.248 Predicted: Rattus norvegicus cytochrome c oxidase, subunit VIa, polypeptide 1 
(COX6A1), mRNA 
NM_012812.1 COX6A2 0.134 -0.008 -0.142 -0.064 0.563 0.627 Rattus norvegicus cytochrome c oxidase, subunit VIa, polypeptide 2 (COX6A2), mRNA 
NM_022864.1 CPLX1 -0.212 -0.255 0.107 -0.441 0.060 0.501 Rattus norvegicus complexin 1 (CPLX1), mRNA 
XM_341625.2 CPLX4 -0.063 0.044 -0.044 nd nd nd Predicted: Rattus norvegicus complexin 4 (predicted; CPLX4_predicted), mRNA 
NM_017096.1 CRP -0.118 0.025 0.143 nd nd nd Rattus norvegicus C-reactive protein, petaxin related (CRP), mRNA 
XM_341363.2 CYPA -0.093 -0.334 -0.241 -0.345 0.252 0.597 Predicted: Rattus norvegicus similar to peptidylprolyl cis-trans isomerase A (PPIase; 
rotamase; cyclophilin A; cyclosporin A-binding protein; P31), mRNA  































NM_031705.1 DPYS 0.304 0.267 -0.037 1.035 0.297 -0.738 Rattus norvegicus dihydropyrimidinase (DPYS), mRNA 
NM_012848.1 FTH1 0.345 0.872 0.168 -0.316 0.141 0.457 Rattus norvegicus ferritin, heavy polypeptide 1 (FTH1), mRNA 
NM_012848.1 FTH1 0.345 0.872 0.168 -0.316 0.141 0.457 Rattus norvegicus ferritin, heavy polypeptide 1 (FTH1), mRNA 
NM_012570.1 GLUD1 -0.695 -0.537 0.158 -0.055 1.193 1.248 Rattus norvegicus glutamate dehydrogenase 1 (GLUD1), mRNA 
NM_012571.1 GOT1 -0.347 1.045 -0.002 -0.026 1.200 1.227 Rattus norvegicus glutamate oxaloacetate transaminase 1 (GOT1), mRNA 
NM_030826.2 GPX1 0.464 0.449 -0.015 -0.749 -0.955 -0.206 Rattus norvegicus glutathione peroxidase 1 (GPX1), mRNA 
NM_183403.1 GPX2 1.257 0.632 -0.625 -0.088 -0.040 0.048 Rattus norvegicus glutathione peroxidase 2 (GPX2), mRNA 
NM_022525.2 GPX3 -0.499 -0.132 0.367 0.240 0.324 0.084 Rattus norvegicus glutathione peroxidase 3 (GPX3), mRNA 
NM_017165.1 GPX4 0.042 0.048 0.007 -1.241 -0.708 0.532 Rattus norvegicus glutathione peroxidase 4 (GPX4), mRNA 
NM_138974.1 GSTP2 -0.329 -0.252 0.077 -0.138 0.614 0.752 Rattus norvegicus glutathione S-transferase, pi 2 (GSTP2), mRNA 
NM_012582.1 HP -0.050 -0.230 -0.180 0.869 2.517 1.648 Rattus norvegicus haptoglobin (HP), mRNA 
NM_053318.1 HPX 0.289 0.042 -0.248 -0.394 0.500 0.895 Rattus norvegicus hemopexin (HPX), mRNA 
NM_019128.2 INEXA -0.162 0.126 0.172 nd nd nd Rattus norvegicus internexin, alpha (INEXA), mRNA 
XM_215776.3 NDUFS3 -0.426 -0.511 -0.085 -0.286 0.939 1.224 Predicted: Rattus norvegicus NADH dehydrogenase (ubiquinone) Fe–S protein 
3(predicted; NDUFS3), mRNA 
NM_031783.1 NFL 0.197 -0.362 -0.559 nd nd nd Rattus norvegicus neurofilament, light polypeptide (NFL), mRNA 
NM_053288.1 ORM1 -0.268 0.152 0.420 0.838 0.672 -0.166 Rattus norvegicus orosomucoid 1 (ORM1), mRNA 
NM_017236.1 PBP 0.141 0.098 -0.043 -0.471 0.133 0.605 Rattus norvegicus phosphatidylethanolamine binding protein (PBP), mRNA 
 NM_017319.1 PDIA3 0.159 0.154 -0.005 0.271 1.190 0.918 Rattus norvegicus protein disulfide isomerase associated 3 (PDIA3), mRNA 









Symbol Brain mRNA Blood mRNA Gene definition 


















NM_017166.1 STMN1 -0.578 -0.214 0.363 0.054 2.308 2.254 Rattus norvegicus stathmin 1 (STMN1), mRNA 
NM_031676.1 TAGLN3 -0.191 -0.032 0.158 nd nd nd Rattus norvegicus transgelin 3 (TAGLN3), mRNA 
XM_579389.1 TF 0.393 0.455 0.062 1.276 3.085 1.488 Predicted: Rattus norvegicus transferrin (TF), mRNA 
NM_031055.1 MMP9 1.221 0.310 -0.911 0.303 1.021 0.719 Rattus norvegicus matrix metallopeptidase 9 (MMP9), mRNA 
NM_024374.2 MTPN 0.009 -0.221 -0.230 0.091 0.542 0.450 Rattus norvegicus myotrophin (MTPN), mRNA 
NM_024359.1 HIF1a 0.673 0.413 -0.260 -0.019 0.667 0.686 Rattus norvegicus hypoxia inducible factor 1, alpha subunit (HIF1α), mRNA 
NM_012889.1 VCAM1 -0.486 -0.390 0.096 -0.209 1.312 1.520 Rattus norvegicus vascular cell adhesion molecule 1 (VCAM1), mRNA 
NM_138887.1 HSPD6 -0.297 -0.361 -0.064 -0.095 0.388 0.484 Rattus norvegicus heat shock protein, alpha-crystallin-related, B6 (HSPB6), mRNA 
NM_012686.1 VSNL1 -0.550 -0.562 -0.012 nd nd nd Rattus norvegicus visinin-like 1 (VSNL1), mRNA 
 
Table 4.4: List of transcripts identified in mRNA array on total RNA from ischemic brain and blood samples of rats subjected to MCAo and 






























































































































































































































(A ii) (A iii) 
(B ii) (B iii) 
Sham operated (brain) MCAo (brain) 
MCAo + MK801 (brain) 




















































 Figure 4.9: Representative proteomes of ischemic rat pooled samples with at least 3 samples in each case. (A i)-(A iii) brain (ipsilateral), (B i)-
(B iii) contralateral and (C i)-(C iii) serum. Protein spots picked for further analysis on MS/MS are circled and labelled in number respectively. 
The molecular weight of each band of the protein ladder was included at the side of each gel in terms of kilodaltons. (i) Sham-operated, (ii) 




Sham operated (serum) MCAo (serum) MCAo + MK801 (serum) 





further characterization via mass spectrometry (MALDI-TOF-TOF). 
 
Identified proteins were also categorised as biomarkers (BMs) or therapeutic 
proteins (TPs). BMs are proteins that are expressed differentially in the sham-
operated brain compared with ischemic brain, whereas TP are proteins that are 
expressed differentially during MCAo compared with MCAo + MK801 treatment. 
A protein which could be classified as BM/TP and BM&TP if it is expressed 
highly during MCAo and demonstrate recovery with low expression on MK-801 
treatment in the ipsilateral hemisphere, or vice versa. All the identified proteins 
were then classified broadly into five different categories (Table 4.5A) based on 
their biological functions according to the PANTHER (Protein Analysis Through 
Evolutionary Relationships) Classification System [362] or Pubmed databases. 
Another three 2D gels were also performed on the serum samples (Figure 4.9C). 
Differentially regulated proteins that have been detected and listed in Table 4.5B 
































1 P19527 Neurofilament, light 
polypeptidea 




2 P50398   
 
Guanosine diphosphate 
dissociation inhibitor 1 
0.74 1.02 1.15 Signalling 
proteins 




4 P07335  Creatine kinase B 0.74 0.66 0.91 Metabolism 
5 O08553 Dihydropyrimidinase-like 2 4.80 2.61 0.54 Metabolism 
6 P11598 Protein disulfide isomerase 
associated 3 
0.41 0.67 1.93 Metabolism 
7 P11598 Protein disulfide isomerase 
associated 3, isoform 
CRA_a 
6.61 3.40 0.65 Metabolism 
 
8 P02770 Albumin 5.69 5.34 0.94 BBB 
breakdown 
9 P10818 Cytochrome c oxidase 
subunit 
0.73 0.49 0.77 Mitochondrial 
proteins 
10 P12346 Transferrin 2.86 3.09 1.07 BBB 
breakdown 
11 Q9ER34 Aconitase 2, mitochondrial 3.72 3.99 1.01 Mitochondrial 
proteins 
12 P10860 Glutamate dehydrogenase 1 2.21 1.67 0.85 Metabolism 
13 P09606 Glutamine synthetase 1 0.93 0.69 0.83 Metabolism 
14 gi|220684 Cytosolic aspartate 
aminotransferase 
1.15 0.95 0.92 Metabolism 
 
15 P04797 Glyceraldehyde-3-phosphate 
dehydrogenase 
0.45 0.90 2.03 Metabolism 
16 gi|149049573 ATPase, H+ transporting, 
V1 subunit E isoform 1, 
isoform CRA_a 
4.85 7.89 1.63 Signalling 
proteins 
 
17 Q6P6D7 Phosphoglycerate mutase 1 1.55 1.17 0.77 Metabolism 
18 P42123 Lactate dehydrogenase B 1.13 0.87 0.76 Metabolism 
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 NADH dehydrogenase 
(ubiquinone) Fe–S protein 3 
1.16 0.86 0.70 Mitochondrial 
proteins 
20 Q99PT1 Rho GDP dissociation 
inhibitor αa 
0.69 0.78 1.12 Signalling 
proteins 




















22 P31044 Phosphatidylethanolamine 
binding protein 
0.63 0.69 1.31 Signalling 
proteins 
23  gi|6978859 Ferritin, heavy polypeptide 1 0.92 0.00  BBB 
breakdown 
24 P13668  Stathmin 1 0.00 0.91  Cytoskeletal 
structure 
25 P31399 ATP synthase, H+ 
transporting, mitochondrial F0 
complex, subunit d 
0.85 0.81 0.95 Metabolism 
 
26 P37805 Transgelin 3 0.58 0.48 0.82 Cytoskeletal 
structure 
27 P39069 Adenylate kinase 1 0.62 0.62 1.21 Metabolism 
28 P04906 Glutathione S-transferase, pi 2 0.72 0.68 0.99 Metabolism 
29 B2RYW3 Similar to NADH 
dehydrogenase (ubiquinone) 1 
beta subcomplex, 9 





P10111 Peptidylprolyl isomerase A 0.68 1.35 1.90 Signalling 
proteins 
31 P10818 Cytochrome c oxidase subunit 
VIa 
0.69 0.95 1.49 Mitochondrial 
proteins 
32 P11240 Cytochrome c oxidase, 
subunit Va 
0.84 0.90 1.08 Mitochondrial 
proteins 
33 Q91VW3 Similar to SH3 domain 
binding glutamic acid-rich 
protein-like 3 
0.81 0.82 1.01 Signalling 
proteins 
34 gi|16974825 Chain A, solution structure of 
calcium-calmodulin 
N-terminal domain 































gi|3212532 Chain A, rat transthyretin 0.99 1.01 1.02 
P23764 Glutathione peroxidase precursor 1.38 1.16 0.84 
gi|204657 Prehaptoglobin 1.00 0.60 0.60 
gi|1854476 Transferrin 1.37 4.81 3.34 
P20059 Hemopexin 1.72 1.36 0.79 
P06866 Preprohaptoglobin 2.22 3.17 1.43 
Q68FY4 Group specific component 1.60 2.09 1.30 
gi|16757980 Orosomucoid 1 0.55 1.50 2.72 
P48199 C-reactive protein, pentraxin-related 1.36 1.37 1.05 
P02651; 
gi|114008 
Apolipoprotein A-IV precursor 0.66 0.55 0.83 
 
Table 4.5 List of proteins identified from the proteomic study. Proteins were 
detected from (A) brain and (B) serum proteome of rats subjected to MCAo and 
MCAo + MK801 treatment with 24hr reperfusion. Proteins identified from the 
brain proteome were classified broadly based on their respective biological 
functions or possible roles in ischemic injury cascade. The expression values of 







miRNA profiling in embolic MCAo
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5.1       Introduction  
Cerebral ischemia is a complex disease with various etiologies and variable clinical 
manifestations. Approximately 45% of ischemic strokes occur as a result of small 
or large artery thrombus, 20% are embolic in origin, and others are due to unknown 
causes [363]. Rat models of focal cerebral ischemia provide the experimental 
backbone for the in vivo determination of the mechanisms upon occlusion and 
reperfusion in ischemic stroke. The establishment of rat focal cerebral ischemic 
models may therefore represent an important tool/strategy to address the 
pathophysiological mechanisms in human stroke. Moreover, such models are 
required for the development and evaluation of novel therapeutic approaches for 
ischemic stroke. The experimental structure and validation of animal stroke models 
play important roles in cerebral ischemia research. Several studies have established 
different models of stroke, of which majority could represent only some of the 
characteristics of human stroke. 
 
Thus far, precise embolic stroke model appears to give the closet representation 
human stroke [212]. In this model, focal middle cerebral artery occlusion (MCAo) 
is induced by the introducing of a blood clot (thromboembolic MCAo) into the 
carotid artery of animal.  
 
The current approach for stroke treatment is mainly by thrombolysis or 
recanalization [53]. Thrombolysis involves the administration of rt-PA which is the 
only approved drug for human stroke treatment, while mechanical vessel 
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recanalization involves surgical procedure to remove the clot from the blocked 
vessels [364].  
 
In order to eliminate estrogen-mediated gender effect as well as to minimize the 
rate of spontaneous recanalization, male Wistar rats were used to create stroke 
model in this study [365, 366]. The MCA is the artery most often occluded in 
stroke [367]. In this study, stroke is induced by the administration of homologous 
blood clot into the MCA of Wistar rats. Rats (n=6) were sacrificed at different time 
points (0, 1, 3, 6, 12, 18, 24 and 48hr post occlusion) to study the progression of 
ischemia.  
 
miRNA profiling is a useful tool to study complex diseases such as ischemic stroke. 
Dysregulation of miRNAs upon the onset of stroke as well as post-stroke could 
provide important information on the gene functions in the ischemic cascade. 
miRNA profiling was performed on the total RNA isolated from ipsilateral 
ischemic brain slices harvested at different time points post occlusion of embolic 
stroke. Analysis of miRNA profilling data showed differential miRNA expression 
at different time points post occlusion. 
 
 
5.2  Embolism and laser-doppler flowmetry 
Homologous blood clots (3 to 5cm) were used to induce occlusion in the ipsilateral 
brain hemisphere of several rats. The cerebral blood flow was measured using 
laser-doppler flowmetry. The frequency of spontaneous recanalization was high 
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when 3cm blood clots were used and inconsistent infarct areas were observed. 
Consistent block in blood flow was observed only when 4cm and 5cm blood clots 
were used. Nevertheless, mortality rate of rats during surgery was found to be 
higher (>60%) when 5cm of blood clot was used. On the other hand, using 4cm of 
blood clot was able to give similar infarct volumes as 5cm blood clot while 
maintaining mortality rate as low as <20%. Hence using 4cm clot eMCAo was 
carried out with different reperfusion time points (0, 1, 3, 6, 12, 18, 24 and 48hr 
post occlusion). 
 
Homologous blood clots measuring in length were 4cm, prepared 24hr prior to 
administration into the ipsilateral MCA region to create embolic stroke. The 
location for the lodgement of blood clot at the MCA region using a syringe via 
modified PE-50 tube is shown in Figure 5.1. Consistent drop in CBF 
approximately 70-80% from the baseline was observed when the clot was placed 
within the ICA, MCA, and ACA region [a Y(most common)/V shape]. Incomplete 
occlusion may occur due to the following reasons: clots were placed too distal or 
proximal from the MCA region, clot were moved away from within MCA and ICA 
region due to the systemic blood circulation as well as a result of partial or 
incomplete lysis of clot (Figure 5.2A and B). 
 
 















Figure 5.2: The intra-arterial location of the clots used in this study. (A)(i) The 
clot is located within the ICA, ECA and ACA (Y-shape); (ii) The clot forms a V-
shape within MCA and ACA; (iii) The clot is located along ICA, ACA and blocks 
MCA, (iv) The clot is lodged within MCA. (B) The inappropriate lodgement of 
blood clot resulting in incomplete blockage of blood flow to MCA region. (i) The 
blood clot is located at proximal region of MCA; (ii) The blood clot is distributed 
at distal region of MCA; (iii) The clot has lysed; (iv) The clot has moved away to 
other region(s) by the blood circulation system. 
 
Rats (n=6) were subjected to transient embolic focal MCAo using homologous clot 
(section 2.2.1.1.2) and sacrificed after 0, 1, 3, 6, 12, 18, 24 and 48hr of reperfusion 
respectively. The cerebral blood flow of each rat model was measured using laser-
doppler flowmetry (section 2.2.1.1.3). The modified catheter was removed slowly 
and gently from the carotid artery after 5min of blood clot administration into the 
MCA region. Figure 5.3A shows representative traces on CBF pre, upon and post  
administration of blood clot into the MCA region. The CBF of rats was monitored 
continuously for 30 to 60min and only rats that showed a drop in CBF by 70 to 
80% from the baseline (pre occlusion) were included in this study. Rats that 
(i)                        (ii)                               (iii)                       (iv)                          





showed spontaneous recanalization within 30 to 60min post occlusion were 































Figure 5.3: Laser-doppler flowmetry. Cerebral blood flow (in bpu unit) was 
measured in the region on the left MCA before occlusion, during occlusion and at 
1hr of reperfusion. (A) CBF drop to 70 to 80% from the baseline (pre occlusion) (B) 
CBF rebound back to the baseline level within 30min post occlusion (spontaneous 
recanalization). 
CBF immediate after introduction  CBF after 1hr of occlusion     
of clot at MCA region          
CBF immediate after                     recanalization take     CBF back to the level  
introduction of clot at     place within 30min    similar to before                  
MCA region      after occlusion           occlusion 
                                               occlusion 
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Figure 5.4 shows the homologous clot segment lodgement within the ipsilateral 
MCA region of rat sacrificed at different time points post occlusion.  Notably, the 
blood clot was not observed at 48hr which may imply that restoration of CBF to 




















Figure 5.4: Homologous clot segment visualized within the ipsilateral MCA of 
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                CBF immediate after   CBF at 24hr after     CBF at 48hr after  
                introduction of clot               introduction of clot      introduction of clot 
                at MCA region    at MCA region    at MCA region  
 
 
Figure 5.5: Laser-doppler flowmetry. Cerebral blood flow (in bpu unit) was 




5.3  Infarct volumes after embolic MCAo (eMCAo)  
Rats were euthanized at the end of each time point and the brain slices were stained 
with TTC (Figure 5.6A and B). Infarct volumes on the ipsilateral region were 
quantitated as described in section 2.2.1.1.5. The infarct areas were not visible for 
samples collected at 0, 1 and 3hr. Infarct areas were only observed at 6hr which 
gradually increased in size to a maximum at 24hr (100±4.84%). Infarct size was 
found to decrease at 48hr (77.08±10.05%) post occlusion. Since the infarct volume 
was the highest at 24hr, this time point was then selected for subsequent 


















































































Figure 5.6: Histopathological analysis of brain slices coronal sections. (A) The 
photographs show the serial coronal sections (2mm thick) from rostral to caudal 
slices stained with TTC at different time points (0, 1, 3, 6, 12, 18, 24 and 48hr) 
post induction of occlusion using 4cm blood clots. Red indicates viable cells while 
white indicates non-viable cells. (B) Infarct volumes were quantitated using Image 
J. Results are representative of at least 3 independent experiments and values 
obtained in mm
3
 and expressed as percentage against saline-treated controls ± 
SEM. Sham-operated rats are the negative control.* denotes p < 0.05, ** denotes p 
< 0.01 as compared to 0hr MCAo. 







5.4 miRNA profiling and analysis  
Total RNA isolated from brain slices was subjected to miRNA profiling according 





6.6. A total of 304 mature miRNAs could be detected from the ischemic 
embolic brain samples (Supplemental Table 2). The expression level of these 
miRNAs is illustrated as a heatmap in Figure. 5.7.  
 
Upon the onset of stroke (0hr post introduction of blood clot to MCAo region), 224 
miRNAs were found upregulated, 64 miRNAs became downregulated and 20 
miRNAs showed no change in expression as compared with sham-operated 
samples. Expression of miRNAs generally showed an upward trend from 0 to 12hr 
of reperfusion. Interestingly, an opposite expression pattern (downregulation) was 
observed at 18hr post occlusion. The proportion of up and dowregulated miRNAs 
was observed to be almost equal at 24hr.   
 
More miRNAs became upregulated at 48hr post occlusion than those observed for 
earlier time points (Table 5.1). In general, dysregulation of miRNAs showed a V-
shaped expression pattern in which the largest number of upregulated miRNAs 
(~74%) being found at 0hr.  This gradually decreased to a minimum number at 














6.6 was used to generate the map. The signal log ratio (SLR) of MCAo 
samples at different reperfusion time points versus sham-operated rats were used to 




  Time point (post occlusion) 








































































Table 5.1: Summary of the expression profiles of miRNAs. 304 miRNAs were 
found expressed in at least one of the time points post occlusion (0, 1, 3, 6, 12, 18, 
24 and 48hr) of embolic stroke. Results are expressed as signal log ratio (SLR) of 
MCAo versus sham-operated animal. Number and percentage of miRNAs 
upregulated, downregulated and no change at all for these 8 time points have been 
shown.   
 





6.6 to get a snapshot of the expression pattern at different time points post 
occlusion and to further categorize the samples. As shown in Figure 5.8, at early 
stages of reperfusion (0, 1 and 3hr) were found to segregate closer to each other 
and remained near the y-axis. However the later time points (24 and 48hr) 
segregated towards the x-axis. The 6 and 18hr post occlusion samples were found 
to deviate from other samples.  
 
Eighteen miRNAs (miR-1, -1*, -101a*, -133a, -135a*, -18a, -196b, -200c, -211, -
217, -28*, -327, -380, -431, -450a, -484, -708* and -758) were not expressed in 
both sham-operated as well as in the ischemic brain samples. Hence these miRNAs 











6.6. The ischemic brain samples were well-segregated by x- and y-axis. 




A group of 4 miRNAs (miR-101a*, -133a, -199a-5p and -758) showed significant 
upregulation at the early time points (0 to 12hr post occlusion). miR-101a* and -
133a were found to be upregulated at 0 and 3hr but were undetected at other time 
points. miR-199a-5p was observed to be upregulated at 0, 1 and 6hr while miR-758 
showed upregulation at 0, 1, 3 and 12hr. The unique upregulation of these 4 
miRNAs at the earlier time points suggests that they could form potential and early 
biomarkers of stroke. Moreover, these miRNAs were not detected during the 
progression of stroke. However miR-133a and -199a-5p were found to be  
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upregulated at 48hr post occlusion.  Both these miRNAs could therefore be used as 
prognostic markers to indicate the point of recovery as the infarct volume became 
reduced at 48hr from the onset of occlusion. 
 
Ten miRNAs (miR-29c*, -340-5p, -344-3p, -346, -384-3p, -409-3p, -433, -495, -
598-3p and -7a) showed opposite profiles for early and later time points. They 
were initially upregulated and later became downregulated. On the other hand, 
miR-206 and -208 were downregulated from 0 to 12hr but became upregulated 
from 18 to 48hr post occlusion. These 12 differentially expressed miRNAs could 
potentially represent the neurological injuries as biphasic expression was observed 
for early and later phases after the onset of occlusion. 
 
A group of 6 miRNAs (miR-133b, -139-3p, -147, -27a*, -449a, -671) were 
detected in ischemic samples from all reperfusion time points but was undetected 
in sham-operated samples. Hence these miRNAs could be considered as important 
key players in the pathology of embolic stroke. Interestingly, 2 miRNAs, miR-192 
(+SLR 6.24) and -429 (+SLR 4.95) were present in sham-operated samples but 
absent in the ischemic brain samples. These miRNAs could therefore be useful in 
the diagnosis of stroke.   
 
K-means clustering of miRNAs using TMeV software yielded 12 clusters of 
miRNAs that could be categorised into 8 different groups (Figure 5.9 and 5.10). 
These clusters were created based on their respective expression patterns across the 
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8 time points. Clusters 1 and 8 consisted of 29 miRNAs (miR-1, -1*, -101a*, -133a, 





Figure 5.9: K-means clustering of miRNAs. 12 clusters of miRNAs identified 



































Figure 5.10: miRNAs categorized using K-means clustering. Signal log ratio 
(SLR) of miRNAs expression versus different time points post embolic stroke. (A) 
Group1: 29 miRNAs that were upregulated (cluster 1 and 8). (B) Group2: 12 
miRNAs that were downregulated (cluster 2 and 6). (C) Group 3: 50 miRNAs that 
were upregulated with expression level closer to baseline (Cluster 9). (D) Group 4: 
22 miRNAs that were downregulated with expression level closer to baseline 
(Cluster 7). (E) Group 5: 172 miRNAs that were expressed closer to baseline 
(unchanged, Cluster 11 and 12). (F) Group 6: 4 miRNAs that were upregulated 
gradually over time and 4 other miRNAs showed biphasic expression pattern. (G) 
Group 7: 4 miRNAs showed a gradual downregulation and 5 other miRNAs 
showed a V-shape expression pattern. (H) 2 miRNAs with their expression 





-223, -27a*, -299, -327, -380, -431, -449a, -450a, -451, -484, -671, -708* and -758) 
showed upregulation upon embolic ischemic stroke. Twelve miRNAs namely miR-
106b*, -122, -182, -183, -200a, -200b, -297, -345-3p, -429, -760-5p, -880, and -
883 in clusters 2 and 6 (Group 2) were found to be downregulated after induction 
of stroke. Cluster 9 (Group 3) consisted of 50 miRNAs that were slightly 
upregulated and their expression level was found to be closer to baseline. Likewise, 
the expression levels of 22 other miRNAs in cluster 7 were also close to baseline. 
Clusters 11 and 12 (Group 5) comprising of 172 miRNAs showed minimal changes 
in expression level across the different time points.     
 
The remaining 3 groups of miRNAs were also found to show unique expression 
pattern in ischemic brain samples at different time points post occlusion. The 
expression of 8 miRNAs (miR-125-3p, -21, -21*, -25*, -291a-5p, -30c-1*, -542-5p 
and -874, Group 6) showed gradual increasing pattern over the time. Clusters 3 and 
5 (Group 7) which included rno-miR-17-3p, -27b, 448, 379* showed a gradual 
downregulation across the 8 time points while 5 other miRNAs of the same group 
(miR-455, -540, -349, -30c-2* and 29b-1*) displayed a V-shape expression pattern. 
The expression of the last group comprising of only 2 miRNAs and one of them 
(miR-10a-3p) showed a constant upregulation.  
 
5.5 Pearson correlation coefficient analysis  
Pearson correlation coefficient analysis was performed on 26 miRNAs as 
mentioned above to compare between sham-operated and ischemic brain samples 





Figure 5.11: Scatter plots on miRNAs expression. The Pearson correlation values 





, R, is typically a measure of correlation between 2 variables. R gives a value 
between -1 and +1. An R value close to 0 indicated little or no linear correlation 




 is a coefficient of determination which gives the proposition of variation in one 
variable that can be explained by the variation in the other variable. For instance, at 
0hr time point post occlusion, R value = 0.8780 and R
2 
gives 0.7709 which means 
77% of the variation in the expression of these selected miRNAs at 0hr time point 
can be explained by the variation of miRNA expression in sham-operated samples. 
At the 24hr time point, R value was found to be 0.7827 which gives an R
2 
of 
0.6126. This means that 39% of the variation of miRNA expression in ischemic 
model at 24hr cannot be explained by the variation of miRNA expression in sham-
operated samples. This indicates a higher degree of changes in miRNA expression 
upon ischemia at 24h. The R value for 48hr time points was closer to sham-
operated samples indicating that a reduction of infarct volume begins and hence the 
later time points could be possibly indicate recovery from ischemia. R value for 
18hr time point showed the lowest (R=0.6776) as compared to others. The scatter 
plot also showed that this time point segregated differently from others. Hence this 
could be a very crucial time point during ischemia that exhibits a higher degree of 












6.6 was used to perform gene ontology (GO) analysis 
on the selected miRNAs (-miR-107, -10a-3p, -125b-3p, -127, -133b, -139-3p, -147, 
-17-3p, -21, -21*, -25*, -27a*, -27b, -291a-5p, -29b-1*, -30c-1*, -30c-2*, -349, -
379*, -448, -449a, -455, -540, -542-5p, -671, -874). There are 3 domains under GO 
a) cellular components which represent the parts of a cell or the extracellular 
environment, b) molecular function that denotes the primary activities carried out 
by certain gene products at the molecular level, and c) biological processes relating 
to the functioning of integrated living units (cells, tissues, organs, and organisms).  
 
The analysis resulted in a total of 5753 functional groups under these 3 domains 
with respective GO enrichment scores and p values (Figure 5.12A, B & C). Of 
these, there were 1651 functional groups with GO enrichment score of less than 
0.05 (p<0.05). The top 20 functional groups have been selected and represented in 
Figure 5.12D (using the data in Table 5.2). Genes involved in cytoplasm under 
cellular component domain had the highest GO enrichment score in the list which 
































Figure 5.12: Gene ontology analysis. (A) Cellular components. (B) Molecular 
function. (C) Biological process. (D) Top 20 Gene ontology bar chart based on the 
highest GO enrichment score with GO enrichment p value <0.05. 
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208.748 2.20E-91 33.3155 
Plasma membrane cellular 
component 
191.157 9.59E-84 37.4324 
Protein binding molecular 
function 
140.542 9.19E-62 42.9971 
Membrane cellular 
component 
106.122 8.16E-47 31.1952 
Extracellular region cellular 
component 
96.1373 1.77E-42 38.5864 
Cytosol cellular 
component 
91.4913 1.84E-40 37.1232 
Extracellular space cellular 
component 
74.5905 4.03E-33 41.0494 
Nucleotide binding molecular 
function 
67.6729 4.07E-30 33.0104 
Soluble fraction cellular 
component 
62.9333 4.66E-28 45.3368 
Nucleus cellular 
component 
58.7945 2.92E-26 27.2283 
Synapse cellular 
component 
54.745 1.68E-24 47.4048 
Cell junction cellular 
component 
54.0129 3.49E-24 44.5714 
ATP binding molecular 
function 
53.0134 9.47E-24 32.5183 
Ion transport biological 
process 
51.5075 4.27E-23 40.7407 
Membrane fraction cellular 
component 
49.4531 3.33E-22 40.1288 
Golgi apparatus cellular 
component 
47.5208 2.30E-21 36.2687 
Cell surface cellular 
component 






45.6127 1.55E-20 38.3562 
Response to drug biological 
process 
45.5348 1.68E-20 39.4737 
Response to hypoxia biological 
process 
40.1015 3.84E-18 46.087 
 
Table 5.2: Top 20 gene ontology data with respective GO Enrichment score and p 
value <0.05) based on Figure 5.12 and % of predicted genes from the miRNAs data 





5.7 Pathway analysis of 26 miRNAs of interest  
The 26 miRNAs that were identified from the K-means clustering (miR-107, -10a-
3p, -125b-3p, -127, -133b, -139-3p, -147, -17-3p, -21, -21*, -25*, -27a*, -27b, -
291a-5p, -29b-1*, -30c-1*, -30c-2*, -349, -379*, -448, -449a, -455, -540, -542-5p, 
-671 and -874) were predicted to regulate 250 pathways (KEGG pathways) by 
controlling the expression of 4899 genes. Of these, top 10 stroke related pathways 
with Enrichment score (3.57 to 8.83) and Enrichment p value (p<0.05) were 
selected. These included Hedgehog signalling pathway, MAPK signalling 
pathway, regulation of actin cytoskeleton, Notch signalling pathway, proteasome, 
GABAergic synapse, apoptosis, VEGF signalling pathway, ECM-receptor 









% genes in pathway 
 that are present 
Hedgehog signalling pathway 8.83 0.0001 39.06 
MAPK signalling pathway 7.23 0.0007 24.66 
Regulation of actin cytoskeleton 6.61 0.0013 25.76 
Notch signalling pathway 6.57 0.0014 34.78 
Proteasome 6.42 0.0016 35.48 
GABAergic synapse 5.23 0.0053 27.89 
Apoptosis 4.46 0.0115 26.85 
VEGF signalling pathway 3.82 0.0220 25.81 
ECM-receptor interaction 3.67 0.0255 26.72 
Calcium signalling pathway 3.57 0.0282 23.04 
 
Table 5.3 Top 10 predicted stroke-related pathways according to their respective 




These 10 pathways were correlated together with the mRNA-miRNA integration to 
give an overall picture of the pathways regulated by the selected these miRNAs 
and their respective predicted mRNAs (Figure 5.13). Predicted targets of these 
miRNAs were found to regulate single or across multiple pathways. Since a single 
miRNA could have hundreds of targets, it is not surprising that certain genes were 
identified as common targets of several miRNAs. Table 5.4 illustrates the predicted 








Figure 5.13: Top10 stroke-related pathways predicted by mRNA-miRNA interaction. Compilation of possible genes affected by 26 








Gene miRNA Gene miRNA 
ADAM 17 rno-miR-540 GNG7 rno-miR-291a-5p, -542-5p 
ADCY2 rno-miR-21 IFNG rno-miR-107 
ADCY3 rno-miR-139-3p, -17-3p, -27b IKBKB rno-miR-21, -542-5p, -671 
ADCY5 rno-miR-107, -17-3p, -542-5p IL1β rno-miR-291a-5p, -455 
ADCY6 rno-miR-133b, rno-miR-540 IL1R1 rno-miR-107, 139-3p 
AKT2 rno-miR-449a, -671 IL3 rno-miR-125b-3p 
AKT3 rno-miR-449a ITGAl rno-miR-30c-1*, -291a-5p 
ATM rno-miR-125b-3p, -291a-5p ITGA5 rno-miR-133b, -29b-1* 
BCL2 rno-miR-448, -449a ITGA6 
 
rno-miR-127, -27b, -291a-5p, -542-
5p 
BID rno-miR-139-3p, 27b ITGA7 rno-miR-107, -27b, -30c-1*, -30c-2* 
BIRC2 rno-miR-21 ITGA2 rno-miR-107 
BIRC4 rno-miR-10a-3p, -127, -21, -448 ITGB1 rno-miR-10a-3p 
BMP2 rno-miR-379* ITGB2 rno-miR-127 
BMP4 rno-miR-30c-1*, -30c-2* ITGB4 rno-miR-17-3p, -21*, -27a*, -540 
BMP7 rno-miR-125b-3p, -449a, -455, -542-5p ITGB6 rno-miR-29b-1* 
CACNA1A rno-miR-17-3p, -27b, -671 ITGB7 rno-miR-874 
CACNA1B rno-miR-133b KRAS rno-miR-21 
CASP8 rno-miR-349, -542-5p LAMA5 rno-miR-455 
CASP9 rno-miR-107, -139-3p, -17-3p LAMB3 rno-miR-542-5p, -874 
COL3A1 rno-miR-29b-1* LAMC2 rno-miR-107, -30c-2*, -349 
COL5A1 rno-miR-127, -27a* MAP2K2 rno-miR-874 
COL5A2 rno-miR-17-3p MAP2K3 rno-miR-10a-3p, -21* 
COL5A3 rno-miR-133b, -874 MAP2K5 rno-miR-349, -540 
COL6A2 rno-miR-125b-3p, -30c-1*, -30c-2* MAP2K7 rno-miR-125b-3p, -874 
COL6A3 rno-miR-139-3p, -21*, -291a-5p MAPK1 rno-miR-125b-3p, -139-3p, -671 
CRK rno-miR-107 MAPK10 rno-miR-139-3p 
DHH rno-miR-125b-3p MAPK11 rno-miR-127 
EGF rno-miR-379* MAPK12 rno-miR-874 
EGFR rno-miR-27b,  -455 MAPK13 rno-miR-133b, -27a*, -27b 
FASLG rno-miR-125b-3p, -21 MAPK14 rno-miR-107, -17-3p 
FGFR2 rno-miR-291a-5p MAPK3 rno-miR-30c-1*, -30c-2*, -542-5p  
FGFR3 rno-miR-125b-3p, -671 MAPK8 rno-miR-107 
FGFR4 rno-miR-25*, -540 MAPK8IP rno-miR-349, -449a 
FN1 rno-miR-25*, -27b MAPK8IP2 rno-miR-291a-5p 
GABBR1 rno-miR-21, -542-5p MAPK8IP3 rno-miR-874 
GABBR2 rno-miR-125b-3p MAPK9 rno-miR-29b-1* 
GLI1 rno-miR-139-3p MYC rno-miR-125b-3p 
GLI2 rno-miR-139-3p NOS3 rno-miR-291a-5p 
GLI3 rno-miR-10a-3p, 133b NOTCH1 rno-miR-449a, -874 
GNAO rno-miR-107, -21*, -30c-1*, -540 NOTCH2 rno-miR-27a* 




Gene miRNA Gene miRNA 
NTF3 rno-miR-21, -30c-1*, -30c-2*, -448 PSMD1 rno-miR-291a-5p 
NTF5 rno-miR-21, -30c-1*, -671 PSMD2 rno-miR-17-3p, -21*, -27a*, -540 
PAK1 rno-miR-125b-3p, -291a-5p PSMD3 rno-miR-449a, -455 
PAK3 rno-miR-291a-5p, -874 PSMD6 rno-miR-27b 
PAK4 rno-miR-30c-1*, -30c-2*, -542-5p PSMD8 rno-miR-139-3p 
PDGFB rno-miR-125b-3p, -540 PSME1 rno-miR-30c-1* 
PDGFD rno-miR-291a-5p PSME2 rno-miR-127 
PIK3R2 rno-miR-10a-3p, -29b-1* PTCH1 rno-miR-10a-3p, -349 
PIK3R3 rno-miR-139-3p, rno-miR-17-3p PTK2 rno-miR-139-3p, -21 
PLCG1 rno-miR-455, -540 PTK2B rno-miR-291a-5p 
PLCG2 rno-miR-127, -27b RAC2 rno-miR-125b-3p 
PRKCA rno-miR-107, -455, -448 RAF1 rno-miR-291a-5p 
PRKX rno-miR-17-3p RELA rno-miR-133b, -874 
PSEN1 rno-miR-139-3p, -291a-5p SH2D2A rno-miR-449a 
PSENEN rno-miR-30c-1*, rno-miR-30c-2* SOS2 rno-miR-21, -349, -449a 
PSMA1 rno-miR-29b-1* SPHK2 rno-miR-133b 
PSMA4 rno-miR-127, -449a SRC rno-miR-874 
PSMA5 rno-miR-448 SUFU rno-miR-27a* 
PSMA6 rno-miR-30c-1* TNFSF10 rno-miR-874 
PSMB1 rno-miR-455 TP53 rno-miR-25*, -349 
PSMB3 rno-miR-139-3p TRADD rno-miR-349 
PSMB4 rno-miR-139-3p, -21*, -448, -874 VEGFA rno-miR-25*,-671 
PSMB5 rno-miR-27a*, -349 WNT11 rno-miR-17-3p, -25*, -671 
PSMB7 rno-miR-125b-3p WNT16 rno-miR-449a 
PSMB8 rno-miR-671 WNT2B rno-miR-17-3p, -671 
PSMC1 
 
rno-miR-17-3p, -30c-1*, rno-miR-30c-2* WNT4 rno-miR-874 
PSMC3 rno-miR-125b-3p WNT5B rno-miR-125b-3p, -25* 
PSMC5 rno-miR-127, -21 WNT7A 
 
rno-miR-107, 139-3p,  -30c-1*, -30c-
2*, -449a 
PSMC6 rno-miR-107, -17-3p WNT9A rno-miR-125b-3p, -349, -540 
 
Table 5.4: Possible miRNA-mRNA interactions among the top 10 pathways 







Effects of anti miRNA-320a  
in ischemic stroke models
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6.1       Introduction  
Inflammatory response plays an important role in host defence against infection 
and injury as well as a contributing factor in multiple acute and chronic diseases 
such as ischemia/reperfusion damage, atherosclerosis [368, 369], cancer [370, 
371], virus infection and rheumatoid arthritis [372, 373]. In acute stroke, 
inflammatory response is also the underlying cause for vascular disease 
predisposition to stroke and as a precipitating process that triggers the acute event. 
Upon the onset of stroke, inflammation acts as an acute response to tissue injury 
which further exacerbates the damage.   
 
Inflammatory response is a process which is regulated by several genes. Among 
them, matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases 
(TIMPs) are known to play crucial roles in the downstream execution of 
inflammatory response. MMPs are matrix-degrading enzymes and they primarily 
regulate tissue remodelling by selective proteolytic degradation [374, 375]. MMPs 
also participate in various homeostatic and pathological processes including 
atherosclerosis, arthritis, cancer, neurodegeneration and cerebral ischemia [376-
382]. The expression and activity of MMPs are closely controlled at the 
transcriptional and posttranslational levels.  
 
The MMPs are primarily synthesized from inactive zymogen to active forms by 
proteolytic processing. The proteolytic activity of MMPs mediates degradation of 
denatured collagens, gelatins and extracellular matrix molecules comprising of 
type IV, V, and XI collagens, laminin and aggrecan core protein [383].  
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Among the many MMPs, MMP9/gelatinase B has been reported to have important 
functions in angiogenesis, tumor invasion, healing, inflammation and metastasis 
[384]. Also, there are studies showing that dysregulation MMP9 is associated with 
detrimental outcome in brain injury of both stroke patients and animal stroke 
models. Following the onset of cerebral ischemia, the expression of MMP9 is 
elevated which consequently results in the breakdown of BBB [295, 385]. The 
BBB consists of endothelial cells which form a protective fortress lining the brain 
capillaries in the neuronal microenvironment. These cells are held tightly to limit 
the movement of molecules between the blood and brain.  
 
MMP9 can degrade a number of extracellular matrix molecules (found in basal 
lamina that surrounds the capillary with pericytes) resulting in BBB breakdown. 
BBB breakdown following ischemic brain injury could initiate another series of 
detrimental episodes and escalate secondary injury and eventually leads to a poor 
outcome [386-388]. Proteolytic breakdown of the BBB also increases the 
permeability of the barrier hence allowing infiltration of inflammatory molecules 
and fluids into the brain which can cause the vasogenic edema, leukocyte 
infiltration, hemorrhagic transformation (HT) and neuronal cell death (Figure 6.1). 
 
A recent study found that the plasma concentration of MMP9 to be significantly 
elevated in acute ischemic stroke patients [389]. An independent study also 
reported an association between increased MMP9 expression with BBB disruption 
in 24hr post-stroke patients [390]. MMP9 has also been found to contribute to the 








Imaging (MRI) studies [393] also confirmed that MMP9 as the most powerful 
predictor of the infarct size. Horstmann et al. [394] found that the serum levels of 
MMP9 and laminin in 50 patients varied significantly with infarct size. Above all, 
studies on MMP9 knockout models as well as the use of MMP9 inhibitors or 
antibodies have demonstrated to provide protective effects to BBB, while reducing 
development of vasogenic edema and infarcts in cerebral ischemia [295, 392, 395-
399]. 
 
MMP9 is initially produced and secreted as inactive zymogen (pro-MMP9) and the 
pro-peptide domain must be cleaved into their active form for catalytic function 
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[400]. As illustrated in Figure 6.1, MMP2 and MMP3 are known activators of 
MMP9 [401, 402]. Pro-inflammatory cytokines such as interleukin1 (IL1α β), 
interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα) can also enhance 
MMP9 activity [403-406]. On the other hand, TIMP1 and TIMP3 have been 
identified as endogenous inhibitors of MMP9 [407-409] while TIMP2 inhibits pro-
MMP2 over 10 fold more effectively than TIMP1 [408-410].  
 
During ischemia, excessive matrix degradation is accompanied with imbalance in 
MMPs and TIMPs which results in an overall net increase in MMP activity [411].  
The stroke induced MMP expression can be expected to shift the protease to 
protease inhibitor balance towards proteolytic activity and ECM degradation [295]. 
In a community-based cohort of elderly men, serum MMP9 and TIMP levels were 
found to correlate with mortality risk and altered extracellular matrix metabolism 
[412]. Hence circulating MMP9 and TIMP1 levels have been considered as 
important biomarkers in stroke. Furthermore, several studies have shown that 
MMPs and TIMPs could control neuronal cell death and apoptosis by regulating 
excitotoxicity [413], activating death receptor [414], anoikis [415], and controlling 
the bioavailability of neurotrophic factors.  
 
Since the expression of MMP9 is elevated in both animal models and human stroke 
patients, MMP9 appears to be a potential diagnostic marker and target for the 
treatment of stroke. Inhibition of MMPs by TIMPs has been considerated as viable 
approach [376, 416-420]. Single or combination therapy with inhibition of MMP9 




miRNAs being endogenous regulators of gene expression could form potential 
modulators for MMPs and TIMPs. In our laboratory, Sepramaniam et al. [294] 
discovered that a particular miRNA, miR-320a could reduce the infarct volume in 
rat stroke models by targeting AQP1 and 4.  Bioinformatics search for targets of 
miR-320a, also identified MMP9 as a potential target.  
 
In the final part of this study, the potential of miR-320a as a regulator of MMP9 
was explored in ischemic setting.  
 
 
6.2 Bioinformatics predictions of miRNAs targeting MMPs and TIMPs  
In silico analysis of databases such as RegRNA (http://regrna.mbc.nctu.edu.tw/ 
html/about.html), Microcosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm 
/htdocs/targets/v5), TargetScanHuman6.1 (http://www.targetscan.org/) and 
microRNA.org (http://www.microrna.org/microrna/home.do) predicted several 
miRNAs that target MMPs (MMP2, 3 and 9) and TIMPs (TIMP1, 2 and 3) in 
human, rat and mouse (Table 6.1).  
 
These predictions are based on specific computational algorithms which may 
include seed matches, sources of target sequence information, conservation of the 
sequence across different species, thermodynamics of the miRNA-mRNA 
interaction and interaction specificity between 5‟ and 3‟ end of the miRNA-mRNA 
sequence [421-423]. TargetScan [424, 425], MicroCosm [426], and microRNA.org 
[427] and RegRNA [428] are the most established and commonly used miRNA- 


























 TargetScan Microcosm Targets microRNA.org RegRNA Union 
Gene Human Mouse Rat Human Mouse Rat Human Mouse Rat Human Mouse Rat Human Mouse Rat 
MMP2 41 54 45 13 20 0 24 7 0 531 415 246 549 434 261 
MMP3 88 24 22 89 62 9 31 5 6 329 300 178 392 330 184 
MMP9 40 30 6 46 18 12 7 10 10 351 435 245 385 444 245 
TIMP1 16 11 13 46 12 1 0 1 8 192 86 74 221 108 86 
TIMP2 93 232 127 2 1 11 36 38 0 555 514 154 593 591 240 







results were obtained from each database [429]. Since none of the databases is 
considered to be more superior than the other, prediction data from 4 databases are 
compiled to get a comprehensive list of predicted miRNA-mRNA interactions. 
 
Rat miRNAs predicted to target MMP2, 3, 9 and TIMP1, 2, 3 were shortlisted 
(Table 6.1). The list of miRNAs was streamlined to 3 miRNAs namely miR-320, -
632 and -665 which were identified as potential regulators of the 6 genes 
mentioned above (Supplementary table 3).  
 
 
6.3 miR-320a and cerebral ischemia created using intraluminal filament  
            (suture method) 
6.3.1    Expression of miRNAs in ischemic rat model 
Differential expression of miRNAs between normal and ischemic samples permits 
the identification of potential miRNAs as biomarkers or therapeutic targets for 
stroke (as reported in chapters 3 and 4).  Table 6.2 shows the selected 25 miRNAs 
that are expressed (in at least 2 samples) at 24 and 48hr reperfusion in ischemic 
brain samples after an hour of MCAo. Mapping the predicted 3 miRNAs (miR-320, 
-632 and -665) with the experimental data (Chapter 3, 4 and 5) identified miR-320 
for further investigation. Both miR-632 and -665 could not be detected from 
experimental models. Besides being conserved across mammals especially human, 
mouse and rat), miR-320 was also found to be highly expressed in ischemic brain 
as well as blood samples at 24 and 48hr (brain 24hr; 17.39±0.17, brain 48hr; 

















rno-miR-292-5p  3150.90 4750.80 33.90   
rno-miR-290  2405.49 12520.60 9.29 24.18 
rno-miR-327  1355.49 3962.35     
rno-miR-494  153.18 8.59 1.17 4.12 
rno-miR-214  114.20 70.28   3.80 
rno-miR-298  42.55 52.81     
rno-miR-215  40.93       
rno-miR-140*  23.45 10.08   1.30 
rno-miR-223  19.79 39.12     
rno-miR-320  17.39 11.42 0.81 1.96 
rno-miR-330  13.70 6.69     
rno-miR-206  11.26 12.71     
rno-miR-206  11.26 12.71     
rno-miR-129*  5.59 6.96     
rno-miR-497  5.47       
rno-miR-191  4.97 2.52 0.85 0.81 
rno-miR-451  4.75   1.37 2.54 
rno-miR-129  4.51 4.60     
rno-miR-422b  4.40       
rno-miR-331  3.69 5.88     
rno-miR-485  3.61 3.26     
rno-miR-99b  2.72 2.55     
rno-miR-185  2.30 1.54 0.54 0.14 
rno-miR-138  2.12 0.28     
rno-miR-324-5p  1.93 3.45     
 
Table 6.2: Relative expression of miRNAs on ischemic brain and blood samples at 
24 and 48hr reperfusion time points. The expression levels of 25 selected miRNAs 







The expression patterns of miR-320 in ischemic stroke samples (from miRNA 
microarray data and stem-loop PCR validation) at different reperfusion time points 
are shown in Table 6.3. The expression of miR-320 gradually increased and 
reached its peak at 24hr and declined at 48hr reperfusion. The expression of miR-
320 also correlated with the infarct volume (Chapter 4). This could imply that 






Relative expression (±SEM) 
miRNA array data stem-loop PCR 
0hr 1.0000±0.0081 1.0000±0.0500 
1hr 0.7556±0.0204 1.4095±0.2337 
3hr 0.7780±0.0104 1.2970±0.1007 
6hr 1.1190±0.0220 0.7957±0.3250 
12hr 1.0094±0.0229 1.1302±0.2268 
18hr 1.1177±0.0373 1.4789±0.3591 
24hr 1.9426±0.0516 1.9683±0.3356 
48hr 1.2248±0.0201 1.0710±0.1707 
 
Table 6.3: Expression of miR-320 at different reperfusion time points after suture 
method MCAo for an hour for both miRNA array data and validation of expression 
using stem-loop PCR. Data presented as relative expression test samples versus 0hr 


















6.3.2 Prediction of binding sites of miR-320 in MMP9 and TIMPs  
Five main different isoforms of miR-320a, b, c, d and e as well as a total of 11 
subtypes including miR-320a, -b, b-1, b-2, c, c-1, c-2, d, d-1, d-2, and e found in 
different locations on chromosomes have been reported in miRNA databases [250, 
424, 425, 427]. The variation between the sequences of miR-320 isoforms was 
only found at the 5‟UTR. Seed region of miRNA that is important for binding 
respective targets remains the same in all isoforms. Although miR-320a has been 
predicted to target MMP2, 3, 9 and TIMP1, 2, 3 in rats, such interaction were not 
conserved in humans for MMP2 and 3. In other words, only four (MMP9, TIMP1, 
2, and 3) out of the six genes of interest were predicted as targets of miR-320 in 
both rat and human. Hence, as a potential translational research, this study was 
limited to MMP9, TIMP1, 2 and 3. The sites of interaction of miR-320a with 
MMP9, TIMP1, 2 and 3 in rats are shown Figures 6.2 to 6.5 (rat) and Figure 6.6 to 
6.9 (human). In rat, the coding sequence (CDS) of MMP9 harbors two binding 
sites for miR-320 while CDS of TIMP1 only has one miRNA-320 binding site. On 
the other hand, each of the 3‟UTR of TIMP2 and 3 has only one binding site for 










    1 atgaacccct ggcagcccct gctcctggtg ctcctggctc taggctacag ctttgctgcc 
           miR-320a                |  |  |   |    : : | :    | |  |    | |  | | 
                                    3’   agcgggag aguugg-guc gaaaa   5’ 
   61 cctcaccagc gccagccgac ttatgtggtc ttcccccgag acctgaaaac ctccaacctc 
  121 acggacacac agctggcaga ggattacctg taccgctatg gttacactcg ggcagcccag 
  181 atgatgggag agaagcagtc cctgcggccc gctttgctga tgcttcagaa gcagctgtcc 
  241 ctgccccaga ctggtgagct ggacagcgag acactaaagg ccattcgttc accgcgctgt 
  301 ggtgtcccag acgtgggcaa attccaaacc ttcgaaggcg acctcaagtg gcaccatcat 
  ……………………………………………………………………………………………………………………………………………………………………………………… 
 1441 acagggggcc ccacagtcgc ccctacaggc gccccctcac ctggccccac aggtccccct 
 1501 actgctggtc cttctgaggc ccctacagag tcttcgactc cagtagacaa tccttgcaat 
 1561 gtggatgttt ttgatgccat tgctgatatc cagggcgctc tgcatttctt caaggacggt 
 1621 cggtattgga agttctcgaa tcacggagga agccaattgc agggcccctt tcttattgcc 
                    | | | 
                                                                                        3’    agcgg 
 1681 cgcacgtggc cagctttgcc tgcaaagttg aactcagcct ttgaggatcc gcagtccaag 
               |    |    |  :    :   |    |  |  |  |  |  |  |         miR-320a          
        gagagu-ugg gucgaaaa   5’ 
 1741 aagattttct tcttctctgg gcgcaaaatg tgggtgtaca caggccagac ggtgctgggc 
 1801 cccaggagtc tggataagtt ggggctaggc tcagaggtaa ccctggtcac cggacttctc 
 1861 ccgcgtcgtg gagggaaggc tctgctgatc agccgggaac gtatctggaa attcgacttg 
 1921 aagtctcaga aggtggatcc ccagagcgtt actcgcttgg ataacgagtt ctctggcgtg 
 1981 ccctggaact cacacaacgt ctttcactac caagacaagg cctatttctg ccatgacaaa 
 2041 tacttctggc gtgtgagttt ccacaaccgg gtgaaccagg tggaccacgt ggcctacgtg 
 2101 acctatgacc tcctgcagtg cccttgaact aaggctcctc ttttgcttca gcggtgcagc 
 2161 gcaagcctct agagaccacc cctgaggggg aggagctagt ttgccggata caaactggtg 
 2221 atctcttcta gagactagga aggagtggag gcgggcaggg ccctctctgc acgctgtcct 
 2281 ttcttgttgg actgtttcta ataaacacgg atcccccaac ctttaccagc tactcgaacc 
 2341 aatcagcttg tctgtagttg tatacacatc caagcctgtg gttggtcaga agacaacttt 
 2401 gtagggtcgg ttctgacctt ttgtttttat ggggcatctg gggattgaac tcagctggct 
 2461 tttgtgacaa gtacttcacc cgctgcacca ccttaccggc ccttttattt attatgtatg 
 2521 tggtcatgtt cacacacatg tatttaacct atagaatgct tactgtgcgt cgggcgctgc 
 2581 tccaactgct gtataaatat taaggtattc agttactcct actggaaggt attatgtaac 
 2641 catttctctc ttacatcgga ggacaccacc gagctatcca ctcatcaaac atttattgtg 
 2701 agcatcccta gggagccagg ctctctactg ggcattaggg acagaggaat ttattggatg 
 2761 ttggttcttc cttcaagaat cgctcaggga ttctcagtgt cctcaaaaca tgctgaaacc 
 2821 ggaccccaga ctccactctg gagaatccaa cccactcaca ggggaaacag cccgtttaaa 
 2881 gtgcatgtgt gctagagagg tagggtagcc gagatgatcc ctcagtggaa ggataaccaa 
 2941 gtatcttcct cggacactct tttttaaata aatgaataaa tgaaaa 
 
Figure 6.2: The sequence of the MMP9 gene (rat). The sequence was obtained 
from NCBI (NM_031055.1). The predicted binding site of miR-320a to the 
sequence of MMP9 is mapped. The seed region of miR-320a is in red. Start and 








    1 cggactccta gagacacgct agagcagata ccacgatggc gccctttgca tctctggcct 
   61 ctggcatcct cttgttgcta tcattgatag cttccagtaa agcctgtagc tgtgccccaa 
          
                         3’   agc 
  121 cccacccaca gacagctttc tgcaactcgg acctggttat aagggctaaa ttcatgggtt 
      ||| | || |   |||||||    miR-320a        
      gggagagu-u gggucgaaaa   5’ 
  181 ccccagaaat catcgagacc accttatacc agcgttatga gatcaagatg actaagatgc 
  241 tcaaaggatt cgacgctgtg ggaaatgcca caggtttccg gttcgcctac accccagcca 
  301 tggagagcct ctgtggatat gtccacaagt cccagaaccg cagcgaggag tttctcatcg 
  361 cgggccgttt aaggaacgga aatttgcaca tcactgcctg cagcttcctg gttccctggc 
  421 ataatctgag ccctgctcag caaaaggcct tcgtaaagac ctatagtgct ggctgtgggg 
  481 tgtgcacagt gtttccctgt tcagccatcc cttgcaaact ggagagtgac agtcattgct 
  541 tgtggacaga tcagatcctc atgggctctg agaagggcta ccagagcgat cactttgcct 
  601 gcctgccacg gaatccagat ttgtgcacct ggcaatacct tggggtctcg atgacccgaa 
  661 gccttcccct ggcaaaagct gaagcctgaa cactgtttac ctttcctcca tctttctttc 
  721 tcttaaatgg tgaaataaag 
 
Figure 6.3: The sequence of the TIMP1 gene (rat). The sequence was obtained 
from NCBI (NM_053819.1). The predicted binding site of miR-320a to the 
sequence of TIMP1 is mapped. The seed region of miR-320a is in red. Start and 












     1 cgcctcttcg cccccttgac aaagaggaca gaaagtttgc gcgggggagc gggccaggtg 
   61 aggaggggcg tgccggcgcc agcccgcgcc ccagcagccg gacccaggcc cctagcgcgc 
  121 ccgccatggg cgccgcggcc cgcagcctcc ggctggcgct cggcctcctg ctgctggcca 
  181 cgctgctgcg cccggccgac gcctgcagct gctccccggt gcacccgcaa caggcgtttt 
  241 gcaatgcaga cgtagtgatc agggccaaag cagtgagcga gaaggaggtg gattccggga 
  301 atgacatcta tggcaacccc atcaagagga ttcaatatga gatcaagcag ataaagatgt 
  361 tcaaaggacc tgacaaggac atcgaattta tctacacggc cccctcctca gcagtgtgcg 
  421 gggtctcgct ggacgttgga ggaaagaagg aatatctaat tgcagggaag gcggaaggag 
  481 atggcaagat gcacattacc ctctgtgact ttattgtgcc ctgggacacg cttagcatca 
  541 cccagaagaa gagcctaaac cacaggtacc agatgggctg cgagtgcaag atcacacgct 
  601 gccctatgat cccatgctac atctcctccc cggatgagtg cctctggatg gactgggtca 
  661 cagagaagag catcaatggg caccaggcca agttctttgc ctgcatcaag agaagtgatg 
  721 gttcttgcgc gtggtaccgc ggggcggcac ccccgaagca ggagtttctt gacatcgagg 
  781 acccgtaagc aggctgacag agccccctgt ggccaattga aaagcctctg agggttcaga 
                      
                                     3’   agcggga 
  841 ct-ggtccagc tttgacatcc cttcctggaa acagcatgaa taaaacatca atcatccaag 
      || :::||||| |||    miR-320a 
      gaguugggucg aaaa   5’ 
  901 tgggttcacg ctagtgtgat tctgcccccc cacccccatt ttccctanac atggtagngg 
  961 gtctagaggg acaggcgggc cagggtncct gccatacccc ctccctctgn cggcctgagc 
 1021 actgtgtgtc tcagtctttg atccttggta cagcaggagt agagcacagg ctttaccagg 
 1081 cctctctggc cctgttgcgt cagcagacag cagcattaag ggtcccctag caccgttagg 
 1141 gcagagcctg ggaacgtgca ttttgcagaa actcttgaag gttgttataa gactgtgtag 
 1201 ccggcctacc aggtcctttt catcctgaga gggtcatgtc cctcattttc tgcagtggcc 
 1261 atccctctgg cccaaggccc ttgcaaatgc tccccatccc tcctgcaccc agtctccctc 
 1321 aggtctaaga attgccctcc aaccagtgtt tcatttgcct aggagtccca gtcagcccta 
 1381 cgaacccaca gacgtccgtg aatggaagcc ctccctgagc cgtgtttctg gcttcatatt 
 1441 tcttccttcc tctctcttcc cctgtctcta cacaccccct cagtggggat ctgtgaggtc 
 1501 tcatgctgag ggcaggaacc tgtggtgagg ggtgcttggc tgtcctcgta atcactctca 
 1561 aggttcccaa gcttcttcac ccccttccaa gcttcaggca cctggggtga gcagcacagc 
 1621 tcatctctct gtcgcgttat gccctcccgc tgttgg 
 
Figure 6.4: The sequence of the TIMP2 gene (rat). The sequence was obtained 
from NCBI (NM_021989.2). The predicted binding site of miR-320a to the 
sequence of TIMP2 is mapped. The seed region of miR-320a is in red. Start and 







     1 cgggcagccg ccagcgccaa ggagcttctt ctcttgcttc tccgcttccc gatccttctc 
   61 ccggaggcca ctcactggct ccgcggactc gtgcgccaga cacccttggc cacttggtca 
  121 catcccgccg ggctacttgg aaggcacttc cccggagctc aaagttgccc accgtgcaca 
  181 gtgcacggtt aaacccggcg agtgagctcg gactgcagca ccggcgctag cgctcggcaa 
  241 ctttgaggaa aagagcggca gtccccgcag cggaccacag cagctaccat gactccctgg 
  301 cttgggcttg tcctgctcct gagctgctgg agccttgggc actggggaac ggaagcgtgc 
  361 acatgctcgc ccagccatcc ccaggatgcc ttctgcaact ccgacatcgt gatccgggcc 
  421 aaagtggtgg gaaagaagct ggtgaaggaa gggccctttg gcactctggt ctacactatt 
  481 aagcaaatga agatgtaccg aggattcagt aagatgcccc atgtgcagta cattcacaca 
  541 gaagcctctg aaagtctctg tggccttaag ctagaagtca acaaatacca gtacctgctg 
  601 acagggcgcg tgtatgaagg caagatgtac acagggctgt gcaactttgt ggagaggtgg 
  661 gaccacctca cactgtccca gcgcaagggc ctcaattacc gctaccacct gggttgcaat 
  721 tgcaagatca agtcctgcta ctacttgcct tgctttgtga cctccaagaa tgaatgtctc 
  781 tggaccgaca tgctctccaa tttcgggtac cctggctatc agtccaaaca ctacgcctgc 
  841 atccggcaga agggtggcta ctgcagctgg taccgaggat gggccccccc agacaagagc 
  901 atcagcaatg ccacagaccc ctgaacccag acctgtccca cctcacctcc ttcccatccc 
  961 gctgagcgtc ccggacacta actcttccca gatgatgaca atgaaattag tgcctgtttt 
 1021 cttgcaaatt tagcactggg ggacagttaa agtctctgcc gtttatggag ttgatttgga 
 1081 aataccttcc tggtcccgcc cccttatacc ccgtcttttt ggttttgaca tcacccattt 
 1141 ccaactgtgg atctctggtg ccaagccaga aagaatgaga ccgcacttcc atagacactt 
 1201 cttcatccaa gtacacagga agcatggata aggaagttgg cagaagtcca actgtttccc 
 1261 cgatcagcca agggcagcaa gcagacagac gccagagtct cctaatatgg cgctcctgat 
 1321 ctaccctgct caatgctctc ccgtatgtac accccagcct ctttcccaag aagtctctgg 
 1381 ccattctcag tccctgtgtg atcagcctcc ctcctacccg gacagacttg aggtgaggcc 
 1441 taagtatgag gcacctgaag ttaacctgaa gataaaacca ttggcagaac cacggcccca 
 1501 ggtggctgtt gaggtcttgg cgagaagtcc tgggcaagga aggtctttcg taaagtcaca 
 1561 tcattggaga gccgtttttg cgctttcaat aagctatagc tttgtttctt tctcctgttc 
                   | | ||:||||     |: :||| |||    miR-320a          
    3’   agc gggagaguu- ---gg-gucg-aaaa   5’ 
 1621 acttactgta taacttaaag tcatttatgt agctgagaca ctttgttatt tcaatcatat 
 1681 cgtgaatgtt ttattttgct aaatcatgtg ccatgtgtag gctgtcgtgt gtacactgtg 
 1741 tctaagagaa gaagaaaaaa aaaaaaaaaa aaaaaaaa 
 
Figure 6.5: The sequence of the TIMP3 gene (rat). The sequence was obtained 
from NCBI (012886.2). The predicted binding site of miR-320a to the sequence of 
TIMP3 is mapped. The seed region of miR-320a is in red. Start and stop codon 








    1 agacacctct gccctcacca tgagcctctg gcagcccctg gtcctggtgc tcctggtgct 
   61 gggctgctgc tttgctgccc ccagacagcg ccagtccacc cttgtgctct tccctggaga 
  121 cctgagaacc aatctcaccg acaggcagct ggcagaggaa tacctgtacc gctatggtta 
  181 cactcgggtg gcagagatgc gtggagagtc gaaatctctg gggcctgcgc tgctgcttct 
  241 ccagaagcaa ctgtccctgc ccgagaccgg tgagctggat agcgccacgc tgaaggccat 
  301 gcgaacccca cggtgcgggg tcccagacct gggcagattc caaacctttg agggcgacct 
  ……………………………………………………………………………………………………………………………………………………………………………………… 
 1441 tgtccacccc tcagagcgcc ccacagctgg ccccacaggt cccccctcag ctggccccac 
 1501 aggtcccccc actgctggcc cttctacggc cactactgtg cctttgagtc cggtggacga 
 1561 tgcctgcaac gtgaacatct tcgacgccat cgcggagatt gggaaccagc tgtatttgtt 
 1621 caaggatggg aagtactggc gattctctga gggcaggggg agccggccgc agggcccctt 
 1681 ccttatcgcc gacaagtggc ccgcgctgcc ccgcaagctg gactcggtct ttgaggagcg 
 1741 gctctccaag aagcttttct tcttctctgg gcgccaggtg tgggtgtaca caggcgcgtc 
 1801 ggtgctgggc ccgaggcgtc tggacaagct gggcctggga gccgacgtgg cccaggtgac 
 1861 cggggccctc cggagtggca gggggaagat gctgctgttc agcgggcggc gcctctggag 
 1921 gttcgacgtg aaggcgcaga tggtggatcc ccggagcgcc agcgaggtgg accggatgtt 
 1981 ccccggggtg cctttggaca cgcacgacgt cttccagtac cgagagaaag cctatttctg 
 2041 ccaggaccgc ttctactggc gcgtgagttc ccggagtgag ttgaaccagg tggaccaagt 
 2101 gggctacgtg acctatgaca tcctgcagtg ccctgaggac tagggctccc gtcctgcttt 
 2161 ggcagtgcca tgtaaatccc cactgggacc aaccctgggg aaggagccag tttgccggat 
 2221 acaaactggt attctgttct ggaggaaagg gaggagtgga ggtgggctgg gccctctctt 
                     ||||||||  
                                                     3’   ag cgggagaguu 
 2281 ctcacctttg ttttttgttg gagtgtttct aataaacttg gattctctaa cctttaaaaa 
      |:|| ||||    miR-320a 
      gggucgaaaa   5’ 
2341 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 
 
Figure 6.6: The sequence of the MMP9 gene (human). The sequence was obtained 
from NCBI (NM_004994.2). The predicted binding site of miR-320a to the 
sequence of MMP9 is mapped. The seed region of miR-320a is in red. Start and 












   1 tttcgtcggc ccgccccttg gcttctgcac tgatggtggg tggatgagta atgcatccag 
  61 gaagcctgga ggcctgtggt ttccgcaccc gctgccaccc ccgcccctag cgtggacatt 
 121 tatcctctag cgctcaggcc ctgccgccat cgccgcagat ccagcgccca gagagacacc 
 181 agagaaccca ccatggcccc ctttgagccc ctggcttctg gcatcctgtt gttgctgtgg 
 241 ctgatagccc ccagcagggc ctgcacctgt gtcccacccc acccacagac ggccttctgc 
 301 aattccgacc tcgtcatcag ggccaagttc gtggggacac cagaagtcaa ccagaccacc 
 361 ttataccagc gttatgagat caagatgacc aagatgtata aagggttcca agccttaggg 
 421 gatgccgctg acatccggtt cgtctacacc cccgccatgg agagtgtctg cggatacttc 
 481 cacaggtccc acaaccgcag cgaggagttt ctcattgctg gaaaactgca ggatggactc 
 541 ttgcacatca ctacctgcag ttttgtggct ccctggaaca gcctgagctt agctcagcgc 
      ||  | ||  | |||  ||| :|||   miR-320a 
 3’ agcg-ggaga guugg — guc gaaaa   5’ 
 601 cggggcttca ccaagaccta cactgttggc tgtgaggaat gcacagtgtt tccctgttta 
 661 tccatcccct gcaaactgca gagtggcact cattgcttgt ggacggacca gctcctccaa 
 721 ggctctgaaa agggcttcca gtcccgtcac cttgcctgcc tgcctcggga gccagggctg 
 781 tgcacctggc agtccctgcg gtcccagata gcctgaatcc tgcccggagt ggaagctgaa 
 841 gcctgcacag tgtccaccct gttcccactc ccatctttct tccggacaat gaaataaaga 
 901 gttaccaccc agcagaaaaa aaaaaaaaaa a 
 
Figure 6.7: The sequence of the TIMP1 gene (human). The sequence was obtained 
from NCBI (NM_003254.2). The predicted binding site of miR-320a to the 
sequence of TIMP1 is mapped. The seed region of miR-320a is in red. Start and 











   1 cgcagcaaac acatccgtag aaggcagcgc ggccgccgag aaccgcagcg ccgctcgccc 
  61 gccgcccccc accccgccgc cccgcccggc gaattgcgcc ccgcgcccct cccctcgcgc 
 121 ccccgagaca aagaggagag aaagtttgcg cggccgagcg gggcaggtga ggagggtgag 
 181 ccgcgcggga ggggcccgcc tcggccccgg ctcagccccc gcccgcgccc ccagcccgcc 
 241 gccgcgagca gcgcccggac cccccagcgg cggcccccgc ccgcccagcc ccccggcccg 
 301 ccatgggcgc cgcggcccgc accctgcggc tggcgctcgg cctcctgctg ctggcgacgc 
 ……………………………………………………………………………………………………………………………………………………………………………………… 
 961 cataagcagg cctccaacgc ccctgtggcc aactgcaaaa aaagcctcca agggtttcga 
1021 ctggtccagc tctgacatcc cttcctggaa acagcatgaa taaaacactc atcccatggg 
1081 tccaaattaa tatgattctg ctcccccctt ctccttttag acatggttgt gggtctggag 
1141 ggagacgtgg gtccaaggtc ctcatcccat cctccctctg ccaggcacta tgtgtctggg 
1201 gcttcgatcc ttgggtgcag gcagggctgg gacacgcggc ttccctccca gtccctgcct 
1261 tggcaccgtc acagatgcca agcaggcagc acttagggat ctcccagctg ggttagggca 
1321 gggcctggaa atgtgcattt tgcagaaact tttgagggtc gttgcaagac tgtgtagcag 
1381 gcctaccagg tccctttcat cttgagaggg acatggccct tgttttctgc agcttccacg 
1441 cctctgcact ccctgcccct ggcaagtgct cccatcgccc cggtgcccac catgagctcc 
1501 cagcacctga ctccccccac atccaagggc agcctggaac cagtggctag ttcttgaagg 
1561 agccccatca atcctattaa tcctcagaat tccagtggga gcctccctct gagccttgta 
1621 gaaatgggag cgagaaaccc cagctgagct gcgttccagc ctcagctgag tctttttggt 
1681 ctgcacccac ccccccaccc cccccccccc gcccacatgc tccccagctt gcaggaggaa 
                       miR-320a       |||| | | |   ||||||||  
                              3’   ag cgggag-a-g uugggucgaa aa   5’ 
1741 tcggtgaggt cctgtcctga ggctgctgtc cggggccggt ggctgccctc aaggtccctt 
1801 ccctagctgc tgcggttgcc attgcttctt gcctgttctg gcatcaggca cctggattga 
                          ||  |||   :| | 
            3’   agcg- gga---gagu 
1861 gttgcacagc tttgctttat ccgggcttgt gtgcagggcc cggctgggct ccccatctgc 
        :| |||| |||    miR-320a 
     ---ugggucg aaaa   5’ 
1921 acatcctgag gacagaaaaa gctgggtctt gctgtgccct cccaggctta gtgttccctc 
1981 cctcaaagac tgacagccat cgttctgcac ggggctttct gcatgtgacg ccagctaagc 
………………………………………………………………………………………………………………………………………………………………………………………… 
3541 gaacacacaa gagttgttga aagttgacaa gcagactgcg catgtctctg atgctttgta 
3601 tcattcttga gcaatcgctc ggtccgtgga caataaacag tattatcaaa gagaaaaaaa 
3661 aaaaaaaaaa 
 
Figure 6.8: The sequence of the TIMP2 gene (human). The sequence was obtained 
from NCBI (NM003255.4). The predicted binding site of miR-320a to the 
sequence of TIMP2 is mapped. The seed region of miR-320a is in red. Start and 






   1 ctgtggcttg ccccagagct gatccttgtc tttgtccact tctcagcgag gatggcactt 
  61 cagggagccc ttcccttact atcgcagaga gagcaggccc tccccagtca tgtccaaccc 
 121 agaactctgt tttgttttct tcatagccct agcatcacag aaaatcaccc tgtgcattca 
 181 tggatgtcca cgggggcaag ggctttgtgt tgcttaaccc agcatcctga accgtgtttg 
 241 ttgaatgaat acagaacccc gtttgctctg ggagagcaca gaaaacagtc ttctatcata 
 301 tatcatagcc agctgcaaac agcagatggc ttcccatatc ccagagagta agaaccagag 
 ……………………………………………………………………………………………………………………………………………………………………………………… 
1081 cggcccggcg ggcgagcgag ctcgggctgc agcagccccg ccggcggcgc gcacggcaac 
1141 tttggagagg cgagcagcag ccccggcagc ggcggcagca gcggcaatga ccccttggct 
1201 cgggctcatc gtgctcctgg gcagctggag cctgggggac tggggcgccg aggcgtgcac 
1261 atgctcgccc agccaccccc aggacgcctt ctgcaactcc gacatcgtga tccgggccaa 
1321 ggtggtgggg aagaagctgg taaaggaggg gcccttcggc acgctggtct acaccatcaa 
1381 gcagatgaag atgtaccgag gcttcaccaa gatgccccat gtgcagtaca tccatacgga 
1441 agcttccgag agtctctgtg gccttaagct ggaggtcaac aagtaccagt acctgctgac 
1501 aggtcgcgtc tatgatggca agatgtacac ggggctgtgc aacttcgtgg agaggtggga 
1561 ccagctcacc ctctcccagc gcaaggggct gaactatcgg tatcacctgg gttgtaactg 
1621 caagatcaag tcctgctact acctgccttg ctttgtgact tccaagaacg agtgtctctg 
1681 gaccgacatg ctctccaatt tcggttaccc tggctaccag tccaaacact acgcctgcat 
1741 ccggcagaag ggcggctact gcagctggta ccgaggatgg gcccccccgg ataaaagcat 
1801 catcaatgcc acagacccct gagcgccaga ccctgcccca cctcacttcc ctcccttccc 
………………………………………………………………………………………………………………………………………………………………………………………… 
4081 gaagtttccc tgcggagtcg ataaattagc agaaccacat ccccatctgt taggccttgg 
4141 tgaggaggcc ctgggcaaag aagggtcttt cgcaaagcga tgtcagaggg cggttttgag 
         |  
                 3’   agc 
4201 ctttctataa gctatagctt tgtttatttc acccgttcac ttactgtata atttaaaatc 
     |::||| :||  |  :||||| |    miR-320a 
     gggaga-guu gg--gucgaa aa   5’ 
4261 atttatgtag ctgagacact tctgtatttc aatcatatca tgaacatttt attttgctaa     
………………………………………………………………………………………………………………………………………………………………………………………… 
5161 ggcgagagga aggggagaac ttggagaata gtttttgctt tgggggtaga ggcttcttag 
5221 attctcccag catccgcctt tccctttagc cagtctgctg tcctgaaacc cagaagtgat 
5281 ggagagaaac caacaagaga tctcgaaccc tgtctagaag gaatgtattt gttgctaaat 
5341 ttcgtagcac tgtttacagt tttcctccat gttatttatg aattttatat tccgtgaatg 
5401 tatattgtct tgtaatgttg cataatgttc actttttata gtgtgtcctt tattctaaac 
5461 agtaaagtgg ttttatttct atcacaaaaa aaaaaa 
 
Figure 6.9: The sequence of the TIMP3 gene (human). The sequence was obtained 
from NCBI (NM_000362.4). The predicted binding site of miR-320a to the 
sequence of TIMP3 is mapped. The seed region of miR-320a is in red. Start and 




6.3.3  MMP9 and TIMPs expression in ischemic brain slices 
The expression level of MMP9, TIMP1, 2 and 3 was obtained from the DNA 
oligonucleotide microarray data. As shown in Table 6.4, the expression of MMP9 
increased while expression of TIMP1 (endogenous inhibitor of MMP9) TIMP1 
decreased at 48hr reperfusion time point. TIMP2 was found to be elevated at 48hr 
time point whereas TIMP3 remained unchanged. Similar expression pattern of 
these genes was observed in 3 independent DNA microarray data. Hence the 
expression levels of MMP9 and TIMP1 correlated with the expression of miR-




Relative expresion at different  
reperfusion time point 
  24hr 48hr 
Mmp9 2.3308 2.6866 
Timp1 12.0041 9.0686 
Timp2 1.0550 1.5342 
Timp3 1.0993 1.0882 
 
 
Table 6.4: The expression of MMP9 and TIMPs in ischemic brain slices at 24 and 
48hr reperfusion time points after MCAo. Similar results obtained from 3 















6.3.4 Intracerebroventricular injection (i.c.v.) of anti miR-320a reduces 
infarct volume in suture MCAo model 
To study the effect of miR-320a in stroke, intracerebroventricular injections of 
50pmoles [430] of anti or pre miR-320a were administered to ischemic rats 
immediately after MCAo (within an hour post MCAo). The coronal sections of 
TTC stained brain slices and percentage of infarct volumes are shown in Figure 
6.10 (A and B). Administration of unmodified anti miR-320a (within an hour) 
resulted in a reduction in the infarct volume by 61% similar to those injected with 
LNA miR-320a at 3hr post MCAo (63%). Interestingly, infarct volume decreased 
further by 74% when LNA anti-miR-320a was administrated at 1hr post MCAo. 
However, i.c.v. treatment with pre miR-320a caused a slight increase in infarct 
volume by 25%. 
 
Stem-loop PCR results showed that the relative expression of miR-320a level was 
0.452±0.23 in anti miR-320a-injected MCAo brain slices which implied a 55% 
reduction in expression as compared with MCAo rats treated with transfection 
agent alone. However, miR-320a expression increased to 9.26±2.31 in pre miR-
320a injected MCAo rats which is about 10 fold higher than MCAo treated with 
transfection agent alone (Table 6.5).  
 
Most importantly, intracerebroventricular (i.c.v.) administration of miR-320a was 
found to be safe with more than 90% survival rate. Moreover, there was no 






























Figure 6.10: Histopathological analysis of coronal sections of brain slices. (A) 
TTC stained brain slices (2mm) after treatment with transfection agent, pre/anti 
miR-320a, LNA anti miR-320a (50pmoles) intracerebroventricularly (i.c.v.) within 
1hr and 3hr post MCAo. Results are representative of at least 6 independent 
experiments and values obtained in mm
3
 are expressed as percentage of 
transfection agent-treated control ± SEM. statistical analyses were done using t 
tests. * p < 0.05. 
* 
* 
  MCAo            MCAo +               MCAo +      MCAo + LNA     MCAo + LNA 
(control)      pre miR-320a       anti miR-320a   anti miR-320a     anti miR-320a 




Treatment Relative expression level of miR-320a 
Anti miR-320a 0.452±0.23 
Pre miR-320a 9.26±2.31 
 
Table 6.5: miR-320a expression in ischemic rats subjected to 
intracerebroventricular injections of anti or pre miR-320a. The expression changes 
in miR-320a were quantitated using stem-loop real-time PCR. Relative expression 
of miR-320a was expressed in relation to the respective anti and pre negative 
controls. Data shown are mean ± SD, n=6 (result obtained from co-worker [294]). 
 
 






Total number of animal 
(n) 
eMCAo 60.47 37.21 2.33 43 
eMCAo + rt-PA 67.12 21.92 10.96 73 
eMCAo + anti miR-320a (i.v.) 90.91 9.1 - 11 
eMCAo + rt-PA + anti miR-320a (IV) 84.12 14.29 1.59 63 
 
Table 6.6: Reduction of mortality in treated MCAo rats. 
 
 
6.3.6 Anti miR-320a reduces BBB permeability  
Evans Blue (EB), an azo dye has been used to perform viability assay based on its 
ability to stain non-viable cells [431]. This dye also has great affinity for serum 
albumin.  The serum albumin could not cross the BBB in the normal neural tissues 
and hence these tissues will remain unstained with EB dye [432]. However, 
albumin-bound EB can enter the CNS when the BBB has been compromised. It 
fluoresces with excitation at 620nm and an emission peak at 680nm [433].  As 
reported previously, elevated expression of MMP9 during stroke is likely to 
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compromise the permeability of BBB which then leads to edema and neuronal cell 
damage.  
 
To investigate the miR-320a mediated modulation of MMP9 and its relevance to 
BBB extravasation, EB dye was first intravenously (IV) infused to MCAo rats via 
femoral vein (section 2.2.1.1.11) and followed by an administration of anti-miR-
320a (i.c.v.) within 30min post introduction of clots. Figure 6.11 shows the results 
of the whole MCAo brain that was infused with EB dye in the presence or absence 
of anti/pre miRNA. The absence of blue colour on the surface of the hemispheres 
of sham-operated or right hemisphere of MCAo rat brains indicated that 
administration of anesthesia or transfection agent as well as the surgical procedures 
did not disturb the BBB (Figure 6.11A). Rats subjected to either MCAo alone or 
MCAo with pre miR-320a showed increased intensity in EB dye which indicated 
breakdown of BBB (Figure 6.11 B and C). On the contrary, rats subjected to 
MCAo followed by administration of anti miR-320a showed minimal diffusion of 
EB dye (Figure 6.11D) which implied that BBB was not compromised to the extent 
as in Figure 6.11 (B and C)  
 
Quantitative evaluation of EB content (Figure 6.12) confirmed the visual 
appearance of incorporation of the dye in Figure 6.11. Low EB contents of the 
hemispheres of sham-operated or contralateral hemispheres of MCAo rat again 
demonstrated that administration of anesthesia or transfection agent as well as the 
surgical procedures did not affect the integrity of BBB. The EB content was found 
to be elevated in ipsilateral hemispheres (lesioned hemisphere) of MCAo + 
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transfection agent to 16.65±3.56 and MCAo + pre miR-320a to 15.04±1.9µg/g 
tissue respectively. There was an 80% reduction in EB content (2.74±0.71µg/g 














Figure 6.11: Photographs of ischemic rat brains administrated with IV infusion of 
EB. (A) The BBB remains intact with almost no extravasation of EB in sham-
operated animals. (B) BBB disruption caused by MCAo leads to accumulation of 
blue dye in ipsilateral hemisphere. (C) BBB disruption enhanced when pre-miR-
320a was administered in MCAo rats. (D) BBB disruption reduced upon treatment 







Figure 6.12: Quantitative representation of EB contents (µg/g) in the brain tissues 
of the right and the right hemispheres of sham-operated, MCAo, MCAo + pre anti-
miR320a and MCAo + anti miR-320a. All values are mean ± SEM. *significantly 
different from Sham and respective right hemisphere (p < 0.05) ** significantly 




6.3.6 Anti miR-320a reduced the swelling of ischemic brain tissues  
The measurement of percentage of tissue swelling (brain swelling) in MCA 
occluded hemispheres was performed using the TTC according to section 
2.2.1.1.12 and the results are shown in Figure 6.13.  The tissue swelling percentage 
of respective rat brains were as follows: MCAo control 18.03±3.16%, pre-miR-
320a treated samples 19.16±3.16%, anti miR-320a (both naked miRNA and LNA 
miRNA) treated samples were 5.13±1.86% and 4.56±0.82% respectively. This 
indicated 75% reduction in brain swelling upon administration of anti-miR-320a 
within an hour of occlusion. Anti miR-320a intervention at 3hr was found to be 











Figure 6.13: Brain tissue swelling of ipsilateral hemispheres (%) upon MCAo, 
MCAo + pre miR320a and MCAo + anti miR-320a. All values are mean ± SEM. * 
significantly different from MCAo (control, p < 0.05). 
 
 
6.3.7 Anti miR-320a treatment in ischemic brain water content and edema  
Breakdown of the BBB allows entry of excessive fluid into the brain which results 
in vasogenic edema. Percentage of brain water content as well as edema was 
evaluated according to section 2.2.1.1.13. As shown in Figure 6.14, significant 
increase in the percentage of brain water content was observed in ipsilateral 
hemispheres of MCAo (control) brain sample (74.87±1.23%) and MCAo + pre 
miR-320a (74.27±0.59%). In the sham-operated group, the mean water content of 
the ipsilateral and contralateral hemispheres was 70.10±0.38% and 69.51±0.24% 
respectively. On the contrary, MCAo rats which were treated with anti miR-320a 
showed a significant reduction in percentage of brain water content (69.54±2.11%) 










Figure 6.14: Brain water content (BWC) (%) of contralateral and ipsilateral 
hemispheres of sham-operated and MCAo + transfection agent, MCAo + pre miR-
320a and MCAo + anti miR-320a. All values are mean ± SEM from (n=6). 
*indicates that water content (%) were significantly different from contralateral 
hemisphere of MCAo and MCAo + pre miR-320a with respective contralateral 
hemispheres. (p<0.05). * denotes that water content (%) was significantly different 
from ipsilateral hemisphere of sham-operated (p < 0.01). ** significantly different 





Figure 6.15 shows the percentage of edema from the 4 groups mentioned above. In 
control (MCAo + transfection agent), percentage of edema was about 5.06±0.62, 
while MCAo + pre miR-320a was 5.11±0.59%. The percentage of edema 



















Figure 6.15: Edema formation. Percentage of edema compared to MCAo are 
shown, when pre miR-320a and anti miR-320a were administered separately. All 
values are mean ± SEM (n=6). * significantly different from sham-operated (p < 













6.4 Effect of anti-miR-320a treatment in embolic stroke models with and 
without rt-PA treatment  
In this section, the study on the effect of anti miRNA-320a was extended to 
embolic stroke models with and without thrombolytic (tissue plasminogen 
activator, rt-PA) therapy. The expression profile of miRNAs in eMCAo has been 
described in Chapter 5.  
 
Wistar rats (n=6) were divided into 9 treatment groups as follows: 
Group Experiments/treatments 
1 Sham-operated transient embolic stroke 
2 Transient embolic stroke and administration of 0.9% saline intravenously 3hr post introduction of 
homologous clot 
3 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 3hr post 
introduction of homologous clot 
4 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 4hr post 
introduction of homologous clot 
5 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 5hr post 
introduction of homologous clot 
6 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 6hr post 
introduction of homologous clot 
7 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 8hr post 
introduction of homologous clot 
8 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 10hr 
post introduction of homologous clot 
9 Transient embolic stroke and administration of 10mg/kg body weight rt-PA intravenously at 12hr 
post introduction of homologous clot 
 
rt-PA was infused at 10mg/kg body weight as 10% bolus followed by 90% 
continuous infusion over 30min according to Fujiwara et al.[322] at 3, 4, 5, 6, 8, 
10, 12 and 18hr post embolic stroke respectively. The CBF of each animal was 
measured using laser-doppler flowmetry. Rats were monitored for about an hour 




6.4.1  rt-PA confers neuroprotection to rats subjected to embolic stroke 
(eMCAo) 
eMCAo rats infused intravenously with 10mg/kg rt-PA via left femoral vein were 
left for recovery for 24hr and then euthanized. The brain slices (n=6 each case) 
were stained with 2% of TTC. The infarct volumes measured were found to be 
reduced by more than 60% when compared with that of eMCAo rats without 
treatment (NA). When rt-PA was given to rats at 3, 4 and 5hr after introduction of 
the clot, the percentage of infarct volume remained at a lower value of 36.18±6.16, 
34.48±10.19% and 38.63±3.58% respectively. The infarct volumes at later time 
points of 6, 8, 10 and 12hr were found to be higher, 78.96 ± 3.82%, 82.45±17.85%, 
77.73±7.93%, 84.99±2.47% respectively (Figure 6.16A & B) showing rt-PA is less 
effective at later time points. Hence these results remain consistent with the recent 
findings by Davis et al. [434] and Baldwin et al. [435] and to the interpretation that 



























Figure 6.16: Histopathological analysis of brain coronal sections. (A) The panels 
of brain slices showing the serial coronal section (2mm) stained with 2% TTC after 
infusion with 10mg/kg rt-PA at different time points post eMCAo (3, 4, 5, 6, 8, 10, 
12 and 18hr). (B) Infarct volumes were quantitated using Image J. Results 
(average) are representative of at least 3 independent experiments and values 
obtained in mm
3
 are expressed as percentage of saline-treated control ± SEM * 
significantly different from MCAo without rt-PA treatment (p < 0.05). (NA 
denotes eMCAo without administration of rt-PA). 
     NA             3hr              4hr             5hr              6hr             8hr            10hr          12hr          
* * * 
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Initially, a preliminary study was carried out to determine whether concentration of 
rt-PA to be administered into eMCAo rats can be reduced by at least 50% (5mg/kg) 
from the recommended 10mg/kg dose [436]. Figure 6.17A & B show the results 
from 5mg/kg rt-PA which was infused intravenously via left femoral vein with a 
10% bolus and 90% continuous infusion over 30min at 30min, 1, 2, 3 and 4hr post 
embolic stroke respectively. Reduction in infarct volume was lesser compared to 
when 10mg/kg rt-PA was administered. Hence the dosage was fixed at 10mg/kg 
for all experiments with rt-PA. Figure 6.18 shows dissolution of clots due to the 
fibrinolytic activity of rt-PA post eMCAo. Ischemic rats exhibiting hemorrhagic 
































Figure 6.17: Histopathological analysis of brain slices (coronal sections). (A) 
Serial coronal sections (2mm) stained with TTC at different time points post 
administration of 5mg/kg rt-PA (30min, 1, 2, 3 and 4hr). (B) Infarct volumes were 
quantitated using Image J and values obtained in mm
3
 are expressed as percentage 
of saline-treated control. (NA denotes eMCAo without administration of rt-PA). 
Sham-operated rats are the negative control. eMCAo rats without rt-PA treatment 
are the positive control. ** denotes p < 0.01 as compared NA. 








Figure 6.18: Rat brain dissection. Examples of clot dissolved (observed 24hr post 











Figure 6.19: (A) eMCAo rats that died due to hemorrhagic transformation. (B) 
eMCAo rats showing hemorrhagic transformation with rt-PA treatment had 
hemorrhagic transformation when treated with rt-PA. Such samples were excluded 
from this study.  
 
 
 (i)                   (ii) 
(i)                           (ii)                                 (iii)                               (iv) 
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6.4.2  Intracerebroventricular injection (i.c.v.) of anti miR-320a reduces 
infarct volume in embolic MCAo model  
To study the effect of miR-320a in embolic stroke model, dose dependent activity 
of anti miR-320a was carried out.  LNA anti miR-320a was administered via i.c.v. 
at 25, 50 and 125pmoles/300g rat upon MCAo. Infarct volume measured at 24hr 
post eMCAo demonstrated that reduction in infarct volume was dose dependent 
and that 125pmoles LNA anti miR-320a resulted in infarct reduction by 67% 
compared with control MCAo (Figure 6.20). 50pmoles of LNA anti miR-320a was 
only able to reduce the infarct volume by 22%. 
 
Time dependent effects of anti miR-320a was also performed to determine the 
optimal time for administration of anti miR-320a to MCA occluded rat. The results 
showed that the infarct volume could be reduced by about 50% when the anti miR-
320a was administered at 3 and 4hr post respectively while only 27% reduction in 






































Figure 6.20: Histopathological analysis of brain slices. (A) Serial coronal sections 
(2mm thick) were stained with TTC after different concentration of LNA anti mR-
320a (25pmoles, 50pmoles, and 125pmoles) was administered i.c.v. at 3hr post 
eMCAo. (B) Infarct volumes quantitated using Image J and the values in mm
3
 are 
expressed as percentage of saline-treated control. Sham-operated rats are the 
negative control. eMCAo rats without treatment are the positive control. * denotes 
p < 0.05 as compared eMCAo. 
 
 
 eMCAo          eMCAo + LNA    eMCAo + LNA   eMCAo + LNA 
 (control)           anti miR-320a      anti miR-320a     anti miR-320a       

















Figure 6.21: Histopathological analysis of brain slices. (A) Serial coronal sections  
(2mm) were stained with TTC after LNA anti-mR-320a (50pmoles) was 
administered i.c.v. at different time points post eMCAo (3, 4 and 5hr post 
eMCAo). (B) Infarct volumes quantitated using Image J and the values in mm
3 
and 
are expressed as percentage of saline-treated control. Sham-operated rats are the 
negative control. eMCAo rats without treatment are the positive control. Scrambled 
miRNA was used as negative control for LNA anti miR-320a treatment. * denotes 
p < 0.05 as compared eMCAo. 
   eMCAo        eMCAo +   eMCAo + LNA  eMCAo + LNA  eMCAo + LNA 
  (control)       scrambled      anti miR-320a    anti miR-320a    anti miR-320a  
                         miRNA           (3hr post)            (4hr post)           (5hr post) 





6.4.3    Effects of combination therapy with rt-PA and miR-320a in eMCAo 
Since rt-PA and anti-miR-320a could independently reduce the infarct size in 
MCAo, a combination treatment was attempted with a view of improving the 
effects of rt-PA as well as widening the therapeutic window. A wider therapeutic 
window for stroke could imply more adequate neuroprotective effect to the 
neuronal cells. Combination therapy with compounds other than miRNAs for 
cerebral ischemia had been reported previously [437-439]. In this study, rats (n=6) 
subjected to eMCAo were administered with 10mg/kg rt-PA plus LNA anti miR-
320a at two concentrations (0.5 and 0.75nmol).  
The following 14 conditions were examined: 
Group Experiments/treatments 
1 Sham-operated transient embolic stroke 
2 Transient embolic stroke and administration of 0.9% saline intravenously 3hr post introduction of 
homologous clot 
3 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol of LNA anti miR-320a 
intravenously at 3hr post introduction of homologous clot 
4 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 4hr post introduction of homologous clot 
5 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 5hr post introduction of homologous clot 
6 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 6hr post introduction of homologous clot 
7 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 8hr post introduction of homologous clot 
8 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 10hr post introduction of homologous clot 
9 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.5nmol  of LNA anti miR-320a 
intravenously at 12hr post introduction of homologous clot 
10 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.75nmol  of LNA anti miR-
320a intravenously at 6hr post introduction of homologous clot 
11 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.75nmol  of LNA anti miR-
320a intravenously at 8hr post introduction of homologous clot 
12 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.75nmol  of LNA anti miR-
320a intravenously at 10hr post introduction of homologous clot 
13 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.75nmol  of LNA anti miR-
320a intravenously at 12hr post introduction of homologous clot 
14 Transient embolic stroke and administration of 10mg/kg rt-PA + 0.75nmol  of LNA anti miR-
320a intravenously at 18hr post introduction of homologous clot 
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As shown in Figure 6.22, combination therapy of 10mg/kg rt-PA and 0.5nmol 
LNA anti miR-320a extended the therapeutic window up to 8hr post eMCAo with 
reduction in infarct volume by 56% as compared to rt-PA treatment alone in which 
the infarct volume was reduced by 18%. The infarct volume was reduced by 60% 
when the concentration of anti miR-320a was increased to 0.75nmol (Figure 6.23). 
Infarct volumes for early time point post eMCAo (3, 4 and 5hr) showed a similar 
reduction as those rats that received single therapy of rt-PA or with a combination 
therapy.  
 
However, at a higher dose of 0.75nmol, the infarct volume showed a significant 
decreased even after 8hr. At 10 and 12hr, the combination therapy was able to 
reduce the infarct volume considerably. These results therefore indicate that anti 
miR-320a in combination with rt-PA is beneficial in the treatment of stroke. 
Moreover, such combination therapy could extend the therapeutic window while at 
the same time reducing the infarct volume considerably. Hemorrhagic 
transformation was also found to be lower in the combination therapy (10.96%) as 








































Figure 6.22: Histopathological analysis of brain slices. (A) Serial coronal sections 
(2mm) were stained with TTC after rt-PA (10mg/kg) was administered together 
with 0.5nmol of LNA anti miR-320a at different time points post eMCAo (3, 4, 5, 
6, 8, 10 and 12hr post eMCAo. (B) Infarct volumes quantitated using Image J and 
the values in mm
3
 are expressed as percentage of saline-treated control. * 
significant different from eMCAo without rt-PA + anti miR-320a treatment 
(p<0.05). (NA denotes eMCAo without administration of rt-PA). 
 















































































































































Figure 6.23: Histopathological analysis of brain slices. (A) Serial coronal sections 
(2mm) were stained with TTC after rt-PA (10mg/kg) was administered together 
with 0.75nmol of LNA anti-miR-320a at different time points post eMCAo (6, 8, 
10, 12 and 18hr post eMCAo). (B) Infarct volumes quantitated using Image J and 
the values in mm
3
 are expressed as percentage of saline-treated control. * 
significant different from eMCAo without rt-PA + anti miR-320a treatment 
(p<0.05).






























































































































7.1 miRNA profiling study on MCAo samples 
Finding a safe and effective neuroprotectant remains a huge challenge in stroke 
treatment. There were many neuroprotectants which showed favourable outcome 
and good tolerability in preclinical evaluations but failed in clinical trials. Also, 
efforts have been made to look for novel biomarkers in stroke and most of them are 
protein biomarkers [81, 140, 150, 440, 441]. A stroke biomarker should benefit and 
facilitate early stage clinical diagnosis by serving as a useful assessment of 
ischemic injury. At present, there are no clinically validated biomarkers of acute 
stroke and hence there is a need to identify them especially at the genetic level as 
they could form early indicators of stroke as compared to proteins.  
 
Cerebral ischemia initiates a series of pathophysiological and biochemical events 
which are believed to be mediated in part by various modifications in molecular 
processes including transcription and translation. An extensive DNA microarray 
analysis reported by Lu et al. [354] identified 12 functional categories that 
contributed to the temporal changes in gene expression after experimental transient 
MCAo in rats. For many years, RNAs have been understood to play only a 
supplementary role as mediators in between genes and proteins. However, the 
recent discovery of a species of short non-coding RNAs, named as miRNAs, has 
revolutionized this thinking. Since the first miRNA was discovered [216, 218], 
numerous studies have reported the roles of specific miRNAs in various diseases 
including cancer [442, 443], Type II diabetes mellitus [444, 445], CNS diseases 
[446, 447], influenza [448, 449] and HIV infections [450].  
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Jeyaseelan et al. [329] was the first to report on miRNA expression profiling of 
transient MCAo on rat models. Following which several studies reported the 
profiling of miRNAs in the blood samples of human stroke patients as well as 
animal models [253, 299, 451].  
 
A total of 114 ischemic brain specific miRNAs were identified [329], of which 106 
and 82 transcripts were detected in the 24 and 48hr reperfusion (ischemic brain) 
samples, respectively. These transcripts included some of the previously reported 
brain miRNAs, [339, 347, 349, 355, 452] as well as several new ones. Interestingly, 
some brain specific miRNAs observed in rat models were also detected in blood 
(24 and 48hr reperfusion). This finding enabled us to postulate that such miRNAs 
(circulating miRNAs) could also be traced in the blood samples of human stroke 
patients [253, 453] and they could serve as potential circulating biomarkers for 
cerebral ischemia.  
 
There are miRNAs which are actively modulated and their expression patterns 
were modified along with different reperfusion time points, indicating temporal 
expression upon ischemic injury. It was demonstrated that neuronal injury was 
elevated with prolonged reperfusion time, and the damage caused was more severe 
than the ischemic insult episode itself [454]. It is noteworthy that the let-7 family 
consisting of let-7a, b, c, and e has been implicated in neural cell specification [452] 
was further upregulated during 48hr reperfusion. Also, expression of miR-125a and 
-150 increased further at later reperfusion time points. miR-125a was reported to 
be involved in the activation of the NF-κ  pathway by targeting the tumor necrosis 
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factor alpha-induced protein 3 (TNFAIP3) [455]. Whereas, miR-150 enhanced 
endothelial cell migration [456].  
 
Distinct upregulation was also observed for miR-138 at 24hr and miR-145 at 48hr 
of reperfusion. miR-138 has been reported to be developmentally regulated, and its 
expression has been found to be restricted to distinct neuronal populations in the 
cerebrum, cerebellum, and midbrain of adult mice [457] and it also promotes 
apoptosis in cancers [458]. miR-145 has been identified as a specific miRNA that 
is downregulated in cancers [459, 460]. miR-145 that targets N-RAS [461], VEGF 
[461, 462] has been found to inhibit tumor angiogenesis.  
  
Among the highly expressed miRNAs, miR-210, -215, -324-3p, -422b, -451, -497 
and the brain-specific miR-134 were upregulated more than 2 fold and were 
detected only in at the 24hr reperfusion MCAo brain samples. miR-290 displayed 
high expression at 24hr (2405.5±0.3) and increased more than 5 times at the 48hr 
reperfusion time. Many genes that are targeted by miR-290 were found to be   
downregulated as demonstrated in the DNA microarray data including genes 
encoding visinin-like 1, a neuronal calcium sensor protein, and aquaporins. The 
miR-292-5p transcript showed the highest expression after ischemic injury in the 
brain, 3150.90±1.34 at 24hr reperfusion, and increased even more, by 1.5 times, at 
48hr reperfusion.  
 
miR-214 was highly expressed in MCAo brain samples at 24hr reperfusion 
(114±0.33) but decreased (70.27±0.201) at the later time point. It was reported that 
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the miR-214 plays a role in the specification of muscle cell fate during 
somitogenesis, and its inhibition could cause the reduction or loss of slow-muscle 
cell types [463]. Among the brain-specific/enriched transcripts which have been 
identified, miR-7, and -9 were downregulated in ischemic rat brains at both 
reperfusion time points whereas miR-124a was upregulated at 24hr reperfusion 
time point. 
 
miR-27a, -29 (b and c), -30e, -98, -101a, -137, -148b, -204, -218, -301, -338, -335, 
-369-5p, -376 (b and b*), and -424 were detected to be downregulated at both 
reperfusion times (24 and 48hr). Notably, the downregulation of these transcripts 
post MCAo, for instance miR-338, was correlated with the upregulation of its 
target gene, such as transgelin (8.815±0.099, Figure 3.6). Transgelin is considered  
as an early marker of smooth muscle cell gene expression during vascular/cardiac 
development [464].  
 
There are 32 unique transcripts in 24hr reperfusion MCAo brain samples (Table 
3.4), whereas the 48hr brain samples had only 8 unique detectable miRNAs (Figure 
3.5). These miRNAs could appear as important indicators for the acute and 








7.2 Regulation of targeted genes by miRNAs  
Upregulation of both brain specific/enriched miRNAs, miR-124 and -134 denotes 
that damaged brain cells could be actively involved in regeneration during the first 
24hr of reperfusion after MCAo. miR-124 has been reported to be involved in the 
inhibition of endogenous laminin-γ1 and integrin-β genes upon neural 
differentiation [356].  In parallel, these 2 genes were found to be downregulated in 
the DNA microarray study. Cao et al. [356] suggested that miR-124 may not act as 
a primary determinant of neuronal differentiation but could involve in ensuring that 
progenitor genes are post transcriptionally inhibited in neurons. On the other hand, 
Schratt et al. [355] proposed that the expression of miR-134 elevates as the brain 
matures and it functions as a modulator for local dendritic translation.  
 
Screening for miRNA targets identified gene encoding VSNL1 (neuronal calcium 
sensor protein), which was expressed in granule cells in the cerebellum as novel 
target for miR-124a, -290, and -494. The VSNL1 protein was reported as a specific 
and promising biomarker in the cerebrospinal fluid of post stroke rats and  in the 
plasma of stroke patients [358]. Suppression of VSNL1 gene expression was 
detected at 24hr reperfusion (Figure 3.6) and consistent with the downregulated 
expression of the VSNL1 gene in the DNA microarray data as well. Expression of 
the gene encoding VSNL1 was observed to be further decreased in the 48hr-
reperfused brain. This was associated with increasing expression of miR-290 from 
24 to 48hr in both ischemic brain as well as blood. Similar expression patterns 
were also seen for miR-494 in ischemic blood samples. Although, the upregulated 
expression of miR-290, brain-specific miR-124a and miR-494 correlated with 
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suppression of the VSNL1 gene, VSNL1 gene could appear as important target of 
miR-290. miR-290 has also shown an increased expression at 24 and 48hr, 
2405.491±0.31 and 12520.60±0.52 respectively (Table 3.4). 
 
Increased expression of MMP9 in both rat and primate stroke models has been 
reported as an early marker of brain damage (within 3hr from the onset of MCAo). 
It is related to the changes in the integrity of BBB and formation of early vasogenic 
edema post transient focal cerebral ischemia [465]. MMP9 plays an important role 
in degradation of the basal lamina and extracellular matrix components. Expression 
level of MMP9 in peripheral blood of stroke patients was detected to be the highest 
at 24hr after admission [466]. In animal models, mRNA encoding MMP9 was 
upregulated in the first 24hr of MCAo and increased further at 48hr. A concomitant 
increase in MMP9 protein levels followed by a decrease in intact laminin 
molecules, and an increase in laminin breakdown products were reported by 
Horstmann et al. [394]. Upregulation of the MMP9 gene correlated with a 
downregulation of the corresponding miR-132 and -664 at both 24 and 48hr of 
reperfusion. Downregulation of laminin and integrin genes were also observed 
with a concomitant upregulation of brain-specific miR-124a. 
 
Several highly expressed miRNAs including miR-223, -290, -292-5p, -327, and -
494 have been predicted to target the genes encoding water channels, aquaporin 1, 
4, 5, 6, and 11. AQP4, which is found to be abundantly expressed in the brain [467, 
468], appeared as a potential target for miR-30a-3p, -99 (a and b), -100, -223, and -
383. Also, it has been reported that miR-320a could modulate AQP1 and 4 and this 
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miRNA form a potential target in cerebral ischemia [294]. Expression of the AQP4 
gene has been shown to be downregulated upon the onset of ischemia but is 
upregulated during recovery, with a concomitant decrease in expression of AQP 
protein in cerebral edema [469]. AQP4-null mice were found to be protected from 
cytotoxic brain edema. However, knocking out AQP4 gene has been found to 
result in vasogenic edema [470]. In our data, the AQP4 gene was downregulated in 
the ischemic brain at 24hr of reperfusion possibly vasogenic edema has been taking 
place, however, AQP4 gene was upregulated at 48hr of reperfusion which could 
imply subsidized edema during recovery phase. The expression profiles of miR-
30a-3p, -320 and -383 also showed a correlation with the elevated expression of 
AQP4 mRNA.  
 
 
7.3 Expression of miRNAs at early reperfusion times in cerebral ischemia 
Profiling of ischemic brain and blood samples at 24 and 48hr post occlusion gave 
the changes in expression of miRNAs and the relationships between miRNAs and 
mRNAs during the disease state. In this section, the changes in miRNA expression 
taking place during the early time points of cerebral ischemia and the progression 
of stroke from the onset, 0 to 48hr were investigated. Studying the expression of 
miRNA at early time points could reveal some of the immediate response to 
expression of miRNAs. 
 
From the miRNA profiling at different reperfusion time points (0, 1, 3, 6, 12, 18, 
24 and 48hr), a correlation to the progression of brain infarct volume could be 
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observed. Notably, a large number of miRNAs have been detected to be 
upregulated after 24hr of reperfusion and this also corresponded with the highest 
infarct volume. 
 
The infarct area of a rat ischemic brain only became visible and quantifiable from 
3hr of reperfusion onwards. However, changes in expression of miRNAs could be 
observed as early as 0hr reperfusion (immediately after 1hr of occlusion). miR- 
140, -143, -363, -425, -433 and - 873, showed the highest level of expression 
(versus sham-operated control) at 0hr of reperfusion while miR-141, -200c, -20b- 
5p, -21*, -217, -223, -323*, -327, -874, -881 and -96 showed the lowest level of 
expression. DIANA miRNA-pathway analysis (http:// diana.cslab.ece.ntua.gr/) 
showed that regulation of actin cytoskeleton, focal adhesion, MAPK signalling, 
ErbB signalling, long-term potentiation, gap junction signalling, adherens junction, 
axon guidance and oxidative phosphorylation were among the pathways that are 
regulated by these dysregulated miRNAs.  
 
Interestingly, miR-223 was found to increase gradually from 0 to 48hr reperfusion 
time as observed previously by Dharap et al. [299]. miR-223 was associated with 
the modulation of inflammatory/immune response [471, 472], hematopoiesis 
processes [473] and cell proliferation[472]. Elevation of miR-223 was also found 
following spinal cord injury [474]. Significantly decreased expression of miR-223 
was reported in the serum of patients diagnosed of sepsis [475]. miR-223 
expression could involve inflammatory responses during the initial stage of 
cerebral ischemia; while at later time points of reperfusion, the same miR-223 
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could be regulating the hematopoietic activity and cell proliferation which are 
crucial for recovery. miRNAs that were observed from 0 to 6hr of reperfusion but 
absent at later reperfusion times included miR-200c, -323* and -327. The miR-200 
family of miRNAs are considered as the „guardians of the epithelial phenotype‟ 
and have been reported to negatively regulate the stem cell renewal mechanisms 
and restore chemosensitivity [476, 477]. Studies have also demonstrated the pro-
inflammatory role of miR-200 in vascular smooth muscle cells [478]. Despite 
being involved in targeting E-cadherin to regulate the epithelial cell-cell adhesion, 
miR-200c was also reported to potentially decrease cell migration by supressing 
adhesion to basement membrane complexes and thus maintaining the membrane 
integrity [476]. miR-200c was also found to target class III beta-tubulin (TUBB3) 
in neuronal cells.  Therefore, it is possible that absence of miR-200c at later time 
points (>6hr) could lead to an increase in cell-cell adhesion or adhesion to laminin. 
 
 
7.4 miRNAs expressed at 48hr reperfusion 
Generally, the downregulation of miRNA expression is considered to bring about 
an enhanced expression of proteins. Since recovery from ischemic stroke could be 
observed with a decrease in infarct volume, miRNAs expressed at this time point 
were considered to exhibit favourable changes associated with the recovery process. 
miR-137, -136, -153, -190, -196a, -301a, -322*, -33, -347, -378*, -411, -487b and -
879 were found to be downregulated (1.5 to 3.8 fold) in the ipsilateral brain slices 
post 48hr reperfusion. Whereas, miR-190, -196a, 322*, -33, -411 and -478 showed 
a very high downregulation of 27, 52, 35, 206, 42 and 12fold respectively (t test 
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p<0.05), at 48hr reperfusion time point when compared to their expression level at 
24hr. Interestingly, these miRNAs are known to be involved in rapamycin 
signalling pathway, axon guidance, neurodegenerative diseases, ErbB signalling 
pathway, vascular endothelial growth factor signalling pathway, MAPK signalling 
pathway, tight junction, focal adhesion, gap junction and calcium signalling 
pathway that are linked to cell proliferation and survival mechanisms.  
 
Some of these miRNAs such as miR-137, -190, -196a and -33 have been reported 
previously by various studies. miR-137 has been demonstrated to promote 
neuronal differentiation in adult neural stem cells [479]. miR-137, a negative 
regulator of COX2 was found to be downregulated in glioblastoma. Restoration of 
its function inhibited cell proliferation and invasion [480], suggesting that 
decreased expression of miR-137 at later time points may facilitate the cell 
proliferation which is important for recovery. miR-190 targets NEUROD 
transcription factor involved in the differentiation and migration of neurons [481]. 
Identified as an oncogenic miRNA, miR-196a is reported to promote pancreatic 
cancer [482] and to suppress apoptosis and promote cell growth via annexin A1 
[483] and miR-33 targets another transcription factor, FOXG1, that promote 
progenitor cell proliferation, self-renewal and suppresses premature neurogenesis 
[484, 485].  
 
miRNAs that were found (or predicted) to modulate cancer pathogenesis and 
related pathways have been listed in chapter 4 as among the highly expressed 
miRNAs. This is in agreement with the observation that miRNAs that are involved 
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in tumour progression could appear as useful modulator for the negative effects of 
stroke. For instance, miR-21 is an oncomir [486-488] regulates apoptosis while  
miR-210 controls cell migration, angiogenesis, proliferation and survival [489]. 
miR-21 and -210 have been found to be upregulated (2.90 and 2.54 fold 
respectively) at 48hr. Hence, it is most likely that at 48hr reperfusion time point, 
the neuronal and support cells had triggered self-repair mechanism as indicated by 
the upregulated miRNAs. Notably, the neuronal differentiation, neurogenesis, cell 
proliferation, and suppression of apoptosis could be the processes involved in the 
early repair mechanisms in stroke pathogenesis. 
 
 
7.5 Changes in the expression level of miRNAs with the administration of  
MK801 (Dizocilpine) 
MK801 (non-competitive antagonist of NMDA receptor) has been extensively 
used in studies involving experimental animal model of stroke to reduce or reverse 
infarct volume. miRNA expression profiling was performed on the MK801- 
administered MCA occluded brain samples of rats that were sacrificed after 24hr of 
reperfusion. DIANA pathway analysis demonstrated that adherens junction, axon 
guidance, WNT signalling pathway, focal adhesion, tight junction and MAPK 
signalling pathway were among the processes that were affected by the upregulated 
miRNAs. Cancer-related pathways including p53 signalling, cell cycle, focal 
adhesion, and adipocytokine signalling were affected by the downregulated 
miRNAs. Notably, cell growth, proliferation and survival mechanisms were also 
controlled by the downregulated miRNAs.  
249 
 
Angiogenic miRNAs such as miR-126, -15b, -16, -221, -222, -27b, and -92a [490, 
491] presented mixed expression patterns in MK801-treated MCAo brain slices. 
miR-143 and miR-145 which are tightly integrated in the function of vascular 
homeostasis and maintenance of vascular smooth muscle cell, [492] showed the 
opposing expression pattern (+1.13 and -1.10 fold, respectively) in the MK801-
treated rats (versus MCAo). Downregulation of both miR-143 and -145 has been 
reported in vascular injury [493].  In a neurobehavioral dysfunction study on mice, 
administration of MK801 has been shown to downregulate miR-219 which is 
related to pharmacological repression and reduction in NMDA receptor activity 
[494].  
 
miR-181b and d (-1.64 and -1.85 fold ) and miR-132 (+1.09 fold) in MK801-
treated rats were found downregulated. miR-181b promotes matrix 
metallopeptidases, MMP2 and MMP9 activity by inhibiting TIMP3 [291]. On the 
other hand, miR-132 has been found to negatively regulate MMP9 expression 
[495]. Importantly, significant upregulation of miR-132 induced by brain-derived 
neurotrophic factor (BDNF) has been identified to stimulate the expression of the 
glutamate receptors in neurons [496]. Thus, it is likely that treatment with MK801 
could have induced the expression of glutamate receptors in neurons for additional 
synaptic plasticity and dendrite formation. Furthermore, upregulation of miR-132 
increases Acetylcholine (ACH) which promotes cholinergic anti-inflammatory 




The expression of miR-223 (in this study) was found to gradually increase in 
ischemic brain samples across different time points of reperfusion. This increase 
could be associated with inflammation or immune and hematopoiesis response 
[471, 473, 475]. As expected, miR-223 was found to be downregulated in the 
blood and brain of MCAo rats that were treated with MK801. Interestingly, we 
found that the Stathmin1 protein (validated target of miR-223) [498], was 
upregulated (fold change 0.91) in the ischemic brain of MK801- treated rats. 
 
 
7.6    miRNAs detected in blood 
There were a substantial number of mRNAs detected in the blood of MCAo and 
MCAo + MK801 samples as well as about 40% of them appeared to have 
originated from brain. Upon comparison between MCAo and sham-operated 
samples, it was observed that stress-associated miRNAs such as miR-195 and -122 
were upregulated while miR-92a and -375 which inhibit angiogenesis [490] and 
exocytosis [499] respectively were found to be downregulated. Besides its role in 
exocytosis control, miR-375 is also known to target myotrophin, a transcription 
factor regulating nuclear factor-kappa β (NF-κβ) in cardiomyocytes [500]. NF-κβ 
activity was reported to facilitate the cytoskeleton organization [501]. DIANA 
pathway analysis demonstrated that modulation of actin cytoskeleton was one of 






7.7 Relationship between miRNAs and protein expression in cerebral 
ischemia  
Cytoskeletal weakening in the cerebral vascular wall renders the permeability of 
BBB towards larger molecules within 24hr from the initial ischemic damage, 
resulting in exchange of molecules between serum and extracellular neuronal space 
[502]. As a result, large molecules such as transferrin (TF) may diffuse across the 
disrupted BBB and play a part in the reperfusion cascade.  
 
Acute phase proteins such as C-reactive protein (CRP), interleukin-6 (IL6) and 
transferrin (TF) were reported to increase upon stroke [134, 503]. TF level was 
found to be inversely correlated to the ischemic damage injury and has been 
postulated to hinder the oxidative damage, thus functioning potentially as a 
protective agent during cerebral ischemia [504]. From our mRNA data, the 
expression level of TF mRNA was +1.31 and +1.37 fold, respectively for both the 
MCAo and MCAo + MK801 brain samples. The expression of TF mRNA was 
increased to 8.48 fold in MK801-treated animal. Similarly, from the proteomic data, 
we noticed that the TF protein level in the ipsilateral hemisphere brain sample 
remained high for both the untreated and MK801-treated at 2.86 and 3.09 fold, 
respectively. Notably, in the serum, the TF level of MK801-treated samples was 
4.81 fold higher than that in the MCAo samples. Similarly, the higher expression 
of TF in MK801-treated samples was consistent with the finding that increased 




Orosomucoid 1 (ORM1) or α1-acid glycoprotein is another acute-phase protein, 
shown to possess beneficial effects, as an anti-inflammatory/immunomodulatory 
compound in rat model of global cerebral ischemia [505]. Increased level of 
ORM1 has also been found in the serum of patients with cerebral ischemic stroke 
[506] as well as severe traumatic brain injury [359]. ORM1 has been reported to 
repress neutrophil aggregation, superoxide anion aggregation and platelet 
aggregation [507, 508]. It has been reported to play a role as a natural anti-
inflammatory agent particularly due to its antineutrophil and anti-complement 
activity. Correspondingly, the mRNA level of ORM1 was also found to be 
considerably upregulated in the brain sample (1.33 fold) and protein level in the 
serum increased by 2.72 fold upon administration of MK801. 
 
In silico analysis and literature search identified several miRNAs and their 
respective mRNA targets for this stroke study. The proteins detected in the brain 
and blood to their potential miRNA regulators also can be correlated. Of the 34 
(brain) and 16 (serum) proteins mapped, miRNAs that could potentially target 
calcium calmodulin dependent protein kinase II alpha & gamma (CAMK2α and γ), 
cytochrome c oxidase, subunit (COX5A & 6A), glutamate dehydrogenase 1 
(GLUD1), protein disulfide isomerase associated 3 (PDIA3), neurofilament-light 
polypeptide (NEFL), dihydropyrimidinase (DYSL), glutathione peroxidase 3 
(GPX3) TF, CRP, and ORM1 could be identified. For instance, miR-128, -132 and 
-218 (brain miRNAs) were predicted to target TF. miR-218 most likely behaved as 
the potential negative regulator for TF since the expression of miR-218 showed 
negative correlation to that of TF.  
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7.8 Expression of miRNAs at early reperfusion time points in embolic  
     MCAo 
In order to have an insight into the miRNA expression patterns in human embolic 
stroke, rat embolic models were created and their miRNAs expression profiles 
were investigated. As in ischemic stroke models, the infarct area became visible 
and measurable only from about 3hr of reperfusion. 121 miRNAs showed high 
levels of expression (compared to sham-operated control) at the 0hr reperfusion 
time point. Of these, miR-425, -433 and -873 found highly expressed at 0hr were 
common in both suture and embolic MCAo. These could be miRNAs that are 
important for the onset of both models of stroke. 
 
miRNAs such as miR-21*, -125b*, -125-3p, -130b, -300-5p, -382*, -471, -872* 
and let-7f showed the lowest level of expression at 0hr reperfusion time. miR-21* 
was the only common miRNAs detected in both MCAo models. Hence miR-21*, -
425, -433 and -873 could be used as early biomarkers of ischemic stroke. In both 
ischemic and embolic models, the expression of miR-21* was found to be the 
lowest at 0hr, gradually increased and reached a higher value at 24hr where the 
infarct volume remained the highest. miR-21* expression began to decline at 48hr 
where recovery is believed to begin with a reduction in infarct volume. miR-21* 
was reported to be involved in the regulation of in vitro apoptosis of eosinophils 
and was also considered useful in the development of novel treatment against 
allergic inflammation [509]. miR-433 was reported to be involved in the regulation 
of growth factor receptor-bound protein 2 (GRB2) [510]. Upregulation of miR-433 
will inhibit the expression of Grb2 leading to the deactivation of various signal 
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transduction proteins including MAPKs which are important in cell growth, 
proliferation and differentiation [510]. 
 
 
7.9 Potential regulatory roles played by selected miRNAs in eMCAo 
Twenty-six miRNAs have been identified based on their expression profiles in 
eMCAo rats (Chapter 5). GO analysis showed that these miRNAs were mostly 
involved in gene regulation in the extracellular region, synapse and cell junction 
among cellular components. In the extracellular space, there exits numerous 
important molecules such as neurotransmitters, ions, protein kinases and 
metabolites including hormones, cytokines, chemokines, enzymes, extracellular 
proteinases which become malfunctional or dysregulated during ischemia. These 
proteins exist in the extracellular region by attaching to different extracellular 
matrix components such as laminin, collagens and fibronectin [511].  
 
Extracellular matrix proteolytic products are found, particularly in tissues 
undergoing remodelling [511]. As for the molecular functions, transporter, 
chemoattractant and enzyme regulatory activities are the top 3 functions with 
respective enrichment scores of 14, 6.9 and 4.3. Upon ischemia, deficiency in 
blood supply accompanied with the reduction in oxygen and glucose initiate a 
series of pathophysiological mechanisms leading to neuronal damage. Energy 
demand which is correlated with profound changes in brain metabolism will 
increase. Hence glucose transport activity may be modulated in order to ensure that 
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there is a continuation in delivery of glucose to sustain normal cellular function. 
[512].  
 
On the other hand, mitochondrial transporter proteins also known as uncoupling 
proteins (UCP2), involved in proton conductance across inner mitochondrial 
membrane, may participate in limiting the mitochondrial dysfunction and cell 
death in cerebral ischemia [513]. AQP1 and 4 which are important in transporting 
mainly water molecules across the cellular membrane are likely to be involved in 
brain edema formation [514].  
 
Chemokines and their respective receptors have been reported to play crucial roles 
in several inflammatory pathologies including ischemia–reperfusion injury. [515, 
516]. Inhibition or knock-out studies of one or more of the chemokines has been 
shown to have beneficial effects on these pathologies [517]. The expression level 
of some chemokines has been identified to be elevated following stroke and 
considered to contribute to its pathogenesis [516]. 
 
Cell proliferation appeared to be one of the most important biological processes in 
cerebral ischemia. Studies have shown the relevance of ischemia-related 
neurogenesis in the brain, particularly on cell proliferation and its correlation to 
recovery of short term memory following stroke-induced hippocampal damage 
[518, 519].  Basic fibroblast growth factor (BFGF), epidermal growth factor 
(EGF) , IGF, transforming growth factor  (TGF) and monoamines were reported to 
be involved in increasing the proliferation of neural precursors whereas glutamate, 
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GABA, and opioid peptides have a tendency to repress proliferation in the 
developing nervous system [520]. Also, ciliary neurotrophic factor (CNTF), 
platelet-derived growth factor (PDGF), vasoactive intestinal peptide (VIP) and 
other compounds can also affect proliferation and differentiation in different 
systems [520].  
 
Some of the above mentioned genes were found in this study on miRNA-mRNA 
prediction target analysis and hence appear to be important genes that are regulated 




7.10 Pathway analysis for selected miRNAs 
To understand the relationship between the selected 26 miRNAs and various 





was performed. About 250 pathways were highlighted with as many as 4899 genes 
being involved in them. To narrow down the list, the top 10 pathways related to 
stroke were chosen. Within these selected pathways 219 genes were predicted to be 
regulated by the 26 miRNAs (miR-10a-3p, -107, -125b-3p, -127, -133b, -139-3p, -
147, -17-3p, -21, -21*, -25*, -27a*, -27b, -291a-5p, -29b-1*, -30c-1*, -30c-2*, -
349, -379*, -448, -449a, -455, -540, -542-5p, -671, -874). 
 
Among the 26 miRNAs, there was a cluster of 6 miRNAs (miR-133b, -139-3p, -
147, -27a*, 449a and -671) that were detected only in lesioned hemisphere and not 
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in the sham-operated samples. They could serve as important miRNAs which could 
differentiate between normal and ischemic stroke. Of these, miR-139-3p was 
highly upregulated (from 13.5 to 86.6fold) during the progression of infarct but the 
expression was suppressed (not detected) after 48hr of reperfusion.  
 
Thirty eight genes were predicted to be regulated by miR-139-3p in all the 10 
stroke related pathways. These included MAP3K1, MAP3K11, MAP4K4, MAPK1 
and MAPK13. MAPKs participate in directing cellular responses to a range of 
stimuli including mitogens, osmotic stress, heat shock and proinflammatory 
cytokines such as neurotrophin factor (NTF), epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF). The MAPKs have to be phosphorylated for 
activation to modulate many transcriptional factors leading to responses such as 
apoptosis, cell survival, proliferation, differentiation and mitosis [521-524]. The 
downregulation of miR-139-3p at 48hr post occlusion could facilitate the 
upregulation of these MAPKs for cell proliferation and angiogenesis which are 
important processes in recovery. The most important upstream activators of this 
pathway are the RAF proteins which are regulated by miR-21 [525]. miR-139-3p 
was reported to be downregulated in benign and malignant adrenocortical tumors 
[526] and its involvement in the cancer could be useful in controlling the negative 
effects of stroke. 
 
Another target for miR-139a-3p is zinc finger protein (GLI). This has been 
characterized as a DNA-binding transcription factor and as a mediator of Sonic 
hedgehog (SHH) signalling [527]. Upregulation of miR-139a-3p during stroke 
could inhibit the expression of GLI, and hence the downregulation of GLI could 
258 
 
supress SHH signalling and aggravate brain injuries in acute ischemic stroke [528]. 
A decrease in miR-139a-3p at the 48hr time point would therefore be useful in 
enhancing SHH signalling. 
 
Expression of miR-449a could not be detected in sham-operated samples. miR-
499a peaked at 1hr post occlusion (116.8 fold) and gradually decreased until it 
became undetectable at 48hr. miR-449a has been shown to block proliferation and 
to induce senescence-like phenotypes in prostate cancer cells [529]. Its expression 
was downregulated in gastric cancer and it could also induce senescence and 
apoptosis via the activation of the p53 pathway [530]. Decrease in expression of 
miR-449a was also found in hypoxic environment [531]. Upregulation of miR-
449a induced by transcription factor E2F1 inhibits cell proliferation and promotes 
apoptosis [532]. Reduction or loss of miR-449a expression is associated with 
actively proliferating cells, age-related tissue dysfunction and cancer [529, 532].  
Another important protein is Neurogenic locus notch homolog protein 1 (NOTCH 
1). It was predicted as one of the targets of miR-449a. The NOTCH pathway is 
highly conserved in the animal kingdom and is known to be involved in controlling 
cell fate decisions in numerous aspects. Ligand (ADAM17) binding leads to the 
proteolytic cleavage of NOTCH followed by the release of an intracellular domain 
which translocates to the nucleus and triggers target gene transcription therefore 
controlling differentiation [533, 534].  The biphasic expression of miR-449a seen 
across different time points post occlusion in relation to NOTCH1 expression 
needs further studies. Expression of RAS and NOTCH1 has been implicated in the 
transformation of immortalized breast epithelial cells as well as in breast stem cell 
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self-renewal [535, 536]. This could also trigger MAPK signalling for proliferation 
and angiogenesis. Furthermore, it is known that miR-449a stimulates centriole 
multiplication and multiciliogenesis by directly supressing the DELTA/NOTCH 
pathway [537, 538]. 
 
Another important target for miR-449a is AKT. AKT signalling pathway related to 
the MAPK and PKC pathways was reported to contribute to protection against 
stroke [539].  Decreased expression of miR-449a could increase the expression of 
BCL2 which could be beneficial as BCL2 overexpression enhanced survival of 
newborn neurons in primary hippocampal cultures. BCL2 also plays a crucial role 
in adult hippocampal neurogenesis under normal and ischemic conditions [527].  
 
Pathway analysis identified 2 subunits of proteasome (PSMA4 and PSMD3) to be 
regulated by miR-449a. Proteasome/ubiquitin (Ub)-proteasome system (UPS) is 
the main non-lysosomal proteolysis pathway in human cells and is responsible for 
the degradation of most proteins. It is a crucial pathway for it modulates a number 
of major biological regulatory machineries [540, 541]. Numerous studies have 
demonstrated that UPS contributes to cerebral ischemic injury [542, 543]. Heavily 
oxidised and cross-linked proteins during ischemic-reperfusion supressed or 
impaired the proteasomal function [544, 545], leading to free radical generation 
[546, 547] which could further exacerbate ischemic injury.  
 
Expression of miR-10a-3p was initially downregulated at early reperfusion time 
points (0 to 3hr) but it reversed from 6hr onwards. Seven genes (BIRC4, ITGB1, 
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GLI3, MAP2K3, PIK3R2, PTCH1 and 2) were predicted to be targeted by miR-
10a-3p. Baculoviral IAP repeat-containing protein 4 (BIRC4) is a member of the 
inhibitor of apoptosis family of proteins (IAP). It binds to caspase 9 (CASP9; [548] 
which causes cell death [549] via the apoptosis pathway. There were 3 other 
miRNAs involved in regulating BIRC4; miR-21, -127 and -448. Together the 4 
miRNAs could be involved in the regulation of apoptosis which is triggered upon 
ischemia. 
 
Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) is involved in 3 
pathways including apoptosis, regulation of actin cytoskeleton and VEGF 
signalling pathways. PIK3R2 phosphorylate phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) which results in activating the downstream signalling 
components, especially protein kinase, AKT (also known as PKB) , which in turn 
triggers various downstream signalling pathways necessary for cell growth and 
survival [550]. AKT binds and modulates several downstream effectors such as 
RELA (v-rel reticuloendotheliosis viral oncogene homolog A), BCL2 family 
proteins and BIRC for cell survival.  
 
Several of these genes and miRNAs identified in this study are involved the 
different pathways which are implicated in the ischemic cascade. Further studies 






7.11 miR-320a as potential therapeutic target in cerebral ischemia  
miR-320a has been reported to inhibit expression of AQP1 and 4 by Sepramaniam 
et al. [294]. They have also shown by intracerebroventricular injection that anti 
miR-320a could reduce infarct volume in ischemic rats. In this study, intravenous 
administration of LNA anti miR-320a was attempted. LNA anti miR-320a 
administration resulted in the most significant reduction in infarct volume. 
Administration of miR-320a mimic (pre miR-320a) showed a significant increase 
in infarct volume. This finding served as a confirmative experiment to show that 
anti miR-320a could indeed reduce the infarct volume. In addition, the effects of 
anti-miR-320a in reducing edema, water content and brain tissue swelling of the 
lesioned-hemisphere (ipsilateral) brain was also examined. Administration of anti 
miR-320a was also found to reduce BBB disruption. BBB disruption occurs as a 
downstream episode of several pathophysiological changes from the onset of 
stroke and could lead to edema, hemorrhagic transformation and cell death.  
 
 
7.12 Administration of rt-PA for insult-limitation in embolic stroke models 
As reported previously [434, 435], 10mg/kg of rt-PA was found to reduce infarct 
volume substantially when administered within 3 to 5hr from the onset of 
embolism (MCAo) in rats. This dose is higher than normally being applied to 
human stroke patients (0.9mg/kg body weight), as the thrombolytic activity of 
human rt-PA (Alteplase
®
) is almost 10 fold less potent in activating rat 
plasminogen [551]. Thus, doses used in experimental rats are usually 10 fold 
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higher than those used in human [552, 553]. An infusion regimen was also needed 
mainly because of the short half-life of rt-PA in blood.  
 
Although rt-PA reduced the infarct volume of MCAo rat when administered up to 
5hr post occlusion, the incidence of hemorrhagic transformation was higher than 
the group without rt-PA treatment (Table 6.6). Hence additional or alternative 
therapy with minimal adverse effects of rt-PA while reducing the infarct volume 
effectively was attempted as a combination therapy using miR-320a 
 
 
7.13 Combination therapy using rt-PA and anti miR-320a 
As discussed, the most promising treatment for ischemic stroke is the FDA 
approved drug rt-PA and it must be administered within a 3 to 4.5hr window from 
the onset of symptoms for any favourable outcome or recovery. If stroke patients 
are treated promptly with rt-PA, the effects of stroke and permanent disability can 
be reduced significantly. However, there are additional risks associated with rt-PA 
administration, including elevated risk of death and greater rate of intracranial 
haemorrhage [554]. Therefore, alternative or additional therapies are needed for 
effective stroke treatment for favourable outcome. 
 
A combination therapy using rt-PA and anti miR-320a when administered 
concurrently post induction of embolic stroke was found to bring about beneficial 
outcomes including improvement of neurological scores, reduction of infarct 
volume, decrease in mortality and incidence of hemorrhagic transformation as well 
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as its associated detrimental effects. The survival percentage increased when anti 
miR-320a was administered individually or in combination with rt-PA while the 
percentage of mortality and incidence of haemorrhagic transformation were also 
significantly reduced. Most importantly, administration of anti-miR-320a, when 
injected intravenously in combination with rt-PA, extended the therapeutic window 
by several hours (from 5 to 8hr) after the onset of ischemic stroke. In addition, an 
intravenous route of delivery for anti miR-320a was found to be successful and 
hence making it an attractive therapeutic option. These findings have to be further 
examined and verified using a larger cohort of animal studies.  
 
 
7.14 Possible targets and pathways for miR-320a in stroke 
The area on miRNA target identification and its implication on cellular pathways is 
being actively researched upon. These have resulted in the identification of several 
miRNAs, their specific targets and related pathways. For example, overexpression 
of miR-126 in mesenchymal stem cells could stimulate ischemic angiogenesis 
through the AKT/ERK-related pathway [555]. Upregulation of miR-29b was found 
to suppress BCL2L2 leading to neuronal cell death after ischemic brain injury 
[556]. Elevated expression of miR-181a was found to aggravate ischemic damage 
both in vitro and in vivo, while inhibiting its expression showed a reduction in 
ischemic injury with increased expression of GRP78 protein. GRP78 protein 
belongs to the HSP70 family that has been extensively studied for its various 




miR-320a also has been studied recently. Ren et al. [558] reported that miR-320a 
is involved in the regulation of ischemia/reperfusion-induced cardiac injury via 
regulating heat-shock protein 20. miR-320a was also reported to target transferrin 
receptor 1 (CD71) and inhibit cell proliferation [559]. Sepramaniam et al. [294] 
reported that miR-320a is capable of regulating the expression of brain aquaporins 
1 and 4. Extending this observation, in this study, anti miR-320a has been found to 
reduce infarct volume, water content, edema (tissue swelling) and BBB disruption. 
Most importantly, anti miR-320a could extend the therapeutic window and reduce 
haemorrhagic transformation as well as the mortality rate of rt-PA therapy. 
Employing web-based databases, miR-320a was also shown to potentially target 
various other genes including MMP9, TIMPs, VEGF, chemokine receptors and 
several others. These genes are involved in controlling or inhibiting various 
ischemic/reperfusion based detrimental changes to the brain. Thus, they are 
important players in controlling the extent of damage to the brain tissues upon 
ischemia. Given the fact that a single miRNA could have multiple targets, it is 
important to understand the molecular targets of miR-320a.  
 
Using miRNA databases, miR-320a could be predicted to target 188 pathways 
(KEGG pathways) and 785 genes. To narrow down the list, 14 stroke related 
pathways and 54 genes have been selected.  Figure 7.1 illustrates the potential 
pathways and genes targeted by miR-320a. AQP 1 and 4 have been reported to be 
regulated by miR-320a for possible survival mechanisms.  Majority of the 
predicted target genes for miR-320a also appeared as important genes in the pro-




Figure 7.1: Potential pathways/genes predicted to be affected by miR-320a. Compilation of possible genes affected by 320a  
modulation was adapted from the KEGG Pathway Database. Orange boxes, targets of miR-320a, yellow boxes, other genes  






potentially bring about beneficial outcome of stroke. Regulation of genes such as 
c-Jun N-terminal kinases (JNK), Extracellular signal-regulated kinases (ERK), 
Vascular endothelial growth factor (VEGF), Iκ  kinase (IKK), MAP kinase 
phosphatase (MKP) are important in cell survival, anti-apoptosis, differentiation, 
anti-inflammation, angiogenesis and proliferation.  
 
miR-320a could modulate ECM, neurotransmitters and important receptors 
including chemokine receptor, NMDA receptor, PTK (protein tyrosine-kinase), 
FGFR (Fibroblast growth factor receptor), Frizzled (a family of G protein-coupled 
receptor proteins) and NOTCH. Activation of NOTCH could activate MAPK 
kinases, JNK and VEGF pathways via RAS and RAF protein which are important 
for cell survival. The stress-activated JNK is a crucial protein which regulates 
neuronal cell injuries and integrates multiple cell death pathways [560]. Inhibition 
of JNK could reduce infarct size in models of cerebral ischemia [561, 562]. MKP 
involved in inactivation of ERK and JNK by dephosphorylation. Overexpression of 
MKP is able to repress the neuronal cell death by regulating JNK signalling in vitro 
[563]. On the other hand, many mediators and mechanisms initiated by the stroke 
cascade are considered to play biphasic roles. Recently, Murata et al. [564] 
reported that delayed treatment with JNK inhibitor SP600125 (7 day post stroke) 
enhanced infarct volumes and worsened neurological outcomes, implying that 
targeting JNK could also play an important role in endogenous processes of 




ERK is one of the best-characterized members from MAPK family which mediates 
a range of processes in cellular functions including cell growth, differentiation, 
proliferation, motility, survival and intracellular trafficking. The phosphorylated 
ERK level is normally elevated after cerebral ischemia/reperfusion. The 
involvement of ERK was reported in both neuroprotection and exacerbation of 
injury. ERK activity may inhibit apoptosis by stimulating the level of antiapoptotic 
protein BCL2 or by repressing the proapoptotic protein Bad [565, 566]. On the 
other hand, ERK activity may also upregulate IL1β which exaggerates 
inflammation and leads to necrosis [567]. As the dual roles played by ERK is 
highly debatable, modulation of ERK by miR-320a could provide important 
information on the mechanisms involved in stroke.   
 
FAK (Focal Adhesion Kinase) is phosphorylated in response to growth factor 
stimulation, integrin engagement and the action of mitogenic neuropeptides [568, 
569]. It has been shown that overexpression of FAK (Focal Adhesion Kinase) 
could repress apoptosis [570]. Tyrosine residue on FAK was reported to be 
targeted by PTEN (Phosphatase and tensin homolog) via the peptide phosphatase 
activity which leads to the disruption of cell adhesion and migration [571]. PTEN 
is involved in the regulation of cell cycle [572]. It is well established that PTEN 
participates in the regulation of several signalling pathways, such as 
phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), focal adhesion kinase 
(FAK), janus kinase (JAK)/signal transducers activators of transcription (STAT) 
and extracellular signal-regulated kinase (ERK) 1/2, whereby activation of these 
pathways typically leads to cancer development and progression. PTEN 
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dephosphorylates phosphatidylinositol 3,4,5-triphosphate (PIP3), a secondary 
messenger for AKT, to PIP2 and blocks the activation of AKT as well as the 
subsequent downstream survival pathways [573].  A recent report by Bronisz et al.  
[574] demonstrated that miR-320a appeared as a critical component of PTEN that 
acts in stromal fibroblasts for the reprogramming of the tumour microenvironment 
and inhibition of tumour progression. 
 
Lei et al. [575] reported that inhibition of β-catenin by siRNA resulted in the 
enlargement of stroke-induced infarct volume and supressed the striatal 
neurogenesis in adult rat brain after transient MCAo. Two other reports also 
demonstrated the importance of β-catenin in stroke [576, 577]. β-catenin is a 
crucial downstream mediator of WNT pathway which plays important roles in 
gene transcription and cell adhesion signalling [578]. WNT signalling is important 
in the differentiation and proliferation of neural progenitor cells (NPCs). Anti-miR-
320a treatment could increase the expression of β-Catenin which could bring about 
neurogenesis and proliferation which are important for neuronal recovery during 
stroke. 
 
There are a few cytoskeletal proteins such as cofilin 1 (CFL1), slit homolog 3 
protein (SLIT3), and filamin (FLN) that are important in actin remodelling, cell 
migration, and axon guidance. Serine3-phosphorylation of cofilin1 has been 
reported to play a role in neuronal migration [579]. SLIT3 is a repulsive axon 
guidance molecule which is expressed and secreted by both vascular smooth 
muscle cells and endothelial cells. Zhang et al. [580] reported that Slit3 is a novel 
269 
 
and potent angiogenic factor which could stimulate the growth of blood vessel in 
vivo. SLIT3 is also involved in enhancing endothelial cell proliferation cell 
migration and chemotaxis [580-582].  
 
MMP9 was reported to cause neurovascular damage during initial stages of stroke 
[583]. Activation of MMP9 has been found to increase inflammatory infiltration, 
BBB permeability, brain edema and infarct volume by degrading collagen and 
laminin [584], as well as disrupting the tight junction proteins (TJPs) including 
occludin and claudin-5 [391]. MMP2 or 9 deletions showed protection against 
hemorrhagic transformation during the initial stages of cerebral ischemia and 
reperfusion [381]. The balance between MMPs and TIMPs is often offset when 
excessive matrix degradation takes place. This causes an overall net increase in 
MMP activity [411]. The modulation of expression between MMP9 and TIMPs is 
very crucial to achieve a beneficial outcome and miR-320a appears as a potential 
modulator targeting these genes. Studies have reported that MMPs and TIMPs are 
involved in controlling neuronal cell death and apoptosis by regulating 
excitotoxicity [413], activating death receptor [414], anoikis [415], as well as the 
bioavailability of neurotrophic factors.  
 
While early activation of MMP9 is detrimental, during later stages of recovery, it 
was found to be essential for neurovascular remodelling [585]. Bergers et al.[586] 
and Lubbe et al. [587] revealed that MMP9 not only degraded the ECM with its 
powerful barrier-breaking capacity but also enhanced the formation of new vessels. 
MMP9 has been found to be involved in the release of VEGF from extracellular 
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stores, and in mediating the angiogenic switch in tumors [586, 588]. Zucker et al. 
[589] reported that VEGF could induce the expression of endothelial urokinase-
type plasminogen activator and its receptor and then enhance the expression and 
activity of MMP9 indirectly. MMP9 is involved directly in angiogenesis as a 
regulating factor in a synergistic manner with VEGF [590]. VEGF is a pleiotropic 
growth factor which has critical role in neurovascular remodelling of the ischemic 
brain. VEGF promotes angiogenesis [591, 592], brain plasticity, neuronal survival, 
anti-inflammation, enhances recruitment and proliferation of neural precursor cells 
[591]. The broad range of activities makes VEGF an interesting target for 
miRNAs.  
 
The genes especially MMP9 and TIMPs when modulated by anti miR-320a 
treatment upon ischemia may have brought about a significant reduction in infarct 
volume, edema, water content, brain swelling and BBB permeability. The findings 
highlight that favourable survival machinery has been triggered with anti-miR-
320a treatment. Further studies should explore the detailed mechanisms involved 










7.15     Conclusion and Future Studies 
In this study, profiling of miRNAs during ischemia at 24hr and 48hr using 
experimental rat MCAo models have identified distinct regulation patterns for 7 
clusters of miRNAs. These miRNA data have been correlated with relevant DNA 
microarray data and as a result, the miRNAs that control the expression of mRNAs 
including MMP9, AQP4, TAGLN and VSNL1 known to be important in the 
cerebral ischemia have been identified.  
 
Changes in the expression of miRNAs could be detected quite instantly following 
the damage and takes place prior to any phenotypic changes occurring due to 
stroke. Intensive studies on these dysregulated miRNAs could prove to be useful in 
studying the progression of stroke. The proteins and their corresponding miRNAs 
that are dysregulated in the ischemic brain can also be detected in the blood. 
Various dysregulated miRNAs, mRNAs and proteins that can be indicative of BBB 
disruption, cytoskeletal remodelling, metabolic changes, mitochondrial dysfunction, 
acute phase reactant and various cellular signalling mechanisms during ischemia-
reperfusion injury have been highlighted. The differential expression of circulating 
miRNAs originating from the lesioned-hemisphere of brain could appear as 
potential novel biomarkers which could be detected during the early and later 
stages of cerebral ischemia. These circulating miRNAs could be very useful in the 
diagnosis and prognosis of stroke. This study also confirms the need for further 
understanding of the molecular mechanisms involving miRNAs and their use in 
biomarker discovery and development of novel therapeutic agents against stroke. 
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Reducing the expression of miR-320a in ischemic models was found to reduce the 
infarct volume, BBB disruption, water content, edema and tissue swelling. Most 
importantly, administration of anti miR-320a together with rt-PA could not only 
reduce the infarct volume, but also extend the therapeutic window from 5hr up to 
8hr (0.5nmol) and 12hr (0.75nmol) respectively and reduce the hemorrahagic 
transformation. These findings highlight the applicability and potential of miRNA 
based therapeutics in stroke. 
 
Generally, miR-320a is implicated with anti-angiogenesis. However, there are 
several potential targets of miR-320a in cerebral ischemia. We have proposed that 
MMP9 and TIMPs could be important targets for miR-320a. In order to understand 
the regulation of these genes by miR-320a, interaction studies have to be carried 
out via luciferase reporter assays and immunochemistry assays. Protein studies 
should be performed to further investigate the action of miR-320a at the 
translational level. Another area where the study could be extended is to isolate 
mRNAs pulled-down with a transfected, biotinylated miRNA for validation 
possible target genes for miR-320a. This will allow us to gain further 
understanding on the overall mechanisms modulated by this miRNA to bring about 
favourable outcomes in ischemic stroke.  
 
Further examination and verification of the findings on the good outcome with 
minimal adverse effect from the combination therapy (rt-PA with anti miR-320a) 
using a larger cohort of animals, should be also completed in the near future. This 
study could be extended to non-human primates before proceeding for any clinical 
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trials on human stroke patients. These studies will definitely uncover useful and 
beneficial effects of miRNAs that could be used in developing therapeutic agents 
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Supplementary Table 1: 
 
miRNA 
SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-let-7a 0.426 -0.003 -0.002 -0.002 -0.002 -0.001 -0.001 -0.001 6.323E-15 
rno-let-7b 0.037 -0.465 -0.420 -0.127 -0.314 0.044 0.597 -0.366 1.326E-10 
rno-let-7b* -0.041 -0.384 -0.346 -0.161 -0.322 0.037 0.660 -0.360 2.447E-12 
rno-let-7c 0.076 -0.379 -0.413 -0.144 -0.333 0.033 0.366 -0.535 1.673E-06 
rno-let-7d -0.428 -0.569 -0.692 -0.341 -0.740 -0.387 0.327 -0.688 2.001E-07 
rno-let-7d* -0.678 -0.849 -0.626 -0.482 -0.450 0.115 0.412 -0.405 4.062E-18 
rno-let-7e* -0.047 -0.463 -0.417 0.102 -0.144 0.020 0.602 0.531 0.0043914 
rno-let-7i -0.166 -0.462 -0.583 -0.386 -0.449 -0.417 0.364 -1.055 2.528E-08 
rno-let-7i* -1.137 0.098 -0.123 0.064 0.162 0.158 -0.008 0.236 3.423E-05 
rno-miR-1 -1.009 -0.094 -0.564 nd 0.038 nd nd nd 0.0237255 
rno-miR-1* -0.806 -0.158 -0.732 -0.396 -0.445 -0.056 0.130 -0.334 4.192E-06 
rno-miR-100 0.345 -0.406 -0.159 0.126 -0.170 0.063 0.930 0.248 2.113E-09 
rno-miR-101a* 0.129 0.014 -0.662 -0.794 -1.152 -0.608 -2.149 -1.014 8.223E-14 
rno-miR-101b 0.021 -0.278 -0.578 -0.459 -0.133 -0.221 0.231 -1.157 1.116E-11 
rno-miR-103 -0.344 -0.486 -0.382 -0.024 -0.074 -0.047 0.593 -0.536 5.517E-14 
rno-miR-106b -0.236 -0.542 -0.512 -0.326 -0.191 -0.147 0.515 -0.586 0.0004329 
rno-miR-106b* -0.062 -2.920 -1.661 -1.612 -1.112 0.373 0.036 -0.653 2.926E-16 
rno-miR-107 0.349 -0.214 -0.323 0.027 -0.060 -0.148 0.565 -0.219 1.507E-06 
rno-miR-10a-3p -0.657 nd -6.976 -0.970 1.538 2.452 3.146 2.812 1.05E-13 
rno-miR-10a-5p -0.430 0.329 0.237 0.022 0.044 -0.644 nd -0.317 9.951E-15 
rno-miR-10b nd -0.420 -0.704 -0.635 -0.544 -0.628 -0.544 -0.502 0.0021488 
rno-miR-124 0.003 0.001 0.001 0.001 0.001 0.000 0.001 0.001 5.251E-10 
rno-miR-124* 0.001 -0.700 -0.415 -0.143 -0.432 0.014 0.445 -0.769 1.183E-07 
rno-miR-125a-3p -0.002 -0.654 -0.271 -0.313 0.244 0.504 0.959 -0.071 1.243E-08 
rno-miR-125a-5p 0.001 -0.122 -0.010 -0.003 -0.052 -0.001 -0.001 -0.008 1.728E-13 
rno-miR-125b* 0.411 -0.552 -0.594 -0.017 0.426 1.039 1.169 0.027 8.747E-20 
rno-miR-125b-3p -0.266 -0.606 -0.417 0.401 0.987 1.928 1.868 0.116 1.515E-08 
rno-miR-125b-5p -0.606 0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.0001472 
rno-miR-126 -0.098 -0.264 -0.101 -0.115 -0.141 -0.109 -0.002 -0.205 7.015E-10 
rno-miR-126* -0.003 -0.064 -0.050 -0.334 0.038 0.052 0.996 -0.194 2.892E-17 
rno-miR-127 -0.006 -0.157 0.040 0.260 0.060 -0.067 0.576 -0.031 9.841E-05 
rno-miR-128 0.104 -0.295 -0.400 -0.198 -0.531 -0.113 -0.001 -0.609 1.596E-10 
rno-miR-129 0.468 -0.139 -0.115 0.277 0.475 0.684 1.265 0.332 3.775E-19 
rno-miR-129* 0.662 -0.212 -0.245 -0.371 -0.091 0.011 0.893 0.106 2.333E-14 
rno-miR-130a -1.224 -0.445 -0.312 -0.201 0.123 -0.017 0.750 0.037 1.447E-14 
rno-miR-130b 0.656 -1.834 -0.638 -0.501 0.816 1.477 1.464 0.643 7.756E-13 
rno-miR-132 4.830 0.044 -0.020 0.000 -0.526 0.204 0.418 -0.449 5.598E-19 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-133b -0.783 -0.379 -0.356 nd nd nd nd nd 2.479E-11 
rno-miR-134 -0.463 -1.676 -0.400 -0.594 -0.286 -0.854 -0.107 0.548 3.728E-06 
rno-miR-135a -0.277 -0.743 -0.352 -0.555 0.180 -0.571 0.390 -0.783 3.738E-05 
rno-miR-135b -0.085 -0.514 -0.484 -0.643 -0.156 -0.634 0.113 -0.935 5.34E-15 
rno-miR-136 -0.239 -0.779 -1.259 -1.011 -0.544 -0.400 -0.399 -1.580 1.686E-10 
rno-miR-136* -1.011 -0.487 -0.454 -0.393 -0.148 -0.092 0.446 -0.840 8.074E-15 
rno-miR-137 0.000 -0.648 -0.563 -0.314 -0.147 -0.545 -0.288 -1.682 3.026E-13 
rno-miR-138 -0.141 0.000 0.000 0.000 0.001 0.000 0.000 0.001 2.203E-10 
rno-miR-138* nd -0.719 -0.520 -0.444 -0.416 0.043 0.316 -0.519 2.033E-10 
rno-miR-139-3p -0.239 nd nd nd nd nd nd nd 7.69E-17 
rno-miR-140* -0.405 -0.581 -0.129 0.023 0.061 0.096 0.978 0.238 1.691E-09 
rno-miR-141 0.124 1.022 0.751 1.080 0.868 0.859 1.201 1.178 1.85E-17 
rno-miR-140 0.711 -0.419 -0.413 -0.330 0.003 -0.172 0.586 -0.800 3.842E-10 
rno-miR-142-3p 0.545 -0.012 -0.531 -0.383 -0.390 -0.297 0.845 0.970 0.018918 
rno-miR-142-5p -0.210 -0.151 -0.378 -0.353 0.244 0.330 0.712 0.718 5.692E-13 
rno-miR-143 1.685 -0.554 -0.249 -0.372 -0.177 -0.268 -0.208 -0.399 1.203E-14 
rno-miR-144 -0.531 0.013 -0.630 -0.493 1.535 1.842 1.218 -2.064 1.257E-09 
rno-miR-145 0.386 -0.672 -0.132 0.068 -0.184 -0.148 -0.674 0.155 8.548E-19 
rno-miR-146a 0.144 -0.178 -0.011 0.310 0.288 0.178 0.702 0.169 5.124E-13 
rno-miR-146b -0.445 -0.281 -0.121 -0.093 -0.024 -0.121 0.611 -0.377 4.639E-12 
rno-miR-147 0.053 0.658 -0.107 -0.049 -1.461 nd nd nd 1.236E-09 
rno-miR-148b-3p 0.241 -0.678 -0.649 -0.509 -0.255 -0.174 0.637 -0.228 4.962E-20 
rno-miR-148b-5p -1.356 -0.338 -0.684 -0.332 -0.514 -0.521 -0.425 -0.082 0.0007761 
rno-miR-150 -0.042 -0.826 -0.245 0.154 0.246 0.411 0.816 -0.009 1.497E-09 
rno-miR-151 -0.110 -0.554 -0.477 -0.101 -0.382 -0.064 0.562 -0.374 1.829E-07 
rno-miR-151* 0.252 -0.599 -0.001 0.356 0.384 0.503 1.154 0.091 2.79E-07 
rno-miR-152 -0.012 -0.373 -0.347 -0.129 0.033 -0.299 0.907 0.442 2.541E-18 
rno-miR-153 -0.371 -0.443 -0.723 -0.897 -0.398 -0.592 -0.275 -1.226 5.887E-05 
rno-miR-154 0.113 -0.877 -0.502 0.142 -0.385 -0.189 0.799 0.384 1.224E-11 
rno-miR-15b 0.095 -0.655 -0.423 -0.054 -0.018 0.268 0.898 0.546 1.925E-06 
rno-miR-16 0.006 -0.557 -0.597 -0.288 -0.265 -0.107 0.100 -0.650 3.632E-15 
rno-miR-17-3p -0.045 nd -1.282 -0.120 0.539 1.353 1.605 1.537 5.426E-13 
rno-miR-17-5p/ 
rno-miR-17 
0.295 -0.370 -0.356 -0.054 0.181 0.236 0.988 0.220 1.593E-13 
rno-miR-181a 0.609 -0.188 -0.208 0.282 0.025 0.382 1.013 -0.037 1.751E-12 
rno-miR-181a* 0.342 -0.621 -0.523 -0.150 -0.198 -0.084 0.545 -0.827 7.492E-10 
rno-miR-181b 0.055 -0.347 -0.326 0.113 0.075 0.313 0.984 -0.149 1.633E-14 
rno-miR-181c 0.373 -0.356 -0.372 -0.600 -0.658 -0.032 0.242 -0.161 1.906E-15 
rno-miR-181d nd -0.143 -0.124 0.149 0.253 0.426 0.969 0.016 3.393E-05 
rno-miR-182 -2.511 nd nd nd nd nd -3.389 nd 1.854E-07 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-184 0.112 -1.514 -0.858 -0.865 0.040 0.612 0.532 -0.415 2.806E-10 
rno-miR-185 -0.017 -0.655 -0.377 -0.325 -0.054 -0.017 0.548 -0.484 4.284E-14 
rno-miR-186 -2.486 -0.412 -0.213 -0.191 -0.186 -0.088 0.607 -0.595 1.305E-10 
rno-miR-187 -1.814 -3.504 -0.405 -1.179 -1.820 -0.853 -0.671 -1.497 1.25E-13 
rno-miR-188 -0.136 0.134 -0.183 -1.615 -0.466 -0.238 0.195 nd 0.0262543 
rno-miR-18a -0.834 -0.097 -0.259 -0.269 -0.372 -0.268 -0.183 -0.358 0.0029044 
rno-miR-190 0.024 -0.276 -0.526 -0.444 -0.154 -0.343 -0.063 -1.732 0.0011341 
rno-miR-191 -0.337 -0.585 -0.386 -0.232 -0.342 -0.297 0.627 -0.362 8.361E-12 
rno-miR-192 0.050 -0.694 -1.016 -1.027 0.209 0.110 0.635 -0.521 4.661E-12 
rno-miR-193 0.171 -0.692 -0.579 -0.457 -0.342 -0.047 0.576 0.356 4.783E-12 
rno-miR-194 0.228 -0.238 -0.793 -0.741 0.085 -0.052 0.161 -0.545 2.811E-10 
rno-miR-195 -0.324 -0.418 -0.479 -0.512 -0.233 0.042 0.594 -0.753 2.96E-08 
rno-miR-196a -0.954 -0.462 -0.897 -0.476 -0.396 -0.346 -0.037 -1.941 2.1E-06 
rno-miR-196a* -0.815 -1.231 -0.689 -0.762 -0.208 0.079 0.156 -0.334 4.731E-12 
rno-miR-199a-5p nd -0.275 nd nd nd nd nd nd 0.0019995 
rno-miR-19a 0.493 -0.002 -0.156 0.083 0.357 0.332 0.784 0.076 3.096E-06 
rno-miR-19b nd -0.087 -0.101 0.174 0.288 0.141 0.936 -0.013 3.907E-11 
rno-miR-200a 0.533 nd nd -1.975 nd nd nd -2.706 9.999E-13 
rno-miR-200b -4.071 -5.151 nd -3.498 -3.390 -2.037 -3.963 -2.302 4.955E-12 
rno-miR-200c 0.242 1.237 0.888 0.222 nd nd nd nd 6.233E-07 
rno-miR-203 0.347 -0.503 -0.872 -1.195 -1.478 -0.010 0.402 -0.791 1.311E-15 
rno-miR-204 0.684 -0.728 -0.045 -0.522 0.597 -0.953 1.351 0.674 1.716E-10 
rno-miR-204* -0.440 -0.668 -0.368 -0.023 0.955 1.384 1.825 0.946 9.311E-23 
rno-miR-205 -0.737 -0.129 -0.324 0.456 1.480 2.022 2.516 1.672 1.824E-15 
rno-miR-206 -0.716 -1.331 -0.789 -0.423 0.717 1.274 1.889 0.827 8.213E-12 
rno-miR-207 -0.221 -0.029 -0.209 -0.164 -0.083 0.000 0.001 -0.834 4.688E-12 
rno-miR-208 0.518 -1.086 -1.126 -1.239 0.031 0.879 1.016 0.141 1.79E-17 
rno-miR-20a 0.589 -0.389 -0.338 -0.155 0.241 0.243 0.942 -0.136 8.283E-12 
rno-miR-20a* -1.212 -0.341 -0.553 -0.113 -0.432 -0.879 -0.727 -0.220 0.0156471 
rno-miR-20b-3p nd 0.272 -0.351 0.108 -0.650 -1.266 -0.189 0.358 3.158E-08 
rno-miR-20b-5p -0.122 1.361 0.866 0.828 0.729 0.479 -0.231 nd 1.297E-15 
rno-miR-21* -0.185 0.603 0.141 0.973 2.605 2.710 2.703 1.534 1.081E-12 
rno-miR-210 -0.151 -1.493 0.316 0.085 1.155 1.489 1.560 1.347 4.466E-26 
rno-miR-211 -0.755 0.062 -0.136 -0.153 -0.714 -0.549 -1.726 -0.606 7.545E-09 
rno-miR-212 -0.516 -0.557 -0.392 -0.453 -0.385 -0.127 0.230 -0.564 2.905E-06 
rno-miR-214 -0.677 -1.371 -0.536 -0.753 0.314 0.739 0.432 -0.497 4.823E-07 
rno-miR-215 -1.912 nd -0.606 -0.721 1.420 1.713 1.074 0.450 1.106E-16 
rno-miR-216a 1.516 -0.125 -0.322 -0.092 -1.020 -1.439 -1.788 -0.748 1.02E-11 
rno-miR-217 -0.035 1.480 0.727 1.225 0.850 0.784 1.460 1.060 0.0001673 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-218* -0.322 -0.658 -0.398 -0.255 -0.724 -0.098 0.229 -0.934 9.022E-12 
rno-miR-219-1-
3p 
-0.700 -0.528 -0.788 -0.601 -0.516 -0.506 -0.082 -0.296 1.953E-05 
rno-miR-219-2-
3p 
0.145 -0.512 -0.514 -0.136 -0.154 0.234 0.859 -0.271 1.089E-07 
rno-miR-219-5p -0.200 -0.205 -0.605 -0.079 -0.041 -0.113 0.011 -0.859 8.885E-20 
rno-miR-22 -0.953 -0.004 -0.003 -0.002 -0.002 -0.002 -0.001 0.000 8.407E-12 
rno-miR-22* -0.003 -0.493 -0.437 -0.358 -0.304 0.024 0.555 -0.560 6.472E-12 
rno-miR-221 0.185 -0.554 -0.622 -0.264 -0.600 -0.364 0.311 -0.738 9.863E-08 
rno-miR-222 0.208 -0.353 -0.379 0.053 -0.360 -0.140 0.528 -0.390 3.777E-13 
rno-miR-223 -0.724 0.113 0.093 0.340 0.857 1.460 2.280 3.496 2.463E-11 
rno-miR-224 -1.467 -0.417 -0.536 -0.435 -0.525 -0.295 -0.080 -0.393 2.342E-30 
rno-miR-23a 0.000 -0.486 -0.338 -0.217 -0.281 -0.029 0.869 0.145 8.489E-18 
rno-miR-23a* 0.311 -3.832 -0.528 -0.637 0.813 1.272 1.099 0.027 0.0039835 
rno-miR-23b 0.160 -0.516 -0.360 -0.023 -0.350 -0.148 0.656 -0.192 2.666E-17 
rno-miR-24 -0.285 0.000 0.000 0.001 0.000 0.000 0.001 0.002 4.361E-14 
rno-miR-24-1* 0.647 -0.798 -0.701 -0.637 -0.597 -0.180 0.330 -0.459 6.278E-09 
rno-miR-24-2* 0.477 -0.395 -0.384 -0.309 -0.211 0.116 0.891 -0.039 8.238E-13 
rno-miR-25 0.000 -0.051 -0.061 0.439 0.085 0.323 1.314 0.642 1.664E-13 
rno-miR-25* 0.463 -0.312 0.028 0.635 1.258 1.924 2.557 1.729 9.979E-13 
rno-miR-26a -0.288 0.000 0.000 0.001 0.000 0.001 0.001 -0.002 4.378E-08 
rno-miR-26b* -0.003 0.169 -0.014 -0.234 -0.267 0.040 -0.152 nd 0.0034887 
rno-miR-27a 1.242 0.008 -0.155 -0.032 -0.010 0.158 1.092 0.355 1.969E-17 
rno-miR-27a* 0.851 -0.325 -0.981 -3.012 nd nd nd nd 0.0003298 
rno-miR-27b -0.317 -0.465 0.242 -0.401 0.190 0.602 1.620 -0.348 5.686E-12 
rno-miR-28 0.440 -0.539 -0.383 -0.203 -0.356 -0.179 0.380 -0.402 4.205E-09 
rno-miR-28* -1.156 0.224 -0.312 -0.104 -0.289 -0.260 -0.178 -0.564 2.886E-07 
rno-miR-290 -0.444 -0.439 -0.572 -0.322 0.816 1.193 1.480 0.746 2.328E-20 
rno-miR-291a-3p 0.592 -0.127 -1.158 -1.849 nd -1.013 0.246 -0.122 5.436E-08 
rno-miR-291a-5p 0.056 -0.769 -0.006 1.372 2.245 3.014 3.648 2.400 4.421E-26 
rno-miR-292-3p -0.642 -0.150 -0.310 -0.173 -0.415 -0.362 -0.071 -0.346 5.18E-05 
rno-miR-292-5p -0.897 -0.314 -0.521 -0.376 -0.950 -1.427 -2.914 -1.290 1.43E-07 
rno-miR-296 -0.576 -2.018 -1.016 -0.315 0.653 1.202 1.448 0.736 0.0114137 
rno-miR-296* -0.079 -0.367 -1.172 -0.751 nd nd nd nd 3.671E-14 
rno-miR-297 nd nd -4.850 -1.839 -0.283 0.405 -2.161 nd 6.286E-12 
rno-miR-298 -0.288 -2.207 -0.669 -0.954 0.520 0.259 0.819 0.408 7.125E-14 
rno-miR-299 -0.127 -0.586 0.273 0.898 0.682 1.438 2.126 0.899 2.393E-14 
rno-miR-29a 0.000 0.000 0.000 0.000 -0.001 -0.001 0.000 0.001 2.544E-12 
rno-miR-29a* 0.000 -0.359 -0.417 -0.353 -0.171 -0.187 0.425 -0.906 1.402E-12 
rno-miR-29b -1.494 0.000 0.000 0.000 0.000 0.001 0.001 -0.006 5.975E-11 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-29b-2* -0.740 -3.319 -0.434 -0.554 -0.765 -0.897 0.215 -1.963 0.0004694 
rno-miR-29c -0.237 -0.491 -0.514 -0.329 0.016 -0.196 0.312 -0.715 1.855E-09 
rno-miR-29c* -0.099 -0.907 -0.734 -0.552 -0.528 -0.651 0.284 -0.973 8.47E-06 
rno-miR-300-3p -0.057 -0.460 -0.206 -0.234 0.181 -0.307 0.642 0.030 1.899E-09 
rno-miR-300-5p -0.601 -0.768 -0.380 0.241 1.319 1.712 1.952 0.848 2.407E-26 
rno-miR-301a -0.072 -0.789 -0.777 -0.658 -0.155 -0.571 -0.171 -1.540 4.89E-10 
rno-miR-301b -1.029 -0.075 -0.477 -0.086 -0.449 -0.789 -1.003 -0.349 6.722E-05 
rno-miR-30a -0.003 -0.004 -0.002 -0.002 -0.002 -0.002 -0.001 -0.003 0.0257404 
rno-miR-30a* -0.003 -0.873 -0.682 -0.070 -0.133 -0.359 0.494 -0.849 1.004E-14 
rno-miR-30b-3p -0.994 -1.435 -0.810 -0.853 -0.153 0.256 -0.073 -0.900 2.141E-19 
rno-miR-30b-5p -0.002 -0.003 -0.003 -0.003 -0.002 -0.002 -0.001 0.000 0.0187382 
rno-miR-30c -0.497 -0.004 -0.002 -0.002 -0.002 -0.001 -0.001 -0.010 1.149E-09 
rno-miR-30c-1* -0.177 -2.218 -0.585 -0.062 1.391 1.713 2.532 1.562 5.851E-06 
rno-miR-30c-2* -0.170 -1.495 -0.042 -0.848 -0.070 0.555 1.454 0.799 1.266E-15 
rno-miR-30d* -0.982 0.596 0.263 0.344 0.192 0.026 0.211 0.508 0.0155815 
rno-miR-30e 0.072 -0.218 -0.363 -0.369 -0.165 -0.261 0.151 -0.925 9.514E-16 
rno-miR-30e* 0.117 -0.533 -0.698 -0.383 -0.349 -0.289 0.427 -0.898 8.491E-17 
rno-miR-31 0.414 -0.400 -0.389 -0.108 -0.254 -0.289 1.038 -0.381 1.313E-14 
rno-miR-32 -0.168 -0.322 -0.552 -0.361 0.202 0.023 0.373 -1.059 1.352E-19 
rno-miR-320 -0.168 -0.573 -0.531 -0.006 -0.155 -0.008 0.789 0.124 1.649E-11 
rno-miR-322 -0.553 -1.222 -0.468 -0.372 -0.063 0.146 0.447 -0.580 1.49E-15 
rno-miR-322* -1.179 0.083 -0.166 -0.151 -0.214 0.013 0.043 -1.492 0.03549 
rno-miR-323 0.567 -0.777 -0.500 -0.359 -0.435 -0.354 0.420 -0.392 1.716E-15 
rno-miR-323* -0.593 1.577 1.194 1.144 -0.010 nd nd nd 2.407E-09 
rno-miR-324-3p 0.178 0.356 -0.088 nd nd nd nd nd 0.0002118 
rno-miR-324-5p -0.356 -0.184 -0.136 -0.014 0.057 -0.023 0.562 -0.610 2.161E-07 
rno-miR-325-3p -0.215 -0.922 -0.682 -0.460 -0.184 0.054 0.480 -0.295 1.506E-13 
rno-miR-325-5p 0.148 -0.509 -0.477 -0.392 -0.279 0.021 0.521 -0.698 1.423E-13 
rno-miR-326 -0.196 -0.514 -0.462 0.036 0.643 0.793 1.646 0.827 3.373E-08 
rno-miR-327 0.201 1.064 0.087 0.572 nd nd nd nd 1.313E-07 
rno-miR-328 -0.750 -0.695 -0.147 -0.005 -0.081 0.171 0.684 0.347 4.5E-12 
rno-miR-329 -0.322 -0.784 -0.480 -0.305 -0.130 0.096 0.448 -0.498 8.558E-11 
rno-miR-33 0.074 -0.361 -0.419 -0.045 0.127 -0.341 0.007 -1.443 1.267E-12 
rno-miR-330 -0.226 -0.640 -0.433 -0.409 -0.324 -0.411 0.187 -0.782 1.62E-08 
rno-miR-330* -0.344 -0.733 -0.330 -0.204 0.176 0.211 0.666 -0.194 9.043E-17 
rno-miR-331 -0.045 -0.554 -0.344 -0.341 -0.066 0.003 0.423 -0.358 1.76E-13 
rno-miR-333 -0.882 -1.222 0.318 0.379 0.219 0.264 0.688 -0.191 3.63E-13 
rno-miR-335 -0.246 -0.742 -0.666 -0.859 -0.202 -0.552 0.050 -0.928 2.19E-08 
rno-miR-336 -0.633 -1.421 -0.739 -1.282 -1.018 -0.452 -0.722 -1.747 3.169E-09 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-338 0.311 -0.529 -0.507 -0.175 0.112 0.274 0.941 -0.269 8.856E-15 
rno-miR-338* nd -0.434 -0.284 0.136 0.177 0.429 1.123 0.192 1.676E-15 
rno-miR-339-3p -0.269 -0.413 -0.834 -0.340 -0.481 -0.351 -1.221 0.113 1.592E-14 
rno-miR-339-5p -0.454 -0.757 -0.256 -0.133 -0.057 0.078 0.703 0.421 0.0010758 
rno-miR-340-3p -0.257 -0.875 -0.289 -0.189 0.205 0.453 0.647 -0.131 2.45E-11 
rno-miR-340-5p 0.121 -0.593 -0.518 -0.456 -0.083 -0.004 0.420 -0.824 1.995E-08 
rno-miR-341 -0.501 -0.582 -0.531 -0.294 0.086 0.169 0.715 -0.287 5.388E-14 
rno-miR-342-3p -1.125 -0.621 -0.399 0.040 -0.247 -0.239 0.560 -0.118 1.015E-07 
rno-miR-342-5p -0.171 -2.177 -0.965 -0.866 -0.561 -0.303 -0.299 -1.184 1.405E-10 
rno-miR-344-3p -0.630 -0.825 -0.570 -0.611 0.159 0.146 0.107 -0.888 1.692E-07 
rno-miR-344-5p -0.960 -2.113 -2.586 -3.714 -1.767 -0.557 -0.037 -1.832 4.754E-11 
rno-miR-345-3p 0.654 -2.679 -1.874 -1.308 0.008 0.387 1.115 -3.374 0.0002791 
rno-miR-345-5p 0.917 -0.112 0.235 0.350 0.861 1.328 1.427 0.265 7.593E-12 
rno-miR-346 -0.123 -0.432 -0.247 0.147 -0.492 0.022 0.757 0.113 0.0001239 
rno-miR-347 -0.482 -0.464 -0.713 -0.960 -1.103 -0.434 -0.265 -1.351 3.659E-06 
rno-miR-349 -2.931 -3.628 -0.788 -1.134 0.222 0.519 -0.453 0.001 0.0021163 
rno-miR-34a 0.090 -0.321 -0.546 -0.538 -0.393 -0.122 0.689 -0.718 3.167E-15 
rno-miR-34b -0.012 -0.835 -0.985 -1.131 0.671 -0.551 1.113 0.497 1.079E-16 
rno-miR-34c 0.383 -0.723 -0.663 -1.076 0.947 -0.216 1.382 0.863 2.55E-17 
rno-miR-34c* -0.702 -1.116 -0.541 -0.701 -0.121 0.167 0.056 -0.836 1.16E-12 
rno-miR-350 -0.003 -0.387 -0.322 -0.311 -0.125 0.264 0.870 -0.314 1.517E-10 
rno-miR-351 0.039 -0.392 -0.309 0.015 1.433 1.336 1.732 0.747 2.588E-21 
rno-miR-352 -0.605 -0.741 -0.885 -0.359 -0.751 -0.570 0.348 -0.778 2.188E-15 
rno-miR-361 -0.384 -0.464 -0.413 -0.189 -0.100 0.163 0.745 -0.167 5.684E-19 
rno-miR-363 1.284 -0.128 -0.291 -0.215 -0.306 -0.128 -0.073 -0.893 3.874E-13 
rno-miR-363* -1.434 -2.289 -0.236 0.512 -0.545 -0.130 0.935 0.447 1.938E-13 
rno-miR-365 -0.051 -0.115 0.122 0.296 0.065 0.441 0.881 0.296 5.797E-07 
rno-miR-369-3p -0.533 -0.346 -0.311 -0.346 -0.046 -0.442 0.257 -0.863 6.569E-12 
rno-miR-369-5p -0.680 -0.722 -0.464 -0.253 -0.100 -0.208 0.549 -0.428 4.453E-11 
rno-miR-370 0.285 -0.295 -0.272 -0.104 -0.086 -0.153 -0.220 -0.224 8.649E-14 
rno-miR-374 0.316 -0.418 -0.100 -0.119 -0.170 -0.322 -0.389 -0.356 2.185E-10 
rno-miR-375 -0.360 -0.483 -0.383 -0.267 -0.381 0.250 1.161 0.493 8.218E-06 
rno-miR-376a -0.155 -0.531 -0.743 -0.839 -0.219 -0.540 -0.214 -1.342 2.939E-15 
rno-miR-376a* -0.136 -1.075 -0.784 -0.702 -0.186 -0.574 0.239 -1.200 2.149E-14 
rno-miR-376b-3p -0.260 -0.491 -0.360 -0.571 -0.123 -0.351 0.296 -0.522 5.498E-14 
rno-miR-376b-5p -0.366 -0.760 -0.579 -0.573 -0.096 -0.483 0.230 -1.160 4.055E-14 
rno-miR-376c 0.361 -0.612 -0.515 -0.542 -0.234 0.050 0.332 -0.863 5.945E-13 
rno-miR-377 -2.269 -0.791 -0.555 -0.611 -0.700 -0.285 -0.006 -0.468 6.955E-09 
rno-miR-378 0.403 -0.640 -0.414 -0.377 -0.252 -0.275 0.564 -0.260 0.0122199 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-379 -0.352 -0.502 -0.550 -0.556 -0.067 -0.347 0.345 -0.803 1.706E-11 
rno-miR-379* 1.025 -0.397 0.150 0.011 0.612 -0.104 1.276 -2.077 7.108E-06 
rno-miR-380 3.439 nd 2.361 1.021 2.716 -0.954 3.172 nd 4.65E-07 
rno-miR-381 -0.446 -0.884 -0.425 -0.337 0.353 0.378 0.896 0.013 6.746E-09 
rno-miR-382 -0.578 -0.692 -0.559 -0.209 -0.185 -0.004 0.672 -0.166 4.839E-12 
rno-miR-382* 0.064 -0.722 -0.860 -1.001 -0.755 0.042 0.361 -0.380 1.189E-09 
rno-miR-383 -0.002 -0.529 -0.293 -0.093 -0.267 -0.018 0.417 -0.349 9.604E-12 
rno-miR-384-3p -0.175 -0.499 -0.560 -0.588 -0.180 -0.441 0.068 -1.322 1.102E-08 
rno-miR-384-5p 0.143 -0.524 -0.396 -0.291 -0.133 -0.220 0.494 -0.825 2.915E-14 
rno-miR-409-3p -0.062 -0.647 -0.446 -0.234 -0.422 -0.398 0.185 -0.335 8.675E-15 
rno-miR-409-5p -0.233 -1.010 -0.526 -0.630 0.128 0.283 0.820 0.037 7.377E-13 
rno-miR-410 0.192 -0.568 -0.262 0.120 0.403 -0.017 0.667 0.110 1.391E-08 
rno-miR-411 -0.661 -0.412 -0.315 -0.475 -0.407 -0.486 0.032 -1.352 2.827E-10 
rno-miR-412 0.069 -0.159 -0.480 -0.399 -0.316 0.045 0.168 -0.445 4.371E-10 
rno-miR-421 -0.630 -0.564 -0.740 -0.590 -0.522 -0.357 -0.148 -0.229 0.0008296 
rno-miR-423 -0.453 -0.351 -0.251 0.336 0.497 0.812 1.218 0.734 3.433E-08 
rno-miR-425 1.794 -0.763 -0.358 -0.128 -0.068 -0.233 0.389 -0.270 1.327E-11 
rno-miR-429 nd nd nd nd nd nd nd -0.191 0.0017952 
rno-miR-431 -0.630 nd nd 0.075 nd -0.976 1.638 nd 4.172E-11 
rno-miR-433 2.401 -0.757 -0.476 -0.189 -0.179 -0.368 0.426 -0.191 2.864E-05 
rno-miR-434 -0.218 -0.477 -0.418 -0.110 -0.289 -0.172 0.639 -0.205 1.589E-09 
rno-miR-448 nd nd 0.733 nd 2.648 nd 2.830 1.039 3.418E-14 
rno-miR-449a 1.574 nd -0.946 -0.834 0.846 1.355 0.297 -2.062 1.532E-16 
rno-miR-450a -0.616 0.341 -0.173 -0.201 -0.229 -1.036 -1.681 -0.553 1.348E-06 
rno-miR-451 0.709 -0.069 -0.336 -0.492 1.206 2.272 1.745 -0.141 0.0344268 
rno-miR-455 -2.000 -0.303 -0.287 -0.258 0.206 0.138 1.245 -0.382 2.38E-13 
rno-miR-463 -1.151 -0.168 -0.289 0.115 -0.663 -0.448 -1.054 -0.410 0.0006885 
rno-miR-466b -1.625 -1.522 -0.648 -0.665 0.470 0.918 0.603 -0.447 2.136E-19 
rno-miR-466c -1.369 -1.679 -0.768 -0.702 0.077 0.636 0.160 -0.878 6.314E-20 
rno-miR-471 -0.757 -1.293 -1.094 -1.151 0.024 0.084 0.282 -0.387 1.92E-11 
rno-miR-483 -0.388 -1.390 0.293 0.134 1.376 1.982 1.859 0.993 2.023E-13 
rno-miR-484 -0.231 0.700 -0.522 -0.418 nd nd nd nd 1.048E-06 
rno-miR-485 -0.410 -0.515 -0.162 0.127 -0.224 -0.403 0.389 -0.221 5.204E-10 
rno-miR-487b -0.642 -0.623 -0.636 -0.569 -0.733 -0.608 -0.086 -1.028 1.087E-05 
rno-miR-488 0.245 -0.483 -0.568 -0.480 0.009 0.094 0.274 -0.888 0.0019421 
rno-miR-489 -0.688 -0.287 -0.400 -0.344 -0.676 -0.236 -0.203 -0.562 0.000469 
rno-miR-493 0.638 0.152 -0.281 0.199 -0.121 -0.224 0.413 0.552 1.187E-10 
rno-miR-494 -0.130 0.079 -0.329 -0.310 0.596 0.833 1.120 0.195 0.0165692 
rno-miR-495 -0.080 -0.398 -0.327 -0.226 -0.197 -0.337 0.311 -0.601 1.875E-13 






SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-499 -0.322 -0.436 -0.540 -0.238 -0.151 -0.745 0.608 -1.020 6.11E-09 
rno-miR-500 0.446 -1.148 -0.682 -0.120 0.431 0.455 1.287 0.944 1.681E-11 
rno-miR-501 -0.282 -0.350 -1.143 -0.648 -0.616 -0.365 -0.380 -0.477 0.0294355 
rno-miR-503 0.380 -0.760 -0.407 -0.296 0.774 1.335 1.466 0.402 2.304E-13 
rno-miR-505 nd -0.766 -0.671 -0.141 -0.231 -0.327 0.520 -0.283 6.735E-10 
rno-miR-532-3p 0.209 -0.325 -0.949 -0.488 -1.798 -3.867 nd nd 2.708E-06 
rno-miR-532-5p -0.549 -0.752 -0.589 -0.570 0.306 -0.275 0.672 -0.350 1.698E-08 
rno-miR-539 -0.079 -0.732 -0.429 -0.228 -0.192 -0.433 0.214 -0.832 8.303E-07 
rno-miR-540 0.837 nd -0.657 -1.352 1.046 1.426 1.373 0.088 3.731E-11 
rno-miR-541 -0.351 -0.758 -0.501 -0.380 -0.538 -0.497 0.221 -0.750 1.742E-10 
rno-miR-542-3p -0.245 -0.959 -0.668 -0.462 -0.120 -0.215 -0.356 -0.978 4.339E-11 
rno-miR-542-5p -1.771 -1.998 -0.889 -0.382 0.974 1.157 2.242 1.748 6.687E-13 
rno-miR-543* -0.074 -0.351 -0.505 -0.203 -0.165 -0.206 -0.260 0.098 2.047E-16 
rno-miR-551b -0.254 -0.405 -0.427 -0.223 0.023 0.131 0.493 -0.322 0.0263209 
rno-miR-598-3p -0.178 -0.611 -0.445 -0.358 -0.118 -0.289 0.459 -0.435 3.157E-08 
rno-miR-652 1.016 -0.605 -0.504 -0.286 -0.274 -0.462 0.413 -0.328 4.588E-12 
rno-miR-664 -0.649 -0.289 -0.190 -0.022 0.196 0.617 0.925 0.031 2.39E-16 
rno-miR-671 -0.618 nd -0.646 nd -1.155 -0.545 1.621 nd 5.871E-09 
rno-miR-672 -0.573 -0.899 -0.691 -0.265 -0.331 -0.453 -0.155 -0.356 0.0030663 
rno-miR-673 -0.997 -0.599 -0.871 -0.548 -0.449 -0.420 -0.081 -0.111 0.0027847 
rno-miR-674-3p 0.880 -0.667 -0.424 -0.308 -0.428 -0.144 0.076 -0.015 1.312E-10 
rno-miR-674-5p -0.394 -0.586 -0.618 -0.203 -0.585 0.109 0.223 -0.294 3.308E-09 
rno-miR-708* -0.033 -2.208 -3.335 -0.986 -1.597 -0.969 -1.185 -0.448 1.855E-12 
rno-miR-742 -0.417 -0.902 -0.805 -0.859 -0.451 -0.055 -0.010 -0.940 4.721E-19 
rno-miR-743a -2.846 0.195 -0.094 -0.010 nd nd nd nd 1.952E-08 
rno-miR-743b -0.148 -1.043 -0.794 -0.799 -0.478 -0.075 -0.072 -0.784 3.634E-11 
rno-miR-758 -1.161 nd 2.530 3.125 2.934 nd 3.560 nd 1.621E-06 
rno-miR-760-3p 0.157 -1.003 -0.293 -0.166 -0.154 -0.553 0.120 -0.299 0.000446 
rno-miR-760-5p -0.500 nd nd nd -6.535 0.551 -0.290 nd 5.822E-08 
rno-miR-770 -0.826 -0.987 -0.465 -0.118 -0.013 -0.384 0.408 0.287 2.396E-12 
rno-miR-7a -3.011 -1.027 -0.623 -0.551 0.092 -0.962 -0.367 -0.791 4.161E-09 
rno-miR-7a* nd -1.189 -0.402 -0.643 -0.931 -0.235 0.188 -1.178 1.082E-12 
rno-miR-7b -0.670 -1.326 -0.842 -0.539 -0.094 -1.530 -0.594 -1.103 1.121E-09 
rno-miR-871 -0.241 -0.262 -0.542 -0.630 nd nd nd -1.299 6.646E-08 
rno-miR-872 0.460 -0.171 -0.215 0.022 0.753 0.620 1.206 -0.275 2.274E-09 
rno-miR-872* -0.346 -0.411 -0.487 -0.304 0.613 0.981 1.041 0.174 7.94E-16 
rno-miR-873 0.825 -0.599 -0.328 -0.611 0.050 -0.041 0.052 -0.762 1.123E-08 
rno-miR-874 -0.645 -0.536 0.453 0.724 1.913 2.610 3.601 2.274 3.683E-10 
rno-miR-877 -0.003 -1.327 -0.589 -0.300 0.580 1.083 1.117 0.113 6.458E-13 





Supplemental Table 1: Expression profile of miRNAs. There are 331 miNAs 
expressed significantly in the miRNAs microarray data. Expression values are 
expressed as SLR. Statistical analysis, single factor ANOVA was performed and 
only miRNAs with expression of p<0.05 are included in this table. Those with 













SLR t test 
p<0.05 0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-879 0.440 -0.831 -0.434 -0.766 0.090 -0.679 -0.254 -1.754 6.572E-11 
rno-miR-880 nd nd -2.773 -3.320 -1.159 -0.749 -5.316 -5.888 2.308E-09 
rno-miR-881 0.546 0.693 0.389 0.719 0.693 0.424 0.966 0.756 0.0129155 
rno-miR-883 -2.290 -2.868 -1.829 -1.940 -0.085 -0.405 -0.840 -1.273 8.874E-08 
rno-miR-9 -0.931 -0.005 -0.002 -0.002 -0.002 -0.002 -0.001 0.000 2.087E-19 
rno-miR-9* 0.000 0.000 0.000 0.001 0.000 0.001 0.001 0.337 7.072E-25 
rno-miR-92a -0.779 0.205 -0.392 -0.831 -0.050 -0.414 -2.015 -2.987 0.0004973 
rno-miR-92b 0.334 -0.506 -0.401 -0.093 -0.217 0.069 0.659 -0.055 2.135E-05 
rno-miR-93 1.478 -0.390 -0.239 -0.001 0.016 0.151 0.944 0.061 3.701E-17 
rno-miR-96 -0.210 1.424 1.515 1.285 0.967 1.192 1.959 1.595 1.044E-12 
rno-miR-98 -0.102 -0.540 -0.592 -0.417 -0.446 -0.485 0.281 -1.115 0.0028994 
rno-miR-99a -0.723 -0.760 -0.719 -0.314 -0.685 -0.299 0.594 -0.178 4.317E-14 
rno-miR-99b 0.145 -0.418 -0.452 -0.110 -0.211 -0.143 0.887 0.262 9.03E-10 
rno-miR-99b* 0.221 -0.972 -0.712 -0.795 -0.288 0.288 0.154 -0.566 2.66E-12 
318 
 




0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-let-7a 0.0005 0.0005 0.0005 0.0003 0.0005 0.0005 0.0005 0.0003 
rno-let-7b 0.3070 0.3366 -0.0799 -0.1248 -0.0126 -0.1248 0.1444 -0.0991 
rno-let-7b* 0.3491 0.4780 0.0661 -0.0213 0.0742 -0.4428 -0.0440 0.1649 
rno-let-7c 0.0482 0.1953 0.0910 -0.1737 0.0640 -0.1216 0.0910 -0.2578 
rno-let-7d 0.3361 0.2220 -0.1683 -0.1070 -0.0603 -0.3884 -0.2634 -0.2088 
rno-let-7d* 0.3125 0.2672 0.0489 -0.3211 -0.3594 -0.4415 -0.3930 -0.4022 
rno-let-7e -0.0020 -0.0118 0.0004 -0.0013 -0.0006 -0.0019 -0.0006 -0.2038 
rno-let-7e* 0.5989 0.3330 0.6712 -0.3366 0.2699 -0.7384 0.0492 0.0627 
rno-let-7f -0.0007 -0.0006 -0.0004 -0.0004 -0.0005 -0.0005 -0.0003 -0.0005 
rno-let-7i 0.4721 0.3662 0.1922 -0.1681 0.1383 -0.3833 -0.1738 nd 
rno-miR-1 nd nd nd nd nd nd nd 4.2479 
rno-miR-1* nd nd nd nd nd 6.7664 nd nd 
rno-miR-100 0.4680 0.3907 0.2551 -0.0169 0.3162 -0.1559 -0.0626 0.3734 
rno-miR-101a 0.5260 0.3434 0.3434 0.1110 0.3069 -0.1333 0.1110 0.1641 
rno-miR-101a* 4.1224 nd 2.7309 nd nd nd nd nd 
rno-miR-101b 0.3127 0.1556 0.3007 0.0087 0.0850 -0.3427 -0.1537 0.0924 
rno-miR-103 0.6330 0.3503 0.6573 0.1114 0.2911 0.1226 0.2016 0.0485 
rno-miR-106b 0.4488 0.3983 0.3622 0.0534 0.3783 0.0255 0.0106 0.3622 
rno-miR-106b* -3.5845 -6.5021 -6.5021 -6.5021 -6.5021 -6.5021 0.1558 -6.5021 
rno-miR-107 0.5655 0.5312 0.3421 0.2396 0.1406 -0.1094 -0.0775 -0.0261 
rno-miR-10a-3p -4.4169 -4.4169 -4.4169 1.1962 1.1689 2.1197 2.5562 3.2545 
rno-miR-122 -4.4521 -0.6943 -3.1791 -4.4521 -4.4521 -4.4521 1.6104 -4.4521 
rno-miR-124 0.1831 0.1839 0.1834 0.1741 0.1827 -0.0352 0.1831 0.1685 
rno-miR-124* 0.5573 0.2352 0.6289 0.1615 0.2883 -0.2496 -0.3664 0.0065 
rno-miR-125a-3p 0.2943 -0.0445 0.3009 -0.3164 0.2877 0.0457 0.1795 0.1826 
rno-miR-125a-5p -0.0001 -0.1214 -0.1214 0.0002 -0.1423 -0.0002 -0.1423 -0.2729 
rno-miR-125b* -0.0172 0.2631 0.1609 0.5716 0.2954 0.2631 0.8667 0.2273 
rno-miR-125b-3p -0.3951 -0.2966 0.2790 0.8876 0.5076 0.8416 1.7201 0.1088 
rno-miR-125b-5p 0.0437 0.0445 0.0442 0.0429 0.0435 -0.1399 0.0442 0.0414 
rno-miR-126 -0.0012 -0.1846 -0.1401 -0.2025 -0.1846 -0.0012 -0.2954 0.0007 
rno-miR-126* 0.6254 0.4740 0.3601 0.2390 0.3670 0.1750 0.0659 0.5372 
rno-miR-127 0.4015 0.3475 0.3282 0.2913 0.1213 -0.0897 0.0209 nd 
rno-miR-128 -0.3253 -0.4990 -0.4246 -0.3552 -0.3552 nd -0.4590 -0.3754 
rno-miR-129 0.6372 0.5296 0.6605 0.3834 0.4968 0.6605 0.8249 0.5472 
rno-miR-129* 0.5849 0.4558 -0.1064 nd -0.2272 -0.6774 -0.4028 -0.2698 
rno-miR-130a 0.3630 0.4096 0.5131 0.0981 0.5131 0.0509 0.5816 0.7292 
rno-miR-130b -0.6014 -0.5034 -0.3538 -0.0080 -0.2695 0.4615 0.7852 0.3619 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-133a 4.8758 3.2895 4.1699 nd nd nd nd 2.1788 
rno-miR-133b nd nd nd 1.0589 2.4374 nd 2.7309 1.2730 
rno-miR-134 0.4312 -0.0665 0.0650 0.2600 -0.3684 -1.8671 -1.4521 -0.1282 
rno-miR-135a 0.3080 0.1774 0.4610 0.1950 -0.0369 0.2122 -0.1973 0.1774 
rno-miR-135a* nd 4.1699 nd nd nd nd nd nd 
rno-miR-135b 0.2679 -0.0220 0.2312 0.2379 -0.0777 -0.0844 -0.1019 -0.0411 
rno-miR-136 -0.2651 -0.5902 -0.4974 -0.3641 -0.4788 -0.7927 -0.6852 -0.4788 
rno-miR-136* 0.4056 0.0389 0.6542 0.3185 0.5132 0.1480 0.4232 0.3527 
rno-miR-137 0.7003 0.1261 0.5812 0.4951 0.1437 0.1328 0.0644 0.2017 
rno-miR-138 0.0808 0.0817 0.0814 0.0666 0.0815 -0.1881 0.0814 0.0808 
rno-miR-138* -0.1031 -0.0431 -0.1410 -0.2544 -0.4204 -0.5257 -0.5517 -0.5141 
rno-miR-139-3p 5.7886 nd 4.5043 6.1882 4.9069 6.4365 3.7579 nd 
rno-miR-139-5p 0.6630 1.0387 0.4568 0.7363 0.4568 0.2848 0.0858 -0.1963 
rno-miR-140 0.2976 0.2083 0.4188 0.0464 0.1687 -0.0342 0.3081 0.2241 
rno-miR-140* 0.6343 0.3939 0.4554 nd 0.3321 -0.0457 0.2824 0.2478 
rno-miR-142-3p 0.5948 0.3768 0.4291 0.3406 0.2782 0.6170 0.1743 1.5036 
rno-miR-142-5p 0.4784 0.1838 0.1931 -0.0751 0.1320 0.2229 0.0294 1.2791 
rno-miR-143 0.2199 0.2325 0.2325 0.1161 0.1505 -0.1953 0.0225 0.2498 
rno-miR-144 2.0065 1.3988 1.3000 1.1465 2.1174 0.9715 2.1267 0.7240 
rno-miR-145 0.5805 0.3642 0.2064 0.0592 -0.0265 -0.1580 -0.0597 0.2286 
rno-miR-146a 0.7346 0.8623 0.7483 0.6557 0.6009 0.5143 0.3992 0.7755 
rno-miR-146b 0.6436 0.4101 0.2980 -0.0518 0.2283 -0.0275 0.0632 0.4623 
rno-miR-147 nd nd nd nd nd 7.5212 6.1565 6.5887 
rno-miR-148b-3p 0.5532 0.3866 0.1651 -0.1269 0.0942 -0.1826 -0.1619 -0.0355 
rno-miR-150 0.4532 0.3881 0.4126 0.2383 0.2679 0.1332 -0.2055 -0.1595 
rno-miR-151 0.6319 0.3731 0.2406 -0.2453 0.1397 -0.3608 -0.1004 -0.1378 
rno-miR-151* 1.0257 0.5963 0.7050 -0.0435 0.5315 -0.6939 -0.0961 0.0376 
rno-miR-152 0.6230 0.8086 0.4984 0.2039 0.6008 -0.3323 -0.1586 0.4928 
rno-miR-153 0.2126 0.0924 0.4329 0.2853 0.3169 -0.4968 -0.4728 nd 
rno-miR-154 1.0911 0.6281 0.8699 0.6879 0.3653 -0.6639 -0.2513 -0.0923 
rno-miR-15b 0.7650 0.5596 0.2226 -0.1096 0.0371 -0.0495 0.0053 0.3788 
rno-miR-16 -0.1236 -0.1771 0.0202 -0.2631 0.0780 -0.0836 0.0202 -0.0492 
rno-miR-17 0.9418 0.5944 0.6867 0.1099 0.3815 0.1452 0.4496 1.0117 
rno-miR-17-3p 1.8930 0.4060 1.6330 -0.5571 1.5988 -5.1520 0.8492 1.4603 
rno-miR-181a 0.7024 0.2161 0.6383 0.1918 0.5617 0.4966 0.7024 0.4365 
rno-miR-181a* 0.5212 0.3141 0.5905 -0.1302 0.0137 -0.1834 -0.2623 -0.1155 
rno-miR-181b 0.6288 0.1897 0.5256 0.0255 0.3600 0.0939 0.4760 0.2733 
rno-miR-181c 0.5021 0.8020 0.3211 0.0069 0.0193 -0.1097 -0.1097 0.0069 
rno-miR-181d 0.7537 0.5711 0.3792 -0.1773 0.4329 0.1800 0.7913 0.4921 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-183 -1.9267 -3.2311 -0.1522 -2.7346 -2.3853 -2.8918 -2.0801 -1.4475 
rno-miR-184 -0.6285 -0.6762 -0.6358 -0.4400 -0.6045 -0.3211 -0.6285 -0.5121 
rno-miR-185 0.4062 0.0105 0.2459 -0.3469 0.1232 -0.1376 -0.3953 -0.0158 
rno-miR-186 0.5631 0.5183 0.3622 0.0104 0.2548 -0.0905 0.0993 0.2025 
rno-miR-187 0.7648 0.8038 1.2110 0.9739 -0.6292 0.3413 -0.2990 -6.8676 
rno-miR-18a nd nd nd 7.0131 nd nd nd nd 
rno-miR-190 0.5757 0.4431 0.7546 0.0952 0.3364 -0.1610 -0.3128 0.0808 
rno-miR-191 0.4571 0.3008 0.3874 -0.0829 0.2663 -0.1694 0.1029 0.1668 
rno-miR-192 0.8081 -0.6364 0.9079 -0.4093 0.4941 -1.5115 0.4684 0.4204 
rno-miR-193 0.5954 -0.0117 0.3524 -0.0241 0.3103 -0.0943 0.0434 0.9056 
rno-miR-194 0.5311 -0.2005 0.3208 -0.3018 0.2469 -0.8109 -0.1602 -0.1032 
rno-miR-195 0.2058 0.0923 nd -0.1530 0.1637 -0.1307 0.0667 -0.1361 
rno-miR-196a* -0.3399 -0.4876 -0.2456 -0.1095 -0.4167 -0.3523 -0.7776 -0.7850 
rno-miR-196b nd nd nd nd nd 6.8968 nd nd 
rno-miR-199a-3p 0.6574 1.0746 1.1657 0.3671 0.9508 0.1647 0.3671 0.6830 
rno-miR-199a-5p 5.5580 1.2730 nd 3.9255 nd nd nd 2.7309 
rno-miR-19a 0.7361 0.5075 0.3722 nd 0.2946 -0.0582 -0.1074 1.0693 
rno-miR-19b 0.7566 0.4671 0.4181 0.0568 0.3864 0.0152 0.0242 0.8421 
rno-miR-200a -8.7980 -8.7980 -3.6237 -8.7980 -2.3160 -8.7980 -6.6192 -8.7980 
rno-miR-200b -3.0725 -5.0440 -1.5625 -1.3741 -1.1064 0.0254 -2.7717 -2.1673 
rno-miR-200c nd nd nd nd nd 6.2725 nd nd 
rno-miR-203 -0.0782 -0.6485 0.5473 0.1563 -0.0375 -0.2270 nd 0.7419 
rno-miR-204 -0.3073 1.2519 0.0288 -0.5426 0.6295 -0.5514 -0.1703 0.2100 
rno-miR-204* 0.1340 0.0742 -0.2709 0.0964 nd 0.8347 0.1575 0.4430 
rno-miR-205 2.2623 2.4257 2.2527 1.6815 2.4384 1.8119 2.9696 2.6084 
rno-miR-206 -0.0700 -0.2970 -0.0938 -0.2021 -0.0411 0.8825 0.4200 0.5950 
rno-miR-207 -0.1583 -0.1583 -0.0821 -0.1841 -0.1583 0.0015 -0.2020 -0.2193 
rno-miR-208 -0.2188 0.0614 -0.1203 0.2122 -0.2780 0.2921 0.2588 0.3414 
rno-miR-20a 0.6001 0.5495 0.1074 0.0625 0.3336 0.1887 0.5153 0.7270 
rno-miR-21 0.3516 0.2546 0.5588 0.1518 0.4692 0.7130 0.6493 2.1537 
rno-miR-21* -0.7705 0.8411 -0.0640 1.3372 0.2517 1.6854 2.1861 0.8808 
rno-miR-210 1.4800 1.1573 0.3746 0.2359 1.1698 -0.2559 0.1476 0.9653 
rno-miR-211 nd nd nd nd nd 4.5950 nd nd 
rno-miR-212 0.1246 0.0260 0.2713 -0.2319 0.1246 -0.1395 0.2713 0.0655 
rno-miR-214 -0.6212 -0.4776 -0.7067 -0.3955 -0.6878 -0.3540 -0.5221 -0.8632 
rno-miR-215 -0.5644 -1.0637 -0.9786 -0.1508 -0.8133 -1.2228 -1.9091 -2.2892 
rno-miR-217 nd nd 4.5950 nd nd nd nd nd 
rno-miR-218 0.4198 0.0406 0.5032 0.0872 0.2220 0.0558 0.2220 -0.0747 
rno-miR-218* 0.4080 0.2851 0.1377 -0.2961 0.0491 -0.5921 -0.9079 -0.7419 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-219-5p 0.2545 -0.1476 -0.0400 -0.1161 0.1337 -0.6637 -0.5121 -0.1161 
rno-miR-22 -0.0004 -0.0004 nd -0.0017 -0.0001 -0.0019 -0.0004 -0.1867 
rno-miR-22* 0.2994 0.1641 -0.0427 -0.2116 nd -0.3844 -0.3844 -0.1407 
rno-miR-221 0.4839 0.2458 0.3964 0.1499 0.1946 -0.0202 0.1499 0.0731 
rno-miR-222 0.7722 0.4638 0.6781 0.2385 0.6781 0.2385 0.6595 0.4638 
rno-miR-223 1.1127 1.4012 1.0967 0.6088 1.1364 2.5274 2.0432 3.2210 
rno-miR-23a 0.2393 0.1102 0.1988 -0.2558 0.2243 0.0369 0.0799 0.5905 
rno-miR-23a* -0.0236 0.1110 -0.7757 -0.4734 -0.6299 -2.0293 -0.9855 -1.5940 
rno-miR-23b 0.3846 0.2059 0.3575 0.1417 0.2059 -0.0361 0.0824 0.2059 
rno-miR-24 0.0019 0.0029 0.0021 0.0009 0.0016 -0.0086 nd 0.0014 
rno-miR-24-1* 0.0369 -0.2776 0.0958 -0.2699 -0.2041 -0.4834 -0.4772 nd 
rno-miR-24-2* 0.2091 -0.1330 0.2991 0.1465 0.2091 0.1512 -0.0926 0.6034 
rno-miR-25 0.9005 0.6769 0.5917 -0.4515 0.2832 -0.2001 0.6948 0.5090 
rno-miR-25* 0.7303 -1.4948 0.6066 0.1782 0.3402 0.9269 1.2270 1.5420 
rno-miR-26a 0.0019 0.0024 0.0013 0.0005 0.0018 nd 0.0013 0.0019 
rno-miR-26b -0.0005 -0.0005 -0.0003 -0.0003 -0.0006 -0.0005 -0.0006 -0.0006 
rno-miR-27a 0.7478 0.4487 0.1838 0.3422 0.2307 0.1227 0.1619 0.8755 
rno-miR-27a* nd nd nd nd nd nd 7.0019 nd 
rno-miR-27b 1.7872 1.6336 1.1550 0.4460 0.8895 -5.9619 0.8346 -0.0698 
rno-miR-28 0.5008 0.5202 0.1676 -0.1376 0.1187 -0.3291 -0.1086 -0.0225 
rno-miR-28* nd nd nd nd nd 1.2730 nd nd 
rno-miR-290 0.0615 0.0246 0.2452 0.1579 0.1930 0.4165 0.4823 0.7708 
rno-miR-291a-3p -0.5679 -0.4126 0.7941 0.1224 0.2192 -0.6008 -0.4599 1.1685 
rno-miR-291a-5p 0.4687 0.1902 0.1326 1.1835 1.5513 2.2509 2.6091 1.6626 
rno-miR-296 -0.2300 -0.2300 0.1950 0.5216 -0.1498 0.2026 -0.1412 -0.3637 
rno-miR-297 -2.3152 -2.1949 -1.2788 -6.6471 -1.9904 -6.6471 -6.6471 -6.6471 
rno-miR-298 0.1032 -0.0251 0.2179 0.0320 0.1214 -0.0665 0.2886 0.4348 
rno-miR-299 1.7406 1.5541 1.6333 1.6565 1.3965 0.9506 1.7035 1.4587 
rno-miR-29a 0.0020 0.0028 0.0025 nd 0.0024 -0.1555 0.0024 0.0023 
rno-miR-29a* 0.2031 0.1228 0.3940 0.0078 0.1515 0.0878 0.1084 0.1309 
rno-miR-29b 0.0020 0.0025 0.0017 0.0018 0.0023 0.0014 0.0018 0.0020 
rno-miR-29b-1* -1.8582 -1.9074 1.1802 -5.8329 -0.2198 -5.8329 -1.5475 0.2640 
rno-miR-29b-2* 0.4857 -0.0608 0.5210 -0.0608 0.1329 -1.0733 -1.1524 -0.7455 
rno-miR-29c 0.0935 -0.0860 0.2272 0.2099 0.2099 0.1771 0.3660 0.2099 
rno-miR-29c* 0.3842 0.0901 0.5274 0.0348 0.2243 -0.1793 -0.1327 -0.1417 
rno-miR-300-3p 0.4565 0.2177 0.3145 0.1904 0.1066 -0.1029 -0.1446 0.0446 
rno-miR-300-5p -0.2856 0.0847 -0.1128 0.5026 0.3677 0.7827 1.0033 0.4864 
rno-miR-301a 0.3558 0.0872 0.6234 -0.1046 0.3920 -0.4704 -0.3856 0.1411 
rno-miR-30a 0.0001 0.0001 0.0001 0.0003 0.0002 0.0001 0.0002 0.0002 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-30b-3p -0.4814 -0.4463 -0.4116 -0.4005 -0.5302 -0.5778 -0.9599 -0.8570 
rno-miR-30b-5p nd 0.0004 0.0006 -0.0003 0.0002 -0.0012 nd -0.0012 
rno-miR-30c 0.0003 0.0003 0.0003 0.0003 0.0002 0.0002 0.0002 0.0003 
rno-miR-30c-1* 0.8879 0.0819 0.4222 -0.4610 0.5002 0.8371 1.4745 1.3114 
rno-miR-30c-2* 1.3960 0.8934 0.9694 -2.1122 0.1174 -5.9451 -4.8862 0.2600 
rno-miR-30d 0.2623 0.1083 0.2749 -0.1728 -0.3390 -0.5077 -0.4696 nd 
rno-miR-30e nd -0.0126 -0.0328 -0.0328 -0.0328 -0.3637 -0.4277 -0.1564 
rno-miR-30e* 0.1086 -0.0468 0.1887 -0.3243 -0.1005 -0.3014 -0.3132 -0.1550 
rno-miR-31 0.8544 0.5984 0.4414 -0.3263 -0.0433 0.3577 -0.4083 0.2182 
rno-miR-32 0.5692 0.3962 0.3436 0.0258 0.4445 -0.2796 0.0544 0.4711 
rno-miR-320 0.4286 0.1539 0.5228 -0.1610 0.2415 -0.3312 0.2535 0.2786 
rno-miR-322 -0.0229 -0.3784 -0.0740 -0.1146 -0.2268 0.0295 -0.3675 -0.5904 
rno-miR-323 0.3278 0.2871 -0.1384 -0.2357 -0.0768 -0.2117 -0.3266 -0.0851 
rno-miR-324-5p 0.7302 0.6165 0.1612 0.0166 0.1248 -0.2393 -0.3749 0.0385 
rno-miR-325-3p 0.2081 0.1035 -0.0112 -0.2027 -0.1122 -0.2373 -0.2373 -0.3231 
rno-miR-325-5p 0.3085 -0.0182 0.1204 -0.3886 -0.1407 -0.2251 -0.2093 -0.2093 
rno-miR-326 0.3227 0.1388 0.1388 0.1085 0.1504 0.2671 0.3317 0.4457 
rno-miR-327 nd nd nd nd nd 6.0969 nd 3.4113 
rno-miR-328 0.7047 0.4605 0.3799 0.3534 0.3709 -0.0385 -0.0120 0.2583 
rno-miR-329 0.1862 0.0189 -0.0912 -0.2124 -0.2124 -0.3785 -0.3585 -0.5157 
rno-miR-33 0.5878 0.1924 0.6692 0.2858 0.8029 -0.4443 -0.1632 0.4766 
rno-miR-330 0.5786 0.4007 0.3906 -0.0811 -0.1500 -0.4688 -0.4482 -0.2208 
rno-miR-330* 0.2745 0.2215 0.2371 nd 0.1263 -0.1443 -0.1137 -0.0167 
rno-miR-331 0.3731 0.1711 0.3967 0.0794 0.1169 -0.1528 -0.3036 0.1711 
rno-miR-335 0.3605 0.2383 0.3123 -0.0168 0.3123 -0.2447 -0.0168 0.3913 
rno-miR-336 -0.2558 -0.3071 0.2552 -1.3184 -0.9239 -1.6324 -1.0410 -1.1973 
rno-miR-337 0.6389 0.5122 0.7395 0.0263 0.4840 -0.0873 0.3748 0.1416 
rno-miR-338 0.5035 0.1033 0.2993 nd 0.0659 0.0911 0.2220 0.0911 
rno-miR-338* 0.7130 0.5274 0.4289 -0.1429 0.3222 -0.0896 0.2588 0.1522 
rno-miR-339-5p 0.4883 0.3247 0.4341 -0.0684 0.3396 0.0376 -0.0828 0.6691 
rno-miR-340-3p 0.2735 0.2393 0.3208 -0.0405 -0.0689 -0.0607 -0.2286 0.0047 
rno-miR-340-5p 0.5788 0.2197 0.3084 0.1556 -0.1554 -0.3105 -0.4658 -0.0441 
rno-miR-341 0.2517 0.0458 0.4747 0.2517 0.3692 0.0583 0.4206 0.1508 
rno-miR-342-3p 0.3601 0.1583 0.2597 nd 0.0884 -0.1324 -0.0492 0.0598 
rno-miR-342-5p -0.1804 -0.5225 -0.0533 -0.7997 -0.3846 -1.2135 -1.2887 -1.1897 
rno-miR-344-3p 0.5468 0.1357 0.1891 0.1177 0.2436 -0.8133 -0.1553 -0.3137 
rno-miR-344-5p -1.1199 -1.8929 -0.0582 -1.3863 -1.4180 -1.4763 -1.2987 0.3377 
rno-miR-345-3p -3.9255 -3.9255 -3.9255 -3.9255 1.7524 -3.9255 2.7638 -3.9255 
rno-miR-345-5p 0.3700 0.3432 -0.0653 1.3183 0.4042 0.3700 0.6270 0.2663 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-347 0.3884 0.3102 0.4027 -0.3480 -0.2517 -0.6032 -0.1526 0.0490 
rno-miR-349 -0.4683 0.6655 -0.2575 -0.8494 -0.4812 -7.3197 -2.8676 -2.2007 
rno-miR-34a 0.2588 0.1532 0.1240 -0.3038 0.3563 -0.2007 -0.3417 0.1240 
rno-miR-34b -0.2956 1.0658 0.4269 -0.2956 0.6870 -1.2641 0.0943 0.1283 
rno-miR-34c -0.4343 1.3306 0.3459 -0.1557 0.6363 -1.6561 0.5823 0.3813 
rno-miR-34c* -0.3069 -0.0582 -0.3697 -0.3255 -0.4939 -0.7459 -0.7362 -1.0736 
rno-miR-350 0.5904 0.4603 0.2473 -0.0506 0.0194 -0.0552 -0.0867 0.0851 
rno-miR-351 0.2483 0.1673 0.0999 0.2483 0.4545 0.4760 0.4760 0.6302 
rno-miR-352 0.3819 0.0954 0.2138 0.1897 0.2240 0.0263 -0.0234 0.0954 
rno-miR-361 0.2593 0.1660 0.3175 0.0442 0.2340 0.2248 0.2248 0.1750 
rno-miR-363* 0.3018 -1.8905 0.0258 -0.3020 -0.3087 0.4378 -1.9567 0.4841 
rno-miR-365 0.6063 0.3432 0.3360 -0.0962 -0.1379 -0.1999 0.1698 0.1823 
rno-miR-369-3p 0.6216 0.5181 0.4834 0.3843 0.4432 0.0709 0.0295 0.3387 
rno-miR-369-5p 0.4694 -0.0044 0.5120 0.0681 0.1141 0.0417 -0.0506 -0.1396 
rno-miR-370 0.3981 0.8947 0.6827 -0.0226 0.4777 -0.3534 0.4458 0.2937 
rno-miR-374 0.7983 0.7009 0.2247 0.1563 0.0938 -0.0912 -0.3347 0.1485 
rno-miR-375 0.0456 -0.2769 0.5447 -0.0429 0.2421 0.2801 0.5535 1.4894 
rno-miR-376a 0.3271 -0.0871 0.2671 0.1108 0.2159 -0.3402 -0.4757 nd 
rno-miR-376a* 0.4227 0.1764 0.5624 0.2204 0.3036 -0.1738 0.1675 0.1930 
rno-miR-376b-3p 0.4361 0.1822 0.2898 0.1917 0.1356 -0.1849 -0.2354 0.0083 
rno-miR-376b-5p 0.4036 0.0919 0.4821 0.2504 0.3161 0.8439 0.1253 0.1564 
rno-miR-376c 0.0553 0.1497 -0.1674 -0.4108 -0.0741 -0.3866 -0.5002 -0.0454 
rno-miR-377 0.4517 0.3029 0.2958 -0.2162 -0.0635 -0.3795 -0.4146 -0.1150 
rno-miR-378 0.2057 0.3677 0.2929 -0.1246 0.1639 -0.2205 -0.1428 0.2057 
rno-miR-379 0.2963 0.3536 0.2460 0.0125 0.2152 -0.1053 -0.0125 0.1761 
rno-miR-379* 0.8899 -5.7571 0.6794 -5.7571 0.8551 -5.7571 -2.0691 -5.7571 
rno-miR-380 2.4374 nd nd nd nd nd nd nd 
rno-miR-381 0.4009 0.0626 0.1258 0.1000 0.1394 -0.0947 0.0552 0.1000 
rno-miR-382 0.3375 -0.1059 0.1300 -0.1195 0.0306 -0.0645 -0.0460 -0.0080 
rno-miR-382* -0.2462 -0.0071 -0.1439 0.3063 -0.1382 0.2852 -0.0071 0.2852 
rno-miR-383 0.5927 0.4445 0.5304 0.0735 0.2091 -0.1514 0.0077 -0.1044 
rno-miR-384-3p 0.2872 0.1801 0.3227 -0.0659 -0.0659 -0.3439 -0.3269 -0.1241 
rno-miR-384-5p 0.6135 0.2246 0.3140 0.1015 0.2246 -0.0800 -0.1664 0.2053 
rno-miR-409-3p 0.5417 0.3074 0.4596 0.0813 0.2391 -0.1133 -0.0807 -0.0185 
rno-miR-409-5p 0.4490 0.2486 0.0333 -0.1769 0.2651 -0.5324 -0.1106 -0.0972 
rno-miR-410 0.7504 0.5501 0.5965 0.5143 0.2882 0.2838 0.4843 0.2334 
rno-miR-411 0.2089 0.1571 0.2713 -0.0428 0.0888 -0.4705 -0.2888 -0.2814 
rno-miR-412 0.3510 0.3979 0.6222 0.0399 0.1248 -0.4341 -0.0780 0.1541 
rno-miR-423 0.4993 0.2963 0.3197 0.0809 0.3291 0.4257 0.6577 0.5717 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-429 -4.9451 -4.9451 -4.9451 -4.9451 -4.9451 -4.9451 -4.9451 -4.9451 
rno-miR-431 nd nd 7.3534 nd 5.4721 6.5783 nd nd 
rno-miR-433 0.5645 0.3278 0.2738 -0.0991 -0.0502 -0.2993 -0.0071 -0.0841 
rno-miR-434 0.3060 0.1583 0.1993 -0.0464 0.1053 -0.1105 nd -0.1105 
rno-miR-448 -3.0248 5.7818 0.2647 -3.0248 4.6340 -3.0248 -1.9659 3.1176 
rno-miR-449a 5.8566 6.8676 6.0456 nd 4.7608 nd 2.9175 nd 
rno-miR-450a nd nd nd nd nd 5.4197 nd nd 
rno-miR-451 1.7957 1.6193 0.9973 0.5197 1.5874 0.6464 1.6497 0.0996 
rno-miR-455 1.2914 0.8944 0.6486 -3.0252 0.9169 -6.4365 -0.6036 0.5086 
rno-miR-466b -0.3756 0.0733 -0.2451 -0.2006 -0.2672 -0.4481 -0.6439 -0.7961 
rno-miR-466c -0.6617 -0.6129 -0.6129 -0.3627 -0.6220 -0.5898 -0.9014 -1.3108 
rno-miR-471 -0.6297 -0.2380 -0.5900 -0.3800 -0.3930 -0.5171 -0.6058 0.1680 
rno-miR-483 0.8392 1.3552 -0.7569 -0.0843 0.2766 -0.3824 1.1381 0.5543 
rno-miR-484 5.0792 nd nd nd nd nd nd nd 
rno-miR-485 0.6898 0.3181 0.6023 0.1781 0.3558 -0.2307 -0.0204 0.1591 
rno-miR-487b 0.1971 -0.0242 0.3297 -0.3528 -0.1273 -0.6090 -0.4446 -0.1356 
rno-miR-488 0.6362 0.2053 0.5949 0.2455 0.3227 -1.0097 -0.1272 0.1508 
rno-miR-494 0.1652 -0.0263 0.0609 -0.1553 0.0609 0.0756 0.2117 0.6309 
rno-miR-495 0.6710 0.2801 0.2801 0.1956 0.0791 -0.2277 -0.0854 -0.0320 
rno-miR-497 0.0955 -0.0943 -0.0943 -0.5109 -0.3988 -2.2457 -1.3820 -0.9038 
rno-miR-499 0.7905 0.6412 0.3581 0.0486 0.3757 -0.9943 -0.7677 0.0486 
rno-miR-500 0.8338 0.2058 1.0025 0.6601 0.7635 -0.0360 0.8993 0.8993 
rno-miR-503 -0.1543 -0.0771 -0.2722 0.1700 -0.0306 0.6365 0.4651 0.3434 
rno-miR-505 0.7380 0.5431 0.4483 0.1426 0.3267 -0.1284 0.1532 0.1273 
rno-miR-532-5p 0.6422 0.4540 0.5302 -0.5721 0.7070 -1.0096 0.4263 0.7604 
rno-miR-539 0.5017 0.1901 0.4371 -0.0307 0.1126 -0.1804 0.0807 0.0473 
rno-miR-540 1.1639 0.4808 1.0282 -0.3024 0.7214 -6.0013 -0.4155 -0.1684 
rno-miR-541 0.6183 0.3735 0.4273 -0.0528 0.1752 -0.3697 0.0400 -0.1775 
rno-miR-542-3p 0.2024 -0.1047 0.3544 -0.3501 -0.0262 -0.2450 -0.2913 -0.1246 
rno-miR-542-5p 0.0700 -0.4475 -0.0697 -0.1523 0.4097 0.8852 1.3512 1.5456 
rno-miR-551b 0.2052 0.2367 0.2976 0.0997 0.4586 0.0690 0.1531 0.0207 
rno-miR-598-3p 0.6392 0.3224 0.5665 0.3172 0.2411 -0.1705 -0.0027 -0.0176 
rno-miR-652 0.5887 0.4065 0.6573 0.2247 0.3599 0.1905 0.1090 0.1905 
rno-miR-664 0.3658 0.1034 0.1846 0.1846 0.3770 0.0185 0.1777 0.1223 
rno-miR-671 nd nd nd nd nd nd 4.5950 5.1744 
rno-miR-672 0.4308 0.6207 0.1884 -0.4630 0.2515 -0.8214 -0.2681 -0.3341 
rno-miR-674-3p 0.1909 0.1726 0.2260 -0.2875 -0.0131 -0.7443 0.0135 0.1200 
rno-miR-674-5p 0.3502 0.1830 0.4121 -0.1684 0.0346 -0.5711 -0.4204 0.2235 
rno-miR-708 0.4042 0.0880 0.4614 0.0586 0.3673 -0.2340 -0.0184 0.1246 







0hr 1hr 3hr 6hr 12hr 18hr 24hr 48hr 
rno-miR-742 -0.5572 -0.4492 -0.3448 -0.3734 -0.3531 -0.6687 -0.7153 -0.4028 
rno-miR-743b -0.4757 -0.4877 -0.3967 -0.2876 -0.4417 -0.5279 -0.7721 -0.4026 
rno-miR-758 7.0131 5.6779 6.5366 nd 5.1744 nd nd nd 
rno-miR-760-3p 0.8531 0.7655 0.5501 0.0774 0.3258 -0.7537 0.1545 -0.0772 
rno-miR-760-5p -5.3179 -5.3179 -0.3104 -5.3179 -5.3179 -5.3179 -5.3179 -5.3179 
rno-miR-770 0.3425 0.3316 0.3270 0.0108 0.1554 -0.3417 nd 0.3098 
rno-miR-7a 0.2988 0.2815 0.2164 0.2164 -0.1108 -0.3290 -0.3531 -0.0884 
rno-miR-7a* 0.4684 -0.3419 0.2691 -0.4788 0.0838 0.3062 -0.4314 -0.3525 
rno-miR-7b 0.2513 -0.0825 0.2737 0.1892 0.0459 -0.7835 -0.4997 0.0895 
rno-miR-872 1.3386 0.9776 0.9583 0.4300 1.0871 nd 0.8110 0.6161 
rno-miR-872* 0.0692 0.3199 0.2389 0.2554 0.1997 0.0881 0.3199 0.2697 
rno-miR-873 0.4478 0.1472 0.2979 0.0206 0.4052 0.2852 0.3773 0.3332 
rno-miR-874 0.5321 -3.2308 -0.1444 0.0437 1.1288 2.0283 1.9409 2.0160 
rno-miR-877 -0.4395 -0.4501 -0.4917 0.1018 0.0195 0.3917 0.2800 -0.4917 
rno-miR-878 -5.9076 -5.9076 -0.4878 1.7248 -0.7332 2.0536 -5.9076 1.9611 
rno-miR-879 0.6047 0.1760 1.0353 0.0700 0.5703 -0.3290 -0.8806 0.5035 
rno-miR-880 -7.8602 -7.8602 -1.1376 -7.8602 -7.8602 -1.5090 -7.8602 -7.8602 
rno-miR-883 -1.5186 -0.9676 -1.9700 -2.8626 -2.3178 -2.2966 -2.2966 -1.9800 
rno-miR-9 0.0002 nd 0.0001 0.0001 0.0001 -0.0004 0.0001 -0.0001 
rno-miR-9* 0.0014 -0.0007 -0.0149 0.0004 0.0014 -0.0021 -0.0815 0.0014 
rno-miR-92b 0.3255 0.1745 0.2357 -0.0910 -0.0623 -0.3296 nd 0.0905 
rno-miR-93 0.6713 0.4494 0.4005 0.0367 0.3090 0.0907 0.3961 0.3556 
rno-miR-98 0.5412 0.2322 0.2515 -0.1910 0.1751 -0.1617 -0.1697 0.1179 
rno-miR-99a nd -0.0542 -0.1891 -0.5403 -0.1336 -0.5403 -0.5780 0.0086 
rno-miR-99b 0.4563 0.0900 0.3225 -0.2387 0.0964 -0.3492 nd 0.0628 
rno-miR-99b* -0.1606 -0.3473 -0.0868 -0.2474 -0.3608 -0.3828 -0.1839 -0.1886 
 
Supplemental Table 2: Expression profile of miRNAs. There are 303 miRNAs 
expressed in at least one of the time points post embolic ischemic stroke in the 
















Supplementary Table 3: 
miRNA Predicted targets miRNA Predicted targets 
rno-let-7a-1* MMP9 rno-miR-127 MMP9, TIMP1 
rno-let-7a-2* MMP2, MMP9, TIMP3 rno-miR-127* MMP2, TIMP2 
rno-let-7b* MMP9 rno-miR-128 MMP2, TIMP2, TIMP3 
rno-let-7c-2* MMP9 rno-miR-128-1* 
 
MMP2, MMP3, MMP9, TIMP2, 
TIMP3 
rno-let-7d MMP9 rno-miR-128-2* MMP2, TIMP2, TIMP3 
rno-let-7e MMP9 rno-miR-129 
 
MMP2, MMP3, MMP9, TIMP2, 
TIMP3 
rno-let-7f-2* MMP2, MMP9, TIMP2 rno-miR-129-1* MMP3, TIMP1 
rno-let-7i* TIMP2 rno-miR-129-2* MMP3, TIMP1 
rno-miR-1 TIMP3 rno-miR-130a TIMP2 
rno-miR-100* TIMP2 rno-miR-130a* TIMP3 
rno-miR-101a TIMP3 rno-miR-130b MMP9, TIMP2 
rno-miR-101a* TIMP3 rno-miR-130b* MMP2, MMP9, TIMP2 
rno-miR-101b TIMP3 rno-miR-132 MMP9, TIMP2, TIMP3 
rno-miR-101b* MMP2 rno-miR-132* TIMP1 
rno-miR-103 MMP2, MMP3, TIMP2 rno-miR-133a MMP2, MMP3 
rno-miR-103-1* MMP3, MMP9, TIMP3 rno-miR-133a* MMP2, MMP9, TIMP1 
rno-miR-103-2* TIMP3 rno-miR-133b MMP2, MMP3 
rno-miR-106b MMP2, MMP3, TIMP2, 
TIMP3 
rno-miR-133b* MMP2, MMP9, TIMP3 
rno-miR-106b* MMP3, TIMP3 rno-miR-134 MMP2, TIMP2, TIMP3 
rno-miR-107 MMP2, MMP3, TIMP2 rno-miR-134* MMP2, MMP9, TIMP1 
rno-miR-107* MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-135a MMP9, TIMP3 
rno-miR-10a-3p TIMP2 rno-miR-135a* MMP9 
rno-miR-10b MMP3, MMP9 rno-miR-135b MMP9 
rno-miR-1188-3p TIMP1 rno-miR-135b* MMP9 
rno-miR-1188-5p TIMP3 rno-miR-136 MMP3, TIMP3 
rno-miR-1193-3p MMP2, MMP9, TIMP3 rno-miR-136* MMP2, MMP3 
rno-miR-1193-5p MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-137 MMP9 
rno-miR-122 MMP2, MMP3, MMP9 rno-miR-137* MMP2 
rno-miR-1224 MMP3, MMP9, TIMP3 rno-miR-138 MMP2, MMP9, TIMP3 
rno-miR-124* TIMP1 rno-miR-138* TIMP2 
rno-miR-1249 MMP2, TIMP2, TIMP3 rno-miR-138-1* MMP3, MMP9, TIMP2 
rno-miR-125a-3p MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-139-3p MMP3 
rno-miR-125a-5p MMP2, MMP9 rno-miR-139-5p 
 
MMP2, MMP3, MMP9, TIMP2, 
TIMP3 
rno-miR-125b* MMP3, TIMP3 rno-miR-140 MMP3, TIMP3 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-141 TIMP1, TIMP2, TIMP3 rno-miR-181d* MMP3, TIMP2 
rno-miR-141* MMP2, MMP3, TIMP3 rno-miR-182 MMP9, TIMP3 
rno-miR-142-3p MMP3, TIMP3 rno-miR-183  MMP3, TIMP3 
rno-miR-142-5p TIMP2, TIMP3 rno-miR-184 MMP2 
rno-miR-143 TIMP2, TIMP3 rno-miR-185 MMP9, TIMP2 
rno-miR-143* MMP2, MMP9 rno-miR-185* MMP9, TIMP2 
rno-miR-144 MMP3, TIMP3 rno-miR-186 MMP2, MMP3, TIMP1 
rno-miR-144* MMP9 rno-miR-186* MMP2, MMP3 
rno-miR-145 MMP2, MMP3, TIMP1 rno-miR-187 MMP9, TIMP1 
rno-miR-145* MMP9, TIMP2 rno-miR-187* TIMP2 
rno-miR-146a MMP9 rno-miR-188 MMP2, TIMP3 
rno-miR-146a* MMP2, MMP3, MMP9 rno-miR-188* MMP3, TIMP1 
rno-miR-146b MMP9 rno-miR-18a* TIMP2, TIMP3 
rno-miR-146b* MMP3, MMP9, TIMP3 rno-miR-190 TIMP3 
rno-miR-148b-3p MMP3, MMP9 rno-miR-191 MMP2 
rno-miR-148b-5p MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-191* MMP3, TIMP2 
rno-miR-150 MMP2, TIMP3 rno-miR-1912-3p TIMP2 
rno-miR-150* MMP2, MMP9, TIMP3 rno-miR-1912-5p TIMP2 
rno-miR-151* MMP3 rno-miR-192* MMP3, MMP9 
rno-miR-152 MMP3, MMP9 rno-miR-193 MMP9, TIMP2 
rno-miR-152* MMP3, TIMP1, TIMP3 rno-miR-193* TIMP1, TIMP2 
rno-miR-153 TIMP3 rno-miR-194* MMP9 
rno-miR-153* MMP3, TIMP3 rno-miR-1949 MMP2 
rno-miR-154 MMP2, MMP9 rno-miR-195 MMP2, MMP3, TIMP2 
rno-miR-154* MMP2, TIMP2, TIMP3 rno-miR-196a MMP9 
rno-miR-15b MM2, MMP3, TIMP2 rno-miR-196a* MMP3 
rno-miR-15b* MMP2, TIMP2 rno-miR-196b MMP9 
rno-miR-16 MMP2, MMP3, TIMP2 rno-miR-196b* MMP2, TIMP3 
rno-miR-16* MMP9 rno-miR-196c MMP9 
rno-miR-17-1-3p TIMP2, TIMP3 rno-miR-199a-5p MMP2, MMP3, TIMP1, TIMP3 
rno-miR-17-2-3p MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-19a TIMP1, TIMP2, TIMP3 
rno-miR-17-5p MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-19b TIMP1, TIMP2, TIMP3 
rno-miR-181a MMP9, TIMP2, TIMP3 rno-miR-19b-1* TIMP3 
rno-miR-181b MMP9, TIMP2, TIMP3 rno-miR-19b-2* MMP3, TIMP2 
rno-miR-181b-1* MMP9 rno-miR-200a TIMP1, TIMP2, TIMP3 
rno-miR-181b-2* MMP2, MMP9 rno-miR-200a* MMP2, TIMP3 
rno-miR-181c  TIMP2, TIMP3 rno-miR-200b MMP9 
rno-miR-181c* MMP3 rno-miR-200b* MMP2, TIMP3 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-203* MMP2, MMP9, TIMP3 rno-miR-222 MMP2, TIMP2, TIMP3 
rno-miR-204 MMP2, MMP3, TIMP3 rno-miR-222* MMP2, MMP9 
rno-miR-204* MMP3, MMP9, TIMP3 rno-miR-223* MMP9, TIMP3 




MMP2, TIMP2, TIMP3 
 
rno-miR-206 TIMP3 rno-miR-23a MMP9 
rno-miR-206* MMP9, TIMP3 rno-miR-23a* MMP9, TIMP2 






rno-miR-208 MMP3, TIMP2 rno-miR-23b* TIMP2 
rno-miR-208* MMP3, TIMP1, TIMP3 rno-miR-24 
 
MMP2, MMP3, TIMP1, TIMP2, 
TIMP3 
rno-miR-208b-3p TIMP2 rno-miR-25 MMP2, TIMP2 
rno-miR-208b-5p TIMP1, TIMP3 rno-miR-26a MMP3 






rno-miR-20a* MMP2, MMP3, TIMP2 rno-miR-27a MMP2, TIMP2, TIMP3 
rno-miR-20b-3p MMP9, TIMP3 rno-miR-27a* TIMP1 




MMP2, TIMP2, TIMP3 
 
rno-miR-21 MMP9, TIMP3 rno-miR-27b* MMP2, MMP9 
rno-miR-21* MMP9 rno-miR-28 MMP9, TIMP3 
rno-miR-210* MMP2, MMP3, TIMP2 rno-miR-291a-3p MMP3, TIMP3 




MMP2, MMP3, TIMP2 
 
rno-miR-211* MMP9 rno-miR-291b TIMP2 
rno-miR-212  MMP9, TIMP2 rno-miR-292-3p MMP2 
rno-miR-212* MMP2, TIMP2, TIMP3 rno-miR-293* MMP9, TIMP2 
rno-miR-214 MMP2, MMP3, TIMP2, 
TIMP3 
rno-miR-294 MMP3 
rno-miR-216a* MMP2 rno-miR-295* TIMP3 
rno-miR-217 MMP3, TIMP3 rno-miR-296 MMP2, MMP9, TIMP1, TIMP2 
rno-miR-217* MMP3 rno-miR-296* MMP9 
rno-miR-218* TIMP1 rno-miR-2964 MMP2, MMP3, MMP9, TIM2, 
TIMP3 
rno-miR-218-2* TIMP3 rno-miR-297 MMP2 




MMP2, MMP9, TIMP1, 
TIMP3 
rno-miR-299 TIMP3 
rno-miR-219-2-3p MMP2, MMP3 rno-miR-299* MMP3 
rno-miR-219-5p TIMP1, TIMP2 rno-miR-29a MMP2, MMP9 
rno-miR-22 TIMP2 rno-miR-29a* MMP2, MMP3, TIMP3 
rno-miR-22* MMP2, MMP3, TIMP3 rno-miR-29b MMP2, MMP9 







miRNA Predicted targets miRNA Predicted targets 
rno-miR-29b-2* MMP2, MMP3, MMP9 rno-miR-328a* MMP2, MMP9, TIMP2 
rno-miR-29c MMP2, MMP9 rno-miR-328b-3p MMP9, TIMP2, TIMP3 
rno-miR-300-3p TIMP3 rno-miR-329 MMP3, TIMP1, TIMP2, TIMP3 
rno-miR-300-5p MMP3 rno-miR-329* MMP3, MMP9, TIMP2, TIMP3 
rno-miR-301a TIMP2 rno-miR-33 MMP2, TIMP2 
rno-miR-301b TIMP2 rno-miR-33* MMP3 
rno-miR-3065-3p MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-330 MMP2, MMP9, TIMP2, TIMP3 
rno-miR-3065-5p TIMP2, TIMP3 rno-miR-330* MMP2, MMP3, TIMP3 
rno-miR-3074 MMP3, MMP9, TIMP3 rno-miR-331 TIMP2, TIMP3 
rno-miR-3085 TIMP2, TIMP3 rno-miR-331* MMP2, MMP9, TIMP3 
rno-miR-30a MMP2, TIMP1, TIMP2, 
TIMP3 
rno-miR-335 TIMP2, TIMP3 
rno-miR-30a* MMP2,MMP9 rno-miR-336 MMP2, TIMP3 
rno-miR-30b-3p MMP2, TIMP2, TIMP3 rno-miR-336* MMP2, MMP3, TIMP1 
rno-miR-30b-5p TIMP1, TIMP2, TIMP3 rno-miR-337 MMP2, MMP3, TIMP 1, TIMP 3 
rno-miR-30c  TIMP1, TIMP2, TIMP3 rno-miR-338 MMP3, MMP9 
rno-miR-30c-1* MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-339-3p MMP9, TIMP2, TIMP3 
rno-miR-30c-2* MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-339-5p MMP3, TIMP2, TIMP3 
rno-miR-30d TIMP 1, TIMP 2, TIMP 3 rno-miR-340-3p MMP9 
rno-miR-30d* MMP2, MMP9, TIMP3 rno-miR-340-5p MMP2 
rno-miR-30e  MMP2, TIMP 1, TIMP 2 rno-miR-342-3p MMP9, TIMP2, TIMP3 
rno-miR-30e* MMP2,MMP9 rno-miR-342-5p MMP3, MMP9, TIMP2, TIMP3 
rno-miR-3120 MMP2,MMP9 rno-miR-343 MMP2, MMP3, TIMP2, TIMP3 
rno-miR-32 MMP2 rno-miR-344a MMP3, MMP9, TIMP1, TIMP2 
rno-miR-320 MMP2, MMP3, MMP9, 
TIMP1, TIMP2, TIMP3 
rno-miR-344a-3p MMP9 
rno-miR-320* MMP2, MMP3, MMP9, 
TIMP1, TIMP2 
rno-miR-344a-5p MMP3, MMP9, TIMP1, TIMP2 
rno-miR-322 MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-344b-1-3p MMP9, TIMP1, TIMP3 
rno-miR-323 TIMP3 rno-miR-344b-2-3p TIMP1, TIMP3 
rno-miR-323* MMP3, MMP9, TIMP1, 
TIMP3 
rno-miR-344b-5p MMP2, TIMP3 
rno-miR-324-3p MMP2, MMP3, TIMP2 rno-miR-345-5p TIMP3 
rno-miR-324-5p MMP2 rno-miR-346 MMP3, TIMP2, TIMP3 
rno-miR-325-3p TIMP2, TIMP3 rno-miR-347 MMP9, TIMP2, TIMP3 
rno-miR-325-5p MMP9, TIMP3 rno-miR-349 MMP2, MMP9, TIMP3 
rno-miR-326 MMP3, MMP9, TIMP2, 
TIMP3 
rno-miR-34a MMP2, TIMP1, TIMP2, TIMP3 
rno-miR-326* MMP2, MMP9, TIMP2 rno-miR-34a* MMP2, MMP9 
rno-miR-327 MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-34b MMP2, TIMP1 
rno-miR-328a MMP9, TIMP1, TIMP2, 
TIMP3 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-34c MMP2, TIMP1, TIMP2 rno-miR-3568 MMP2, MMP3, TIMP3 
rno-miR-350 MMP9, TIMP2, TIMP3 rno-miR-3569 MMP2, MMP3, MMP9, TIMP2 
rno-miR-351 MMP2, MMP9 rno-miR-3571 MMP3, TIMP2, TIMP3 
rno-miR-351* TIMP2, TIMP3 rno-miR-3573-3p TIMP2, TIMP3 
rno-miR-352 MMP2, TIMP3 rno-miR-3573-5p MMP2, MMP9, TIMP2 
rno-miR-3541 MMP9, TIMP3 rno-miR-3574 TIMP3 
rno-miR-3542 TIMP1, TIMP2, TIMP3 rno-miR-3575 MMP9, TIMP2 
rno-miR-3543 MMP2, MMP9, TIMP1, 
TIMP3 
rno-miR-3576 MMP2, MMP3, MMP9, TIMP3 
rno-miR-3544 MMP9, TIMP2 rno-miR-3577 MMP2, MMP9, TIMP2, TIMP3 
rno-miR-3545-3p MMP2 rno-miR-3580-3p MMP9 
rno-miR-3545-5p MMP9, TIMP2, TIMP3  rno-miR-3580-5p TIMP3 
rno-miR-3546 TIMP2 rno-miR-3581 MMP2, MMP9, TIMP2, TIMP3 
rno-miR-3547 MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-3582 MMP2, MMP9 
rno-miR-3548 MMP9 rno-miR-3583-3p MMP2, TIMP3 
rno-miR-3549 MMP9, TIMP2, TIMP3 rno-miR-3583-5p MMP3 
rno-miR-3550 MMP9, TIMP3 rno-miR-3584-5p MMP2, MMP9, TIMP1, TIMP2, 
TIMP4 
rno-miR-3551-3p MMP2, MMP3, MMP9 rno-miR-3585-3p TIMP1 
rno-miR-3551-5p MMP2, TIMP2, TIMP3 rno-miR-3585-5p TIMP1 
rno-miR-3552 MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-3586-5p MMP3, TIMP3 
rno-miR-3554 MMP3, TIMP1 rno-miR-3587 MMP9 
rno-miR-3555 MMP3 rno-miR-3588 TIMP1 
rno-miR-3556a TIMP2 rno-miR-3589 MMP2, MMP3, TIMP1, TIMP3 
rno-miR-3557-3p MMP2, TIMP2, TIMP3 rno-miR-3590-3p MMP2, MMP3, TIMP2 
rno-miR-3557-5p MMP2, MMP9, TIMP2, 
TIMP3 
rno-miR-3590-5p MMP3, TIMP3 
rno-miR-3558-3p MMP3, TIMP2, TIMP3 rno-miR-3591 MMP2, MMP3, TIMP3 
rno-miR-3558-5p MMP2, TIMP2 rno-miR-3593-3p MMP2, TIMP2 
rno-miR-3559-3p TIMP3 rno-miR-3593-5p MMP2, TIMP3 
rno-miR-3559-5p MMP2, TIMP2, TIMP3 rno-miR-3594-3p MMP2, MMP9 
rno-miR-3560 MMP2 rno-miR-3594-5p MMP2, MM9, TIMP2 
rno-miR-3561-3p MMP2, MMP9, TIMP2, 
TIMP3 
rno-miR-3595 MMP2 
rno-miR-3561-5p MMP2, MMP9, TIMP2, 
TIMP3 
rno-miR-3596a TIMP3 
rno-miR-3562 MMP2, MMP9, TIMP1, 
TIMP2, TIMP3 
rno-miR-3596d TIMP3 
rno-miR-3563-3p MMP3, TIMP3 rno-miR-3597-3p MMP9 
rno-miR-3563-5p TIMP3 rno-miR-3597-5p MMP9 
rno-miR-3564 MMP2, MMP3, TIMP2, 
TIMP3 
rno-miR-361 MMP2 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-362 MMP2, MMP9, TIMP3 rno-miR-423 MMP9 
rno-miR-362* MMP3 rno-miR-423* MMP3, MMP9, TIMP3 
rno-miR-363 MMP2, TIMP2 rno-miR-425  MMP3 
rno-miR-363* MMP2, TIMP3 rno-miR-425* MMP3, TIMP3 
rno-miR-365 MMP9, TIMP2, TIMP3 rno-miR-431 MMP9, TIMP2 
rno-miR-365* MMP9, TIMP3 rno-miR-433 MMP2, TIMP3 
rno-miR-369-3p TIMP2 rno-miR-434 MMP2, TIMP2 
rno-miR-370 MMP9, TIMP2, TIMP3 rno-miR-434* MMP9 
rno-miR-370* MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-448 TIMP3 
rno-miR-374 TIMP2 rno-miR-448* MMP3 
rno-miR-374* MMP9 rno-miR-449a MMP2, TIMP1 
rno-miR-375 TIMP2, TIMP3 rno-miR-449c-3p MMP2, MMP9, TIMP2, TIMP3 
rno-miR-375* MMP2 rno-miR-449c-5p MMP2, TIMP1 
rno-miR-376a MMP2, TIMP2 rno-miR-450a MMP2 
rno-miR-376b-3p MMP2, MMP3, TIMP2 rno-miR-450a* MMP3 
rno-miR-376b-5p MMP9, TIMP1, TIMP2 rno-miR-451* MMP2, MMP9, TIMP2, TIMP3 
rno-miR-376c MMP3, TIMP3 rno-miR-455 MMP2, MMP9 
rno-miR-376c* TIMP2 rno-miR-455* MMP3, MMP9, TIMP2 
rno-miR-377 TIMP2, TIMP3 rno-miR-463 TIMP2, TIMP3 
rno-miR-377* MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-465* MMP2, MMP9 
rno-miR-378 TIMP2, TIMP3 rno-miR-466b MMP2, MMP9, TIMP3 
rno-miR-380 MMP2, TIMP1, TIMP3 rno-miR-466b-1* MMP9, TIMP3 
rno-miR-380* MMP2, TIMP2 rno-miR-466c MMP2, MMP9, TIMP1, TIMP3 
rno-miR-381 TIMP3 rno-miR-466c* MMP9 
rno-miR-382 MMP2, MMP9, TIMMP1, 
TIMP3 
rno-miR-466d MMP2, MMP9, TIMP2, TIMP3 
rno-miR-382* MMP2, Timp2 rno-miR-471* MMP3, TIMP1 
rno-miR-383 TIMP3 rno-miR-483 MMP2, MMP9 
rno-miR-383* MMP3, MMP9 rno-miR-483* MMP3, TIMP1, TIMP2 
rno-miR-384-3p MMP3, MMP9, TIMP2, 
TIMP3 
rno-miR-483* TIMP2, TIMP3 
rno-miR-384-5p MMP2, TIMP1, TIMP2, 
TIMP3 
rno-miR-484 MMP3, TIMP1, TIMP2 
rno-miR-409-3p MMP2, TIMP2 rno-miR-485 TIMP1, TIMP2, TIMP3 
rno-miR-409-5p MMP9 rno-miR-485* MMP2, TIMP3 
rno-miR-410 MMP9, TIMP3 rno-miR-487b TIMP2 
rno-miR-410* MMP2, MMP9 rno-miR-487b* MMP9 
rno-miR-411 MMP9, TIMP3 rno-miR-488 MMP9, TIMP2, TIMP3 
rno-miR-412 MMP2, MMP9, TIMP1, 
TIMP2 
rno-miR-488* MMP2, MMP9 
rno-miR-421 TIMP2, TIMP3 rno-miR-489 MMP3 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-490* MMP2, MMP3 rno-miR-568 TIMP3 
rno-miR-493 MMP2, TIMP1 rno-miR-582 MMP9, TIMP3 
rno-miR-493* MMP3, MMP9, TIMP3 rno-miR-592 MMP2, MMP3, TIMP2 
rno-miR-494 MMP3, TIMP2, TIMP3 rno-miR-598-3p MMP3, TIMP2 
rno-miR-494* MMP2, TIMP2 rno-miR-598-5p MMP2, MMP9, TIMP2 
rno-miR-495  MMP3, TIMP2, TIMP3 rno-miR-615 MMP2, MMP3, MMP9, 
TIMP2, TIMP3 
rno-miR-496 MMP2 rno-miR-628 MMP3, TIMP2, TIMP3 
rno-miR-496* MMP2, MMP9, TIMP2 rno-miR-632 MMP2, MMP3, MMP9, 
TIMP1, TIMP2, TIMP3 
rno-miR-497 MMP2, MMP3, MMP9, 
TIMP2 
rno-miR-652 MMP9, TIMP2 
rno-miR-497* MMP3 rno-miR-652* MMP2 
rno-miR-499 TIMPp2 rno-miR-653 MMP3, TIMP2, TIMP3 
rno-miR-499* MMP2, MMP3, MMP9 rno-miR-653* MMP9 
rno-miR-500 MMP9 rno-miR-664 MMP2, MMP9, TIMP2 
rno-miR-500* MMP2, MMP9, IMP3 rno-miR-664-1* MMP3, MMP9, TIMP1, TIMP3 
rno-miR-501 MMP2, MMP3, MP9, TIMP1 rno-miR-664-2* MMP2, MMP3, MMP9, 
TIMP1, TIMP3 
rno-miR-503 MMP2, MMP9, TIMP2 rno-miR-665 MMP2, MMP3, MMP9, 
TIMP1, TIMP2, TIMP3 
rno-miR-503* MMP2, MMP9 rno-miR-666 MMP9, TIMP1 
rno-miR-504 MMP2, TIMP2 rno-miR-666* TIMP1, TIMP2, TIMP3 
rno-miR-505 TIMP2 rno-miR-667 MMP2, TIMP3 
rno-miR-505* MMP2, MMP9, TIMP1, 
TIMP2, TIMP3 
rno-miR-667* MMP3, MMP9, TIMP2, TIMP3 
rno-miR-511 MMP2, MMP9, TIMP1  rno-miR-668 TIMP1 
rno-miR-511* MMP2, MMP9, TIMP2 rno-miR-672 MMP3, MMP9, TIMP3 
rno-miR-532-3p MMP3, TIMP3 rno-miR-672* MMP3, TIMP2, TIMP3 
rno-miR-532-5p MMP9 rno-miR-673 MMP2, TIMP1, TIMP2 
rno-miR-539 MMP2, MMP9, TIMP1 rno-miR-673* TIMP3 
rno-miR-540 MMP9, TIMP1, TIMP2, 
TIMP3 
rno-miR-674-3p MMP2 
rno-miR-540* MMP9 rno-miR-674-5p MMP9, TIMP2 
rno-miR-541 MMP3, MMP9, TIMP3 rno-miR-675 MMP2, MMP9 
rno-miR-542-3p MMP2, TIMP2 rno-miR-675* MMP2 
rno-miR-542-5p MMP2, MMP3, TIMP3 rno-miR-678 MMP2, MMP3, MMP9, TIMP2 
rno-miR-543 MMP9, TIMP3 rno-miR-702-3p MMP2, TIMP3 
rno-miR-543* MMP9, TIMP3 rno-miR-702-5p MMP3, MMP9, TIMP2, TIMP3 
rno-miR-544 MMP2, MMP3, TIMP2 rno-miR-708 MMP3, MMP9, TIMP3 
rno-miR-547 MMP3, TIMP3 rno-miR-711 MMP2, TIMP2 
rno-miR-547* MMP2, MMP3 rno-miR-741-5p TIMP3 
rno-miR-551b MMP9 rno-miR-742 MMP3, MMP9, TIMP2, TIMP3 




miRNA Predicted targets miRNA Predicted targets 
rno-miR-743a MMP9, TIMP2, TIMP3 rno-miR-761 MMP2, MMP3, TIMP2, TIMP3 
rno-miR-743a* MMP9, TIMP2 rno-miR-764 TIMP2 
rno-miR-743b MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-764* MMP2, MMP3, TIMP1, 
TIMP2, TIMP3 
rno-miR-758 TIMP2 rno-miR-770 MMP2, TIMP3 
rno-miR-758* MMP2, MMP3 rno-miR-7a MMP2, MMP3, MMP9 
rno-miR-759 MMP2, MMP3, MMP9, 
TIMP3 
rno-miR-7a-1* MMP3, MMP9 
rno-miR-760-3p TIMP2, TIMP3 rno-miR-7b MMP2, MMP3, MMP9 




Supplementary Table 3: miRNAs prediction from TargetScan, MicroCosm 
Targets, microRNAs.org, RegRNA. miRNAs target predictions for rat MMPs and 
TIMPs genes from all four sources are shown. The sequences were retrieced from 
NCBI GenBank database MMP2 (NM_031054.2), MMP3 (NM_133523.2), MMP9 
(NM_031055.1), TIMP1 (NM_053819.1), TIMP2 (NM_021989.2) and TIMP3 
(NM_012886.2).  
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